0001104659-21-062496.txt : 20210506 0001104659-21-062496.hdr.sgml : 20210506 20210506171154 ACCESSION NUMBER: 0001104659-21-062496 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 87 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210506 DATE AS OF CHANGE: 20210506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cryoport, Inc. CENTRAL INDEX KEY: 0001124524 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 880313393 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-34632 FILM NUMBER: 21898912 BUSINESS ADDRESS: STREET 1: 112 WESTWOOD PLACE, SUITE 350 CITY: BRENTWOOD STATE: TN ZIP: 37027 BUSINESS PHONE: (949) 232-1900 MAIL ADDRESS: STREET 1: 112 WESTWOOD PLACE, SUITE 350 CITY: BRENTWOOD STATE: TN ZIP: 37027 FORMER COMPANY: FORMER CONFORMED NAME: CRYOPORT SYSTEMS LLC DATE OF NAME CHANGE: 20010614 FORMER COMPANY: FORMER CONFORMED NAME: CRYOPORT SYSTEMS INC DATE OF NAME CHANGE: 20000923 10-Q 1 cyrx-20210331x10q.htm FORM 10-Q
0001124524--12-312021Q1000000002000002000004569369239837058P3YP7YP4YP3YP7YP0YP0YP0YP0YP0Yfalse00011245242020-09-300001124524cyrx:ClassCConvertiblePreferredStockMember2021-02-052021-02-050001124524us-gaap:RetainedEarningsMember2021-03-310001124524us-gaap:AdditionalPaidInCapitalMember2021-03-310001124524us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001124524us-gaap:RetainedEarningsMember2020-12-310001124524us-gaap:AdditionalPaidInCapitalMember2020-12-310001124524us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001124524us-gaap:RetainedEarningsMember2020-03-310001124524us-gaap:AdditionalPaidInCapitalMember2020-03-310001124524us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-310001124524us-gaap:RetainedEarningsMember2019-12-310001124524us-gaap:AdditionalPaidInCapitalMember2019-12-310001124524us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001124524us-gaap:OverAllotmentOptionMember2019-06-240001124524us-gaap:PreferredClassBMember2021-03-310001124524us-gaap:PreferredClassAMember2021-03-310001124524us-gaap:CommonStockMember2021-03-310001124524cyrx:PreferredClassCMember2021-03-310001124524us-gaap:PreferredClassBMember2020-12-310001124524us-gaap:PreferredClassAMember2020-12-310001124524us-gaap:CommonStockMember2020-12-310001124524cyrx:PreferredClassCMember2020-12-310001124524us-gaap:PreferredClassBMember2020-03-310001124524us-gaap:PreferredClassAMember2020-03-310001124524us-gaap:CommonStockMember2020-03-310001124524cyrx:PreferredClassCMember2020-03-310001124524us-gaap:PreferredClassBMember2019-12-310001124524us-gaap:PreferredClassAMember2019-12-310001124524us-gaap:CommonStockMember2019-12-310001124524cyrx:PreferredClassCMember2019-12-310001124524us-gaap:EmployeeStockOptionMember2020-12-310001124524us-gaap:EmployeeStockOptionMembercyrx:Plan2018Member2021-03-310001124524us-gaap:EmployeeStockOptionMembercyrx:Plan2018Member2018-05-310001124524us-gaap:RestrictedStockUnitsRSUMember2020-12-310001124524us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-03-310001124524us-gaap:CostOfSalesMember2021-01-012021-03-310001124524cyrx:EngineeringAndDevelopmentMember2021-01-012021-03-310001124524us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-03-310001124524us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-03-310001124524us-gaap:CostOfSalesMember2020-01-012020-03-310001124524cyrx:EngineeringAndDevelopmentMember2020-01-012020-03-310001124524cyrx:ReproductiveMedicineMembercyrx:GlobalLogisticsSolutionsMember2021-01-012021-03-310001124524cyrx:BiopharmaceuticalMembercyrx:GlobalLogisticsSolutionsMember2021-01-012021-03-310001124524cyrx:AnimalHealthMembercyrx:GlobalLogisticsSolutionsMember2021-01-012021-03-310001124524us-gaap:EMEAMember2021-01-012021-03-310001124524srt:AsiaPacificMember2021-01-012021-03-310001124524srt:AmericasMember2021-01-012021-03-310001124524cyrx:GlobalLogisticsSolutionsMember2021-01-012021-03-310001124524cyrx:ForeignCustomersMember2021-01-012021-03-310001124524cyrx:ReproductiveMedicineMembercyrx:GlobalLogisticsSolutionsMember2020-01-012020-03-310001124524cyrx:BiopharmaceuticalMembercyrx:GlobalLogisticsSolutionsMember2020-01-012020-03-310001124524cyrx:AnimalHealthMembercyrx:GlobalLogisticsSolutionsMember2020-01-012020-03-310001124524us-gaap:EMEAMember2020-01-012020-03-310001124524srt:AsiaPacificMember2020-01-012020-03-310001124524srt:AmericasMember2020-01-012020-03-310001124524cyrx:GlobalLogisticsSolutionsMember2020-01-012020-03-310001124524srt:MinimumMemberus-gaap:ComputerEquipmentMember2021-01-012021-03-310001124524srt:MinimumMemberus-gaap:BuildingMember2021-01-012021-03-310001124524srt:MinimumMembercyrx:TruckAndAutoMember2021-01-012021-03-310001124524srt:MinimumMembercyrx:FreezerMember2021-01-012021-03-310001124524srt:MinimumMembercyrx:EquipmentAndFurnitureMember2021-01-012021-03-310001124524srt:MaximumMemberus-gaap:ComputerEquipmentMember2021-01-012021-03-310001124524srt:MaximumMemberus-gaap:BuildingMember2021-01-012021-03-310001124524srt:MaximumMembercyrx:TruckAndAutoMember2021-01-012021-03-310001124524srt:MaximumMembercyrx:FreezerMember2021-01-012021-03-310001124524srt:MaximumMembercyrx:EquipmentAndFurnitureMember2021-01-012021-03-310001124524us-gaap:OverAllotmentOptionMember2019-06-242019-06-240001124524us-gaap:ConvertiblePreferredStockMember2021-03-310001124524cyrx:ClassCConvertiblePreferredStockMember2021-03-310001124524cyrx:ClassBConvertiblePreferredStockMember2021-03-310001124524us-gaap:ConvertiblePreferredStockMember2020-12-310001124524cyrx:ClassCConvertiblePreferredStockMember2020-12-310001124524cyrx:ClassBConvertiblePreferredStockMember2020-12-310001124524cyrx:ClassCConvertiblePreferredStockMemberus-gaap:PrivatePlacementMember2020-10-010001124524cyrx:ClassCConvertiblePreferredStockMember2021-02-050001124524cyrx:MveCryobiologicalStorageBusinessMember2020-08-242020-08-2400011245242020-05-012020-05-310001124524us-gaap:USTreasurySecuritiesMember2021-03-310001124524cyrx:MutualFundsMember2021-03-310001124524us-gaap:USTreasurySecuritiesMember2020-12-310001124524cyrx:MutualFundsMember2020-12-310001124524cyrx:InstallmentTwoMembercyrx:CryopdpMember2021-03-310001124524cyrx:InstallmentOneMembercyrx:CryopdpMember2021-03-310001124524cyrx:MveCryobiologicalStorageBusinessMember2021-01-012021-03-310001124524cyrx:MveCryobiologicalStorageBusinessMember2021-03-310001124524cyrx:CryopdpMember2020-10-010001124524us-gaap:UseRightsMember2021-01-012021-03-310001124524us-gaap:TrademarksAndTradeNamesMember2021-01-012021-03-310001124524us-gaap:TechnologyBasedIntangibleAssetsMember2021-01-012021-03-310001124524us-gaap:OrderOrProductionBacklogMember2021-01-012021-03-310001124524us-gaap:NoncompeteAgreementsMember2021-01-012021-03-310001124524us-gaap:CustomerRelationshipsMember2021-01-012021-03-310001124524cyrx:PatentsAndTrademarksMember2021-01-012021-03-310001124524cyrx:AgentNetworkMember2021-01-012021-03-310001124524us-gaap:UseRightsMember2020-01-012020-12-310001124524us-gaap:TrademarksAndTradeNamesMember2020-01-012020-12-310001124524us-gaap:TechnologyBasedIntangibleAssetsMember2020-01-012020-12-310001124524us-gaap:OrderOrProductionBacklogMember2020-01-012020-12-310001124524us-gaap:NoncompeteAgreementsMember2020-01-012020-12-310001124524us-gaap:CustomerRelationshipsMember2020-01-012020-12-310001124524cyrx:PatentsAndTrademarksMember2020-01-012020-12-310001124524cyrx:AgentNetworkMember2020-01-012020-12-310001124524us-gaap:UseRightsMember2021-03-310001124524us-gaap:TrademarksAndTradeNamesMember2021-03-310001124524us-gaap:TechnologyBasedIntangibleAssetsMember2021-03-310001124524us-gaap:OrderOrProductionBacklogMember2021-03-310001124524us-gaap:NoncompeteAgreementsMember2021-03-310001124524us-gaap:CustomerRelationshipsMember2021-03-310001124524cyrx:PatentsAndTrademarksMember2021-03-310001124524cyrx:AgentNetworkMember2021-03-310001124524us-gaap:UseRightsMember2020-12-310001124524us-gaap:TrademarksAndTradeNamesMember2020-12-310001124524us-gaap:TechnologyBasedIntangibleAssetsMember2020-12-310001124524us-gaap:OrderOrProductionBacklogMember2020-12-310001124524us-gaap:NoncompeteAgreementsMember2020-12-310001124524us-gaap:CustomerRelationshipsMember2020-12-310001124524cyrx:PatentsAndTrademarksMember2020-12-310001124524cyrx:AgentNetworkMember2020-12-310001124524us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-03-310001124524us-gaap:EmployeeStockOptionMember2021-01-012021-03-310001124524cyrx:ClassCConvertiblePreferredStockMember2020-01-012020-12-310001124524us-gaap:ConvertibleDebtMember2020-05-310001124524us-gaap:PrivatePlacementMember2020-05-3100011245242020-05-310001124524us-gaap:SeniorNotesMember2021-03-310001124524us-gaap:WarrantMember2021-03-312021-03-310001124524us-gaap:SeniorNotesMember2021-01-012021-03-310001124524us-gaap:ServiceMember2021-01-012021-03-310001124524us-gaap:ProductMember2021-01-012021-03-310001124524us-gaap:ServiceMember2020-01-012020-03-310001124524cyrx:ClassCConvertiblePreferredStockMember2020-10-010001124524cyrx:ForeignCustomersMemberus-gaap:RevenueFromContractWithCustomerMember2021-01-012021-03-310001124524cyrx:CustomerOneMemberus-gaap:RevenueFromContractWithCustomerMember2021-01-012021-03-310001124524cyrx:CustomerOneMemberus-gaap:AccountsReceivableMember2021-01-012021-03-310001124524cyrx:CustomerTwoMemberus-gaap:RevenueFromContractWithCustomerMember2020-01-012020-03-310001124524cyrx:CustomerThreeMemberus-gaap:RevenueFromContractWithCustomerMember2020-01-012020-03-310001124524cyrx:CustomerOneMemberus-gaap:RevenueFromContractWithCustomerMember2020-01-012020-03-310001124524cyrx:ForeignCustomersMember2020-01-012020-03-310001124524us-gaap:CommonStockMember2021-02-0500011245242020-10-010001124524us-gaap:RestrictedStockUnitsRSUMember2021-03-310001124524us-gaap:EmployeeStockOptionMember2021-03-310001124524cyrx:ClassCConvertiblePreferredStockMember2021-03-3100011245242021-03-112021-03-1100011245242020-03-310001124524cyrx:MveCryobiologicalStorageBusinessMember2020-10-010001124524cyrx:CryopdpMember2021-03-310001124524cyrx:CriticalTransportSolutionsAustraliaPtyLtdMemberus-gaap:SubsequentEventMember2021-04-012021-04-010001124524cyrx:MveCryobiologicalStorageBusinessMember2020-10-012020-10-010001124524cyrx:CryopdpMember2020-10-012020-10-010001124524us-gaap:USTreasuryNotesSecuritiesMember2021-03-310001124524us-gaap:USTreasuryNotesSecuritiesMember2020-12-310001124524us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001124524us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001124524us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001124524us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryNotesSecuritiesMember2021-03-310001124524us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MutualFundMember2021-03-310001124524us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryNotesSecuritiesMember2021-03-310001124524us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MutualFundMember2021-03-310001124524us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryNotesSecuritiesMember2021-03-310001124524us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MutualFundMember2021-03-310001124524us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001124524us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryNotesSecuritiesMember2021-03-310001124524us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MutualFundMember2021-03-310001124524us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001124524us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001124524us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001124524us-gaap:FairValueMeasurementsRecurringMember2021-03-310001124524us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001124524us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001124524us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001124524us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryNotesSecuritiesMember2020-12-310001124524us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MutualFundMember2020-12-310001124524us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryNotesSecuritiesMember2020-12-310001124524us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MutualFundMember2020-12-310001124524us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryNotesSecuritiesMember2020-12-310001124524us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MutualFundMember2020-12-310001124524us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001124524us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryNotesSecuritiesMember2020-12-310001124524us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MutualFundMember2020-12-310001124524us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001124524us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001124524us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001124524us-gaap:FairValueMeasurementsRecurringMember2020-12-310001124524us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-03-310001124524us-gaap:EmployeeStockOptionMember2021-01-012021-03-310001124524cyrx:ConvertibleSeniorNotesMember2021-01-012021-03-310001124524cyrx:ClassCConvertiblePreferredStockMember2021-01-012021-03-310001124524us-gaap:WarrantMember2020-01-012020-03-310001124524us-gaap:EmployeeStockOptionMember2020-01-012020-03-3100011245242020-07-012020-09-3000011245242019-12-310001124524cyrx:PublicOfferingMember2021-01-012021-03-3100011245242021-04-230001124524us-gaap:PrivatePlacementMember2020-05-012020-05-310001124524us-gaap:RetainedEarningsMember2021-01-012021-03-310001124524us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001124524us-gaap:RetainedEarningsMember2020-01-012020-03-310001124524us-gaap:PreferredClassBMember2020-01-012020-03-310001124524us-gaap:PreferredClassAMember2020-01-012020-03-310001124524us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-310001124524us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310001124524us-gaap:PreferredClassBMember2021-01-012021-03-310001124524us-gaap:PreferredClassAMember2021-01-012021-03-310001124524us-gaap:CommonStockMember2021-01-012021-03-310001124524us-gaap:CommonStockMember2020-01-012020-03-310001124524cyrx:PreferredClassCMember2020-01-012020-03-3100011245242020-06-292020-06-290001124524cyrx:PreferredStockRedemptionPeriodOneMembercyrx:ClassCConvertiblePreferredStockMember2021-02-052021-02-050001124524cyrx:PreferredStockRedemptionPeriodTwoMembercyrx:ClassCConvertiblePreferredStockMember2020-10-012020-10-010001124524cyrx:PreferredStockRedemptionPeriodThreeMembercyrx:ClassCConvertiblePreferredStockMember2020-10-012020-10-010001124524cyrx:PreferredStockRedemptionPeriodOneMembercyrx:ClassCConvertiblePreferredStockMember2020-10-012020-10-010001124524us-gaap:CommonStockMember2021-02-052021-02-0500011245242021-02-052021-02-050001124524cyrx:CryopdpMember2020-08-212020-08-210001124524srt:DirectorMember2021-01-012021-03-310001124524srt:DirectorMember2020-01-012020-03-310001124524us-gaap:RevenueFromContractWithCustomerMember2021-01-012021-03-310001124524us-gaap:AccountsReceivableMember2021-01-012021-03-310001124524us-gaap:AccountsReceivableMember2020-01-012020-12-310001124524us-gaap:RevenueFromContractWithCustomerMember2020-01-012020-03-310001124524cyrx:ClassCConvertiblePreferredStockMember2020-10-012020-10-010001124524us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2020-10-012020-10-010001124524cyrx:ClassCConvertiblePreferredStockMemberus-gaap:PrivatePlacementMember2020-10-012020-10-010001124524us-gaap:PrivatePlacementMember2020-10-012020-10-010001124524srt:MinimumMember2021-01-012021-03-310001124524srt:MaximumMember2021-01-012021-03-3100011245242020-10-012020-10-010001124524cyrx:ScenarioTwoMember2021-01-012021-03-310001124524cyrx:ScenarioOneMember2021-01-012021-03-3100011245242020-01-012020-03-3100011245242020-01-012020-12-3100011245242021-03-3100011245242020-12-310001124524cyrx:PreferredClassCMember2021-01-012021-03-310001124524us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-3100011245242021-01-012021-03-310001124524cyrx:CryopdpMember2021-01-012021-03-31iso4217:USDcyrx:itemxbrli:purecyrx:customercyrx:directoriso4217:USDxbrli:sharesxbrli:sharesiso4217:EUR

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2021

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______ to ______.

Commission File Number: 001-34632

Graphic

CRYOPORT, INC.

(Exact Name of Registrant as Specified in its Charter)

Nevada

88-0313393

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer
Identification No.)

112 Westwood Place, Suite 350

Brentwood, TN 37027

(Address of principal executive offices, including zip code)

(949470-2300

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:

    

Trading Symbol(s)

    

Name of each exchange on which registered:

Common Stock, $0.001 par value

 CYRX

The Nasdaq Stock Market LLC (The Nasdaq Capital Market)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

  

Smaller reporting company

Emerging growth company

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   Yes      No  

As of April 23, 2021 there were 45,681,456 shares of the registrant’s common stock outstanding.

TABLE OF CONTENTS

 

Page

PART I. FINANCIAL INFORMATION

3

ITEM 1. Financial Statements

3

Condensed Consolidated Balance Sheets at March 31, 2021 (Unaudited) and December 31, 2020

3

Unaudited Condensed Consolidated Statements of Operations for the three months ended March 31, 2021 and 2020

4

Unaudited Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2021 and 2020

5

Unaudited Condensed Consolidated Statements of Stockholders’ Equity for the three months ended March 31, 2021 and 2020

6

Unaudited Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2021 and 2020

7

Notes to Condensed Consolidated Financial Statements (Unaudited)

8

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

33

ITEM 3. Quantitative and Qualitative Disclosures About Market Risk

41

ITEM 4. Controls and Procedures

42

PART II. OTHER INFORMATION

43

ITEM 1. Legal Proceedings

43

ITEM 1A. Risk Factors

43

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds

43

ITEM 3. Defaults Upon Senior Securities

43

ITEM 4. Mine Safety Disclosures

43

ITEM 5. Other Information

43

ITEM 6. Exhibits

44

SIGNATURES

45

2

PART I. FINANCIAL INFORMATION

ITEM 1. Financial Statements

Cryoport, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(in thousands, except share data)

March 31, 

December 31, 

2021

    

2020

(unaudited)

ASSETS

Current Assets:

  

  

Cash and cash equivalents

$

85,494

$

36,873

Short-term investments

 

267,721

 

56,444

Accounts receivable, net

 

36,504

 

31,377

Inventories

 

11,544

 

10,535

Prepaid expenses and other current assets

 

18,485

 

11,928

Total current assets

 

419,748

 

147,157

Property and equipment, net

 

31,694

30,036

Operating lease right-of-use assets

15,996

14,044

Intangible assets, net

 

209,267

213,908

Goodwill

141,305

145,282

Deposits

 

946

1,184

Other long-term assets

752

794

Total assets

$

819,708

$

552,405

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

  

 

  

Current Liabilities:

 

  

 

  

Accounts payable and other accrued expenses

$

27,083

$

24,844

Accrued compensation and related expenses

 

8,233

7,441

Deferred revenue

 

495

445

Operating lease liabilities

2,002

2,231

Finance lease liabilities

 

60

59

Total current liabilities

 

37,873

 

35,020

Convertible senior notes, net of discount of $3.5 million and $3.7 million, respectively

 

111,536

 

111,344

Note payable, net of discount of $1.2 million and $0, respectively

3,497

4,912

Operating lease liabilities, net of current portion

14,502

12,261

Finance lease liabilities, net of current portion

92

112

Deferred tax liability

4,626

5,882

Other long-term liabilities

307

176

Total liabilities

 

172,433

 

169,707

Commitments and contingencies

 

  

 

  

Stockholders’ Equity:

 

  

 

  

Preferred stock, $0.001 par value; 2,500,000 shares authorized:

 

  

 

  

Class A convertible preferred stock — $0.001 par value; 800,000 shares authorized; none issued and outstanding

 

 

Class B convertible preferred stock — $0.001 par value; 585,000 shares authorized; none issued and outstanding

 

 

Class C convertible preferred stock, $0.001 par value; 250,000 shares authorized; 200,000 issued and outstanding

4,275

2,844

Common stock, $0.001 par value; 100,000,000 shares authorized; 45,693,692 and 39,837,058 issued and outstanding at March 31, 2021 and December 31, 2020, respectively

45

40

Additional paid-in capital

 

837,615

 

566,451

Accumulated deficit

 

(195,540)

 

(192,013)

Accumulated other comprehensive income

 

880

 

5,376

Total stockholders’ equity

 

647,275

 

382,698

Total liabilities and stockholders’ equity

$

819,708

$

552,405

See accompanying notes to condensed consolidated financial statements.

3

Cryoport, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(in thousands, except share and per share data)

(unaudited)

Three Months Ended

March 31, 

    

2021

    

2020

    

Service revenues

$

26,765

$

9,774

Product revenues

26,519

Total revenues

53,284

9,774

Cost of service revenues

15,552

4,516

Cost of product revenues

 

13,182

 

Total cost of revenues

28,734

4,516

Gross margin

 

24,550

 

5,258

 

  

 

  

Operating costs and expenses:

 

  

 

  

Selling, general and administrative

 

21,388

 

7,111

Engineering and development

 

4,304

 

1,733

Total operating costs and expenses

 

25,692

 

8,844

 

 

Loss from operations

 

(1,142)

 

(3,586)

Other income (expense):

 

  

 

  

Investment income

398

307

Interest expense

 

(1,210)

 

(2)

Other expense, net

 

(535)

 

(628)

Total other expense, net

(1,347)

 

(323)

Loss before provision for income taxes

 

(2,489)

 

(3,909)

Provision for income taxes

 

(1,038)

 

(33)

Net loss

$

(3,527)

$

(3,942)

Paid-in-kind dividend on Series C convertible preferred stock

(2,196)

Net loss attributable to common stockholders

$

(5,723)

$

(3,942)

Net loss per share attributable to common stockholders – basic and diluted

$

(0.13)

$

(0.11)

Weighted average common shares outstanding – basic and diluted

 

43,804,483

 

37,548,549

See accompanying notes to condensed consolidated financial statements.

4

Cryoport, Inc. and Subsidiaries

Condensed Consolidated Statements of Comprehensive Loss

(in thousands)

For the Three Months Ended

March 31, 

    

2021

    

2020

Net loss

$

(3,527)

$

(3,942)

Other comprehensive income (loss), net of tax:

 

  

 

  

Net unrealized gain (loss) on available-for-sale debt securities

 

(768)

 

471

Reclassification of realized (gain) loss on available-for-sale debt securities to earnings

30

(1)

Foreign currency translation adjustments

 

(3,758)

 

(2)

Other comprehensive income (loss)

 

(4,496)

 

468

Total comprehensive loss

$

(8,023)

$

(3,474)

5

Cryoport, Inc. and Subsidiaries

Condensed Consolidated Statements of Stockholders’ Equity

(In thousands, except share data)

Other 

Class A

Class B

Class C

Comprehensive 

Total 

Preferred Stock

Preferred Stock

Preferred Stock

Common Stock

Additional

Accumulated 

Income

Stockholders’

    

Shares

    

Amount

    

Shares

    

Amount

    

Shares

    

Amount

    

Shares

    

Amount

    

Paid–In Capital

    

Deficit

    

(Loss)

    

Equity  (Deficit)

Balance at December 31, 2019

 

$

 

$

$

 

37,339,787

$

37

$

285,609

$

(159,320)

$

(45)

$

126,281

Net loss

 

 

 

 

 

 

 

 

 

(3,942)

 

 

(3,942)

Other comprehensive income, net of taxes

 

 

 

 

 

 

 

 

 

 

468

 

468

Stock-based compensation expense

 

 

 

 

 

 

 

 

1,600

 

 

 

1,600

Issuance of common stock for board of director compensation

 

 

 

 

 

 

1,269

 

 

21

 

 

 

21

Proceeds from exercise of common stock options and warrants

 

 

 

 

 

 

589,199

 

1

 

2,877

 

 

 

2,878

Balance at March 31, 2020

$

$

$

37,930,255

$

38

$

290,107

$

(163,262)

$

423

$

127,306

Balance at December 31, 2020

 

 

250,000

2,844

 

39,837,058

40

566,451

(192,013)

5,376

382,698

Net loss

 

 

 

 

 

 

 

 

 

(3,527)

 

 

(3,527)

Other comprehensive loss, net of taxes

(4,496)

(4,496)

Stock-based compensation expense

 

 

 

 

 

 

 

 

2,979

 

 

 

2,979

Issuance of common stock for board of director compensation

 

 

 

 

 

 

229

 

 

11

 

 

 

11

Cost of Series C preferred stock conversion

(1,800)

(1,800)

Issuance of common stock in public offering, net of costs of $17.7 million

4,356,059

4

269,821

269,825

Conversion of Series C preferred shares to common stock

(50,000)

(765)

1,312,860

1

764

Paid-in-kind preferred stock dividend, including beneficial conversion feature

2,196

(2,196)

Proceeds from exercise of stock options and warrants

 

 

 

 

 

 

187,486

 

 

1,585

 

 

 

1,585

Balance at March 31, 2021

 

$

 

$

200,000

$

4,275

 

45,693,692

$

45

$

837,615

$

(195,540)

$

880

$

647,275

See accompanying notes to condensed consolidated financial statements.

6

Cryoport, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(unaudited, in thousands)

For the Three Months Ended

March 31, 

    

2021

    

2020

Cash Flows From Operating Activities:

 

  

 

  

Net loss

$

(3,527)

$

(3,942)

Adjustments to reconcile net loss to net cash used in operating activities:

 

  

 

Depreciation and amortization

 

4,837

 

824

Amortization of debt discount

 

264

 

Unrealized loss (gain) on investments in equity securities

 

263

 

(144)

Realized loss on investments in equity securities

793

Realized loss (gain) on available-for-sale investments

40

(11)

Stock-based compensation expense

 

2,990

 

1,620

Loss on disposal of property and equipment

 

71

 

80

Provision for bad debt

 

63

 

4

Changes in operating assets and liabilities:

Accounts receivable

 

(5,213)

 

955

Inventories

 

(988)

 

9

Prepaid expenses and other current assets

 

(6,545)

 

95

Deposits

 

229

 

(46)

Change in operating lease right-of-use assets and lease liabilities

60

7

Accounts payable and other accrued expenses

 

532

 

65

Accrued compensation and related expenses

 

804

 

768

Deferred revenue

 

49

 

(27)

Deferred tax liability

80

9

Net cash provided by (used in) operating activities

 

(5,991)

 

1,059

 

  

 

Cash Flows From Investing Activities:

 

  

 

Purchases of property and equipment

 

(2,811)

 

(596)

Software development costs

 

(193)

 

Purchases of short-term investments

(215,318)

(16,195)

Sales/maturities of short-term investments

 

3,000

 

16,279

Patent and trademark costs

(48)

(30)

Net cash used in investing activities

 

(215,370)

 

(542)

 

  

 

Cash Flows From Financing Activities:

 

  

 

Proceeds from exercise of stock options and warrants

 

1,586

 

2,878

Proceeds from public offering, net of $17.7 million in offering costs

269,825

Repayment of finance lease liabilities

(18)

(14)

Net cash provided by financing activities

 

271,393

 

2,864

 

 

Effect of exchange rates on cash and cash equivalents

 

(1,411)

 

7

Net change in cash and cash equivalents

48,621

 

3,388

Cash and cash equivalents — beginning of period

 

36,873

 

47,234

Cash and cash equivalents — end of period

$

85,494

$

50,622

Supplemental Disclosure of Non-Cash Financing Activities:

Conversion of Series C Preferred Stock to common stock

$

765

$

Cost of Series C Preferred stock conversion included in additional paid-in-capital and accounts payable and accrued liabilities

$

1,800

$

CRYOPDP goodwill adjustment included in deferred tax liability

$

1,394

$

CRYOPDP goodwill adjustment included in fixed assets

$

71

$

Note valuation adjustment included in note payable and goodwill

$

1,266

$

Net unrealized gain on available-for-sale securities

$

768

$

471

Reclassification of realized gain on available-for-sale debt securities to earnings

$

30

$

Purchase of equipment through capital lease obligations

$

$

203

Fixed assets included in accounts payable and accrued liabilities

$

198

$

608

See accompanying notes to condensed consolidated financial statements.

7

Cryoport, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

For the Three Months Ended March 31, 2021 and 2020

(Unaudited)

Note 1. Management’s Representation and Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared by Cryoport, Inc. (the “Company”, “Cryoport”, “our” or “we”) in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X promulgated by the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statement presentation. However, the Company believes that the disclosures are adequate to make the information presented not misleading. In the opinion of management, all adjustments (consisting primarily of normal recurring accruals) considered necessary for a fair presentation have been included.

Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. The unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

The Company has evaluated subsequent events through the date of this filing and determined that no subsequent events have occurred that would require recognition in the unaudited condensed consolidated financial statements or disclosure in the notes thereto other than as disclosed in the accompanying notes.

Note 2. Nature of the Business

Cryoport is a life sciences services company that is an integral part of the temperature-controlled supply chain supporting the biopharma/pharma, animal health, and reproductive medicine markets. We are redefining logistics for the life sciences industry by providing a unique platform of critical solutions including highly differentiated temperature-controlled supply chain solutions, which include advanced packaging, informatics, specialty logistics services, biostorage services and cryogenic life sciences equipment. Through our products, services and expertise, we enable our clients to ship, store and deliver cellular-based materials and drug products as well as other life sciences commodities in a precise, defined temperature-controlled state.

Cryoport’s advanced platform, comprised of comprehensive and technology-centric systems and solutions are designed to support the global high-volume distribution of commercial biologic and cell-based products and therapies regulated by the United States Food and Drug Administration (FDA) and other international regulatory bodies for distribution in the Americas, EMEA (Europe, the Middle East, and Africa) and APAC (Asia-Pacific) regions. Cryoport’s solutions are also designed to support pre-clinical, clinical trials, Biologics License Applications (BLA), Investigational New Drug Applications (IND), New Drug Applications (NDA) and Commercialized Products with the FDA, as well as global clinical trials and commercialized products initiated in other countries, where strict regulatory compliance and quality assurance is mandated. Our industry standard setting Chain of ComplianceTM solutions, which include vital analytics, such as ‘chain-of-condition’ and ‘chain-of-custody’ information in a single data stream, empower our clients’ continuous vigilance over their respective commodities. In addition, our Chain of ComplianceTM standard ensures full traceability of all equipment used and the processes employed, further supporting each client’s goal of minimizing risk and maximizing success of their respective biologics or other products and therapies as they are introduced into the global markets.

On August 21, 2020, the Company entered into a Securities Purchase Agreement to acquire CRYOPDP, a leading global provider of innovative temperature-controlled logistics solutions to the clinical research, pharmaceutical and cell and gene therapy markets, headquartered in Paris, France. Under the terms of the Securities Purchase Agreement, the Company acquired 100% of the equity interests in Advanced Therapy Logistics and Solutions, a company organized under the laws of France, which is the holding company that owns CRYOPDP (the “CRYOPDP Acquisition”). The purchase price under the Securities Purchase Agreement was €49 million (approximately $58.0 million).

8

On August 24, 2020, the Company entered into a Purchase Agreement with Chart Industries, Inc. (“Chart”) pursuant to which the Company acquired Chart’s MVE Biological Solutions’ cryobiological storage business (the “MVE Acquisition”) for a cash purchase price at closing of $320 million, subject to customary closing working capital and other adjustments. The MVE Acquisition was structured as the acquisition of certain equity interests and assets and the transfer of certain liabilities in connection therewith.

On October 1, 2020, the Company completed both the MVE Acquisition and the CRYOPDP Acquisition.

The Company is a Nevada corporation and its common stock is traded on the NASDAQ Capital Market exchange under the ticker symbol “CYRX.”

Note 3. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Cryoport, Inc. and its wholly-owned subsidiaries, Cryoport Systems, LLC, Cryogene, Inc., MVE Biological Solutions US LLC, and Cryoport Netherlands B.V. and subsidiaries (collectively, the “Company”). All intercompany accounts and transactions have been eliminated.

Cash and Cash Equivalents

Our cash and cash equivalents represent demand deposits, and money market funds which are readily convertible into cash, have maturities of 90 days or less when purchased and are considered highly liquid and easily tradeable.

Short-Term Investments

Our investments in equity securities consist of mutual funds with readily determinable fair values which are carried at fair value with changes in fair value recognized in earnings.

Investments in debt securities are classified as available-for-sale and are carried at fair value, with unrealized gains and losses, net of tax, reported as accumulated other comprehensive income (loss) and included as a separate component of stockholders’ equity.

Gains and losses are recognized when realized. When we have determined that an other than temporary decline in fair value has occurred, the amount related to a credit loss is recognized in earnings. Gains and losses are determined using the specific identification method.

Short-term investments are classified as current assets even though maturities may extend beyond one year because they represent investments of cash available for operations.

Use of Estimates

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from estimated amounts. The Company’s significant estimates include the allowance for doubtful accounts, fair value of short-term investments, valuations and purchase price allocations related to business combinations, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, intangible asset useful lives and amortization methods, allowance for inventory obsolescence, equity-based instruments, tax reserves and recoverability of the Company’s net deferred tax assets and related valuation allowance.

9

Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.

Future events, including the extent and the duration of the COVID-19 related economic impacts, and their effects cannot be predicted with certainty, and, accordingly the Company’s accounting estimates require the exercise of judgment.

Fair Value of Financial Instruments

The Company’s financial instruments consist of cash and cash equivalents, short-term investments, accounts receivable, accounts payable and accrued expenses, finance lease liabilities, note payable, and the Company’s 3.00% convertible senior notes due in 2025 (the “Senior Notes”). The carrying value for all such instruments, except finance lease liabilities, note payable and the Senior Notes, approximates fair value at March 31, 2021 and December 31, 2020 due to their short-term nature. The carrying value of finance lease liabilities approximates fair value because the interest rate approximates market rates available to us for similar obligations with the same maturities. For additional information related to fair value measurements, including the note payable and the Senior Notes, see Notes 9 and 10.

Concentrations of Credit Risk

Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. From time to time, we maintain cash, cash equivalent and short-term investment balances in excess of amounts insured by the Federal Deposit Insurance Corporation (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”).  Primarily all of our cash, cash equivalents and short-term investments at March 31, 2021 were in excess of amounts insured by the FDIC and SIPC.  The Company performs ongoing evaluations of these institutions to limit its concentration risk exposure.  We manage such risks in our portfolio by investing in highly liquid, highly-rated instruments, and limit investing in long-term maturity instruments.

Our investment policy requires that purchased instruments in marketable securities may only be in highly-rated instruments, which are primarily U.S. Treasury bills or treasury-backed securities, and also limits our investment in securities of any single issuer.

Customers

The Company grants credit to customers within the U.S. and international customers and does not require collateral. Revenues from international customers are generally secured by advance payments except for established foreign customers. The Company generally requires advance or credit card payments for initial revenues from new customers. The Company’s ability to collect receivables can be affected by economic fluctuations in the geographic areas and industries served by the Company. Reserves for uncollectible amounts are provided based on past experience and a specific analysis of the accounts, which management believes to be sufficient. Accounts receivable at March 31, 2021 and December 31, 2020 are net of reserves for doubtful accounts of $1.2 million and $1.1 million, respectively. Although the Company expects to collect amounts due, actual collections may differ from the estimated amounts. The Company maintains reserves for bad debt and such losses, in the aggregate, historically have not exceeded its estimates.

The Company’s customers are in the biopharma, pharmaceutical, animal health, reproductive medicine and other life science industries. Consequently, there is a concentration of accounts receivable within these industries, which is subject to normal credit risk. At March 31, 2021, there was one customer that accounted for 10.5% of net accounts receivable. At December 31, 2020, there were no customers that accounted for more than 10% of net accounts receivable. There were no other single customers that owed us more than 10% of net accounts receivable at March 31, 2021 and December 31, 2020.

The Company has revenue from foreign customers primarily in United Kingdom, Switzerland, France, Netherlands, Singapore, China and India. During the three months ended March 31, 2021 and 2020, the Company had revenues from foreign customers of approximately $25.5 million and $2.1 million, respectively, which constituted approximately 48.0% and 21.4%, respectively, of total revenues. There was one customer that accounted for 12.5% of revenues during the three months ended March 31, 2021. There were three customers that accounted for 17.9%, 16.7% and 10.8% of revenues during the three months ended March 31, 2020, respectively. No other single customer generated over 10% of revenues during the three months ended March 31, 2021 and 2020.

10

Inventories

Inventories are stated at the lower of cost and net realizable value. Cost is determined using the first-in, first-out (“FIFO”) method. Inventories are reviewed periodically for slow-moving or obsolete status. The Company writes down the carrying value of its inventories to reflect situations in which the cost of inventories is not expected to be recovered. Once established, write-downs of inventories are considered permanent adjustments to the cost basis of the obsolete or excess inventories. Raw materials and finished goods include material costs less reserves for obsolete or excess inventories. The Company evaluates the current level of inventories considering historical trends and other factors, such as selling prices and costs of completion, disposal and transportation, and based on the evaluation, records adjustments to reflect inventories at net realizable value. These adjustments are estimates, which could vary significantly from actual results if future economic conditions, customer demand, competition or other relevant factors differ from expectations. These estimates require us to make assessments about future demand for the Company’s products in order to categorize the status of such inventories items as slow-moving, obsolete or in excess-of-need. These estimates are subject to the ongoing accuracy of the Company’s forecasts of market conditions, industry trends, competition and other factors.

Property and Equipment

Property and equipment are stated at cost, less accumulated depreciation.  We compute depreciation using the straight-line method over the estimated useful lives of the assets which is generally three to twelve years for computer hardware and software, seven to ten years for freezers, four to ten years for trucks and autos, three to fifteen years for furniture and equipment and over the shorter of the lease term or useful live of the assets for leasehold improvements. Buildings are depreciated over a useful life ranging from 20 to 45 years. Maintenance and repairs are expensed as incurred.

Betterments, renewals and extraordinary repairs that extend the lives of the assets are capitalized; other repairs and maintenance charges are expensed as incurred. The cost and related accumulated depreciation and amortization applicable to assets retired are removed from the accounts, and the gain or loss on disposition is recognized in the consolidated statements of operations.

Leases

The Company determines if an arrangement is a lease at inception. Operating lease right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset during the lease term, and operating lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating leases are included in ROU assets, current operating lease liabilities, and long-term operating lease liabilities on our consolidated balance sheets. Finance leases are included in property and equipment, current finance lease liabilities, and long-term finance lease liabilities on our consolidated balance sheets.

Lease ROU assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments over the lease term at commencement date calculated using our incremental borrowing rate applicable to the lease asset, unless the implicit rate is readily determinable. ROU assets also include any lease payments made at or before lease commencement and exclude any lease incentives received. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets. The Company’s leases do not contain any residual value guarantees. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.

The Company accounts for lease and non-lease components as a single lease component for all its leases.

Business Combinations

Total consideration transferred for acquisitions is allocated to the assets acquired and liabilities assumed based on their fair values at the dates of acquisition. This purchase price allocation process requires management to make significant estimates and assumptions primarily with respect to intangible assets. The fair value of identifiable intangible assets is based on detailed valuations that use information and assumptions determined by management. Any excess of purchase price over the fair value of the net tangible and intangible assets acquired is allocated to goodwill. While the Company uses its best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date as well as any contingent consideration, where applicable, the Company’s estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company records adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill.

11

Goodwill

The Company evaluates goodwill on an annual basis in the fourth quarter or more frequently if management believes indicators of impairment exist. Such indicators could include, but are not limited to: (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. The Company compares the fair value of the reporting unit’s with its carrying amount and then recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting units fair value up to the total amount of goodwill allocated to the reporting unit. The Company assessed  triggering events indicating potential goodwill impairment, including the effects of the COVID-19 pandemic, and after assessment, concluded that there was no impairment during the three months ended March 31, 2021.

Intangible Assets

Intangible assets are comprised of patents, trademarks, software development costs and the intangible assets acquired in the MVE, CRYOPDP and Cryogene acquisitions which include a non-compete agreement, technology, customer relationships, trade name/trademark, agent network, order backlog, developed technology and land use rights. The Company capitalizes costs of obtaining patents and trademarks, which are amortized, using the straight-line method over their estimated useful life of five years once the patent or trademark has been issued. The non-compete agreement, technology, customer relationships, trade name/trademark, agent network, order backlog, developed technology and land use rights, acquired in the MVE, CRYOPDP and Cryogene acquisitions are amortized using the straight-line method over the estimated useful lives (see Note 8). The Company uses the following valuation methodologies to value the significant intangible assets acquired: income approach for customer relationships, replacement cost for agent network and software, and relief from royalty for trade name/trademarks and developed technology.

The Company evaluates the recoverability of identifiable intangible assets whenever events or changes in circumstances indicate that an intangible asset's carrying amount may not be recoverable. Such circumstances could include, but are not limited to: (1) a significant decrease in the market value of an asset, (2) a significant adverse change in the extent or manner in which an asset is used, or (3) an accumulation of costs significantly in excess of the amount originally expected for the acquisition of an asset. The Company measures the carrying amount of the asset against the estimated undiscounted future cash flows associated with it. Should the sum of the expected future net cash flows be less than the carrying value of the asset being evaluated, an impairment loss would be recognized. The impairment loss would be calculated as the amount by which the carrying value of the asset exceeds its fair value. The estimate of fair value is based on various valuation techniques, including the discounted value of estimated future cash flows. The evaluation of asset impairment requires the Company to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results may differ from assumed and estimated amounts. There was no impairment of intangible assets during the three months ended March 31, 2021.

Other Long-lived Assets

If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the fair value to the carrying value. We believe the future cash flows to be received from the long-lived assets will exceed the assets’ carrying value, and accordingly, we have not recognized any impairment losses through March 31, 2021.

Deferred Financing Costs

Deferred financing costs represent costs incurred in connection with the issuance of debt instruments and equity financings. Deferred financing costs related to the issuance of debt are amortized over the term of the financing instrument using the effective interest method and are presented in the consolidated balance sheets as an offset against the related debt. Offering costs from equity financings are netted against the gross proceeds received from the equity financings.

Income Taxes

The Company accounts for income taxes under the provision of ASC 740, “Income Taxes”, or ASC 740. As of March 31, 2021 and December 31, 2020, there were no material unrecognized tax benefits included in the accompanying consolidated balance sheets that would, if recognized, affect the effective tax rate.

12

Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. Based on the weight of available evidence, the Company’s management has determined that it is not more likely than not that the U.S. based net deferred tax assets will be realized. Therefore, the Company has recorded a full valuation allowance against its U.S. based net deferred tax assets. With respect to the foreign based deferred tax assets, the Company's management has reviewed these deferred tax assets on a jurisdictional basis. Based on the weight of each jurisdiction's evidence available, the Company's management has made separate determinations for each foreign jurisdiction regarding whether it is more likely than not that a net deferred tax asset within a particular jurisdiction will be realized. The Company has recorded full valuation allowances in jurisdictions where deferred tax assets are not deemed more likely than not to be realized.

Additionally, the Company maintains a deferred tax liability related to indefinite-lived assets that have been netted against deferred tax assets that also allow for indefinite carryforward periods subject to limitations.  The remaining taxable temporary difference cannot serve as a source for future taxable income to realize federal net operating losses, due to the fact that post-2017 federal net operating losses are only eligible to offset 80% of income in a given year or in the case of state net operating losses, the state net operating losses will expire prior to the reversal of the taxable temporary difference.

The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company has immaterial accruals for interest or penalties on its consolidated balance sheets at March 31, 2021 and December 31, 2020 and has recorded only immaterial interest and/or penalties in the consolidated statements of operations for the three months ended March 31, 2021 and 2020. The Company is subject to taxation in the U.S., various state jurisdictions and in various foreign countries. As of March 31, 2021, the Company is no longer subject to U.S. federal examinations for years before 2017 and for California franchise and income tax examinations for years before 2016. However, to the extent allowed by law, the taxing authorities may have the right to examine prior periods where net operating losses were generated and carried forward and make adjustments up to the amount of the net operating loss carry forward amount. The Company is not currently under examination by U.S. federal or state jurisdictions. Our foreign subsidiaries are generally subject to examination three years following the year in which the tax obligation originated.  The years subject to audit may be extended if the entity substantially understates corporate income tax. The Company's subsidiary in India is currently under examination by the Indian tax authorities for 2012-2013, 2013-2014 and 2015-2016 tax periods. Other than India, the Company does not have any foreign subsidiaries currently under audit by their local taxing authorities.

In December of 2019, the FASB issued Accounting Standards Update (“ASU”) 2019-12 Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. The Board issued this Update as part of its Simplification Initiative to improve areas of U.S. GAAP and reduce cost and complexity while maintaining usefulness. The main provision that impacts the company is the removal of the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, discontinued operations and other comprehensive income). ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 31, 2020. Different components of the guidance require retrospective, modified retrospective or prospective adoption. The Company elected to early adopt ASU 2019-12 on January 1, 2020, and the adoption of the standard did not have a material impact to our consolidated financial statements.

On March 27, 2020, the United States enacted the Coronavirus Aid, Relief and Economic Security Act (CARES Act). The Cares Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund a nationwide effort to curtail the effect of COVID-19. The CARES Act provides sweeping tax changes in response to the COVID-19 pandemic, some of the more significant provisions are removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years, and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act. At March 31, 2021, the Company has not recorded any income tax provision/(benefit) resulting from the CARES Act mainly due the Company’s history of net operating losses generated and the maintenance of a full valuation allowance against its net deferred tax assets.  

On June 29, 2020, the State of California passed Assembly Bill 85 which suspends the California net operating loss deduction for the 2020-2022 tax years and the R&D credit usage for the same period (for credit usages in excess of $5 million). These suspensions were considered in preparation of the March 31, 2021 and December 31, 2020 financial statements.

On December 27, 2020, the United States enacted the Consolidated Appropriations Act of 2021 (“CAA”).  The CAA includes provisions extending certain CARES Act provisions and adds coronavirus relief, tax and health extenders. The Company will continue to evaluate the impact of the CAA and its impact on our financial statements in 2021 and beyond.

13

On March 11, 2021, the United States enacted the American Rescue Plan (“ARP”). The ARP includes provisions extending certain CARES Act provisions, repeals a worldwide interest allocation election, modifies the $1 million executive compensation limitation for years after 2026 and extends the employee retention credit. The Company will continue to evaluate the impact of the ARP and its impact on our financial statements in 2021 and beyond.

Revenue Recognition

Revenues are recognized when control is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods and services. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied.

Performance Obligations

At contract inception, an assessment of the goods and services promised in the contracts with customers is performed and a performance obligation is identified for each distinct promise to transfer to the customer a good or service (or bundle of goods or services). To identify the performance obligations, the Company considers all of the goods or services promised in the contract regardless of whether they are explicitly stated or are implied by customary business practices. Revenue is recognized when our performance obligation has been met. The Company considers control to have transferred upon delivery because the Company has a present right to payment at that time, the Company has transferred use of the asset, and the customer is able to direct the use of, and obtain substantially all of the remaining benefits from, the asset.

For arrangements under which the Company provides biological specimen storage services and logistics support and management to the customer, the Company satisfies its performance obligations as those services are performed whereby the customer simultaneously receives and consumes the benefits of such services under the agreement.

Revenue generated from short-term logistics and engineering consulting services provided to customers is recognized when the Company satisfies the contractually defined performance obligations. When a contract includes multiple performance obligations, the contract price is allocated among the performance obligations based upon the stand-alone selling prices. Approved contract modifications are accounted for as either a separate contract or as part of the existing contract depending on the nature of the modification.

Our performance obligations on our orders and under the terms of agreements with customers are generally satisfied within one year from a given reporting date and, therefore, we omit disclosure of the transaction price allocated to remaining performance obligations on open orders.

Shipping and handling activities related to contracts with customers are accounted for as costs to fulfill our promise to transfer the associated products pursuant to the accounting policy election allowed under Topic 606 and are not considered a separate performance obligation to our customers. Accordingly, the Company records amounts billed for shipping and handling as a component of revenue. Shipping and handling fees and costs are included in cost of revenues in the accompanying condensed consolidated statements of operations.

Revenues are recognized net of any taxes collected from customers, which are subsequently remitted to governmental agencies.

Significant Payment Terms

Pursuant to the Company’s contracts with its customers, amounts billed for services or products delivered by the Company are generally due and payable in full within 15  to 60 days from the date of the invoice (except for any amounts disputed by the customer in good faith). Accordingly, the Company determined that its contracts with customers do not include extended payment terms or a significant financing component.

Variable Consideration

When a contract includes variable consideration, the Company evaluates the estimate of the variable consideration to determine whether the estimate needs to be constrained. Variable consideration is estimated at the most likely amount that is expected to be earned.

14

Estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the anticipated performance and all information (historical, current and forecasted) that is reasonably available. Variable consideration estimates are updated at each reporting date. Revenues are recorded net of variable consideration, such as discounts and allowances.

Warranties

The Company provides product warranties with varying terms and durations for some of its products. The Company estimates product warranty costs and accrues for these costs as products are sold with a charge to cost of sales. Factors considered in estimating warranty costs include historical and projected warranty claims, historical and projected cost-per-claim, and knowledge of specific product issues that are outside of typical experience. Warranty accruals are evaluated and adjusted as necessary based on actual claims experience and changes in future claim and cost estimates.

Product warranty accrued liabilities totaled $0.2 million and $0.2 million at March 31, 2021 and December 31, 2020, respectively, and are included in accounts payable and other accrued expenses. Warranty expense was not material for the three months ended March 31, 2021 and 2020.

Incremental Direct Costs

Incremental direct costs are expensed when incurred when the amortization period of the asset that would have been recognized is one year or less; otherwise, incremental contract costs are recognized as an asset and amortized over time as promised goods and services are transferred to a customer. Incremental direct costs were not material for the three months ended March 31, 2021 and 2020.

The Company expenses incremental direct costs of obtaining a contract (sales commissions) when incurred because the amortization period is generally 12 months or less. The Company does not incur costs to fulfill a customer contract that meet the requirements for capitalization.

Contract Assets

Typically, we invoice the customer and recognize revenue once we have satisfied our performance obligation. Accordingly, our contract assets comprise accounts receivable, which are recognized when payment is unconditional and only the passage of time is required before payment is due. Generally, we do not have material amounts of other contract assets since revenue is recognized as control of goods is transferred or as services are performed.

Contract Liabilities (Deferred Revenue)

Contract liabilities are recorded when cash payments are received in advance of the Company’s performance. Deferred revenue was $0.5 million and $0.3 million at March 31, 2021 and 2020, respectively.  During the three months ended March 31, 2021, the Company recognized revenues of $0.2 million from the related contact liabilities outstanding as the services were performed.

Nature of Goods and Services

The Company provides Cryoport Express® Shippers to its customers and charges a fee in exchange for the use of the Cryoport Express® Shipper under long-term master service agreements with customers. The Company’s arrangements convey to the customers the right to use the Cryoport Express® Shippers over a period of time. The Company retains title to the Cryoport Express® Shippers and provides its customers the use of the Cryoport Express® Shipper for a specified shipping cycle. At the culmination of the customer’s shipping cycle, the Cryoport Express® Shipper is returned to the Company.

The Company recognizes revenue for the use of the Cryoport Express® Shippers at the time of the delivery of the Cryoport Express® Shipper to the end user of the enclosed materials, and at the time that collectability is probable.

The Company also provides vacuum insulated aluminum dewars and cryogenic freezers systems to its customers. Revenue is recognized when the Company satisfies performance obligations by transferring the equipment to a customer, and at the time that collectability is probable.

15

The Company also provides global temperature-controlled logistics services, support and management. Revenue is recognized for these services as services are rendered and at the time that collectability is probable.

The Company also provides comprehensive and integrated temperature-controlled biostorage solutions to customers in the life sciences industry and charges a fee under long-term master service agreements with customers. These services include (1) biological specimen cryopreservation storage and maintenance, (2) archiving, monitoring, tracking, receipt and delivery of samples, (3) transport of frozen biological specimens to and from customer locations, and (4) management of incoming and outgoing biological specimens. The Company recognizes revenue for its biostorage solutions as services are rendered over time and at the time that collectability is probable.

The Company also provides short-term logistics and engineering consulting services to some customers, with fees tied to the completion of contractually defined services. We recognize revenue from these services over time as the customer simultaneously receives and consumes the benefit of these services as they are performed.

A significant portion of our revenues are covered under long-term agreements. We have determined that individual Statements of Work or Scope of Work (“SOW”), whose terms and conditions taken with a Master Services Agreement (“MSA”), create the Topic 606 contracts which are generally short-term in nature (e.g., 15-day shipping cycle) for the Cryoport Express® solutions and up to 12 months for biostorage solutions. Our agreements (including SOWs) generally do not have multiple performance obligations and, therefore, do not require an allocation of a single price amongst multiple goods or services.  Prices under these agreements are generally fixed.

Revenue Disaggregation

The Company views its operations, makes decisions regarding how to allocate resources and manages its business as one reportable segment and one reporting unit. As a result, the financial information disclosed herein represents all of the material financial information related to the Company. When disaggregating revenue, the Company considered all of the economic factors that may affect its revenues. We consider sales disaggregated by end-market to depict how the nature, amount, timing and uncertainty of revenues and cash flows are impacted by changes in economic factors. The following table disaggregates our revenues by major markets for the three months ended March 31, 2021 and 2020 (in thousands):

Three Months Ended March 31, 

    

2021

    

2020

Biopharma/Pharma

$

42,393

$

8,786

Animal Health

 

8,997

 

225

Reproductive Medicine

1,894

763

Total revenues

$

53,284

$

9,774

Given that the Company’s revenues are generated in different geographic regions, factors such as regulatory and geopolitical factors within those regions could impact the nature, timing and uncertainty of the Company’s revenues and cash flows. Our geographical revenues, by origin, for the three months ended March 31, 2021 and 2020, were as follows (in thousands):

Three Months Ended March 31, 

    

2021

    

2020

Americas

$

27,734

$

7,685

Europe, the Middle East and Africa (EMEA)

 

14,208

 

1,932

Asia Pacific (APAC)

 

11,342

 

157

Total revenues

$

53,284

$

9,774

Cost of Services Revenues

Our cost of services revenues is primarily comprised of freight charges, payroll and associated expenses related to our global logistics and supply chain centers, depreciation expenses of our Cryoport Express® Shippers and supplies and consumables used for our solutions.

16

Cost of Product Revenues

Our cost of product revenues is primarily comprised of materials, direct and indirect labor, inbound freight charges, purchasing and receiving, inspection, and distribution and warehousing of inventory. In addition, shop supplies, facility maintenance costs and depreciation expense for assets used in the manufacturing process are included in cost of product revenues.

Engineering and Development Expenses

Expenditures relating to engineering and development are expensed in the period incurred to engineering and development expense in the statement of operations.

Acquisition Costs

Acquisition costs consist of legal, accounting, third-party valuations, and other due diligence costs related to our MVE Biological Solutions and CRYOPDP acquisitions.

Stock-Based Compensation

Under our stockholder approved stock-based compensation plan, we have granted incentive stock options, non-qualified stock options and restricted stock units that vest over four years.  Incentive and non-qualified stock options expire from seven to ten years from date of grant. The Company accounts for stock-based payments in accordance with stock-based payment accounting guidance which requires all stock-based payments to be recognized based upon their fair values. The fair value of stock options is estimated at the grant date using the Black-Scholes Option Pricing Model (“Black-Scholes”) and the portion that is ultimately expected to vest is recognized as compensation cost over the requisite service period.  The determination of fair value using Black-Scholes is affected by the Company’s stock price as well as assumptions regarding a number of complex and subjective variables, including expected stock price volatility, risk-free interest rate, expected dividends and expected term. The Company accounts for forfeitures of unvested awards as they occur.

The grant date fair value per share for restricted stock units is based upon the closing market price of our common stock on the award grant date.

The Company’s stock-based compensation plans are discussed further in Note 14.

Basic and Diluted Net Loss Per Share

We calculate basic and diluted net loss per share using the weighted average number of common shares outstanding during the periods presented. In periods of a net loss position, basic and diluted weighted average common shares are the same. For the diluted earnings per share calculation, we adjust the weighted average number of common shares outstanding to include dilutive stock options, warrants and shares associated with the conversion of the Senior Notes and convertible preferred stock outstanding during the periods.

The following shows the amounts used in computing net loss per share (in thousands except per share data):

Three Months Ended March 31, 

    

2021

    

2020

Net loss

$

(3,527)

$

(3,942)

Paid-in-kind dividend on Series C convertible preferred stock

 

(2,196)

 

Net loss attributable to common shareholders

$

(5,723)

$

(3,942)

Weighted average common shares outstanding - basic and diluted

43,804,483

37,548,549

Basic and diluted net loss per share

$

(0.13)

$

(0.11)

17

The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:

Three Months Ended March 31, 

    

2021

    

2020

Stock options

6,149,186

 

3,867,924

Warrants

 

502,632

Restricted stock units

304,157

Series C convertible preferred stock

5,283,411

Convertible senior notes

4,810,002

 

16,546,756

 

4,370,556

Foreign Currency Transactions

Management has determined that the functional currency of its subsidiaries is the local currency.  Assets and liabilities of the Netherlands and United Kingdom subsidiaries are translated into U.S. dollars at the period-end exchange rates.  Income and expenses are translated at an average exchange rate for the period and the resulting translation gain (loss) adjustments are accumulated as a separate component of stockholders’ equity.  The translation gain (loss) adjustment totaled $(3.8) million and $0 for the three months ended March 31, 2021 and 2020, respectively. Foreign currency gains and losses from transactions denominated in other than respective local currencies are included in earnings.

Off-Balance Sheet Arrangements

We do not currently have any off-balance sheet arrangements.

Reclassification

Prior year amounts in sales and marketing expense have been reclassified to selling, general and administrative expense to conform to the current period presentation, which reflects how the Company tracks operating costs. These reclassifications had no effect on the previously reported net loss.

Recently Adopted Accounting Pronouncements

In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. Under ASU 2020-06, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost, as long as no other features require bifurcation and recognition as derivatives. Similarly, equity-classified convertible preferred stock instruments will be accounted for as single units of account in equity unless the conversion feature needs to be bifurcated under Topic 815. The new guidance also made amendments to the earnings per share guidance in Topic 260, Earnings Per Share, for convertible instruments, the most significant impact of which is requiring the use of the if- converted method for diluted earnings per share calculation. Further, ASU 2020-06 made revisions to Topic 815-40, which provides guidance on how an entity must determine whether a contract qualifies for a scope exception from derivative accounting. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted. Adoption of the standard requires using either a modified retrospective or a full retrospective approach. Effective January 1, 2021, we early adopted ASU 2020-06 using the modified retrospective approach. Adoption of the new standard did not have a material impact on the Company’s consolidated financial statements or disclosures.

In January 2020, the FASB issued ASU 2020-01, “Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815): Clarifying the Interactions between Topic 321, Topic 323, and Topic 815.” The new guidance clarifies the interaction of accounting for the transition into and out of the equity method and the accounting for measuring certain purchased options and forward contracts to acquire investments. ASU 2020-01 is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The adoption of this guidance did not have an impact on the Company’s consolidated financial statements or disclosures.

18

Accounting Guidance Issued but Not Adopted at March 31, 2021

In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This ASU replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information for credit loss estimates on certain types of financial instruments, including trade receivables. In addition, new disclosures are required. The ASU, as subsequently amended, is effective for fiscal years beginning after December 15, 2022 for smaller reporting companies, as defined by the SEC. As a smaller reporting company, we are currently evaluating the impact of adopting this guidance.

Note 4. Acquisitions

2020 Acquisitions – CRYOPDP and MVE

CRYOPDP Acquisition

On October 1, 2020, the Company completed its acquisition of CRYOPDP for a cash consideration of €48.3 million (approximately $57.0 million, the “CRYOPDP Acquisition”). This acquisition was funded with existing cash on hand. CRYOPDP, based in France, is a leading global provider of innovative temperature-controlled logistics solutions to the clinical research, pharmaceutical and cell and gene therapy markets. CRYOPDP conducts its business activities in the Americas, EMEA and APAC. As a result of the CRYOPDP Acquisition, the Company has extended its solutions to include broader temperature-controlled logistics and specialty courier services and has significantly expanded its global network through CRYOPDP’s 22 facilities in 12 countries.

The final purchase price for the CRYOPDP Acquisition was $56.7 million, after receiving $0.3 million net working capital settlement from the sellers during the three months ended March 31, 2021. As of October 1, 2020, the Company recorded net assets acquired of $57.0 million, including goodwill of $25.5 million. Through March 31, 2021, the Company recorded measurement period adjustments of $2.9 million, mainly comprised of $1.3 million fair value on the note payable and $1.5 million deferred tax adjustments, resulting in adjusted goodwill of $22.6 million and adjusted net assets acquired of $56.7 million. The purchase price allocation for the assets acquired and liabilities assumed remains open due to the finalization of the purchase price allocation during the measurement process.

MVE Acquisition

On October 1, 2020, the Company completed its acquisition of Chart Industries, Inc.’s MVE cryobiological storage business (the “MVE Acquisition”) for a cash consideration of $317.5 million, subject to customary closing working capital and other adjustments. The Company financed a portion of the closing cash payment of the MVE Acquisition with the net proceeds of the Blackstone Private Placement, as further discussed in Note 13. MVE is a global leader in manufactured vacuum insulated products and cryogenic freezer systems for the life sciences industry. MVE has manufacturing and distribution operations in the Americas, EMEA and APAC. As a result of the MVE Acquisition, the Company has extended its integrated logistics solutions to provide a broad range of cryogenic dewars and freezers to the life sciences industry.

As of October 1, 2020, the Company recorded net assets acquired of $317.5 million, including goodwill of $106.2 million. Through March 31, 2021, the Company did not record any material measurement period adjustments. The purchase price allocation for the assets acquired and liabilities assumed remains open due to the finalization of the purchase price allocation during the measurement process.

19

Note 5. Cash, Cash Equivalents and Short-Term Investments

Cash, cash equivalents and short-term investments consisted of the following as of March 31, 2021 and December 31, 2020 (in thousands):

March 31, 

December 31, 

    

2021

    

2020

Cash

$

23,913

$

25,053

Cash equivalents:

 

Money market mutual fund

 

61,581

11,820

Total cash and cash equivalents

 

85,494

36,873

Short-term investments:

 

U.S. Treasury notes and bills

 

234,578

23,309

Mutual funds

 

33,143

33,135

Total short-term investments

 

267,721

56,444

Cash, cash equivalents and short-term investments

$

353,215

$

93,317

Available-for-sale investments

The amortized cost, gross unrealized gains, gross unrealized losses and fair value of available-for-sale investments by type of security at March 31, 2021 were as follows (in thousands):

    

Amortized

    

Unrealized

    

Unrealized

    

Cost

Gains

Losses

Fair Value

U.S. Treasury notes

$

235,185

$

128

$

(735)

$

234,578

Total available-for-sale investments

$

235,185

$

128

$

(735)

$

234,578

The following table summarizes the fair value of available-for-sale investments based on stated contractual maturities as of March 31, 2021:

    

Amortized Cost

    

Fair Value

Due within one year

$

41,030

$

41,058

Due between one and two years

 

194,155

 

193,520

Total

$

235,185

$

234,578

The amortized cost, gross unrealized gains, gross unrealized losses and fair value of available-for-sale investments by type of security at December 31, 2020 were as follows (in thousands):

    

    

Unrealized 

    

Unrealized 

    

Amortized Cost

Gains

Losses

Fair Value

U.S. Treasury notes

$

23,179

 

$

173

 

$

(43)

$

23,309

Total available-for-sale investments

$

23,179

 

$

173

$

(43)

$

23,309

The following table summarizes the fair value of available-for-sale investments based on stated contractual maturities as of December 31, 2020:

    

Amortized Cost

    

Fair Value

Due within one year

$

14,084

 

$

14,111

Due between one and two years

 

9,095

 

 

9,198

Total

$

23,179

 

$

23,309

The primary objective of our investment portfolio is to enhance overall returns in an efficient manner while maintaining safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with primarily investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer.

20

We review our available-for-sale investments for other-than-temporary declines in fair value below our cost basis each quarter and whenever events or changes in circumstances indicate that the cost basis of an asset may not be recoverable. The evaluation is based on a number of factors, including the length of time and the extent to which the fair value has been below our cost basis, as well as adverse conditions related specifically to the security such as any changes to the credit rating of the security and the intent to sell or whether we will more likely than not be required to sell the security before recovery of its amortized cost basis. Our assessment of whether a security is other-than-temporarily impaired could change in the future based on new developments or changes in assumptions related to that particular security.

During the three months ended March 31, 2021, we had realized gains of $40,000 on available-for-sale investments.

Equity Investments

We held investments in equity securities with readily determinable fair values of $33.1 million at March 31, 2021. These investments consist of mutual funds that invest primarily in tax-free municipal bonds and treasury inflation protected securities.

Unrealized gains (losses) during 2021 and 2020 related to equity securities held at March 31, 2021 and 2020 are as follows (in thousands):

    

2021

2020

Net losses recognized during the three months on equity securities

    

$

(263)

$

(649)

Less: net gains (losses) recognized during the year on equity securities sold during the year

 

   

(793)

Unrealized gains (losses) recognized during the three months on equity securities still held at March 31, 2021 and 2020

$

(263)

$

144

Note 6. Fair Value Measurements

We measure fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include the following:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that are accessible at the measurement date. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. These inputs include quoted prices for similar assets or liabilities; quoted market prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as consider counterparty credit risk in the assessment of fair value.

We did not elect the fair value option, as allowed, to account for financial assets and liabilities that were not previously carried at fair value. Therefore, material financial assets and liabilities that are not carried at fair value, such as trade accounts receivable and payable, are reported at their historical carrying values.

21

The carrying values of our assets that are required to be measured at fair value on a recurring basis as of March 31, 2021 and 2020 approximate fair value because of our ability to immediately convert these instruments into cash with minimal expected change in value which are classified in the table below in one of the three categories of the fair value hierarchy described above (in thousands):

    

Fair Value Measurements

    

Level 1

    

Level 2

    

Level 3

    

Total

March 31, 2021

 

  

 

  

 

  

 

  

Cash equivalents:

 

  

 

  

 

  

 

  

Money market mutual fund

$

61,581

$

$

$

61,581

Marketable equity securities:

 

  

 

  

 

  

 

  

Mutual funds

 

33,143

 

 

 

33,143

Available-for-sale debt securities:

 

 

  

 

  

 

U.S. Treasury notes

 

234,578

 

 

 

234,578

$

329,302

$

$

$

329,302

Fair Value Measurements 

 

Level 1

 

Level 2

 

Level 3

 

Total

December 31, 2020

    

  

    

  

    

  

    

  

Cash equivalents:

 

  

 

  

 

  

 

  

Money market mutual fund

$

11,820

$

$

$

11,820

Marketable equity securities:

 

  

 

  

 

  

 

  

Mutual funds

 

33,135

 

 

 

33,135

Available-for-sale debt securities:

 

  

 

  

 

  

 

  

U.S. Treasury notes

 

23,309

 

 

 

23,309

$

68,264

$

$

$

68,264

Our equity securities and available-for-sale debt securities, including U.S. treasury notes and U.S. treasury bills are valued using inputs observable in active markets for identical securities and are therefore classified as Level 1 within the fair value hierarchy.

We did not have any financial liabilities measured at fair value on a recurring basis as of March 31, 2021.

We carry the Senior Notes (see Note 9) at face value less the unamortized discount and issuance costs on our consolidated balance sheets and present fair value for disclosure purposes only. As of March 31, 2021, the estimated fair value of the Notes was $108.8 million and was determined using the net present value of the payments, discounted at an interest rate that is consistent with market and risk-adjusted interest rates, which is a Level 2 input.

Note 7. Inventory

Inventories consist of the following (in thousands):

    

March 31,

    

December 31,

2021

2020

Raw materials

$

8,318

$

7,544

Work-in-process

 

307

 

227

Finished goods

 

2,919

 

2,764

$

11,544

$

10,535

The inventory balance at December 31, 2020 includes an $0.8 million step up in inventory related to the acquisition of MVE.

22

Note 8. Goodwill and Intangible Assets

Goodwill

The following table represents the changes in the carrying value of goodwill for the three months ended March 31, 2021 and 2020 (in thousands):

    

March 31,

2021

    

2020

Balance at beginning of year

 

145,282

 

11,000

Foreign currency adjustment

 

(1,405)

 

Goodwill related to MVE acquisition

 

18

 

Goodwill related to CRYOPDP acquisition

 

(2,590)

 

Total

 

$

141,305

 

$

11,000

Intangible Assets

The following table presents our intangible assets as of March 31, 2021 (in thousands):

Weighted

Net

Average

Gross

Accumulated

Carrying

Amortization

    

Amount

    

Amortization

    

Amount

    

Period (years)

Non-compete agreement

$

390

$

143

$

247

 

3

Technology

34,438

2,576

31,862

11

Customer relationships

128,640

5,218

123,422

14

Cryogene trade name/trademark

480

59

421

13

CRYOPDP agent network

8,597

1,415

7,182

4

MVE order backlog

2,600

2,600

MVE land use rights

2,378

36

2,342

37

Patents and trademarks

44,360

569

43,791

Total

$

221,883

$

12,616

$

209,267

The following table presents our intangible assets as of December 31, 2020 (in thousands):

Weighted

Net

Average

Gross

Accumulated

Carrying

Amortization

    

Amount

    

Amortization

    

Amount

    

Period (years)

Non-compete agreement

$

390

$

123

$

267

 

3

Technology

34,245

1,630

32,615

11

Customer relationships

128,640

2,708

125,932

14

Cryogene trade name/trademark

480

51

429

13

CRYOPDP agent network

8,597

537

8,060

4

MVE order backlog

2,600

2,600

MVE land use rights

2,378

16

2,362

37

Patents and trademarks

44,312

69

44,243

 

Total

$

221,642

$

7,734

$

213,908

Amortization expense for intangible assets for the three months ended March 31, 2021 and 2020, was $3.6 million and $0.1 million, respectively.

23

Expected future amortization of intangible assets as of March 31, 2021 is as follows:

Years Ending March 31, 

    

Amount

Remainder of 2021

$

10,722

2022

 

14,296

2023

 

14,296

2024

 

13,678

2025

 

12,064

Thereafter

 

100,051

$

165,107

Note 9. Convertible Senior Notes

In May 2020, the Company issued $115.0 million aggregate principal amount of 3.00% convertible senior notes due in 2025 (the "Senior Notes"), which includes the initial purchasers’ exercise in full of their option to purchase an additional $15.0 million principal amount of the Senior Notes, in a private placement exempt from registration under the Securities Act of 1933. The Senior Notes are governed by an indenture (the “Indenture”) dated May 26, 2020 between the Company, as issuer, and U.S. Bank National Association, as trustee (the “Trustee”). The Company received $111.3 million from the offering, net of underwriting discounts and commissions of $3.7 million, and incurred approximately $0.3 million in third-party offering related costs. The Senior Notes bear cash interest at a rate of 3.00%, payable semi-annually on June 1 and December 1 of each year, beginning on December 1, 2020 and will mature on June 1, 2025, unless earlier repurchased, redeemed, or converted in accordance with the terms of the Senior Notes. At March 31, 2021 accrued interest of $1.2 million is included in accounts payable and accrued liabilities in the accompanying consolidated financial statements.  The Notes comprise the Company’s senior, unsecured obligations and are (i) equal in right of payment with the Company’s existing and future senior, unsecured indebtedness; (ii) senior in right of payment to the Company’s existing and future indebtedness that is expressly subordinated to the Senior Notes; (iii) effectively subordinated to the Company’s existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness; and (iv) structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to the extent the Company is not a holder thereof) preferred equity, if any, of the Company’s subsidiaries.

At any time before the close of business on the scheduled trading day immediately before the maturity date, holders of the Senior Notes may convert their Senior Notes at their option into shares of the Company’s common stock. The Senior Notes are initially convertible into approximately 4,810,002 shares of the Company’s common stock based on the initial conversion rate of 41.8261 shares of the Company’s common stock per $1,000 principal amount of the Senior Notes, which represents an initial conversion price of approximately $23.91 per share of the Company’s common stock. The conversion rate and conversion price are subject to customary adjustments upon the occurrence of certain events. Also, if certain corporate events that constitute a “Make-Whole Fundamental Change” (as defined in the Indenture) occur, then the conversion rate will, in certain circumstances, be increased for a specified period of time and is determined by reference to a make-whole table set forth in the Indenture governing the Senior Notes. However, in no event will the conversion rate be increased to an amount that exceeds 48.10 shares of the Company’s common stock per $1,000 principal amount of Senior Notes. In addition, the holders of the Senior Notes may require the Company to repurchase the Senior Notes at par value plus accrued and unpaid interest following the occurrence of a “Fundamental Change” (as described in the Indenture).

On or after June 5, 2023, we may redeem the Senior Notes at our option, in whole and not in part, at a cash redemption price equal to the principal amount of the Senior Notes to be redeemed, plus accrued and unpaid interest, if any, if:

(1)The last reported sale price per share of the Company’s common stock exceeds 130% of the conversion price on (i) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company send the related redemption notice; and (ii) the trading day immediately before the date the Company sends such notice; and
(2)A registration statement covering the resale of the shares of the Company’s common stock issuable upon conversion of the Senior Notes is effective and available for use and is expected to remain effective and available during the redemption period as of the date the redemption notice is sent.

24

The Senior Notes contain customary terms and events of default. If an event of default arising out of certain events of bankruptcy, insolvency, or reorganization involving the Company or a significant subsidiary (as set forth in the Indenture) occurs with respect to the Company, the principal amount of the Senior Notes and accrued and unpaid interest, if any, will automatically become immediately due and payable. If any other event of default (as defined in the Indenture) occurs and is continuing, either the Trustee or the holders of at least 25% in aggregate principal amount of the outstanding Senior Notes may declare the principal amount of the Senior Notes to be due and payable immediately by notice to the Company. There were no events of default at March 31, 2021.

The Senior Notes are accounted for in accordance with ASC 470-20, Debt with Conversion and Other Options (“ASC 470-20”) and ASC 815-40, Contracts in Entity’s Own Equity (“ASC 815-40”). Under ASC 815-40, to qualify for equity classification (or nonbifurcation, if embedded) the instrument (or embedded feature) must be both (1) indexed to the issuer’s stock and (2) meet the requirements of the equity classification guidance. Based upon the Company’s analysis, it was determined the Senior Notes do contain embedded features indexed to its own stock, but do not meet the requirements for bifurcation, and therefore do not need to be separately accounted for as an equity component. Since the embedded conversion feature meets the equity scope exception from derivative accounting, and also since the embedded conversion option does not need to be separately accounted for as an equity component under ASC 470-20, the proceeds received from the issuance of the convertible debt was recorded as a liability on the consolidated balance sheet.

The Company incurred approximately $4.1 million of debt issuance costs relating to the issuance of the Senior Notes, which were recorded as a reduction to the Senior Notes on the consolidated balance sheet. The debt issuance costs are being amortized and recognized as additional interest expense over the expected life of the Senior Notes using the effective interest rate method. We determined the expected life of the debt is equal to the five-year term of the Senior Notes. The effective interest rate on the Senior Notes is 3.74%.

Senior Notes payable consisted of the following at March 31, 2021 (in thousands):

    

March 31, 2021

Principal amount of Senior Notes

$

115,000

Unamortized debt issuance costs

 

(3,464)

Net carrying value of Senior Notes payable

$

111,536

Interest expense incurred in connection with the Notes consisted of the following for the three months ended March 31, 2021 (in thousands):

    

Three Months Ended

March 31, 2021

Coupon interest

$

862

Amortization of debt issuance costs

192

Total interest expense on Senior Notes

$

1,054

The Company’s Senior Notes payable of $115.0 are due and payable in 2025.

In connection with the issuance of the Senior Notes, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) to use its best efforts to file a registration statement for the resale of the Senior Notes and the shares of the Company's common stock issuable upon conversion of the Senior Notes, to cause the registration statement to become effective by January 31, 2021, and to keep the registration statement continuously effective for a specified period of time. If the Company fails to satisfy certain of its obligations under the Registration Rights Agreement (a “Registration Default”), it will be required to pay additional interest on the Senior Notes. Such additional interest will accrue at a rate per annum equal to 0.25% of the principal amount thereof for the first 90 days beginning on, and including the date on which such Registration Default occurs and, thereafter, at a rate per annum equal to 0.50% of the principal amount thereof. However, in no event will such additional interest, together with any special interest that accrues pursuant to the Indenture accrue on any day on a Note at a combined rate per annum that exceeds 0.50%. Additionally, if a Registration Default exists on the maturity date for the Senior Notes, then, in addition to any additional interest otherwise payable, the Company will be required to make a cash payment to each noteholder in an amount equal to 3% of the principal amount of Senior Notes outstanding and held by such holder as of the close of business on the business day immediately before the maturity date. As of March 31, 2021, the Company has not accrued any fees or expenses associated with the Registration Rights Agreement as no Registration Default exists and, therefore, it is not probable that a payment would be required. In December 2020, the Company filed an automatic shelf registration statement to register the resale of the Senior Notes and the shares of the Company’s common stock issuable upon conversion of the Senior Notes.

25

Note 10. Note Payable

In connection with the acquisition of CRYOPDP, the Company assumed an interest free unsecured note payable of €4.0 million ($4.9 million) repayable in two installments of €0.5 million ($0.6 million) to be repaid in 2025 and €3.5 million ($4.3 million) to be repaid in 2028.  A fair market value discount of €1.1 million ($1.3 million) was recorded and is amortized to interest expense using the effective interest method over the term of the note.  During the three months ended March 31, 2021, the Company amortized €0.06 million ($0.07 million) of the debt discount to interest expense for this note.

Note 11. Leases

The Company has operating and finance leases for corporate offices and certain equipment. These leases have remaining lease terms of one year to approximately nine years, some of which include options to extend the leases for multiple renewal periods of five years each. Under the terms of the facilities leases, the Company is required to pay its proportionate share of property taxes, insurance and normal maintenance costs. As of March 31, 2021 and December 31, 2020, assets recorded under finance leases were $0.3 million and $0.3 million, respectively, and accumulated depreciation associated with finance leases was $0.1 million and $0.08 million, respectively.

The components of lease cost were as follows (in thousands):

March 31, 

    

2021

    

2020

Operating lease cost

$

922

$

290

Finance lease cost:

 

  

Amortization of right-of-use assets

15

6

Interest on finance lease liabilities

3

2

18

 

8

Total lease cost

$

940

$

298

Other information related to leases was as follows (in thousands):

Three Months Ended

 

Supplemental Cash Flows Information

    

March 31, 2020

 

Cash paid for amounts included in the measurement of lease liabilities:

 

Operating cash flows from operating leases

 

$

851

Operating cash flows from finance leases

 

$

22

Financing cash flows from finance leases

$

20

Right-of-use assets obtained in exchange for lease liabilities (in thousands):

Operating leases

 

$

2,781

Finance leases

$

Weighted-Average Remaining Lease Term

Operating leases

 

6.3 years

Finance leases

 

2.7 years

Weighted-Average Discount Rate

Operating leases

5.4

%

Finance leases

5.3

%

26

Future minimum lease payments under non-cancellable leases that have commenced as of March 31, 2021 were as follows (in thousands):

Years Ending March 31

Operating Leases

Finance Leases

2021 (excluding the three months ended March 31, 2021)

$

1,688

$

45

2022

 

2,730

 

58

2023

 

2,256

 

61

2024

 

2,049

 

2025

 

1,866

 

Thereafter

9,738

Total future minimum lease payments

 

20,327

 

164

Less imputed interest

 

(3,823)

 

(12)

Total

$

16,504

$

152

Operating

Finance 

Reported as of March 31, 2021

    

 Leases

    

Leases

Current lease liabilities

$

2,002

$

60

Noncurrent lease liabilities

 

14,502

 

92

Total

$

16,504

$

152

Note 12. Commitments and Contingencies

Facility and Equipment Leases

We lease various corporate, global logistics and supply chain centers, biostorage, manufacturing, and research and development facilities in Tennessee, California, New Jersey, the Netherlands, Texas, Georgia, Minnesota, China, Portugal and France under operating leases. These lease agreements contain certain scheduled annual rent increases which are accounted for on a straight-line basis.   In addition, we lease certain equipment which expires through July 2024 (See Note 11).

Employment Agreements

We have entered into employment agreements with certain of our officers under which payment and benefits would become payable in the event of termination by us for any reason other than cause, or upon a change in control of our Company, or by the employee for good reason.

Litigation

The Company may become a party to product litigation in the normal course of business. The Company accrues for open claims based on its historical experience and available insurance coverage. We record a loss contingency when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. We also disclose material contingencies when we believe a loss is not probable but reasonably possible. Accounting for contingencies requires us to use judgment related to both the likelihood of a loss and the estimate of the amount or range of loss. The outcomes of our legal proceedings are inherently unpredictable, subject to significant uncertainties, and could be material to our financial condition, results of operations, and cash flows for a particular period.

Indemnities and Guarantees

The Company has made certain indemnities and guarantees, under which it may be required to make payments to a guaranteed or indemnified party, in relation to certain actions or transactions. The guarantees and indemnities do not provide for any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not been obligated nor incurred any payments for these obligations and, therefore, no liabilities have been recorded for these indemnities and guarantees in the accompanying consolidated balance sheets.

The Company indemnifies its directors, officers, employees and agents, as permitted under the laws of the States of California and Nevada. In connection with its facility and equipment leases, the Company has indemnified its lessors for certain claims arising from the use of the facilities and equipment. The duration of the guarantees and indemnities varies and is generally tied to the life of the agreements.

27

Note 13. Stockholders’ Equity

Authorized Stock

The Company has 100,000,000 authorized shares of common stock with a par value of $0.001 per share, and 2,500,000 undesignated or “blank check” preferred stock, with a par value of $0.001, of which, 800,000 shares have been designated as Class A Preferred Stock, 585,000 shares have been designated as Class B Preferred Stock and 250,000 shares have been designated as 4.0% Series C Convertible Preferred Stock.

Common Stock Issued for Services

During the three months ended March 31, 2021, 229 shares of common stock with a fair value of $11,500 were issued to one member of the board of directors as compensation for services.

During the three months ended March 31, 2020, 1,269 shares of common stock with a fair value of $20,700 were issued to two members of the board of directors as compensation for services.

January 2021 Public Offering

On January 25, 2021, the Company completed an underwritten public offering of 4,356,059 shares of its common stock. The shares were issued and sold pursuant to an underwriting agreement dated January 20, 2021, by and among the Company, on the one hand, and Morgan Stanley & Co. LLC, Jefferies LLC, SVB Leerink LLC and UBS Securities LLC, as representatives of certain underwriters at a public offering price per share of $66.00, before deducting underwriting discounts and commissions. The shares include 568,181 shares issued and sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares of common stock pursuant to the underwriting agreement. The Company received net proceeds of approximately $269.8 million from the offering after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.

Blackstone Private Placement

In connection with the MVE Acquisition, on October 1, 2020 (the “Closing Date”), the Company completed a private placement with an investment vehicle of funds affiliated with The Blackstone Group Inc. (collectively, “Blackstone”), consisting of (i) 250,000 shares of a newly designated 4.0% Series C Convertible Preferred Stock, par value $0.001 per share (“Series C Preferred Stock”), at a price of $1,000 per share, for $250.0 million, and (ii) 675,536 shares of common stock of the Company, par value $0.001 per share (“Common Stock”) for $25.0 million, for an aggregate purchase price of $275.0 million. The Company paid Blackstone $1.0 million as reimbursement for transactional expenses incurred in connection with the private placement at the Closing Date. Also, the Company incurred direct and incremental expenses of approximately $8.6 million, including financial advisory fees, closing costs, legal expenses and other offering-related expenses. The Company allocated the net proceeds of $265.4 million on a relative fair value basis to the Series C Preferred Stock and the Common Stock, resulting in allocated proceeds of $28.2 million and $237.2 million, respectively.

The Series C Preferred Stock ranks senior to the shares of the Company’s Common Stock, with respect to dividend rights and rights upon the voluntary or involuntary liquidation, dissolution, or winding up of the affairs of the Company (a “Liquidation”). The Series C Preferred Stock has the following rights, preferences and privileges:

Dividend Rights. Holders of the Series C Preferred Stock (the “Holders”) are entitled to dividends at the rate of 4.0% per annum, paid-in-kind, accruing daily and paid quarterly in arrears when and if declared by the Board of Directors. The Holders are also entitled to participate in dividends declared or paid on the Common Stock on an as-converted basis. The Company and Holders do not have the option to pay dividends in kind, in cash, or in other form. Paid in-kind dividends for the three months ended March 31, 2021 and the year ended December 31, 2020 were $2.2 million and $2.5 million, respectively.

Liquidation Preference. Upon a Liquidation, each share of Series C Preferred Stock is entitled to receive an amount per share equal to the greater of (i) $1,000 per share, plus all accrued and unpaid dividends and (ii) the amount that the Holders of the Series C Preferred Stock would have been entitled to receive at such time if the Series C Preferred Stock were converted into Common Stock (the ”Liquidation Preference”).

28

Conversion Features. The Series C Preferred Stock is convertible at the option of the Holders at any time into shares of Common Stock at a conversion price of $38.6152 per share and a conversion rate of 25.90 shares of Common Stock per share of Series C Preferred Stock. The maximum number of Common Stock that could be required to be issued if converted is 6,474,135 shares. The conversion price is subject to certain customary adjustments in the event of certain adjustments to the Company’s Common Stock, including stock dividends, splits, combinations, tender offers, and exchange offers.  

After the second anniversary of the Closing Date, subject to certain conditions, the Company may at its option require conversion of all of the outstanding shares of the Series C Preferred Stock to Common Stock if, for at least 20 trading days during the 30 consecutive trading days immediately preceding the date the Company notifies the Holders of the election to convert, the closing price of the Common Stock is at least 150% of the conversion price.

On the October 1, 2020 issuance date, the effective conversion price per share was less than the fair value of the underlying Common Stock and, as a result, the Company determined that there was a beneficial conversion feature on that date. Accordingly, the Company recognized the resulting beneficial conversion feature amount of $39.5 million as a deemed dividend, equal to the number of common shares into which the Series C Preferred Stock is convertible multiplied by the difference between the fair value of the Common Stock and the effective conversion price per share on that date. Because the Series C Preferred Stock does not have a stated conversion date and was immediately convertible at the issuance date, the dividend is reflected as a one-time, non-cash, deemed dividend to the Holders of the Series C Preferred Stock on the date of issuance.

Additionally, the Company determined that the nature of the Series C Preferred Stock is more akin to an equity instrument and that the economic characteristics and risks of the embedded conversion options are clearly and closely related to the Series C Preferred Stock. As such, the conversion options were not required to be bifurcated from the host under ASC 815, Derivatives and Hedging.

Since the paid-in-kind dividends are nondiscretionary, the Company measures the beneficial conversion feature in the paid-in-kind dividend on the issuance date of the preferred stock and records such amount when the paid-in-kind dividend are accrued. Accordingly, the associated paid-in-kind dividends for the year ended December 31, 2020 generated a beneficial conversion feature amount of $0.3 million. On February 5, 2021, the Company received a waiver and conversion notice from Blackstone Freeze Parent L.P. and Blackstone Tactical Opportunities Fund – FD L.P. and converted an aggregate of 50,000 shares of the Series C Preferred Stock (see “—Blackstone Conversion” below for additional information).

Redemption Rights. The Company may redeem the Series C Preferred Stock for cash, as follows:

(1)

At any time beginning five years after the Closing Date (but prior to six years after the Closing Date), all of the Series C Preferred Stock at a price equal to 105% of the purchase price paid plus any accrued and unpaid dividends.

(ii)

At any time beginning six years after the Closing Date, all of the Series C Preferred Stock at a price equal to 100% of the purchase price paid plus any accrued and unpaid dividends.

Within 6 months of the Closing Date, the Company also had the right to redeem up to 50,000 shares of the Series C Preferred Stock at a price equal to 125% of the purchase price paid plus any accrued and unpaid dividends, which the Company waived (see “—Blackstone Conversion” below for additional information).

Upon a “Fundamental Change” (involving a change of control or de-listing of the Company as further described in the Certificate of Designation), each Holder has the right to require the Company to redeem all or any part of the Holder’s Series C Preferred Stock for an amount equal to the Liquidation Preference plus any accrued and unpaid dividends.  If the Company does not have sufficient funds legally available to pay the repurchase price, then the Company is required to (a) pay the maximum amount of the repurchase price that can be paid out of funds legally available for payment, and (b) purchase any shares of the Series C Preferred Stock not purchased because of the foregoing limitations at the repurchase price as soon as practicable after the Company is able to make such purchase out of assets legally available for the purchase of such shares. If the Company fails to pay the repurchase price in full when due, then the Company will pay dividends on such shares not repurchased at a rate of 5.5% per annum until such shares are repurchased, payable quarterly in arrears.

29

The Company evaluated the Series C Preferred Stock for liability or equity classification under the applicable accounting guidance including ASC 480, Distinguishing Liabilities from Equity, and determined that equity treatment was appropriate because the Series C Preferred Stock did not meet the definition of the liability instruments defined thereunder for convertible instruments. Specifically, the convertible preferred shares are not mandatorily redeemable and do not embody an obligation to buy back the shares outside of the Company’s control in a manner that could require the transfer of assets. Additionally, the Company determined that the Series C Preferred Stock would be recorded as permanent equity given that they are not redeemable for cash or other assets (i) on a fixed or determinable date, (ii) at the option of the holder, or (iii) upon the occurrence of an event that is not solely within control of the Company.

The Company also evaluated the embedded put and call options within the Series C Preferred Stock in accordance with the accounting guidance for derivatives to determine if bifurcation is required.  The Company determined that the economic characteristics and risks of the embedded put and call options are not clearly and closely related to the Series C Preferred Stock. Therefore, the Company assessed the put and call options further and determined they did not meet the definition of a derivative under ASC 815.

Under the same analysis, the Company determined that the economic characteristics and risks of the embedded participating dividend feature are considered clearly and closely related to the equity host. Accordingly, the participating dividend feature is not required to be bifurcated under ASC 815. Also, the Company determined that the value of the contingent dividend feature is minimal and insignificant relative to the other components of the Series C Preferred Stock due to the circumstances surrounding the scenarios under which the provision would be triggered.

Voting Rights. Holders of the Series C Preferred Stock are generally entitled to vote with the holders of the shares of Common Stock on an as-converted basis, subject to certain Nasdaq voting limitations, if applicable. Also, the consent of the Holders of a majority of the outstanding shares of the Series C Preferred Stock is required with respect to (i) amendments to the Company’s organizational documents that have an adverse effect on the Holders of the Series C Preferred Stock, and (ii) issuances by the Company of securities that are senior to, or equal in priority with, the Series C Preferred Stock. Holders of the Series C Preferred Stock have the right to nominate for election one member to the board of directors of the Company for so long as they hold 66.67% of the Series C Preferred Stock issued to them at the Closing Date.

Registration Rights. Holders of the Series C Preferred Stock have certain customary registration rights with respect to the Series C Preferred Stock and the shares of common stock into which they are converted, pursuant to the terms of a registration rights agreement. The Company is required to file within 90 days of the Closing Date, and use its commercially reasonable efforts to cause to go effective as promptly as practicable, a registration statement covering the sale or distribution of Common Stock issued or issuable upon conversion of the Series C Preferred Stock.   In December 2020, the Company filed an automatic shelf registration statement to register the resale of the Common Stock issued or issuable upon conversion of the Series C Preferred Stock.

Blackstone Conversion

On February 5, 2021, the Company received a waiver and conversion notice from Blackstone Freeze Parent L.P. and Blackstone Tactical Opportunities Fund – FD L.P. to convert an aggregate of 50,000 shares of the Company’s Series C Preferred Stock. Pursuant to the terms of the waiver and conversion notice, the Company also agreed to waive its right under the certificate of designations of the Series C Preferred Stock to redeem up to 50,000 shares of the Series C Preferred Stock prior to the 180-day anniversary of October 1, 2020, the issue date of the Series C Preferred Stock. Each share of Series C Preferred Stock has a liquidation preference of $1,000 per share plus any accumulated and unpaid dividends and is convertible into shares of the Company’s common stock, par value $0.001 per share, at a conversion price of $38.6152 per share. The forgoing conversion, effective as of February 5, 2021, resulted in the issuance of an aggregate of 1,312,860 shares of Common Stock and $1.8 million in expenses.

30

Common Stock Reserved for Future Issuance

As of March 31, 2021, approximately 18.2 million shares of common stock were issuable upon conversion or exercise of rights granted under prior financing arrangements, stock options, RSU’s and the conversion of senior notes and series C Preferred stock, as follows:

Exercise of stock options

    

7,793,769

Vesting of restricted stock units

 

304,157

Conversion of Series C Preferred Stock

 

5,283,411

Conversion of convertible senior notes

 

4,810,002

Total shares of common stock reserved for future issuances

 

18,191,339

Note 14. Stock-Based Compensation

Stock Options

We have five stock incentive plans: the 2002 Stock Incentive Plan (the “2002 Plan”), the 2009 Stock Incentive Plan (the “2009 Plan”), the 2011 Stock Incentive Plan (the “2011 Plan”), the 2015 Omnibus Equity Incentive Plan (the “2015 Plan”), and the 2018 Omnibus Equity Incentive Plan (the “2018 Plan”), (collectively, the “Plans”). The 2002 Plan, the 2009 Plan, the 2011 Plan and the 2015 Plan (the “Prior Plans”) have been superseded by the 2018 Plan. In May 2018, the stockholders approved the 2018 Plan for issuances up to an aggregate of 3,730,179 shares. The Prior Plans will remain in effect until all awards granted under such Prior Plans have been exercised, forfeited, cancelled, or have otherwise expired or terminated in accordance with the terms of such awards, but no awards will be made pursuant to the Prior Plans after the effectiveness of the 2018 Plan. As of March 31, 2021, the Company had 190,181 shares available for future awards under the 2018 Plan.

During the three months ended March 31, 2021, we granted stock options at exercise prices equal to the quoted market price of our common stock on the grant date. The fair value of each option grant was estimated on the date of grant using Black-Scholes with the following weighted average assumptions:

Expected life (years)

3.56.1

 

Risk-free interest rate

0.5% - 0.9

%

Volatility

64.4% - 80.8

%

Dividend yield

0

%

The expected option life assumption is estimated based on the simplified method. Accordingly, the Company has utilized the average of the contractual term of the options and the weighted average vesting period for all options to calculate the expected option term. The risk-free interest rate assumption is based upon observed interest rates appropriate for the expected term of our employee stock options. The expected volatility is based on the average of the historical volatility and the implied volatility of our stock commensurate with the expected life of the stock-based award. We do not anticipate paying dividends on the common stock in the foreseeable future.

We recognize stock-based compensation cost on a straight-line basis over the vesting period. Stock-based compensation expense is recognized only for those awards that ultimately vest.

Total stock-based compensation expense related to all of our share-based payment awards is comprised of the following:

Three months ended March 31,

    

2021

    

2020

Cost of revenues

$

239

$

69

Selling, general and administrative

 

2,505

 

1,443

Engineering and development

 

246

 

108

$

2,990

$

1,620

31

A summary of stock option activity is as follows:

    

    

    

Weighted-

    

Weighted-

Average

Average

Remaining

Aggregate

Number of

Exercise

Contractual

Intrinsic

Shares

Price/Share

Term (Years)

Value (1)

Outstanding — December 31, 2020

 

7,554,305

$

10.29

 

  

 

  

Granted (weighted-average fair value of $32.66 per share)

 

435,298

55.74

 

  

 

  

Exercised

 

(187,486)

 

8.46

 

  

 

  

Forfeited

 

(8,348)

 

16.48

 

  

 

  

Outstanding — March 31, 2021

 

7,793,769

$

12.86

 

6.4

$

306,822

Vested (exercisable) — March 31, 2021

 

5,904,443

$

7.76

 

5.8

$

261,287

Expected to vest after March 31, 2021 (unexercisable)

 

1,889,326

$

28.82

 

7.9

$

40,001

(1)Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of our common stock on March 31, 2021, which was $52.01 per share.

Total intrinsic value of options exercised during the three months ended March 31, 2021 was $9.4 million.

As of March 31, 2021, there was unrecognized compensation expense of $32.5 million related to unvested stock options, which we expect to recognize over a weighted average period of 3.4 years.

Restricted stock units

A summary of our restricted stock unit activity is as follows:

Weighted Average

Number of Restricted

 Fair Value per 

Stock Units

Share 

Outstanding – December 31, 2020

    

    

$

Granted

 

304,157

 

53.94

Share issuance

 

 

Outstanding March 31, 2021

 

304,157

$

53.94

For the three months ended March 31, 2021 and 2020, we recorded stock-based compensation expense on our issued restricted stock units of $0.3 million and $0, respectively.  As of March 31, 2021 there was unrecognized compensation expense of $16.1 million related to unvested restricted stock units, which we expect to recognize over a weighted average period of 4.0 years.

Note 15. Subsequent Event

Effective April 1, 2021, the Company completed the acquisition of Critical Transport Solutions Australia Pty Ltd. (“CTSA”) a market leader in providing premium healthcare logistics management services, specializing in time and temperature critical solutions for the medical and pharmaceutical industries based in Australia, for approximately $5.0 million.

The agreement includes an earnout provision which is (a) subject to and dependent on the Company achieving a 2024 EBITDA, as defined; and (b) is subject to certain employment requirements through December 31, 2024.  CTSA will be a part of the Company’s CRYOPDP business unit and will continue to be run by the current management team.

32

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

In this Quarterly Report on Form 10-Q (this “Quarterly Report”), the terms “Cryoport,” “Company” and similar terms refer to Cryoport, Inc. and its consolidated subsidiaries, unless the context suggest otherwise.

SAFE HARBOR FOR FORWARD LOOKING STATEMENTS:

This Quarterly Report contains forward-looking statements that have been made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 and concern matters that involve risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements. In some cases, you can identify these statements by terminology such as “may,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” or similar words which are intended to identify forward-looking statements, although not all forward-looking statements contain these words.  Reference is made in particular to forward-looking statements regarding our expectations about future business plans, new products or services, regulatory approvals, strategies, development timelines, prospective financial performance and opportunities, including potential acquisitions, expectations about future benefits of our acquisitions, including Cryogene Partners, CRYOPDP and MVE Biological Solutions, our ability to successfully integrate those businesses and our plans related thereto; liquidity and capital resources; projected trends in the market in which we operate; anticipated impacts from the coronavirus strain COVID-19 (“COVID-19”) on us, including to our business operations, results of operations, cash flows, and financial position, and our future responses to the COVID-19 pandemic; our expectations about securing and maintaining strategic relationships with global couriers or large clinical research organizations; our future capital needs and ability to raise capital on favorable terms or at all; results of our research and development efforts; and approval of our patent applications.  

Although we believe that our opinions and expectations reflected in the forward-looking statements are reasonable as of the date of this Quarterly Report, we cannot guarantee future results, levels of activity, performance or achievements, and our actual results may differ substantially from the views and expectations set forth in this Quarterly Report. You should be aware that these statements are projections or estimates as to future events and are subject to a number of factors that may tend to influence the accuracy of the statements. These forward-looking statements should not be regarded as a representation by the Company or any other person that the events or plans of the Company will be achieved. You should not unduly rely on these forward-looking statements, which speak only as of the date of this Quarterly Report. We undertake no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this Quarterly Report or to reflect the occurrence of unanticipated events. You should, however, review the factors and risks we describe in the reports we file from time to time with the Securities and Exchange Commission (“SEC”), including those contained in our Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the SEC on March 1, 2021, and those reports filed after the date of this Quarterly Report. Actual results may differ materially from any forward looking statement.

The following management’s discussion and analysis of the Company’s financial condition and results of operations (“MD&A”) should be read in conjunction with the condensed consolidated balance sheet as of March 31, 2021 (unaudited) and the consolidated balance sheet as of December 31, 2020 (audited) and the related unaudited condensed consolidated statements of operations, comprehensive loss, and stockholders equity for the three months ended March 31, 2021 and 2020, and cash flows for the three months ended March 31, 2021 and 2020 and the related notes thereto (see Item 1. Financial Statements), as well as the audited consolidated financial statements of the Company for years ended December 31, 2020 and 2019, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

33

Overview

We are redefining the temperature-controlled supply chain for the life sciences industry by providing a unique and evolving platform of critical products and solutions including advanced packaging, informatics, specialty logistics services, biostorage services, and cryogenic life sciences equipment. With over 650 employees spread across 30 locations worldwide, we are engaged in providing global solutions to the biopharma/pharma, animal health, and reproductive medicine markets. Our primary focus is on addressing the critical temperature-controlled supply chain needs within the biopharmaceutical space with an emphasis on serving the rapidly growing cell and gene therapy, or C&GT market.

Our Strategy

We are focused on establishing best-in-class, comprehensive temperature-controlled supply chain solutions that support the expanding global landscape of the life sciences industry. We believe our growth strategy aligns with the growth of the markets we serve and our customers within them. In particular, we have identified the C&GT market as a high growth market, with unmet supply chain needs that we believe can benefit significantly from our solutions. The global C&GT market was valued at approximately $4.2 billion in 2019 and is projected to grow to over $33.1 billion by 2024.

Over the last several years, we have grown to become a leader in supporting C&GT clinical trials globally. As of the end of the first quarter of 2021, we supported 543 clinical trials and seven commercial therapies, including KYMRIAH by Novartis, YESCARTA and TECARTUS by Gilead/Kite, and BREYANZI by Bristol-Myers Squibb. In addition, two additional Cryoport supported therapies filed for commercial approval with the U.S. Food and Drug Administration, or FDA, or the European Medicines Agency, or EMA in 2020 and could be approved in 2021. Based on publicly disclosed information, industry data, and internal forecasts, we estimate that up to 21 additional Cryoport supported C&GTs, currently in clinical trials, may file for regulatory approval during the course of 2021. Commercial approvals of these therapies provide an opportunity to become significant revenue drivers for us in the future as each of them requires comprehensive temperature-controlled supply chain support and services at commercial scale, and we expect that many will select us as their critical supply chain solution as a result of our work in connection with their respective clinical trials.

We intend to build on our recent history of developing market-leading, temperature-controlled supply chain solutions and delivering strong growth through the following strategies:

Superior service to our clients. We strive to provide our clients with best-in-class solutions to help manage some of the most critical aspects of their evolving businesses with advanced temperature-controlled supply chain solutions tailored to their specific requirements.

Continuous innovation. We plan to capitalize on our internal technological expertise to develop products and solutions that address unmet needs in the global supply chain of the C&GT market and the other life sciences markets we serve. We plan to strengthen our existing products and solutions with complementary products, solutions and innovative technologies that are designed to provide our customers with tailored solutions to manage the critical aspects of the supply chain effectively and efficiently.

Geographical expansion. We intend to expand our global commercial presence by continuing to broaden our capabilities within our existing network and selectively build out new global supply chain centers, manufacturing facilities, and infrastructure in support of known and anticipated growth in demand for our solutions and equipment.

Strategic logistics alliances and collaborations. We have been successful in establishing strategic alliances around the world as a means for our current and prospective client base to utilize our solutions. We have focused our efforts on market leading companies in the logistics services industry as well as participants in the life sciences industry. These strategies drive integration of our solutions into our alliance partners’ services. We currently support the three largest integrators in the world: FedEx, DHL and UPS, with advanced cryogenic logistics solutions for the life sciences industry. Our Compliance Unified Ecosystem(TM) includes alliance partners such as McKesson Specialty Health, a division of McKesson Corporation, Be The Match BioTherapies, Brooks Life Sciences, EVERSANA, Lonza, Medipal and Vineti. The overarching goal of these partnerships is to provide fully integrated solutions including, but not limited to, process optimization that reduces risk, increases transparency, and improves certainty.

34

Targeted acquisitions. We intend to continue to selectively pursue acquisitions that may include innovative technologies and solutions and/or geographic competencies and capabilities to ensure we further enhance and broaden our market leadership and enable our clients to successfully bring products and life-saving therapies to market.

Setting industry standards. Our supply chain solutions are designed to support our clients’ initiatives through early-stage studies, clinical trials, and their global commercialization. We believe our ‘first mover’ advantage and the experience we have gained in supporting the C&GT market have positioned us as a market leader in the space with a strong platform of comprehensive solutions, products and service that have been adopted by many leading life sciences companies. A key strategy for further accelerating market adoption of our enabling solutions is to maintain and extend our position as the industry leader in the markets we serve. We believe this approach can further strengthen our market position, expand the breadth of services our clients utilize, increase our competitive advantage and contribute to our long-term growth.

Our Solutions

We use our competencies and capabilities to develop comprehensive and reliable, technology-centric solutions that address the specific needs of our customers. Our platform of temperature-controlled supply chain solutions, products and service includes cold-chain and cryogenic life sciences equipment, advanced packaging, informatics, specialty logistics services, biostorage services, kitting, labeling, fulfillment and consulting. These solutions, products and services are utilized for temperature-controlled supply chain services in the life sciences industry for personalized medicine, cell therapies, stem cells, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to certain and specific ranges of precision-controlled temperatures and environments.

Our Cryoport solutions are comprised primarily of a sophisticated, cloud-based, logistics management platform, which is branded as the Cryoportal Logistics Management Platform®, or the Cryoportal, Cryoport Express® Shippers and the SmartPak Condition Monitoring System®, or the SmartPak®. The Cryoportal® supports the management of shipments through a single interface, which includes order entry, document preparation, customs documentation, courier management, near real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements. In addition, it provides unique and incisive information dashboards and validation documentation for every shipment through data collected by the SmartPak®. The Cryoportal® can record and retain a fully documented history of all Cryoport Express® Shippers, including chain-of-custody, chain-of-condition, chain-of-identity, and Chain of Compliance® information for each shipment, which is used to ensure that the stability of shipped biologic commodities are maintained throughout the shipping cycle. At the client’s option, recorded information is archived, allowing the client to meet exacting requirements necessary for scientific work and/or proof of regulatory compliance during the logistics process.

During 2018 we introduced our Chain of Compliance® solution, as a new industry standard within the C&GT market. Our Chain of Compliance® goes beyond chain of condition, chain of custody and chain of identity by providing traceability of the equipment, equipment components and processes supporting each client or patient therapy. The Chain of Compliance enables us to recall any single or every transport that an individual Cryoport Express Shipper has taken, the client(s) it supported, the commodity transported, its performance during transit, and each step that we perform before the shipper is put back into service. This includes Cryoport Express Shipper performance and requalification history, commodity history, courier handling and performance history, calibration history, and correlation competencies that can link in field events to equipment performance. Many of these standards have now been incorporated in the recently released ISO-21973 standard and we believe they are likely to become regulatory requirements in the near future.

In September 2019, the Cryoport Express Advanced Therapy Shipper™ was launched to address specific needs of biopharma companies developing and commercializing C&GTs. The Cryoport Express Advanced Therapy Shippers provide verification processes to ensure that it has only been used for human-based therapies and materials and employ advanced validated cleaning methods to minimize the risk of cross-contamination of equipment and materials during use, delivery, and distribution of biopharmaceutical materials.

35

We further extended our solutions, capabilities, and global logistics network through the following recent acquisitions:

In October 2020, we further expanded our capabilities by acquiring CRYOPDP, a leading global provider of innovative temperature-controlled logistics solutions for high value, time critical and temperature-sensitive pharmaceuticals. CRYOPDP covers a significant portion of the healthcare temperature-controlled supply chain including packaging, pick-pack kit preparation, premium services and specialty biopharma/pharma courier support. This acquisition increased our global presence to a network of 27 global supply chain centers in 13 countries. This expanded network gives us a new advantage when serving global multi-national customers and also provides redundancies and backup that reduce supply chain risk for our customers. CRYOPDP has also developed a cloud-based logistics platform branded as UnITy™, which we plan to integrate with our Cryoportal Logistics Management Platform. UnITy™, provides functionalities such as a Transport Management System, Warehousing Management System, Quality Management System, a Customer Experience portal, mobile apps for track and trace during transport and storage as well as integration with transportation agents and business partners.

Also in October 2020, we made a second acquisition, acquiring MVE Biological Solutions from Chart Industries, Inc. MVE Biological Solutions, or MVE, provides cryobiological storage and transportation solutions for the life sciences industry through its advanced line of cryogenic stainless-steel freezers, aluminum dewars and related ancillary equipment used in the storage and transport of life sciences commodities, which includes the rapidly growing C&GT business. With three primary facilities, located in Ball Ground, Georgia, New Prague, Minnesota and Cheng-du, China, MVE Biological Solutions is a leader in serving the life sciences industry throughout the world. The acquisition is a vertical integration that, in addition to expanding our footprint to handle the growing demand driven by the growth in the C&GT market, helps to secure our supply of cryogenic shippers and biostorage equipment. MVE strengthens Cryoport’s presence in its Animal Health, Reproductive and Biopharma/Pharma markets.  Its cryobiological storage and transport clients include cell and gene therapy, medical laboratories, biotech/pharmaceutical research facilities, blood and tissue banks, breeders, veterinary laboratories, large-scale bio-repositories, and fertility clinics. The addition of MVE Biological Solutions allows us to capture a greater share of the global spend on supply chain products and services that supports C&GT.

In May 2019, we expanded our capabilities by acquiring Cryogene Partners, a Texas general partnership doing business as Cryogene Labs, or Cryogene. Cryogene is an expanding state-of-the-art temperature-controlled biostorage solutions business strategically located in Houston, Texas. Cryogene is an industry leader in the management of pre-clinical services which include critical biological commodities to support clinical research, the advancement of C&GTs, GMP biologics, and public health research. It provides customized, end-to-end chain of custody/chain of condition solutions for its clients.

As demonstrated by our organic growth and acquisitions, we are continually focused on establishing comprehensive temperature-controlled supply chain solutions to support the rapidly expanding global landscape of the life sciences industry.

The Markets We Serve

Biopharma/Pharma.   In the biopharma/pharma market we are focused on supporting the saving of lives. From clinical research and development to clinical research organizations to clinical trials for C&GTs to the storage and delivery of life-saving C&GTs to the customers of biopharmaceutical and biotechnology organizations to crucial points of care, we strive to address fundamental-to-advanced temperature-controlled storage, transport, packaging, fulfillment, and information challenges. In particular, C&GTs have become a rapidly growing area of biological drug development, with over 1,200 global clinical trials underway in 2021. This therapeutic approach has certain supply chain challenges that we believe our solutions are tailored to address.

Animal Health. In the animal health market we provide support for animal reproduction, which primarily involves the production of protein for sustaining life. We also support the health of recreational and companion animals. Animal disease prevention and control rely on the safe transport and storage of vaccines and other biological materials around the world. Our temperature-controlled supply chain solutions are designed to help avoid costly delays through nonstop monitoring and complete fleet management from and to the origin and destination points as well as provide cryobiological storage equipment.

Reproductive Medicine. In the reproductive medicine market we are focused on the support of the creation of human life by supporting In Vitro Fertilization, or IVF, and related technologies along with clinical networks globally. Through our CryoStork services, we transport reproductive materials through dedicated medical transport services to help ensure that IVF materials are on the next flight out to their destination. IVF materials also receive one-on-one handling and individualized attention during the entire logistics process. In addition, we also provide cryobiological storage equipment to fertility clinics around the world.

36

Impact of COVID-19

In late 2019, a novel strain of coronavirus that causes coronavirus disease (COVID-19) was reported to have surfaced in Wuhan, China, which has since spread globally. In March 2020, the World Health Organization declared COVID-19 a global pandemic.  Further, the COVID-19 outbreak has resulted in government authorities around the world implementing numerous measures to try to reduce the impact of COVID-19, such as travel bans and restrictions, quarantines, shelter in place or total lock-down orders. Many countries around the world have also implemented the temporary closure of non-essential businesses and other material limitations on the conduct of business. As a provider of life saving therapies, Cryoport is deemed to be an essential business and has remained fully open and operational.  However, the full extent and duration of this pandemic is still unknown at this point and the related governmental, business and travel restrictions in order to contain this virus are continuing to evolve globally. Accordingly, there is significant uncertainty related to the ultimate impact that this global pandemic will have on the results of our operations.

For example, several life sciences companies, including some of our clients, announced during 2020 the temporary suspension of clinical studies and trials as well as other COVID-19 related risks that may impact their preclinical and clinical trials, including delays in patient enrollment or difficulties in initiating or expanding clinical trials, interruption of clinical trial activity, and diversion of healthcare resources to focus on COVID-19 activities. While these temporary suspensions and restrictions have been lifted, these may be reinstated, and other measures may be implemented. In addition, with respect to the impact of the pandemic on the reproductive medicine market, the American Society for Reproductive Medicine (ASRM) and European Society of Human Reproduction and Embryology (ESHRE) both issued recommendations in March of 2020 to temporarily defer fertility treatments and related activities. Both organizations have since updated and reaffirmed their recommendation to resume activities. While these actions have negatively impacted our revenue in the markets we serve temporarily, we cannot determine the longer-term impact at this point. A number of public announcements by government and clients indicate a regional or partially reinstating of COVID-19 related restrictions and while we have experienced revenue ramping back up gradually over time, this may be curtailed by new restrictions. Further, virus containment efforts as a result of governmental actions or policies or other initiatives could lead to further disruption in the supply chain and as a result, we may have difficulties sourcing raw materials and equipment or may incur additional direct costs to provide our solutions.

While longer-term client demand for our services overall remains strong, the effects of the COVID-19 pandemic, including the measures above taken by some of our clients have adversely impacted our revenue growth.  We continue to monitor the evolving situation caused by the COVID-19 pandemic, and we may take further actions required by governmental authorities or that we determine are prudent to support the well-being of our employees, customers, suppliers, business partners and others. The degree to which COVID-19 impacts our business operations, financial performance and results of operations will depend on future developments, which are highly uncertain, continuously evolving and cannot be predicted, including, but not limited to, the duration and spread of the COVID-19 outbreak, its severity, the actions to contain the virus or treat its impact,  such as the efficacy of vaccines (particularly with respect to emerging strains of the virus), and how quickly and to what extent normal economic and operating conditions can resume.   See “Risk Factors—Risk Related to Our Business—The recent global pandemic caused by COVID-19 has already and may continue to adversely affect our business operations, financial performance and results of operations, the extent of which is uncertain and difficult to predict” and our other risk factors discussed in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2020.

37

Results of Operations

Three months ended March 31, 2021 compared to three months ended March 31, 2020:

The following table summarizes certain information derived from our condensed consolidated statements of operations (in thousands):

Three Months Ended March 31, 

 

    

2021

    

2020

    

$ Change

    

% Change

 

($ in 000’s)

 

Service revenues

 

$

26,765

$

9,774

$

16,991

 

173.8

%

Product revenues

 

26,519

 

 

26,519

 

100

%

Total revenues

 

53,284

 

9,774

 

43,510

 

445.2

%

Cost of service revenues

(15,552)

(4,516)

(11,036)

244.4

%

Cost of product revenues

(13,182)

(13,182)

100

%

Total cost of revenues

28,734

4,516

24,218

536.3

%

Gross margin

 

24,550

 

5,258

 

19,292

 

366.9

%

Selling, general and administrative

 

(21,388)

 

(7,111)

 

(14,277)

 

200.7

%

Engineering and development

 

(4,304)

 

(1,733)

 

(2,571)

 

148.4

%

Investment income

398

307

91

29.8

%

Interest expense

 

(1,210)

 

(2)

 

(1,208)

 

49,265

%

Other expense, net

 

(535)

 

(628)

 

93

 

(14.8)

%

Provision for income taxes

 

(1,038)

 

(33)

 

(1,005)

 

3,045

%

 

  

 

  

 

 

Net loss

$

(3,527)

$

(3,942)

$

415

 

(10.5)

%

Paid-in-kind dividend on Series C convertible preferred stock

(2,196)

(2,196)

100

%

Net loss attributatble to common stockholders

$

(5,723)

$

(3,942)

$

(1,781)

 

45.2

%

Total revenues by market (in thousands):

Three Months Ended March 31, 

 

    

2021

    

2020

    

$ Change

    

% Change

 

Biopharma/Pharma

$

42,393

$

8,786

$

33,607

 

382.5

%

Animal health

 

8,997

 

225

 

8,772

 

3893.1

%

Reproductive medicine

 

1,894

 

763

 

1,131

 

148.4

%

Total revenues

$

53,284

$

9,774

$

43,510

 

445.2

%

Revenues. Revenues increased by $43.5 million, or 445.2%, from $9.8 million to $53.3 million for three months ended March 31, 2021, as compared to the same period in 2020. This increase was primarily driven by revenue from the acquisition of MVE biological Solutions and CRYOPDP on October 1, 2020, which contributed $26.5 million and $13.5 million, respectively, and the increase in organic revenue by $3.5 million, or 35.3%, to $13.2 million for three months ended March 31, 2021, as compared to the same period in 2020, primarily driven by increased activity from our biopharmaceutical customers. During the first quarter of 2021 we experienced an increase in the number of customers utilizing our services and the number of clinical trials we support.

Service revenues increased by $17.0 million, or 173.8%, from $9.8 million to $26.8 million for the three months ended March 31, 2021, as compared to the same period in 2020. This increase was driven by the acquisition of CRYOPDP on October 1, 2020, which contributed $13.5 million in revenue from temperature-controlled specialty courier and supply chain services, including packaging, pick-pack kit preparation, the continuing ramp of revenue from our Cryoport Express® solutions, which increased by $3.3 million, or 38%, and revenue from our biostorage services, which increased by $0.2 million, or 14%.

Product revenues were $26.5 million for the three months ended March 31, 2021, primarily a result of the acquisition of MVE Biological Solutions on October 1, 2020, representing revenue from our portfolio of cryogenic stainless-steel freezers, aluminum dewars and related ancillary equipment used in the storage and transport of life sciences commodities, which includes the rapidly growing Cell and Gene Therapy market through a global network of distributors and direct client relationships.

38

Revenues by market

Revenue from the biopharma/pharma market increased $33.6 million, or 382.5%, from $8.8 million to $42.4 million for the three months ended March 31, 2021, as compared to the same period in 2020. This increase was driven by revenue from the acquisition of MVE Biological Solutions and CRYOPDP on October 1, 2020, which contributed $17.3 million and $13.5 million, respectively, and the increase in organic revenue by $2.8 million, or 32.1%, to $11.6 million driven by revenue growth from the support of clinical trials. We now support 543 clinical trials, of which 429 are in the Americas, 86 are in EMEA and 28 are in APAC, compared to 465 clinical trials supported as of March 31, 2020 (384 in the Americas, 65 in EMEA and 16 APAC). The number of Phase III clinical trials supported increased to 69 trials as of March 31, 2021, of which 49 are in the Americas, 19 are in EMEA, and 1 is in APAC. This compares to 62 Phase III trials (45 in the Americas, 16 in EMEA and 1 APAC) supported as of March 31, 2020. The activity in the clinical trial space, particularly in the Cell and Gene Therapy market is expected to drive future revenue growth as these clinical trials advance and resulting therapies are commercialized on a global basis.

Our revenue from the animal health market increased $8.8 million, or 3,893.1%, from $0.2 million to $9.0 million for the three months ended March 31, 2021, as compared to the same period in 2020. This increase was primarily driven by the acquisition of MVE Biological Solutions on October 1, 2020.

Revenues in the reproductive medicine market increased $1.1 million, or 148.4%, from 0.8 million to $1.9 million for the three months ended March 31, 2021, as compared to the same period in 2020. This increase was driven by an increase in organic revenue of $0.6 million, or 76.9%, to $1.4 million, demonstrating the continued success of our CryoStork®-branded offering, and revenue of $0.5 million contributed by MVE Biological Solutions during the first quarter of 2021.

Gross margin and cost of revenues. Gross margin for the three months ended March 31, 2021 was 46.1% of total revenues, as compared to 53.8% of total revenues for the three months ended March 31, 2020. The decrease in gross margin was primarily a result of the margin profiles and related margin contributions from the acquisitions of MVE Biological Solutions and CRYOPDP. Cost of total revenues increased $24.2 million to $28.7 million for the three months ended March 31, 2021, as compared to $4.5 million in the same period in 2020. The increase in cost of total revenues is commensurate with the increase in business volume and the addition of cost of revenue from the acquisitions of MVE Biological Solutions and CRYOPDP in October 2020.

Gross margin for our service revenues was 41.9% of service revenues, as compared to 53.8% of service revenues for the three months ended March 31, 2020. This decrease was a result of the lower margin contribution from the acquisition of CRYOPDP in October 2020. Our cost of revenues is primarily comprised of freight charges, payroll and associated expenses related to our global logistics and supply chain centers, depreciation expenses of our Cryoport Express® Shippers and supplies and consumables used for our solutions.

Gross margin for our product revenues was 50.3% of product revenues. Product revenues, related cost of revenues and resulting gross margins were primarily a result of the acquisition of MVE Biological Solutions. Our cost of product revenues were primarily comprised of materials, direct and indirect labor, inbound freight charges, purchasing and receiving, inspection, and distribution and warehousing of inventory. In addition, shop supplies, facility maintenance costs and depreciation expense for assets used in the manufacturing process were included in cost of product revenues.

Selling, general and administrative expenses. Selling, general and administrative (“SG&A”) expenses include the costs associated with selling our products and services and costs required to support our marketing efforts including legal, accounting, patent, shareholder services, amortization of intangible assets and other administrative functions.

For the first quarter of 2021, SG&A expenses increased by $14.3 million, or 200.7% as compared to the first quarter of 2020. This increase is primarily due to the addition of $9.5 million of SG&A expenses from the acquisition of MVE Biological Solutions and CRYOPDP in October 2020, as well as the continued expansion of our infrastructure to support the acquisitions and expected future growth. Wages and associated employee costs increased $5.6 million from $3.4 million in 2020 to $9.1 million in 2021.  Intangible asset amortization expense is included in SG&A and consists of charges related to the amortization of intangible assets associated with the acquisitions of CRYOPDP and MVE Biological Solutions in 2020 and Cryogene in 2019, in which we acquired definite-lived intangible assets.  Intangible asset amortization expense increased by $3.5 million, from $0.1 million in 2020, to $3.6 million in 2021. Facility and other overhead intercompany allocations increased $1.6 million, public company related expenses (including legal, audit and internal control audit fees) increased by $1.2 million and stock compensation expense increased by $1.2 million compared to the same period in 2020.

39

Engineering and development expenses. Engineering and development expenses increased $2.6 million, or 148.4%, for three months ended March 31, 2021, as compared to the same period in 2020. The increase was primarily due to an increase of $1.4 million in consulting, prototype and development costs directed at further enhancing our logistics and supply chain solutions and $0.9 million in wages and associated employee costs to add software development and engineering resources. We continually strive to improve and expand the features of our Cryoport Express® Solutions and portfolio of services and suite of temperature-controlled products. Our primary developments are directed towards facilitating the safe, reliable and efficient transport and storage of life science commodities through innovative and technology-based solutions. This includes significantly enhancing our Cryoportal® Logistics Management Platform and related technology solutions as well as developments to expand our Cryoport Express® Shipper fleet, such as the CryosphereTM shipper, a cryogenic dry-vapor shipper utilizing patent pending technology that passively stabilizes the payload through an internal gravitational sphere, thereby further mitigating transport risks. In addition, engineering and development efforts are also focused on MVE Biological Solutions’ portfolio of advanced cryogenic stainless-steel freezers, aluminum dewars and related ancillary equipment used in the storage and transport of life sciences commodities. We supplement our internal engineering and development resources with subject matter experts and consultants to enhance our capabilities and shorten development cycles.

Investment Income. Investment income increased by $0.1 million, for the three months ended March 31, 2021, as compared to the prior year as a result of higher average invested cash balances offset by lower interest rates on such invested cash balances.

Interest expense.  Interest expense increased $1.2 million for the three months ended March 31, 2021, as compared to the three months ended March 31, 2020 due to interest on the convertible senior notes.

Other expense, net.  The increase in other expense, net for the three months ended March 31, 2021is primarily due to realized and unrealized gains and losses on short-term investments and foreign currency fluctuations.  

Provision for income taxes.  The provision for income taxes increased $1.0 million for the three months ended March 31, 2021, as compared to the three months ended March 31, 2020.  This increase represents taxes on both U.S. and foreign earnings at a combined effective income tax rate of negative 41.7% and 0.8%, respectively.  The negative effective tax rate of 41.7% for the three months ended March 31, 2021 differed from the U.S. federal statutory rate of 21% primarily due to changes in the valuation allowance that we maintain against our deferred tax assets, income earned by certain foreign subsidiaries being taxed at higher rates than the U.S. federal statuary rate, and excess tax benefits associated with share-based compensation. The effective tax rate for the three months ended March 31, 2021 varied significantly from the effective tax rate from the prior year primarily due to our acquisitions of MVE Biological Solutions and CRYOPDP during the fourth quarter of 2020, which include international operations.

Paid-in-kind dividend on Series C convertible preferred stock. The paid-in-kind dividend of $2.2 million relates to the private placement of Series C Preferred Stock with Blackstone.

Non-GAAP Financial Measures

We provide adjusted EBITDA as a supplemental measure to GAAP measures regarding our operating performance. This financial measure excludes the impact of certain acquisition related items and other expenses and, therefore, has not been calculated in accordance with GAAP. A detailed explanation and a reconciliation of this non-GAAP financial measure to its most comparable GAAP financial measure is described below.

We include this financial information because we believe this measure provides a more accurate comparison of our financial results between periods and more accurately reflects how management reviews its financial results. We excluded the impact of certain acquisition related items because we believe that the resulting charges do not accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.

40

Cryoport, Inc. and Subsidiaries

Adjusted EBITDA Reconciliation

(Unaudited, in thousands)

    

Three Months Ended

March 31,

2021

2020

GAAP net loss

$

(3,527)

$

(3,942)

Non-GAAP adjustments to net loss:

 

  

 

  

Depreciation and amortization expense

 

4,837

 

824

Acquisition and integration costs

 

828

 

Investment income

 

(398)

 

(307)

Interest expense, net

 

1,210

 

2

Stock-based compensation expense

 

2,990

 

1,620

Income taxes

 

1,038

 

33

Adjusted EBITDA

$

6,978

$

(1,770)

Adjusted EBITDA is measured by taking net income/loss as reported in accordance with GAAP, excluding depreciation and intangible amortization expenses, acquisition and integration costs, stock-based compensation expense, investment income, interest expense and income taxes included in the condensed consolidated statements of operations.

Liquidity and Capital Resources

As of March 31, 2021, the Company had cash and cash equivalents of $85.5 million, $267.7 million in short-term investments and had working capital of $381.9 million. Historically, we have financed our operations primarily through sales of equity securities and debt instruments.

For the three months ended March 31, 2021, we used $6.0 million of cash for operations primarily as a result of the net loss of $3.5 million offset by non-cash expenses of $8.5 million comprised of $4.8 million of depreciation and amortization, $3.0 million of stock-based compensation, $0.3 million of unrealized losses on our equity securities as well as $0.3 million of amortization of debt discount. Also contributing to the cash impact of our net operating loss, excluding non-cash items, was an increase in prepaids and other current assets of $6.5 million primarily due to a receivable from Chart Industries resulting from the transition services agreement, an increase in accounts receivable of $5.2 million, an increase in inventory of $1.0 million, an increase in accrued compensation of $0.8 million and an increase in accounts payable and accrued expenses of $0.5 million.  

Net cash used in investing activities of $215.4 million during the three months ended March 31, 2021 was primarily due to the  $215.3 million purchase of short-term investments, and $3.0 million for the capitalization of software development costs for our Cryoportal® Logistics Management Platform, and additional purchases of Cryoport Express® Shippers, Smart Pak IITM Condition Monitoring Systems, freezers and computer equipment, partially offset by the maturity of short-term investments of $3.0 million.

Net cash provided by financing activities totaled $271.4 million during the three months ended March 31, 2021, primarily as a result of $269.8 million in net proceeds from our February 2021 public offering of common stock and $1.6 million proceeds from the exercise of stock options and warrants.

The Company’s management believes that, based on its current plans and assumptions, the current cash and cash equivalents on hand, short-term investments, together with projected cash flows, will satisfy our operational and capital requirements for at least the next twelve months. The Company’s management recognizes that the Company may need to obtain additional capital to fund its operations and potential acquisitions until sustained profitable operations are achieved. Additional funding plans may include obtaining additional capital through equity and/or debt funding sources. No assurance can be given that additional capital, if needed, will be available when required or upon terms acceptable to the Company.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to market risk for the effect of interest rate changes, foreign currency fluctuations, and changes in the market values of our investments.

41

Interest Rate Risk

Our exposure to market risk for changes in interest rates relates primarily to our investment portfolio and our long-term debt. Our long-term debt is carried at amortized cost and fluctuations in interest rates do not impact our consolidated financial statements. However, the fair value of our debt, which pays interest at a fixed rate, will generally fluctuate with movements of interest rates, increasing when interest rates are declining and declining when interest rates are increasing. We invest our excess cash in high investment grade money market funds and investment grade short to intermediate-term fixed income securities. Fixed income securities may have their fair market value adversely affected due to a rise in interest rates, and we may suffer losses if forced to sell securities that have declined in market value due to changes in interest rates. As of March 31, 2021, the estimated fair value of the Senior Notes was $108.8 million. For additional information about the Senior Notes, see Notes 6 and 9 to the consolidated financial statements in Part I, Item 1 of this Quarterly Report.

Foreign Exchange Risk

We operate in the United States and other foreign countries, which creates exposure to foreign currency exchange fluctuations. Net sales and related expenses generated from our international business are primarily denominated in the functional currencies of the corresponding subsidiaries and primarily include Euros, British Pounds, Chinese Yuan, and Indian Rupee.

We have foreign exchange risk related to foreign-denominated cash and cash equivalents. Based on the balance of as of March 31, 2021, of $15.3 million, an assumed 5%, 10%, and 20% adverse change to foreign exchange would result in declines of $0.8 million, $1.5 million and $3.1 million, respectively, recorded in “Accumulated other comprehensive income (loss)”, a separate component of stockholders’ equity.

We have foreign exchange risk related to our long-term intercompany balances denominated in Euros. Based on the long-term intercompany balances as of March 31, 2021, an assumed 5%, 10%, and 20% adverse change to foreign exchange would result in losses of $3.1 million, $6.3 million, and $12.6 million, respectively, recorded to “Accumulated other comprehensive income (loss)”.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures.

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we have conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2021. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of March 31, 2021.

In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

As permitted by SEC guidance for newly acquired businesses, management’s assessment of our disclosure controls and procedures did not include an assessment of the controls and procedures of MVE and CRYOPDP, which were acquired October 1, 2020.  MVE and CRYOPDP accounted for 42% and 12% of total assets and 50% and 5% of net assets, respectively, as of March 31, 2021 and 50% and 25% of revenues and (193)% and 22% of net loss, respectively, for the three months ended March 31, 2021.

42

Changes in internal control over financial reporting.

There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter ended March 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

In the ordinary course of business, we are at times subject to various legal proceedings and disputes, including product liability claims. We currently are not aware of any such legal proceedings or claim that we believe will have, individually or in the aggregate, a material adverse effect on our business, operating results or cash flows. It is our practice to accrue for open claims based on our historical experience and available insurance coverage.

ITEM 1A.

RISK FACTORS

In addition to the other information set forth in this Quarterly Report, the risks described in Part I, Item 1A, Risk Factors, in our Annual report on Form 10-K for the year ended December 31, 2020 could materially and adversely affect our business, financial condition and results of operations. These risk factors do not identify all of the risks that we face. Our business, financial condition and results of operations could also be affected by factors that are not presently known to us or that we currently consider to be immaterial.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Recent Sale of Unregistered Securities

There were no unregistered sales of equity securities during the quarter ended March 31, 2021 other than as reported in our Current Reports on Form 8-K filed with the SEC.

Issuer Purchases of Equity Securities

We did not purchase any shares of our common stock during the quarter ended March 31, 2021.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4. MINE SAFETY DISCLOSURES

Not Applicable

ITEM 5. OTHER INFORMATION

None

43

ITEM 6. EXHIBITS

Exhibit

    

 

Index

 

 

10.1

Cryoport, Inc. 2018 Omnibus Equity Incentive Plan (as amended by the First Amendment). Incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K dated March 3, 2021.

31.1+

 

Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

31.2+

 

Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

32.1+

 

Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

101.INS+

 

Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

 

 

 

101.SCH+

 

Inline XBRL Taxonomy Extension Schema Document.

 

 

 

101.CAL+

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document.

 

 

 

101.DEF+

 

Inline XBRL Taxonomy Extension Definition Linkbase Document.

 

 

 

101.LAB+

 

Inline XBRL Taxonomy Extension Label Linkbase Document.

 

 

 

101.PRE+

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document.

104+

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

+  Filed or furnished herewith.

44

SIGNATURES

In accordance with the requirements of the Exchange Act, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Cryoport, Inc.

Dated: May 6, 2021

 

 

 

 

By:

/s/ Jerrell W. Shelton

 

 

Jerrell W. Shelton

 

 

President and Chief Executive Officer

 

 

 

Dated: May 6, 2021

 

 

 

 

 

 

By:

/s/ Robert S. Stefanovich

 

 

Robert S. Stefanovich

 

 

Chief Financial Officer

45

EX-31.1 2 cyrx-20210331xex31d1.htm EXHIBIT 31.1

EXHIBIT 31.1

CERTIFICATION

CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Jerrell W. Shelton, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Cryoport, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 6, 2021

/s/ Jerrell W. Shelton

 

JERRELL W. SHELTON

President and Chief Executive Officer

(Principal Executive Officer)


EX-31.2 3 cyrx-20210331xex31d2.htm EXHIBIT 31.2

EXHIBIT 31.2

CERTIFICATION

CHIEF FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Robert S. Stefanovich, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Cryoport, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 6, 2021

/s/ Robert S. Stefanovich

 

ROBERT S. STEFANOVICH

Chief Financial Officer

(Principal Financial Officer)


EX-32.1 4 cyrx-20210331xex32d1.htm EXHIBIT 32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Cryoport, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jerrell W. Shelton, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge that:

(1)     The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)     The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Jerrell W. Shelton

 

JERRELL W. SHELTON

President and Chief Executive Officer

 

May 6, 2021

In connection with the Quarterly Report of Cryoport, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Robert S. Stefanovich, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge that:

(1)     The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)     The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Robert S. Stefanovich

 

ROBERT S. STEFANOVICH

Chief Financial Officer

 

May 6, 2021

A signed original of this written statement required by Section 906 has been provided to Cryoport, Inc. and will be retained by Cryoport, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

This Certification is being furnished pursuant to Rule 15(d) and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act (15 U.S.C. 78r), or otherwise subject to the liability of that section. This Certification shall not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.


EX-101.SCH 5 cyrx-20210331.xsd XBRL TAXONOMY EXTENSION SCHEMA 00100 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Condensed Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00500 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Cash, Cash Equivalents and Short-Term Investments (Details) link:presentationLink link:calculationLink link:definitionLink 40503 - Disclosure - Cash, Cash Equivalents and Short-Term Investments - Contractual Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - Goodwill and Intangible Assets - Expected Future Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Convertible Senior Notes - Components of Convertible notes payable (Details) link:presentationLink link:calculationLink link:definitionLink 40903 - Disclosure - Convertible Senior Notes - Summary of total gross principal payments due under the Convertible notes payable (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Leases - Components Of Lease Cost (Detail) link:presentationLink link:calculationLink link:definitionLink 41103 - Disclosure - Leases - Payments Under Non-Cancellable Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00405 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00505 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 20302 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 31403 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Nature of the Business (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Summary of Significant Accounting Policies - Disaggregates Our Revenues by Major Source (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - Summary of Significant Accounting Policies - Disaggregation Our Geographical Revenues by Origin (Details) link:presentationLink link:calculationLink link:definitionLink 40303 - Disclosure - Summary of Significant Accounting Policies - Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 40304 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Shares (Details) link:presentationLink link:calculationLink link:definitionLink 40305 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Acquisition of CryoGene Partners - Preliminary Purchase Price Allocation (Details link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - Cash, Cash Equivalents and Short-Term Investments - Available-for-sale debt securities (Details) link:presentationLink link:calculationLink link:definitionLink 40504 - Disclosure - Cash, Cash Equivalents and Short-Term Investments - Equity Investments (Details) link:presentationLink link:calculationLink link:definitionLink 40505 - Disclosure - Cash, Cash Equivalents and Short-Term Investments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 40803 - Disclosure - Goodwill and Other Intangible Assets - Schedule of goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 40904 - Disclosure - Convertible Senior Notes - Additional information (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Note Payable (Details) link:presentationLink link:calculationLink link:definitionLink 41102 - Disclosure - Leases - Supplemental Cash Flows Information (Detail) link:presentationLink link:calculationLink link:definitionLink 41104 - Disclosure - Leases - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - Stockholders' Equity - Common Stock Reserved for Future Issuance (Details) link:presentationLink link:calculationLink link:definitionLink 41302 - Disclosure - Stockholders' Equity - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 41401 - Disclosure - Stock-Based Compensation - Assumptions Used to Estimate Fair Value of Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 41402 - Disclosure - Stock-Based Compensation - Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 41403 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 41404 - Disclosure - Stock-Based Compensation - Restricted stock unit (Details) link:presentationLink link:calculationLink link:definitionLink 41405 - Disclosure - Stock-Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 41501 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Management's Representation and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Nature of the Business link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Cash, Cash Equivalents and Short-Term Investments link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Goodwill and Intangible Assets link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Convertible Senior Notes link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Note Payable link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 11401 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 11501 - Disclosure - Subsequent Event link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Cash, Cash Equivalents and Short-Term Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Goodwill and Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Convertible Senior Notes (Tables) link:presentationLink link:calculationLink link:definitionLink 31103 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 31303 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40804 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - Convertible Senior Notes - Interest expenses incurred on Convertible notes payable (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 cyrx-20210331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 cyrx-20210331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 cyrx-20210331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 9 cyrx-20210331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 10 cyrx-20210331x10q004.jpg GRAPHIC begin 644 cyrx-20210331x10q004.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **3-+0 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!12%E'4@?4T @C@@_2@ +!023@"N>U#QCI=A(8VEW,.N*7QA?266A2-$2"W& M17.>$_#-CJU@;V\!E9CP#VKKHTH>S]K4V//Q&(JNLJ%&U[7U.DT[Q?IFH2!% MD"L>F:WPP(R*\U\7^'K31((KVRS&2V"N:Z_PM=O>:)#)(26'&:*U&'(JM/86 M&Q-7VKH5MUKH;E%%%LBNNY&##U!S7R#; M:/\ $75H/ML,>I/&_P P8,W-.TCXA^+_ 7J@ANY)F"'YX+CGC\: /KTL!U( M'UH# ]"#]*\#^)?CN]U'P-I6KZ;)-9M,V' XYYKC_#?QCU30= NX7D>ZOYF_ M=O(@#ZLR!2>8G]X?G7RMX<\4>.M=\365P\EW):M.F_8ORXR,UL_&& M?Q%X8\01W5IJ-REG=(& #'"M@9'\Z /I'.:6O.O@_P",CXJ\+*EQ+OO;7Y), M]3[_ *UZ%+(L43R.<*@+$^PH 4NHZL!]32A@>AS]*^3?&7C_ %W6?&]S#I5] M*D7F^3$D;$ XX_I7?>)/B7-X#\-6>C03?:M9:+,TCG/EDT >XO/%'Q)(BG_: M.*$GBD_U>/O&<[W%HU]<#N8B0H_*FSZAX\\%W237-/%-O;Z38/.Q1= MN(?O-[DU7O\ 3?B#H40O;I=1BC7G>6; ^M 'V)17SK\-?C3>"_ATGQ!()(9" M$2<]03QS7OFI:M::7I4NI74H6UC3>7]L9H ND@?]X5\P>,O MC+KGB'4'L]%+6]KNVH$^\]8R^'OB/+;?:Q#J>PC=GHHR*^ M3?#/Q9\3>$]16WU%GN(%;$D4WW@/K7T%=>)[;7?AW>:QI<_6 L"IY1O2@#KP MZGHP/XTN>*^0O"?Q.U71]>%YJ-Y/TR1Y. MV. =!0!Z%\>O$>KZ'?:8NFWTMNKQDL(V(R^D\.^&6U$/]K-N=_F=<[C7*^'G\8KIY&B+>&US_P LKZ9+;$@DC@^]>?Z3J.I^$;F2UGMWDMB> !53X*MXD9-0_M];DCZ38+INGQ6R_PCFK,5K! ,11*GT%2XHK5^>*A%62##83V4G4F[R?46BBB MN<[0HHHH **** "BBB@#SKXT:Q-I/@.X\ABKS$1DCT/!KQ7X)^%K;Q'XL:XO M4$L-J-Y1NC'BO;OC%HDVL^!+D0*6DA/F8 Z@;"P8,HP3[&N@M[VV MNH%F@GBDC89#*X(KE?%GQ*T'PBT27IQF@#SS]H&T@L?#.F6 MUM&L<4;!551QWKA?@OX)MO%.O27-\N^UM &*'HQ_R:[/X[:M9ZUX2TN^L9EE MAD8$%3G'7BK/[.*C^RM3..?,Z_@* /:K:PM+.)8K>VBC1>@51Q7(_%'PJGBC MPA$O&Z6]PQ2"X;R90>Q_SBO?? MBOXG7P]X(N)(I );D>7&0?7@_P Z\)^,/A1_"WC(WMNNVVNF\V,CL?3]*QO% MWCJ[\6:7I=A)N_T5 A_VFXYH T_A/HC:EXBGUFX3?;V"&9R1P6ZC^M8,"/XM M^(*1W#D_:KG!)]!_^JOHOX8>#5TKX^O;F-1&N0FX;F/H!0!\ M@A)O"OQ \F!R'M;H*"#V_P FN@^,\YNO&@N",&2!6(_$U@VHN/%_Q!62)&9[ MJZW<#.!_^H5O_&F 6OC;[.#GRX%7/XF@#VWX,^%[+2?!MO>B)&NKGYVD(YQV M'ZUZ)<6D%W \,\2/&XP585Y=\%?&ECJ?A:+2IITBO+7Y=KL!N';%>G7FI6EC M;/<7%S%'&B[B6<"@#Y#^*?A^'PQXZN(;(;(6(EC _AY/^%=AXZ\77-S\)-$M M!,V^X&)#ZA>/ZUQGQ+\0Q^+O'-Q/99>$L(HO?DX_G7=^/?!=S:_"31KD0GS; M50T@ Y 89_I0!+^S_P"%;*^>[UB\A65XFVQ!AG!XYKZ'"*%QM7'IBOFSX$>- M;+1KJXT?4)1$MPV8G8X&>.#7T@MQ T?F+-&4_O!AB@#Q/X]^#[1M%37K:!(Y MXF"R%1C<#_\ JKC/A1J\X\->(]+9BT+6Y=03T.0*ZOX\>.+*335\/64ZRRNP M>4HV0,=N/K7,_"G0YU\)>(]7D0K%]G,:$CKR* /./#6B/XA\2VNF)QYT@#'T M&>?TK[*\/>%-*\.:;%9V=I$-B@,^W)8^M?+_ ,&@#\2+3([-_(U]> 4 ?._[ M1X"WVD@ >4>!]377_ 1$;P,=R*?WIZCV%".#CZXJQ0 4444 M%%%% !1110 4444 %%%% #)8UEC:-U#(PP01P17@/Q"^!UQ->2ZEX< ;S"6: MW/&#[5] T8H ^/(])^(>D!K.*+4D7IM5FQ^%:F@?"'Q7XEOTFU5988&(+RSL M2V/QKZL,,9.3&A/NHIP4 8 P/:@#PSXD?#BZMO!VFZ/X>M9+D0OE^I.>@I:\K^-@UM M=&M)M$$_FI)EC#U YH L?&[3M-O/ \LU[*L<\!W0$]2>F/YU\^_#/PTWB?QE M:6Y0M#$PDD^@Y_I3Y;3QOXQN(K6XCO;G!P XP!7T/\+?AVG@K2C)<[7U&"_'OA2Y*V]O>1C/!@9MI_*G1>"?'OBNY47,%XX)Y,[-M'YU]>M&C_>56^HS M0L:+]U57Z#% 'F_PU^%5IX,C^V71$^HN.6(X3Z5XO\=/^2AS_P#7-?YFOK*O ME7XW6%W)X='L];T0R2I,FX^2Q#+^55)-"^ M(&L.+2:'4I!TVNSXKZ9^'$3)X#TQ)$*L(QE6%=2(HP1=C(1QBK.*6@#YI\:_ W5;"^ MDO/#P,]N3N" D,GTKDEL/B)!&;%4U0)G;C<]?86.*;Y,6<^6F?7:* /E_P * M_!+7]C:3;@ 0%$4#EC74@ =*",T ? M-'PM\!^)-&\=VUY?:;+%;J&W.P.!P:^F*3:!V'Y4M 'G7Q8^'[^-=&C>T(%] M;#_ !UHMPUK;VE]"6."(BP!_*OLBF&-"MTF,4M !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 &:0X/!&:Y/X@ZCJFG: )=*EBCF+@,9#C*YYQ[UQ]IXPOM M0L;&S_M VJ2L5FNY5QM(.,#_ #VH ]9CABBSLC5<]<"GYKS"^\2ZEI]Q;6T& MHI=QFV9S,H&&(S_A6'!XL\2'PM%>P72R7LSH%4].2.* /:\T9KQP?$36[@:@ MOE&"6W1(Y R_ZMBO+?3(J]JNO:AI7AMY+37([Z5W4;E ^3./>@#U;-)G%XD8[03R:SH_%,\/BG5K*61&$$8:"$\%CCH* .YS5>6RMIGWR MP([>I%>41^+M7BCM=4CU%+FXN)6233E490#/^ [4D/C:^74X+JZO'5IYS$;1 M$SY?3&?SH ]=1%C4*BA5'0"GYKQ_7/%FO1627$=PB6ZS2"7'W\!N,#OQ5^^U M75IM3\/&RU)UMM1!W!DY& WO_LT >H9HS7F&H^)]5#?8OM2V\;W31-=,.$ Q M_C5?Q'KVLZ;I5K]BU>"[@#-YLJX#D ]O6@#U?-&:PO#.MV^K:-;2)/YDQ3+! MAAORJ".^GN+V6Y58B.HJHQ0:6C>?NGE8XXZ 4 M^77KB2*)HGP?+.[C^(8H]A(7UR!UV:,UR-EK-]=7<%I+^[=D))QU]ZLVTNH& MTN9A/O>%S@$=0*'1:W94<5&6J1TN:6LG1[J>YA\RY=1))RL8["M45E)6=C>$ MN90#D+C^M:=% &>NAZ:J(@M(PJ+M7CH*A@\-Z3; "&R1 M0""!S@$5K44 46TBP9YG-I$6F&)#M^\/>JZ^&](2U>V6QC\ESEE]36M10!0M MM%L+0H8+94\O.WD\4V70]-FOQ?/:H;D=).]:-% &;%H.F07INX[*)9SU;%!T M#2S?&\-E%]H/\6/Z5I44 9EQX?TNZ0)-9QLH);'N:L'3+,M QMTS!_JN/N_3 M\ZMT4 49M'L+F!X9K6-HW.Y@1U/K4#^'-)DM4MFLHS"GW5YXK5HH J6^G6EJ MX>"!(V"[?E]*5[*V>;S6A4R>M6L48HNT)I/ XML 11 cyrx-20210331x10q_htm.xml IDEA: XBRL DOCUMENT 0001124524 2020-09-30 0001124524 cyrx:ClassCConvertiblePreferredStockMember 2021-02-05 2021-02-05 0001124524 us-gaap:RetainedEarningsMember 2021-03-31 0001124524 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001124524 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001124524 us-gaap:RetainedEarningsMember 2020-12-31 0001124524 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001124524 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001124524 us-gaap:RetainedEarningsMember 2020-03-31 0001124524 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001124524 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001124524 us-gaap:RetainedEarningsMember 2019-12-31 0001124524 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001124524 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001124524 us-gaap:OverAllotmentOptionMember 2019-06-24 0001124524 us-gaap:PreferredClassBMember 2021-03-31 0001124524 us-gaap:PreferredClassAMember 2021-03-31 0001124524 us-gaap:CommonStockMember 2021-03-31 0001124524 cyrx:PreferredClassCMember 2021-03-31 0001124524 us-gaap:PreferredClassBMember 2020-12-31 0001124524 us-gaap:PreferredClassAMember 2020-12-31 0001124524 us-gaap:CommonStockMember 2020-12-31 0001124524 cyrx:PreferredClassCMember 2020-12-31 0001124524 us-gaap:PreferredClassBMember 2020-03-31 0001124524 us-gaap:PreferredClassAMember 2020-03-31 0001124524 us-gaap:CommonStockMember 2020-03-31 0001124524 cyrx:PreferredClassCMember 2020-03-31 0001124524 us-gaap:PreferredClassBMember 2019-12-31 0001124524 us-gaap:PreferredClassAMember 2019-12-31 0001124524 us-gaap:CommonStockMember 2019-12-31 0001124524 cyrx:PreferredClassCMember 2019-12-31 0001124524 us-gaap:EmployeeStockOptionMember 2020-12-31 0001124524 us-gaap:EmployeeStockOptionMember cyrx:Plan2018Member 2021-03-31 0001124524 us-gaap:EmployeeStockOptionMember cyrx:Plan2018Member 2018-05-31 0001124524 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001124524 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-03-31 0001124524 us-gaap:CostOfSalesMember 2021-01-01 2021-03-31 0001124524 cyrx:EngineeringAndDevelopmentMember 2021-01-01 2021-03-31 0001124524 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-03-31 0001124524 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-03-31 0001124524 us-gaap:CostOfSalesMember 2020-01-01 2020-03-31 0001124524 cyrx:EngineeringAndDevelopmentMember 2020-01-01 2020-03-31 0001124524 cyrx:ReproductiveMedicineMember cyrx:GlobalLogisticsSolutionsMember 2021-01-01 2021-03-31 0001124524 cyrx:BiopharmaceuticalMember cyrx:GlobalLogisticsSolutionsMember 2021-01-01 2021-03-31 0001124524 cyrx:AnimalHealthMember cyrx:GlobalLogisticsSolutionsMember 2021-01-01 2021-03-31 0001124524 us-gaap:EMEAMember 2021-01-01 2021-03-31 0001124524 srt:AsiaPacificMember 2021-01-01 2021-03-31 0001124524 srt:AmericasMember 2021-01-01 2021-03-31 0001124524 cyrx:GlobalLogisticsSolutionsMember 2021-01-01 2021-03-31 0001124524 cyrx:ForeignCustomersMember 2021-01-01 2021-03-31 0001124524 cyrx:ReproductiveMedicineMember cyrx:GlobalLogisticsSolutionsMember 2020-01-01 2020-03-31 0001124524 cyrx:BiopharmaceuticalMember cyrx:GlobalLogisticsSolutionsMember 2020-01-01 2020-03-31 0001124524 cyrx:AnimalHealthMember cyrx:GlobalLogisticsSolutionsMember 2020-01-01 2020-03-31 0001124524 us-gaap:EMEAMember 2020-01-01 2020-03-31 0001124524 srt:AsiaPacificMember 2020-01-01 2020-03-31 0001124524 srt:AmericasMember 2020-01-01 2020-03-31 0001124524 cyrx:GlobalLogisticsSolutionsMember 2020-01-01 2020-03-31 0001124524 srt:MinimumMember us-gaap:ComputerEquipmentMember 2021-01-01 2021-03-31 0001124524 srt:MinimumMember us-gaap:BuildingMember 2021-01-01 2021-03-31 0001124524 srt:MinimumMember cyrx:TruckAndAutoMember 2021-01-01 2021-03-31 0001124524 srt:MinimumMember cyrx:FreezerMember 2021-01-01 2021-03-31 0001124524 srt:MinimumMember cyrx:EquipmentAndFurnitureMember 2021-01-01 2021-03-31 0001124524 srt:MaximumMember us-gaap:ComputerEquipmentMember 2021-01-01 2021-03-31 0001124524 srt:MaximumMember us-gaap:BuildingMember 2021-01-01 2021-03-31 0001124524 srt:MaximumMember cyrx:TruckAndAutoMember 2021-01-01 2021-03-31 0001124524 srt:MaximumMember cyrx:FreezerMember 2021-01-01 2021-03-31 0001124524 srt:MaximumMember cyrx:EquipmentAndFurnitureMember 2021-01-01 2021-03-31 0001124524 us-gaap:OverAllotmentOptionMember 2019-06-24 2019-06-24 0001124524 us-gaap:ConvertiblePreferredStockMember 2021-03-31 0001124524 cyrx:ClassCConvertiblePreferredStockMember 2021-03-31 0001124524 cyrx:ClassBConvertiblePreferredStockMember 2021-03-31 0001124524 us-gaap:ConvertiblePreferredStockMember 2020-12-31 0001124524 cyrx:ClassCConvertiblePreferredStockMember 2020-12-31 0001124524 cyrx:ClassBConvertiblePreferredStockMember 2020-12-31 0001124524 cyrx:ClassCConvertiblePreferredStockMember us-gaap:PrivatePlacementMember 2020-10-01 0001124524 cyrx:ClassCConvertiblePreferredStockMember 2021-02-05 0001124524 cyrx:MveCryobiologicalStorageBusinessMember 2020-08-24 2020-08-24 0001124524 2020-05-01 2020-05-31 0001124524 us-gaap:USTreasurySecuritiesMember 2021-03-31 0001124524 cyrx:MutualFundsMember 2021-03-31 0001124524 us-gaap:USTreasurySecuritiesMember 2020-12-31 0001124524 cyrx:MutualFundsMember 2020-12-31 0001124524 cyrx:InstallmentTwoMember cyrx:CryopdpMember 2021-03-31 0001124524 cyrx:InstallmentOneMember cyrx:CryopdpMember 2021-03-31 0001124524 cyrx:MveCryobiologicalStorageBusinessMember 2021-01-01 2021-03-31 0001124524 cyrx:MveCryobiologicalStorageBusinessMember 2021-03-31 0001124524 cyrx:CryopdpMember 2020-10-01 0001124524 us-gaap:UseRightsMember 2021-01-01 2021-03-31 0001124524 us-gaap:TrademarksAndTradeNamesMember 2021-01-01 2021-03-31 0001124524 us-gaap:TechnologyBasedIntangibleAssetsMember 2021-01-01 2021-03-31 0001124524 us-gaap:OrderOrProductionBacklogMember 2021-01-01 2021-03-31 0001124524 us-gaap:NoncompeteAgreementsMember 2021-01-01 2021-03-31 0001124524 us-gaap:CustomerRelationshipsMember 2021-01-01 2021-03-31 0001124524 cyrx:PatentsAndTrademarksMember 2021-01-01 2021-03-31 0001124524 cyrx:AgentNetworkMember 2021-01-01 2021-03-31 0001124524 us-gaap:UseRightsMember 2020-01-01 2020-12-31 0001124524 us-gaap:TrademarksAndTradeNamesMember 2020-01-01 2020-12-31 0001124524 us-gaap:TechnologyBasedIntangibleAssetsMember 2020-01-01 2020-12-31 0001124524 us-gaap:OrderOrProductionBacklogMember 2020-01-01 2020-12-31 0001124524 us-gaap:NoncompeteAgreementsMember 2020-01-01 2020-12-31 0001124524 us-gaap:CustomerRelationshipsMember 2020-01-01 2020-12-31 0001124524 cyrx:PatentsAndTrademarksMember 2020-01-01 2020-12-31 0001124524 cyrx:AgentNetworkMember 2020-01-01 2020-12-31 0001124524 us-gaap:UseRightsMember 2021-03-31 0001124524 us-gaap:TrademarksAndTradeNamesMember 2021-03-31 0001124524 us-gaap:TechnologyBasedIntangibleAssetsMember 2021-03-31 0001124524 us-gaap:OrderOrProductionBacklogMember 2021-03-31 0001124524 us-gaap:NoncompeteAgreementsMember 2021-03-31 0001124524 us-gaap:CustomerRelationshipsMember 2021-03-31 0001124524 cyrx:PatentsAndTrademarksMember 2021-03-31 0001124524 cyrx:AgentNetworkMember 2021-03-31 0001124524 us-gaap:UseRightsMember 2020-12-31 0001124524 us-gaap:TrademarksAndTradeNamesMember 2020-12-31 0001124524 us-gaap:TechnologyBasedIntangibleAssetsMember 2020-12-31 0001124524 us-gaap:OrderOrProductionBacklogMember 2020-12-31 0001124524 us-gaap:NoncompeteAgreementsMember 2020-12-31 0001124524 us-gaap:CustomerRelationshipsMember 2020-12-31 0001124524 cyrx:PatentsAndTrademarksMember 2020-12-31 0001124524 cyrx:AgentNetworkMember 2020-12-31 0001124524 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0001124524 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001124524 cyrx:ClassCConvertiblePreferredStockMember 2020-01-01 2020-12-31 0001124524 us-gaap:ConvertibleDebtMember 2020-05-31 0001124524 us-gaap:PrivatePlacementMember 2020-05-31 0001124524 2020-05-31 0001124524 us-gaap:SeniorNotesMember 2021-03-31 0001124524 us-gaap:WarrantMember 2021-03-31 2021-03-31 0001124524 us-gaap:SeniorNotesMember 2021-01-01 2021-03-31 0001124524 us-gaap:ServiceMember 2021-01-01 2021-03-31 0001124524 us-gaap:ProductMember 2021-01-01 2021-03-31 0001124524 us-gaap:ServiceMember 2020-01-01 2020-03-31 0001124524 cyrx:ClassCConvertiblePreferredStockMember 2020-10-01 0001124524 cyrx:ForeignCustomersMember us-gaap:RevenueFromContractWithCustomerMember 2021-01-01 2021-03-31 0001124524 cyrx:CustomerOneMember us-gaap:RevenueFromContractWithCustomerMember 2021-01-01 2021-03-31 0001124524 cyrx:CustomerOneMember us-gaap:AccountsReceivableMember 2021-01-01 2021-03-31 0001124524 cyrx:CustomerTwoMember us-gaap:RevenueFromContractWithCustomerMember 2020-01-01 2020-03-31 0001124524 cyrx:CustomerThreeMember us-gaap:RevenueFromContractWithCustomerMember 2020-01-01 2020-03-31 0001124524 cyrx:CustomerOneMember us-gaap:RevenueFromContractWithCustomerMember 2020-01-01 2020-03-31 0001124524 cyrx:ForeignCustomersMember 2020-01-01 2020-03-31 0001124524 us-gaap:CommonStockMember 2021-02-05 0001124524 2020-10-01 0001124524 us-gaap:RestrictedStockUnitsRSUMember 2021-03-31 0001124524 us-gaap:EmployeeStockOptionMember 2021-03-31 0001124524 cyrx:ClassCConvertiblePreferredStockMember 2021-03-31 0001124524 2021-03-11 2021-03-11 0001124524 2020-03-31 0001124524 cyrx:MveCryobiologicalStorageBusinessMember 2020-10-01 0001124524 cyrx:CryopdpMember 2021-03-31 0001124524 cyrx:CriticalTransportSolutionsAustraliaPtyLtdMember us-gaap:SubsequentEventMember 2021-04-01 2021-04-01 0001124524 cyrx:MveCryobiologicalStorageBusinessMember 2020-10-01 2020-10-01 0001124524 cyrx:CryopdpMember 2020-10-01 2020-10-01 0001124524 us-gaap:USTreasuryNotesSecuritiesMember 2021-03-31 0001124524 us-gaap:USTreasuryNotesSecuritiesMember 2020-12-31 0001124524 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001124524 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001124524 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001124524 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryNotesSecuritiesMember 2021-03-31 0001124524 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2021-03-31 0001124524 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryNotesSecuritiesMember 2021-03-31 0001124524 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2021-03-31 0001124524 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryNotesSecuritiesMember 2021-03-31 0001124524 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2021-03-31 0001124524 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001124524 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryNotesSecuritiesMember 2021-03-31 0001124524 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2021-03-31 0001124524 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001124524 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001124524 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001124524 us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001124524 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001124524 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001124524 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001124524 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryNotesSecuritiesMember 2020-12-31 0001124524 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2020-12-31 0001124524 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryNotesSecuritiesMember 2020-12-31 0001124524 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2020-12-31 0001124524 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryNotesSecuritiesMember 2020-12-31 0001124524 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2020-12-31 0001124524 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001124524 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryNotesSecuritiesMember 2020-12-31 0001124524 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2020-12-31 0001124524 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001124524 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001124524 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001124524 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001124524 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0001124524 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001124524 cyrx:ConvertibleSeniorNotesMember 2021-01-01 2021-03-31 0001124524 cyrx:ClassCConvertiblePreferredStockMember 2021-01-01 2021-03-31 0001124524 us-gaap:WarrantMember 2020-01-01 2020-03-31 0001124524 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001124524 2020-07-01 2020-09-30 0001124524 2019-12-31 0001124524 cyrx:PublicOfferingMember 2021-01-01 2021-03-31 0001124524 2021-04-23 0001124524 us-gaap:PrivatePlacementMember 2020-05-01 2020-05-31 0001124524 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001124524 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001124524 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001124524 us-gaap:PreferredClassBMember 2020-01-01 2020-03-31 0001124524 us-gaap:PreferredClassAMember 2020-01-01 2020-03-31 0001124524 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001124524 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001124524 us-gaap:PreferredClassBMember 2021-01-01 2021-03-31 0001124524 us-gaap:PreferredClassAMember 2021-01-01 2021-03-31 0001124524 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001124524 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001124524 cyrx:PreferredClassCMember 2020-01-01 2020-03-31 0001124524 2020-06-29 2020-06-29 0001124524 cyrx:ClassCConvertiblePreferredStockMember cyrx:PreferredStockRedemptionPeriodOneMember 2021-02-05 2021-02-05 0001124524 cyrx:ClassCConvertiblePreferredStockMember cyrx:PreferredStockRedemptionPeriodTwoMember 2020-10-01 2020-10-01 0001124524 cyrx:ClassCConvertiblePreferredStockMember cyrx:PreferredStockRedemptionPeriodThreeMember 2020-10-01 2020-10-01 0001124524 cyrx:ClassCConvertiblePreferredStockMember cyrx:PreferredStockRedemptionPeriodOneMember 2020-10-01 2020-10-01 0001124524 us-gaap:CommonStockMember 2021-02-05 2021-02-05 0001124524 2021-02-05 2021-02-05 0001124524 cyrx:CryopdpMember 2020-08-21 2020-08-21 0001124524 srt:DirectorMember 2021-01-01 2021-03-31 0001124524 srt:DirectorMember 2020-01-01 2020-03-31 0001124524 us-gaap:RevenueFromContractWithCustomerMember 2021-01-01 2021-03-31 0001124524 us-gaap:AccountsReceivableMember 2021-01-01 2021-03-31 0001124524 us-gaap:AccountsReceivableMember 2020-01-01 2020-12-31 0001124524 us-gaap:RevenueFromContractWithCustomerMember 2020-01-01 2020-03-31 0001124524 cyrx:ClassCConvertiblePreferredStockMember 2020-10-01 2020-10-01 0001124524 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2020-10-01 2020-10-01 0001124524 cyrx:ClassCConvertiblePreferredStockMember us-gaap:PrivatePlacementMember 2020-10-01 2020-10-01 0001124524 us-gaap:PrivatePlacementMember 2020-10-01 2020-10-01 0001124524 srt:MinimumMember 2021-01-01 2021-03-31 0001124524 srt:MaximumMember 2021-01-01 2021-03-31 0001124524 2020-10-01 2020-10-01 0001124524 cyrx:ScenarioTwoMember 2021-01-01 2021-03-31 0001124524 cyrx:ScenarioOneMember 2021-01-01 2021-03-31 0001124524 2020-01-01 2020-03-31 0001124524 2020-01-01 2020-12-31 0001124524 2021-03-31 0001124524 2020-12-31 0001124524 cyrx:PreferredClassCMember 2021-01-01 2021-03-31 0001124524 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001124524 2021-01-01 2021-03-31 0001124524 cyrx:CryopdpMember 2021-01-01 2021-03-31 iso4217:USD cyrx:item pure cyrx:customer cyrx:director iso4217:USD shares shares iso4217:EUR 0001124524 --12-31 2021 Q1 0 0 0 0 0 0 0 0 200000 200000 45693692 39837058 P3Y P7Y P4Y P3Y P7Y P0Y P0Y P0Y P0Y P0Y false 10-Q true 2021-03-31 false 001-34632 CRYOPORT, INC. NV 88-0313393 112 Westwood Place, Suite 350 Brentwood TN 37027 949 470-2300 Common Stock, $0.001 par value CYRX NASDAQ Yes Yes Large Accelerated Filer false false false 45681456 85494000 36873000 267721000 56444000 36504000 31377000 11544000 10535000 18485000 11928000 419748000 147157000 31694000 30036000 15996000 14044000 209267000 213908000 141305000 145282000 946000 1184000 752000 794000 819708000 552405000 27083000 24844000 8233000 7441000 495000 445000 2002000 2231000 60000 59000 37873000 35020000 3500000 3700000 111536000 111344000 1200000 0 3497000 4912000 14502000 12261000 92000 112000 4626000 5882000 307000 176000 172433000 169707000 0.001 0.001 2500000 2500000 0.001 0.001 800000 800000 0 0 0.001 0.001 585000 585000 0 0 0.001 0.001 250000 250000 200000 200000 4275000 2844000 0.001 0.001 100000000 100000000 45693692 39837058 45000 40000 837615000 566451000 -195540000 -192013000 880000 5376000 647275000 382698000 819708000 552405000 26765000 9774000 26519000 53284000 9774000 15552000 4516000 13182000 28734000 4516000 24550000 5258000 21388000 7111000 4304000 1733000 25692000 8844000 -1142000 -3586000 398000 307000 1210000 2000 -535000 -628000 -1347000 -323000 -2489000 -3909000 1038000 33000 -3527000 -3942000 2196000 -5723000 -3942000 -0.13 -0.11 43804483 37548549 -3527000 -3942000 768000 -471000 -30000 1000 -3758000 -2000 -4496000 468000 -8023000 -3474000 0 0 0 0 0 0 37339787 37000 285609000 -159320000 -45000 126281000 0 0 0 0 0 0 0 0 0 -3942000 0 -3942000 0 0 0 0 0 0 0 0 0 0 468000 468000 0 0 0 0 0 0 0 0 1600000 0 0 1600000 0 0 0 0 0 0 1269 0 21000 0 0 21000 0 0 0 0 0 0 589199 1000 2877000 0 0 2878000 0 0 0 0 0 0 37930255 38000 290107000 -163262000 423000 127306000 0 0 0 0 250000 2844000 39837058 40000 566451000 -192013000 5376000 382698000 0 0 0 0 0 0 0 0 0 -3527000 0 -3527000 0 0 0 0 0 0 0 0 0 0 -4496000 -4496000 0 0 0 0 0 0 0 0 2979000 0 0 2979000 0 0 0 0 0 0 229 0 11000 0 0 11000 -1800000 -1800000 17700000 4356059 4000 269821000 269825000 50000 -765000 1312860 1000 764000 2196000 -2196000 0 0 0 0 0 0 187486 0 1585000 0 0 1585000 0 0 0 0 200000 4275000 45693692 45000 837615000 -195540000 880000 647275000 -3527000 -3942000 4837000 824000 264000 0 -263000 144000 0 793000 -40000 11000 2990000 1620000 -71000 -80000 63000 4000 5213000 -955000 988000 -9000 6545000 -95000 -229000 46000 -60000 -7000 532000 65000 804000 768000 49000 -27000 80000 9000 -5991000 1059000 2811000 596000 193000 0 215318000 16195000 3000000 16279000 48000 30000 -215370000 -542000 1586000 2878000 17700000 269825000 0 18000 14000 271393000 2864000 -1411000 7000 48621000 3388000 36873000 47234000 85494000 50622000 765000 0 1800000 0 1394000 0 71000 0 1266000 0 768000 471000 30000 0 0 203000 198000 608000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 1. Management’s Representation and Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared by Cryoport, Inc. (the “Company”, “Cryoport”, “our” or “we”) in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X promulgated by the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statement presentation. However, the Company believes that the disclosures are adequate to make the information presented not misleading. In the opinion of management, all adjustments (consisting primarily of normal recurring accruals) considered necessary for a fair presentation have been included.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. The unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company has evaluated subsequent events through the date of this filing and determined that no subsequent events have occurred that would require recognition in the unaudited condensed consolidated financial statements or disclosure in the notes thereto other than as disclosed in the accompanying notes.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 2. Nature of the Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cryoport is a life sciences services company that is an integral part of the temperature-controlled supply chain supporting the biopharma/pharma, animal health, and reproductive medicine markets. We are redefining logistics for the life sciences industry by providing a unique platform of critical solutions including highly differentiated temperature-controlled supply chain solutions, which include advanced packaging, informatics, specialty logistics services, biostorage services and cryogenic life sciences equipment. Through our products, services and expertise, we enable our clients to ship, store and deliver cellular-based materials and drug products as well as other life sciences commodities in a precise, defined temperature-controlled state.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cryoport’s advanced platform, comprised of comprehensive and technology-centric systems and solutions are designed to support the global high-volume distribution of commercial biologic and cell-based products and therapies regulated by the United States Food and Drug Administration (FDA) and other international regulatory bodies for distribution in the Americas, EMEA (Europe, the Middle East, and Africa) and APAC (Asia-Pacific) regions. Cryoport’s solutions are also designed to support pre-clinical, clinical trials, Biologics License Applications (BLA), Investigational New Drug Applications (IND), New Drug Applications (NDA) and Commercialized Products with the FDA, as well as global clinical trials and commercialized products initiated in other countries, where strict regulatory compliance and quality assurance is mandated. Our industry standard setting Chain of Compliance<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> solutions, which include vital analytics, such as ‘chain-of-condition’ and ‘chain-of-custody’ information in a single data stream, empower our clients’ continuous vigilance over their respective commodities. In addition, our Chain of Compliance<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> standard ensures full traceability of all equipment used and the processes employed, further supporting each client’s goal of minimizing risk and maximizing success of their respective biologics or other products and therapies as they are introduced into the global markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 21, 2020, the Company entered into a Securities Purchase Agreement to acquire CRYOPDP, a leading global provider of innovative temperature-controlled logistics solutions to the clinical research, pharmaceutical and cell and gene therapy markets, headquartered in Paris, France. Under the terms of the Securities Purchase Agreement, the Company acquired 100% of the equity interests in Advanced Therapy Logistics and Solutions, a company organized under the laws of France, which is the holding company that owns CRYOPDP (the “CRYOPDP Acquisition”). The purchase price under the Securities Purchase Agreement was €49 million (approximately $58.0 million). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 24, 2020, the Company entered into a Purchase Agreement with Chart Industries, Inc. (“Chart”) pursuant to which the Company acquired Chart’s MVE Biological Solutions’ cryobiological storage business (the “MVE Acquisition”) for a cash purchase price at closing of $320 million, subject to customary closing working capital and other adjustments. The MVE Acquisition was structured as the acquisition of certain equity interests and assets and the transfer of certain liabilities in connection therewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 1, 2020, the Company completed both the MVE Acquisition and the CRYOPDP Acquisition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company is a Nevada corporation and its common stock is traded on the NASDAQ Capital Market exchange under the ticker symbol “CYRX.”</p> 1 49000000 58000000.0 320000000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 3. Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements include the accounts of Cryoport, Inc. and its wholly-owned subsidiaries, Cryoport Systems, LLC, Cryogene, Inc., MVE Biological Solutions US LLC, and Cryoport Netherlands B.V. and subsidiaries (collectively, the “Company”). All intercompany accounts and transactions have been eliminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our cash and cash equivalents represent demand deposits, and money market funds which are readily convertible into cash, have maturities of 90 days or less when purchased and are considered highly liquid and easily tradeable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Short-Term Investments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our investments in equity securities consist of mutual funds with readily determinable fair values which are carried at fair value with changes in fair value recognized in earnings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Investments in debt securities are classified as available-for-sale and are carried at fair value, with unrealized gains and losses, net of tax, reported as accumulated other comprehensive income (loss) and included as a separate component of stockholders’ equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Gains and losses are recognized when realized. When we have determined that an other than temporary decline in fair value has occurred, the amount related to a credit loss is recognized in earnings. Gains and losses are determined using the specific identification method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Short-term investments are classified as current assets even though maturities may extend beyond one year because they represent investments of cash available for operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from estimated amounts. The Company’s significant estimates include the allowance for doubtful accounts, fair value of short-term investments, valuations and purchase price allocations related to business combinations, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, intangible asset useful lives and amortization methods, allowance for inventory obsolescence, equity-based instruments, tax reserves and recoverability of the Company’s net deferred tax assets and related valuation allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Future events, including the extent and the duration of the COVID-19 related economic impacts, and their effects cannot be predicted with certainty, and, accordingly the Company’s accounting estimates require the exercise of judgment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s financial instruments consist of cash and cash equivalents, short-term investments, accounts receivable, accounts payable and accrued expenses, finance lease liabilities, note payable, and the Company’s 3.00% convertible senior notes due in 2025 (the “Senior Notes”). The carrying value for all such instruments, except finance lease liabilities, note payable and the Senior Notes, approximates fair value at March 31, 2021 and December 31, 2020 due to their short-term nature. The carrying value of finance lease liabilities approximates fair value because the interest rate approximates market rates available to us for similar obligations with the same maturities. For additional information related to fair value measurements, including the note payable and the Senior Notes, see Notes 9 and 10.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. From time to time, we maintain cash, cash equivalent and short-term investment balances in excess of amounts insured by the Federal Deposit Insurance Corporation (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”).  Primarily all of our cash, cash equivalents and short-term investments at March 31, 2021 were in excess of amounts insured by the FDIC and SIPC.  The Company performs ongoing evaluations of these institutions to limit its concentration risk exposure.  We manage such risks in our portfolio by investing in highly liquid, highly-rated instruments, and limit investing in long-term maturity instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our investment policy requires that purchased instruments in marketable securities may only be in highly-rated instruments, which are primarily U.S. Treasury bills or treasury-backed securities, and also limits our investment in securities of any single issuer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Customers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company grants credit to customers within the U.S. and international customers and does not require collateral. Revenues from international customers are generally secured by advance payments except for established foreign customers. The Company generally requires advance or credit card payments for initial revenues from new customers. The Company’s ability to collect receivables can be affected by economic fluctuations in the geographic areas and industries served by the Company. Reserves for uncollectible amounts are provided based on past experience and a specific analysis of the accounts, which management believes to be sufficient. Accounts receivable at March 31, 2021 and December 31, 2020 are net of reserves for doubtful accounts of $1.2 million and $1.1 million, respectively. Although the Company expects to collect amounts due, actual collections may differ from the estimated amounts. The Company maintains reserves for bad debt and such losses, in the aggregate, historically have not exceeded its estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s customers are in the biopharma, pharmaceutical, animal health, reproductive medicine and other life science industries. Consequently, there is a concentration of accounts receivable within these industries, which is subject to normal credit risk. At March 31, 2021, there was one customer that accounted for 10.5% of net accounts receivable. At December 31, 2020, there were no customers that accounted for more than 10% of net accounts receivable. There were no other single customers that owed us more than 10% of net accounts receivable at March 31, 2021 and December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has revenue from foreign customers primarily in United Kingdom, Switzerland, France, Netherlands, Singapore, China and India. During the three months ended March 31, 2021 and 2020, the Company had revenues from foreign customers of approximately $25.5 million and $2.1 million, respectively, which constituted approximately 48.0% and 21.4%, respectively, of total revenues. There was one customer that accounted for 12.5% of revenues during the three months ended March 31, 2021. There were three customers that accounted for 17.9%, 16.7% and 10.8% of revenues during the three months ended March 31, 2020, respectively. No other single customer generated over 10% of revenues during the three months ended March 31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Inventories</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Inventories are stated at the lower of cost and net realizable value. Cost is determined using the first-in, first-out (“FIFO”) method. Inventories are reviewed periodically for slow-moving or obsolete status. The Company writes down the carrying value of its inventories to reflect situations in which the cost of inventories is not expected to be recovered. Once established, write-downs of inventories are considered permanent adjustments to the cost basis of the obsolete or excess inventories. Raw materials and finished goods include material costs less reserves for obsolete or excess inventories. The Company evaluates the current level of inventories considering historical trends and other factors, such as selling prices and costs of completion, disposal and transportation, and based on the evaluation, records adjustments to reflect inventories at net realizable value. These adjustments are estimates, which could vary significantly from actual results if future economic conditions, customer demand, competition or other relevant factors differ from expectations. These estimates require us to make assessments about future demand for the Company’s products in order to categorize the status of such inventories items as slow-moving, obsolete or in excess-of-need. These estimates are subject to the ongoing accuracy of the Company’s forecasts of market conditions, industry trends, competition and other factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at cost, less accumulated depreciation.  We compute depreciation using the straight-line method over the estimated useful lives of the assets which is generally <span style="-sec-ix-hidden:Hidden_-G5mNnSKckOfaZpQo-AVKw;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">three</span></span> to twelve years for computer hardware and software, <span style="-sec-ix-hidden:Hidden_WDqkCQrR3EGqQCXq917rKQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">seven</span></span> to ten years for freezers, <span style="-sec-ix-hidden:Hidden_ayLcr64IlU-c8Gqm0VGJ-w;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">four</span></span> to ten years for trucks and autos, <span style="-sec-ix-hidden:Hidden_Bobn8gC6S0K8Ts0TGX6Sww;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">three</span></span> to fifteen years for furniture and equipment and over the shorter of the lease term or useful live of the assets for leasehold improvements. Buildings are depreciated over a useful life ranging from 20 to 45 years. Maintenance and repairs are expensed as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Betterments, renewals and extraordinary repairs that extend the lives of the assets are capitalized; other repairs and maintenance charges are expensed as incurred. The cost and related accumulated depreciation and amortization applicable to assets retired are removed from the accounts, and the gain or loss on disposition is recognized in the consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company determines if an arrangement is a lease at inception. Operating lease right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset during the lease term, and operating lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating leases are included in ROU assets, current operating lease liabilities, and long-term operating lease liabilities on our consolidated balance sheets. Finance leases are included in property and equipment, current finance lease liabilities, and long-term finance lease liabilities on our consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Lease ROU assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments over the lease term at commencement date calculated using our incremental borrowing rate applicable to the lease asset, unless the implicit rate is readily determinable. ROU assets also include any lease payments made at or before lease commencement and exclude any lease incentives received. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets. The Company’s leases do not contain any residual value guarantees. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for lease and non-lease components as a single lease component for all its leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Business Combinations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Total consideration transferred for acquisitions is allocated to the assets acquired and liabilities assumed based on their fair values at the dates of acquisition. This purchase price allocation process requires management to make significant estimates and assumptions primarily with respect to intangible assets. The fair value of identifiable intangible assets is based on detailed valuations that use information and assumptions determined by management. Any excess of purchase price over the fair value of the net tangible and intangible assets acquired is allocated to goodwill. While the Company uses its best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date as well as any contingent consideration, where applicable, the Company’s estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company records adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Goodwill</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates goodwill on an annual basis in the fourth quarter or more frequently if management believes indicators of impairment exist. Such indicators could include, but are not limited to: (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. The Company compares the fair value of the reporting unit’s with its carrying amount and then recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting units fair value up to the total amount of goodwill allocated to the reporting unit. The Company assessed  triggering events indicating potential goodwill impairment, including the effects of the COVID-19 pandemic, and after assessment, concluded that there was no impairment during the three months ended March 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Intangible assets are comprised of patents, trademarks, software development costs and the intangible assets acquired in the MVE, CRYOPDP and Cryogene acquisitions which include a non-compete agreement, technology, customer relationships, trade name/trademark, agent network, order backlog, developed technology and land use rights. The Company capitalizes costs of obtaining patents and trademarks, which are amortized, using the straight-line method over their estimated useful life of five years once the patent or trademark has been issued. The non-compete agreement, technology, customer relationships, trade name/trademark, agent network, order backlog, developed technology and land use rights, acquired in the MVE, CRYOPDP and Cryogene acquisitions are amortized using the straight-line method over the estimated useful lives (see Note 8). The Company uses the following valuation methodologies to value the significant intangible assets acquired: income approach for customer relationships, replacement cost for agent network and software, and relief from royalty for trade name/trademarks and developed technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates the recoverability of identifiable intangible assets whenever events or changes in circumstances indicate that an intangible asset's carrying amount may not be recoverable. Such circumstances could include, but are not limited to: (1) a significant decrease in the market value of an asset, (2) a significant adverse change in the extent or manner in which an asset is used, or (3) an accumulation of costs significantly in excess of the amount originally expected for the acquisition of an asset. The Company measures the carrying amount of the asset against the estimated undiscounted future cash flows associated with it. Should the sum of the expected future net cash flows be less than the carrying value of the asset being evaluated, an impairment loss would be recognized. The impairment loss would be calculated as the amount by which the carrying value of the asset exceeds its fair value. The estimate of fair value is based on various valuation techniques, including the discounted value of estimated future cash flows. The evaluation of asset impairment requires the Company to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results may differ from assumed and estimated amounts. There was no impairment of intangible assets during the three months ended March 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Long-lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the fair value to the carrying value. We believe the future cash flows to be received from the long-lived assets will exceed the assets’ carrying value, and accordingly, we have not recognized any impairment losses through March 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Deferred Financing Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Deferred financing costs represent costs incurred in connection with the issuance of debt instruments and equity financings. Deferred financing costs related to the issuance of debt are amortized over the term of the financing instrument using the effective interest method and are presented in the consolidated balance sheets as an offset against the related debt. Offering costs from equity financings are netted against the gross proceeds received from the equity financings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes under the provision of ASC 740, “<i style="font-style:italic;">Income Taxes”</i>, or ASC 740. As of March 31, 2021 and December 31, 2020, there were no material unrecognized tax benefits included in the accompanying consolidated balance sheets that would, if recognized, affect the effective tax rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. Based on the weight of available evidence, the Company’s management has determined that it is not more likely than not that the U.S. based net deferred tax assets will be realized. Therefore, the Company has recorded a full valuation allowance against its U.S. based net deferred tax assets. With respect to the foreign based deferred tax assets, the Company's management has reviewed these deferred tax assets on a jurisdictional basis. Based on the weight of each jurisdiction's evidence available, the Company's management has made separate determinations for each foreign jurisdiction regarding whether it is more likely than not that a net deferred tax asset within a particular jurisdiction will be realized. The Company has recorded full valuation allowances in jurisdictions where deferred tax assets are not deemed more likely than not to be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, the Company maintains a deferred tax liability related to indefinite-lived assets that have been netted against deferred tax assets that also allow for indefinite carryforward periods subject to limitations.  The remaining taxable temporary difference cannot serve as a source for future taxable income to realize federal net operating losses, due to the fact that post-2017 federal net operating losses are only eligible to offset 80% of income in a given year or in the case of state net operating losses, the state net operating losses will expire prior to the reversal of the taxable temporary difference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company has immaterial accruals for interest or penalties on its consolidated balance sheets at March 31, 2021 and December 31, 2020 and has recorded only immaterial interest and/or penalties in the consolidated statements of operations for the three months ended March 31, 2021 and 2020. The Company is subject to taxation in the U.S., various state jurisdictions and in various foreign countries. As of March 31, 2021, the Company is no longer subject to U.S. federal examinations for years before 2017 and for California franchise and income tax examinations for years before 2016. However, to the extent allowed by law, the taxing authorities may have the right to examine prior periods where net operating losses were generated and carried forward and make adjustments up to the amount of the net operating loss carry forward amount. The Company is not currently under examination by U.S. federal or state jurisdictions. Our foreign subsidiaries are generally subject to examination three years following the year in which the tax obligation originated.  The years subject to audit may be extended if the entity substantially understates corporate income tax. The Company's subsidiary in India is currently under examination by the Indian tax authorities for 2012-2013, 2013-2014 and 2015-2016 tax periods. Other than India, the Company does not have any foreign subsidiaries currently under audit by their local taxing authorities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December of 2019, the FASB issued Accounting Standards Update (“ASU”) 2019-12 Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. The Board issued this Update as part of its Simplification Initiative to improve areas of U.S. GAAP and reduce cost and complexity while maintaining usefulness. The main provision that impacts the company is the removal of the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, discontinued operations and other comprehensive income). ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 31, 2020. Different components of the guidance require retrospective, modified retrospective or prospective adoption. The Company elected to early adopt ASU 2019-12 on January 1, 2020, and the adoption of the standard did not have a material impact to our consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 27, 2020, the United States enacted the Coronavirus Aid, Relief and Economic Security Act (CARES Act). The Cares Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund a nationwide effort to curtail the effect of COVID-19. The CARES Act provides sweeping tax changes in response to the COVID-19 pandemic, some of the more significant provisions are removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years, and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act. At March 31, 2021, the Company has not recorded any income tax provision/(benefit) resulting from the CARES Act mainly due the Company’s history of net operating losses generated and the maintenance of a full valuation allowance against its net deferred tax assets.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 29, 2020, the State of California passed Assembly Bill 85 which suspends the California net operating loss deduction for the 2020-2022 tax years and the R&amp;D credit usage for the same period (for credit usages in excess of $5 million). These suspensions were considered in preparation of the March 31, 2021 and December 31, 2020 financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 27, 2020, the United States enacted the Consolidated Appropriations Act of 2021 (“CAA”).  The CAA includes provisions extending certain CARES Act provisions and adds coronavirus relief, tax and health extenders. The Company will continue to evaluate the impact of the CAA and its impact on our financial statements in 2021 and beyond.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 11, 2021, the United States enacted the American Rescue Plan (“ARP”). The ARP includes provisions extending certain CARES Act provisions, repeals a worldwide interest allocation election, modifies the $1 million executive compensation limitation for years after 2026 and extends the employee retention credit. The Company will continue to evaluate the impact of the ARP and its impact on our financial statements in 2021 and beyond.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue Recognition </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Revenues are recognized when control is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods and services. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;">Performance Obligations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At contract inception, an assessment of the goods and services promised in the contracts with customers is performed and a performance obligation is identified for each distinct promise to transfer to the customer a good or service (or bundle of goods or services). To identify the performance obligations, the Company considers all of the goods or services promised in the contract regardless of whether they are explicitly stated or are implied by customary business practices. Revenue is recognized when our performance obligation has been met. The Company considers control to have transferred upon delivery because the Company has a present right to payment at that time, the Company has transferred use of the asset, and the customer is able to direct the use of, and obtain substantially all of the remaining benefits from, the asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For arrangements under which the Company provides biological specimen storage services and logistics support and management to the customer, the Company satisfies its performance obligations as those services are performed whereby the customer simultaneously receives and consumes the benefits of such services under the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Revenue generated from short-term logistics and engineering consulting services provided to customers is recognized when the Company satisfies the contractually defined performance obligations. When a contract includes multiple performance obligations, the contract price is allocated among the performance obligations based upon the stand-alone selling prices. Approved contract modifications are accounted for as either a separate contract or as part of the existing contract depending on the nature of the modification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our performance obligations on our orders and under the terms of agreements with customers are generally satisfied within one year from a given reporting date and, therefore, we omit disclosure of the transaction price allocated to remaining performance obligations on open orders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Shipping and handling activities related to contracts with customers are accounted for as costs to fulfill our promise to transfer the associated products pursuant to the accounting policy election allowed under Topic 606 and are not considered a separate performance obligation to our customers. Accordingly, the Company records amounts billed for shipping and handling as a component of revenue. Shipping and handling fees and costs are included in cost of revenues in the accompanying condensed consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Revenues are recognized net of any taxes collected from customers, which are subsequently remitted to governmental agencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;">Significant Payment Terms</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Company’s contracts with its customers, amounts billed for services or products delivered by the Company are generally due and payable in full within 15  to 60 days from the date of the invoice (except for any amounts disputed by the customer in good faith). Accordingly, the Company determined that its contracts with customers do not include extended payment terms or a significant financing component.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;">Variable Consideration</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">When a contract includes variable consideration, the Company evaluates the estimate of the variable consideration to determine whether the estimate needs to be constrained. Variable consideration is estimated at the most likely amount that is expected to be earned. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the anticipated performance and all information (historical, current and forecasted) that is reasonably available. Variable consideration estimates are updated at each reporting date. Revenues are recorded net of variable consideration, such as discounts and allowances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;">Warranties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company provides product warranties with varying terms and durations for some of its products. The Company estimates product warranty costs and accrues for these costs as products are sold with a charge to cost of sales. Factors considered in estimating warranty costs include historical and projected warranty claims, historical and projected cost-per-claim, and knowledge of specific product issues that are outside of typical experience. Warranty accruals are evaluated and adjusted as necessary based on actual claims experience and changes in future claim and cost estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Product warranty accrued liabilities totaled $0.2 million and $0.2 million at March 31, 2021 and December 31, 2020, respectively, and are included in accounts payable and other accrued expenses. Warranty expense was not material for the three months ended March 31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;">Incremental Direct Costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Incremental direct costs are expensed when incurred when the amortization period of the asset that would have been recognized is one year or less; otherwise, incremental contract costs are recognized as an asset and amortized over time as promised goods and services are transferred to a customer. Incremental direct costs were not material for the three months ended March 31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company expenses incremental direct costs of obtaining a contract (sales commissions) when incurred because the amortization period is generally 12 months or less. The Company does not incur costs to fulfill a customer contract that meet the requirements for capitalization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;">Contract Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Typically, we invoice the customer and recognize revenue once we have satisfied our performance obligation. Accordingly, our contract assets comprise accounts receivable, which are recognized when payment is unconditional and only the passage of time is required before payment is due. Generally, we do not have material amounts of other contract assets since revenue is recognized as control of goods is transferred or as services are performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;">Contract Liabilities (Deferred Revenue)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Contract liabilities are recorded when cash payments are received in advance of the Company’s performance. Deferred revenue was $0.5 million and $0.3 million at March 31, 2021 and 2020, respectively.  During the three months ended March 31, 2021, the Company recognized revenues of $0.2 million from the related contact liabilities outstanding as the services were performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;">Nature of Goods and Services</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company provides Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> Shippers to its customers and charges a fee in exchange for the use of the Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> Shipper under long-term master service agreements with customers. The Company’s arrangements convey to the customers the right to use the Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> Shippers over a period of time. The Company retains title to the Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> Shippers and provides its customers the use of the Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> Shipper for a specified shipping cycle. At the culmination of the customer’s shipping cycle, the Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> Shipper is returned to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue for the use of the Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> Shippers at the time of the delivery of the Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> Shipper to the end user of the enclosed materials, and at the time that collectability is probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company also provides vacuum insulated aluminum dewars and cryogenic freezers systems to its customers. Revenue is recognized when the Company satisfies performance obligations by transferring the equipment to a customer, and at the time that collectability is probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company also provides global temperature-controlled logistics services, support and management. Revenue is recognized for these services as services are rendered and at the time that collectability is probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company also provides comprehensive and integrated temperature-controlled biostorage solutions to customers in the life sciences industry and charges a fee under long-term master service agreements with customers. These services include (1) biological specimen cryopreservation storage and maintenance, (2) archiving, monitoring, tracking, receipt and delivery of samples, (3) transport of frozen biological specimens to and from customer locations, and (4) management of incoming and outgoing biological specimens. The Company recognizes revenue for its biostorage solutions as services are rendered over time and at the time that collectability is probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company also provides short-term logistics and engineering consulting services to some customers, with fees tied to the completion of contractually defined services. We recognize revenue from these services over time as the customer simultaneously receives and consumes the benefit of these services as they are performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A significant portion of our revenues are covered under long-term agreements. We have determined that individual Statements of Work or Scope of Work (“SOW”), whose terms and conditions taken with a Master Services Agreement (“MSA”), create the Topic 606 contracts which are generally short-term in nature (e.g., 15-day shipping cycle) for the Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> solutions and up to 12 months for biostorage solutions. Our agreements (including SOWs) generally do not have multiple performance obligations and, therefore, do not require an allocation of a single price amongst multiple goods or services.  Prices under these agreements are generally fixed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;">Revenue Disaggregation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company views its operations, makes decisions regarding how to allocate resources and manages its business as one reportable segment and one reporting unit. As a result, the financial information disclosed herein represents all of the material financial information related to the Company. When disaggregating revenue, the Company considered all of the economic factors that may affect its revenues. We consider sales disaggregated by end-market to depict how the nature, amount, timing and uncertainty of revenues and cash flows are impacted by changes in economic factors. The following table disaggregates our revenues by major markets for the three months ended March 31, 2021 and 2020 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Biopharma/Pharma</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,393</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,786</p></td></tr><tr><td style="vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Animal Health</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,997</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 225</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Reproductive Medicine</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,894</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 763</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 53,284</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,774</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Given that the Company’s revenues are generated in different geographic regions, factors such as regulatory and geopolitical factors within those regions could impact the nature, timing and uncertainty of the Company’s revenues and cash flows. Our geographical revenues, by origin, for the three months ended March 31, 2021 and 2020, were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Americas</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,734</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,685</p></td></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Europe, the Middle East and Africa (EMEA)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,208</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,932</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Asia Pacific (APAC)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,342</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 157</p></td></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 53,284</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">9,774</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cost of Services Revenues</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our cost of services revenues is primarily comprised of freight charges, payroll and associated expenses related to our global logistics and supply chain centers, depreciation expenses of our Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> Shippers and supplies and consumables used for our solutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cost of Product Revenues</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our cost of product revenues is primarily comprised of materials, direct and indirect labor, inbound freight charges, purchasing and receiving, inspection, and distribution and warehousing of inventory. In addition, shop supplies, facility maintenance costs and depreciation expense for assets used in the manufacturing process are included in cost of product revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Engineering and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Expenditures relating to engineering and development are expensed in the period incurred to engineering and development expense in the statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Acquisition Costs </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Acquisition costs consist of legal, accounting, third-party valuations, and other due diligence costs related to our MVE Biological Solutions and CRYOPDP acquisitions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under our stockholder approved stock-based compensation plan, we have granted incentive stock options, non-qualified stock options and restricted stock units that vest over four years.  Incentive and non-qualified stock options expire from <span style="-sec-ix-hidden:Hidden_ZfG7O0jahE-k_hKsMSMQbg;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">seven</span></span> to ten years from date of grant. The Company accounts for stock-based payments in accordance with stock-based payment accounting guidance which requires all stock-based payments to be recognized based upon their fair values. The fair value of stock options is estimated at the grant date using the Black-Scholes Option Pricing Model (“Black-Scholes”) and the portion that is ultimately expected to vest is recognized as compensation cost over the requisite service period.  The determination of fair value using Black-Scholes is affected by the Company’s stock price as well as assumptions regarding a number of complex and subjective variables, including expected stock price volatility, risk-free interest rate, expected dividends and expected term. The Company accounts for forfeitures of unvested awards as they occur. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The grant date fair value per share for restricted stock units is based upon the closing market price of our common stock on the award grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s stock-based compensation plans are discussed further in Note 14.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basic and Diluted Net Loss Per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We calculate basic and diluted net loss per share using the weighted average number of common shares outstanding during the periods presented. In periods of a net loss position, basic and diluted weighted average common shares are the same. For the diluted earnings per share calculation, we adjust the weighted average number of common shares outstanding to include dilutive stock options, warrants and shares associated with the conversion of the Senior Notes and convertible preferred stock outstanding during the periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following shows the amounts used in computing net loss per share (in thousands except per share data):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,527)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,942)</p></td></tr><tr><td style="vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Paid-in-kind dividend on Series C convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,196)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to common shareholders</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,723)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,942)</p></td></tr><tr><td style="vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average common shares outstanding - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,804,483</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 37,548,549</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net loss per share</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.13)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.11)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,149,186</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,867,924</p></td></tr><tr><td style="vertical-align:bottom;width:72.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 502,632</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 304,157</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:72.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series C convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,283,411</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Convertible senior notes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,810,002</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:72.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,546,756</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,370,556</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Foreign Currency Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Management has determined that the functional currency of its subsidiaries is the local currency.  Assets and liabilities of the Netherlands and United Kingdom subsidiaries are translated into U.S. dollars at the period-end exchange rates.  Income and expenses are translated at an average exchange rate for the period and the resulting translation gain (loss) adjustments are accumulated as a separate component of stockholders’ equity.  The translation gain (loss) adjustment totaled $(3.8) million and $0 for the three months ended March 31, 2021 and 2020, respectively. Foreign currency gains and losses from transactions denominated in other than respective local currencies are included in earnings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Off-Balance Sheet Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not currently have any off-balance sheet arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Reclassification</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior year amounts in sales and marketing expense have been reclassified to selling, general and administrative expense to conform to the current period presentation, which reflects how the Company tracks operating costs. These reclassifications had no effect on the previously reported net loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Adopted Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2020, the FASB issued ASU 2020-06,<i style="font-style:italic;"> Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity</i>. Under ASU 2020-06, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives under Topic 815, <i style="font-style:italic;">Derivatives and Hedging</i>, or that do not result in substantial premiums accounted for as paid-in capital. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost, as long as no other features require bifurcation and recognition as derivatives. Similarly, equity-classified convertible preferred stock instruments will be accounted for as single units of account in equity unless the conversion feature needs to be bifurcated under Topic 815. The new guidance also made amendments to the earnings per share guidance in Topic 260, <i style="font-style:italic;">Earnings Per Share</i>, for convertible instruments, the most significant impact of which is requiring the use of the if- converted method for diluted earnings per share calculation. Further, ASU 2020-06 made revisions to Topic 815-40, which provides guidance on how an entity must determine whether a contract qualifies for a scope exception from derivative accounting. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted. Adoption of the standard requires using either a modified retrospective or a full retrospective approach. Effective January 1, 2021, we early adopted ASU 2020-06 using the modified retrospective approach. Adoption of the new standard did not have a material impact on the Company’s consolidated financial statements or disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2020, the FASB issued ASU 2020-01, “Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815): Clarifying the Interactions between Topic 321, Topic 323, and Topic 815.” The new guidance clarifies the interaction of accounting for the transition into and out of the equity method and the accounting for measuring certain purchased options and forward contracts to acquire investments. ASU 2020-01 is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The adoption of this guidance did not have an impact on the Company’s consolidated financial statements or disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Accounting Guidance Issued but Not Adopted at March 31, 2021 </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This ASU replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information for credit loss estimates on certain types of financial instruments, including trade receivables. In addition, new disclosures are required. The ASU, as subsequently amended, is effective for fiscal years beginning after December 15, 2022 for smaller reporting companies, as defined by the SEC. As a smaller reporting company, we are currently evaluating the impact of adopting this guidance.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements include the accounts of Cryoport, Inc. and its wholly-owned subsidiaries, Cryoport Systems, LLC, Cryogene, Inc., MVE Biological Solutions US LLC, and Cryoport Netherlands B.V. and subsidiaries (collectively, the “Company”). All intercompany accounts and transactions have been eliminated.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our cash and cash equivalents represent demand deposits, and money market funds which are readily convertible into cash, have maturities of 90 days or less when purchased and are considered highly liquid and easily tradeable.</p> P90D <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Short-Term Investments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our investments in equity securities consist of mutual funds with readily determinable fair values which are carried at fair value with changes in fair value recognized in earnings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Investments in debt securities are classified as available-for-sale and are carried at fair value, with unrealized gains and losses, net of tax, reported as accumulated other comprehensive income (loss) and included as a separate component of stockholders’ equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Gains and losses are recognized when realized. When we have determined that an other than temporary decline in fair value has occurred, the amount related to a credit loss is recognized in earnings. Gains and losses are determined using the specific identification method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Short-term investments are classified as current assets even though maturities may extend beyond one year because they represent investments of cash available for operations.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from estimated amounts. The Company’s significant estimates include the allowance for doubtful accounts, fair value of short-term investments, valuations and purchase price allocations related to business combinations, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, intangible asset useful lives and amortization methods, allowance for inventory obsolescence, equity-based instruments, tax reserves and recoverability of the Company’s net deferred tax assets and related valuation allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Future events, including the extent and the duration of the COVID-19 related economic impacts, and their effects cannot be predicted with certainty, and, accordingly the Company’s accounting estimates require the exercise of judgment.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s financial instruments consist of cash and cash equivalents, short-term investments, accounts receivable, accounts payable and accrued expenses, finance lease liabilities, note payable, and the Company’s 3.00% convertible senior notes due in 2025 (the “Senior Notes”). The carrying value for all such instruments, except finance lease liabilities, note payable and the Senior Notes, approximates fair value at March 31, 2021 and December 31, 2020 due to their short-term nature. The carrying value of finance lease liabilities approximates fair value because the interest rate approximates market rates available to us for similar obligations with the same maturities. For additional information related to fair value measurements, including the note payable and the Senior Notes, see Notes 9 and 10.</p> 0.0300 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. From time to time, we maintain cash, cash equivalent and short-term investment balances in excess of amounts insured by the Federal Deposit Insurance Corporation (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”).  Primarily all of our cash, cash equivalents and short-term investments at March 31, 2021 were in excess of amounts insured by the FDIC and SIPC.  The Company performs ongoing evaluations of these institutions to limit its concentration risk exposure.  We manage such risks in our portfolio by investing in highly liquid, highly-rated instruments, and limit investing in long-term maturity instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our investment policy requires that purchased instruments in marketable securities may only be in highly-rated instruments, which are primarily U.S. Treasury bills or treasury-backed securities, and also limits our investment in securities of any single issuer.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Customers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company grants credit to customers within the U.S. and international customers and does not require collateral. Revenues from international customers are generally secured by advance payments except for established foreign customers. The Company generally requires advance or credit card payments for initial revenues from new customers. The Company’s ability to collect receivables can be affected by economic fluctuations in the geographic areas and industries served by the Company. Reserves for uncollectible amounts are provided based on past experience and a specific analysis of the accounts, which management believes to be sufficient. Accounts receivable at March 31, 2021 and December 31, 2020 are net of reserves for doubtful accounts of $1.2 million and $1.1 million, respectively. Although the Company expects to collect amounts due, actual collections may differ from the estimated amounts. The Company maintains reserves for bad debt and such losses, in the aggregate, historically have not exceeded its estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s customers are in the biopharma, pharmaceutical, animal health, reproductive medicine and other life science industries. Consequently, there is a concentration of accounts receivable within these industries, which is subject to normal credit risk. At March 31, 2021, there was one customer that accounted for 10.5% of net accounts receivable. At December 31, 2020, there were no customers that accounted for more than 10% of net accounts receivable. There were no other single customers that owed us more than 10% of net accounts receivable at March 31, 2021 and December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has revenue from foreign customers primarily in United Kingdom, Switzerland, France, Netherlands, Singapore, China and India. During the three months ended March 31, 2021 and 2020, the Company had revenues from foreign customers of approximately $25.5 million and $2.1 million, respectively, which constituted approximately 48.0% and 21.4%, respectively, of total revenues. There was one customer that accounted for 12.5% of revenues during the three months ended March 31, 2021. There were three customers that accounted for 17.9%, 16.7% and 10.8% of revenues during the three months ended March 31, 2020, respectively. No other single customer generated over 10% of revenues during the three months ended March 31, 2021 and 2020.</p> 1200000 1100000 1 0.105 0 0.10 0.10 0.10 25500000 2100000 0.480 0.214 1 0.125 3 0.179 0.167 0.108 0.10 0.10 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Inventories</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Inventories are stated at the lower of cost and net realizable value. Cost is determined using the first-in, first-out (“FIFO”) method. Inventories are reviewed periodically for slow-moving or obsolete status. The Company writes down the carrying value of its inventories to reflect situations in which the cost of inventories is not expected to be recovered. Once established, write-downs of inventories are considered permanent adjustments to the cost basis of the obsolete or excess inventories. Raw materials and finished goods include material costs less reserves for obsolete or excess inventories. The Company evaluates the current level of inventories considering historical trends and other factors, such as selling prices and costs of completion, disposal and transportation, and based on the evaluation, records adjustments to reflect inventories at net realizable value. These adjustments are estimates, which could vary significantly from actual results if future economic conditions, customer demand, competition or other relevant factors differ from expectations. These estimates require us to make assessments about future demand for the Company’s products in order to categorize the status of such inventories items as slow-moving, obsolete or in excess-of-need. These estimates are subject to the ongoing accuracy of the Company’s forecasts of market conditions, industry trends, competition and other factors.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at cost, less accumulated depreciation.  We compute depreciation using the straight-line method over the estimated useful lives of the assets which is generally <span style="-sec-ix-hidden:Hidden_-G5mNnSKckOfaZpQo-AVKw;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">three</span></span> to twelve years for computer hardware and software, <span style="-sec-ix-hidden:Hidden_WDqkCQrR3EGqQCXq917rKQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">seven</span></span> to ten years for freezers, <span style="-sec-ix-hidden:Hidden_ayLcr64IlU-c8Gqm0VGJ-w;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">four</span></span> to ten years for trucks and autos, <span style="-sec-ix-hidden:Hidden_Bobn8gC6S0K8Ts0TGX6Sww;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">three</span></span> to fifteen years for furniture and equipment and over the shorter of the lease term or useful live of the assets for leasehold improvements. Buildings are depreciated over a useful life ranging from 20 to 45 years. Maintenance and repairs are expensed as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Betterments, renewals and extraordinary repairs that extend the lives of the assets are capitalized; other repairs and maintenance charges are expensed as incurred. The cost and related accumulated depreciation and amortization applicable to assets retired are removed from the accounts, and the gain or loss on disposition is recognized in the consolidated statements of operations.</p> P12Y P10Y P10Y P15Y P20Y P45Y <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company determines if an arrangement is a lease at inception. Operating lease right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset during the lease term, and operating lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating leases are included in ROU assets, current operating lease liabilities, and long-term operating lease liabilities on our consolidated balance sheets. Finance leases are included in property and equipment, current finance lease liabilities, and long-term finance lease liabilities on our consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Lease ROU assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments over the lease term at commencement date calculated using our incremental borrowing rate applicable to the lease asset, unless the implicit rate is readily determinable. ROU assets also include any lease payments made at or before lease commencement and exclude any lease incentives received. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets. The Company’s leases do not contain any residual value guarantees. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for lease and non-lease components as a single lease component for all its leases.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Business Combinations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Total consideration transferred for acquisitions is allocated to the assets acquired and liabilities assumed based on their fair values at the dates of acquisition. This purchase price allocation process requires management to make significant estimates and assumptions primarily with respect to intangible assets. The fair value of identifiable intangible assets is based on detailed valuations that use information and assumptions determined by management. Any excess of purchase price over the fair value of the net tangible and intangible assets acquired is allocated to goodwill. While the Company uses its best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date as well as any contingent consideration, where applicable, the Company’s estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company records adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Goodwill</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates goodwill on an annual basis in the fourth quarter or more frequently if management believes indicators of impairment exist. Such indicators could include, but are not limited to: (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. The Company compares the fair value of the reporting unit’s with its carrying amount and then recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting units fair value up to the total amount of goodwill allocated to the reporting unit. The Company assessed  triggering events indicating potential goodwill impairment, including the effects of the COVID-19 pandemic, and after assessment, concluded that there was no impairment during the three months ended March 31, 2021.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Intangible assets are comprised of patents, trademarks, software development costs and the intangible assets acquired in the MVE, CRYOPDP and Cryogene acquisitions which include a non-compete agreement, technology, customer relationships, trade name/trademark, agent network, order backlog, developed technology and land use rights. The Company capitalizes costs of obtaining patents and trademarks, which are amortized, using the straight-line method over their estimated useful life of five years once the patent or trademark has been issued. The non-compete agreement, technology, customer relationships, trade name/trademark, agent network, order backlog, developed technology and land use rights, acquired in the MVE, CRYOPDP and Cryogene acquisitions are amortized using the straight-line method over the estimated useful lives (see Note 8). The Company uses the following valuation methodologies to value the significant intangible assets acquired: income approach for customer relationships, replacement cost for agent network and software, and relief from royalty for trade name/trademarks and developed technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates the recoverability of identifiable intangible assets whenever events or changes in circumstances indicate that an intangible asset's carrying amount may not be recoverable. Such circumstances could include, but are not limited to: (1) a significant decrease in the market value of an asset, (2) a significant adverse change in the extent or manner in which an asset is used, or (3) an accumulation of costs significantly in excess of the amount originally expected for the acquisition of an asset. The Company measures the carrying amount of the asset against the estimated undiscounted future cash flows associated with it. Should the sum of the expected future net cash flows be less than the carrying value of the asset being evaluated, an impairment loss would be recognized. The impairment loss would be calculated as the amount by which the carrying value of the asset exceeds its fair value. The estimate of fair value is based on various valuation techniques, including the discounted value of estimated future cash flows. The evaluation of asset impairment requires the Company to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results may differ from assumed and estimated amounts. There was no impairment of intangible assets during the three months ended March 31, 2021.</p> P5Y 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Long-lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the fair value to the carrying value. We believe the future cash flows to be received from the long-lived assets will exceed the assets’ carrying value, and accordingly, we have not recognized any impairment losses through March 31, 2021.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Deferred Financing Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Deferred financing costs represent costs incurred in connection with the issuance of debt instruments and equity financings. Deferred financing costs related to the issuance of debt are amortized over the term of the financing instrument using the effective interest method and are presented in the consolidated balance sheets as an offset against the related debt. Offering costs from equity financings are netted against the gross proceeds received from the equity financings.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes under the provision of ASC 740, “<i style="font-style:italic;">Income Taxes”</i>, or ASC 740. As of March 31, 2021 and December 31, 2020, there were no material unrecognized tax benefits included in the accompanying consolidated balance sheets that would, if recognized, affect the effective tax rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. Based on the weight of available evidence, the Company’s management has determined that it is not more likely than not that the U.S. based net deferred tax assets will be realized. Therefore, the Company has recorded a full valuation allowance against its U.S. based net deferred tax assets. With respect to the foreign based deferred tax assets, the Company's management has reviewed these deferred tax assets on a jurisdictional basis. Based on the weight of each jurisdiction's evidence available, the Company's management has made separate determinations for each foreign jurisdiction regarding whether it is more likely than not that a net deferred tax asset within a particular jurisdiction will be realized. The Company has recorded full valuation allowances in jurisdictions where deferred tax assets are not deemed more likely than not to be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, the Company maintains a deferred tax liability related to indefinite-lived assets that have been netted against deferred tax assets that also allow for indefinite carryforward periods subject to limitations.  The remaining taxable temporary difference cannot serve as a source for future taxable income to realize federal net operating losses, due to the fact that post-2017 federal net operating losses are only eligible to offset 80% of income in a given year or in the case of state net operating losses, the state net operating losses will expire prior to the reversal of the taxable temporary difference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company has immaterial accruals for interest or penalties on its consolidated balance sheets at March 31, 2021 and December 31, 2020 and has recorded only immaterial interest and/or penalties in the consolidated statements of operations for the three months ended March 31, 2021 and 2020. The Company is subject to taxation in the U.S., various state jurisdictions and in various foreign countries. As of March 31, 2021, the Company is no longer subject to U.S. federal examinations for years before 2017 and for California franchise and income tax examinations for years before 2016. However, to the extent allowed by law, the taxing authorities may have the right to examine prior periods where net operating losses were generated and carried forward and make adjustments up to the amount of the net operating loss carry forward amount. The Company is not currently under examination by U.S. federal or state jurisdictions. Our foreign subsidiaries are generally subject to examination three years following the year in which the tax obligation originated.  The years subject to audit may be extended if the entity substantially understates corporate income tax. The Company's subsidiary in India is currently under examination by the Indian tax authorities for 2012-2013, 2013-2014 and 2015-2016 tax periods. Other than India, the Company does not have any foreign subsidiaries currently under audit by their local taxing authorities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December of 2019, the FASB issued Accounting Standards Update (“ASU”) 2019-12 Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. The Board issued this Update as part of its Simplification Initiative to improve areas of U.S. GAAP and reduce cost and complexity while maintaining usefulness. The main provision that impacts the company is the removal of the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, discontinued operations and other comprehensive income). ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 31, 2020. Different components of the guidance require retrospective, modified retrospective or prospective adoption. The Company elected to early adopt ASU 2019-12 on January 1, 2020, and the adoption of the standard did not have a material impact to our consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 27, 2020, the United States enacted the Coronavirus Aid, Relief and Economic Security Act (CARES Act). The Cares Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund a nationwide effort to curtail the effect of COVID-19. The CARES Act provides sweeping tax changes in response to the COVID-19 pandemic, some of the more significant provisions are removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years, and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act. At March 31, 2021, the Company has not recorded any income tax provision/(benefit) resulting from the CARES Act mainly due the Company’s history of net operating losses generated and the maintenance of a full valuation allowance against its net deferred tax assets.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 29, 2020, the State of California passed Assembly Bill 85 which suspends the California net operating loss deduction for the 2020-2022 tax years and the R&amp;D credit usage for the same period (for credit usages in excess of $5 million). These suspensions were considered in preparation of the March 31, 2021 and December 31, 2020 financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 27, 2020, the United States enacted the Consolidated Appropriations Act of 2021 (“CAA”).  The CAA includes provisions extending certain CARES Act provisions and adds coronavirus relief, tax and health extenders. The Company will continue to evaluate the impact of the CAA and its impact on our financial statements in 2021 and beyond.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 11, 2021, the United States enacted the American Rescue Plan (“ARP”). The ARP includes provisions extending certain CARES Act provisions, repeals a worldwide interest allocation election, modifies the $1 million executive compensation limitation for years after 2026 and extends the employee retention credit. The Company will continue to evaluate the impact of the ARP and its impact on our financial statements in 2021 and beyond.</p> 0 0 0.80 P3Y 5000000 1000000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue Recognition </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Revenues are recognized when control is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods and services. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;">Performance Obligations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At contract inception, an assessment of the goods and services promised in the contracts with customers is performed and a performance obligation is identified for each distinct promise to transfer to the customer a good or service (or bundle of goods or services). To identify the performance obligations, the Company considers all of the goods or services promised in the contract regardless of whether they are explicitly stated or are implied by customary business practices. Revenue is recognized when our performance obligation has been met. The Company considers control to have transferred upon delivery because the Company has a present right to payment at that time, the Company has transferred use of the asset, and the customer is able to direct the use of, and obtain substantially all of the remaining benefits from, the asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For arrangements under which the Company provides biological specimen storage services and logistics support and management to the customer, the Company satisfies its performance obligations as those services are performed whereby the customer simultaneously receives and consumes the benefits of such services under the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Revenue generated from short-term logistics and engineering consulting services provided to customers is recognized when the Company satisfies the contractually defined performance obligations. When a contract includes multiple performance obligations, the contract price is allocated among the performance obligations based upon the stand-alone selling prices. Approved contract modifications are accounted for as either a separate contract or as part of the existing contract depending on the nature of the modification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our performance obligations on our orders and under the terms of agreements with customers are generally satisfied within one year from a given reporting date and, therefore, we omit disclosure of the transaction price allocated to remaining performance obligations on open orders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Shipping and handling activities related to contracts with customers are accounted for as costs to fulfill our promise to transfer the associated products pursuant to the accounting policy election allowed under Topic 606 and are not considered a separate performance obligation to our customers. Accordingly, the Company records amounts billed for shipping and handling as a component of revenue. Shipping and handling fees and costs are included in cost of revenues in the accompanying condensed consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Revenues are recognized net of any taxes collected from customers, which are subsequently remitted to governmental agencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;">Significant Payment Terms</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Company’s contracts with its customers, amounts billed for services or products delivered by the Company are generally due and payable in full within 15  to 60 days from the date of the invoice (except for any amounts disputed by the customer in good faith). Accordingly, the Company determined that its contracts with customers do not include extended payment terms or a significant financing component.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;">Variable Consideration</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">When a contract includes variable consideration, the Company evaluates the estimate of the variable consideration to determine whether the estimate needs to be constrained. Variable consideration is estimated at the most likely amount that is expected to be earned. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the anticipated performance and all information (historical, current and forecasted) that is reasonably available. Variable consideration estimates are updated at each reporting date. Revenues are recorded net of variable consideration, such as discounts and allowances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;">Warranties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company provides product warranties with varying terms and durations for some of its products. The Company estimates product warranty costs and accrues for these costs as products are sold with a charge to cost of sales. Factors considered in estimating warranty costs include historical and projected warranty claims, historical and projected cost-per-claim, and knowledge of specific product issues that are outside of typical experience. Warranty accruals are evaluated and adjusted as necessary based on actual claims experience and changes in future claim and cost estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Product warranty accrued liabilities totaled $0.2 million and $0.2 million at March 31, 2021 and December 31, 2020, respectively, and are included in accounts payable and other accrued expenses. Warranty expense was not material for the three months ended March 31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;">Incremental Direct Costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Incremental direct costs are expensed when incurred when the amortization period of the asset that would have been recognized is one year or less; otherwise, incremental contract costs are recognized as an asset and amortized over time as promised goods and services are transferred to a customer. Incremental direct costs were not material for the three months ended March 31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company expenses incremental direct costs of obtaining a contract (sales commissions) when incurred because the amortization period is generally 12 months or less. The Company does not incur costs to fulfill a customer contract that meet the requirements for capitalization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;">Contract Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Typically, we invoice the customer and recognize revenue once we have satisfied our performance obligation. Accordingly, our contract assets comprise accounts receivable, which are recognized when payment is unconditional and only the passage of time is required before payment is due. Generally, we do not have material amounts of other contract assets since revenue is recognized as control of goods is transferred or as services are performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;">Contract Liabilities (Deferred Revenue)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Contract liabilities are recorded when cash payments are received in advance of the Company’s performance. Deferred revenue was $0.5 million and $0.3 million at March 31, 2021 and 2020, respectively.  During the three months ended March 31, 2021, the Company recognized revenues of $0.2 million from the related contact liabilities outstanding as the services were performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;">Nature of Goods and Services</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company provides Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> Shippers to its customers and charges a fee in exchange for the use of the Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> Shipper under long-term master service agreements with customers. The Company’s arrangements convey to the customers the right to use the Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> Shippers over a period of time. The Company retains title to the Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> Shippers and provides its customers the use of the Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> Shipper for a specified shipping cycle. At the culmination of the customer’s shipping cycle, the Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> Shipper is returned to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue for the use of the Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> Shippers at the time of the delivery of the Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> Shipper to the end user of the enclosed materials, and at the time that collectability is probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company also provides vacuum insulated aluminum dewars and cryogenic freezers systems to its customers. Revenue is recognized when the Company satisfies performance obligations by transferring the equipment to a customer, and at the time that collectability is probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company also provides global temperature-controlled logistics services, support and management. Revenue is recognized for these services as services are rendered and at the time that collectability is probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company also provides comprehensive and integrated temperature-controlled biostorage solutions to customers in the life sciences industry and charges a fee under long-term master service agreements with customers. These services include (1) biological specimen cryopreservation storage and maintenance, (2) archiving, monitoring, tracking, receipt and delivery of samples, (3) transport of frozen biological specimens to and from customer locations, and (4) management of incoming and outgoing biological specimens. The Company recognizes revenue for its biostorage solutions as services are rendered over time and at the time that collectability is probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company also provides short-term logistics and engineering consulting services to some customers, with fees tied to the completion of contractually defined services. We recognize revenue from these services over time as the customer simultaneously receives and consumes the benefit of these services as they are performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A significant portion of our revenues are covered under long-term agreements. We have determined that individual Statements of Work or Scope of Work (“SOW”), whose terms and conditions taken with a Master Services Agreement (“MSA”), create the Topic 606 contracts which are generally short-term in nature (e.g., 15-day shipping cycle) for the Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> solutions and up to 12 months for biostorage solutions. Our agreements (including SOWs) generally do not have multiple performance obligations and, therefore, do not require an allocation of a single price amongst multiple goods or services.  Prices under these agreements are generally fixed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;">Revenue Disaggregation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company views its operations, makes decisions regarding how to allocate resources and manages its business as one reportable segment and one reporting unit. As a result, the financial information disclosed herein represents all of the material financial information related to the Company. When disaggregating revenue, the Company considered all of the economic factors that may affect its revenues. We consider sales disaggregated by end-market to depict how the nature, amount, timing and uncertainty of revenues and cash flows are impacted by changes in economic factors. The following table disaggregates our revenues by major markets for the three months ended March 31, 2021 and 2020 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Biopharma/Pharma</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,393</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,786</p></td></tr><tr><td style="vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Animal Health</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,997</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 225</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Reproductive Medicine</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,894</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 763</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 53,284</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,774</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Given that the Company’s revenues are generated in different geographic regions, factors such as regulatory and geopolitical factors within those regions could impact the nature, timing and uncertainty of the Company’s revenues and cash flows. Our geographical revenues, by origin, for the three months ended March 31, 2021 and 2020, were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Americas</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,734</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,685</p></td></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Europe, the Middle East and Africa (EMEA)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,208</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,932</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Asia Pacific (APAC)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,342</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 157</p></td></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 53,284</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">9,774</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cost of Services Revenues</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our cost of services revenues is primarily comprised of freight charges, payroll and associated expenses related to our global logistics and supply chain centers, depreciation expenses of our Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> Shippers and supplies and consumables used for our solutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cost of Product Revenues</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our cost of product revenues is primarily comprised of materials, direct and indirect labor, inbound freight charges, purchasing and receiving, inspection, and distribution and warehousing of inventory. In addition, shop supplies, facility maintenance costs and depreciation expense for assets used in the manufacturing process are included in cost of product revenues.</p> true 200000 200000 500000 300000 200000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Biopharma/Pharma</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,393</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,786</p></td></tr><tr><td style="vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Animal Health</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,997</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 225</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Reproductive Medicine</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,894</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 763</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 53,284</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,774</p></td></tr></table> 42393000 8786000 8997000 225000 1894000 763000 53284000 9774000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Given that the Company’s revenues are generated in different geographic regions, factors such as regulatory and geopolitical factors within those regions could impact the nature, timing and uncertainty of the Company’s revenues and cash flows. Our geographical revenues, by origin, for the three months ended March 31, 2021 and 2020, were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Americas</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,734</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,685</p></td></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Europe, the Middle East and Africa (EMEA)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,208</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,932</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Asia Pacific (APAC)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,342</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 157</p></td></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 53,284</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">9,774</p></td></tr></table> 27734000 7685000 14208000 1932000 11342000 157000 53284000 9774000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Engineering and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Expenditures relating to engineering and development are expensed in the period incurred to engineering and development expense in the statement of operations.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Acquisition Costs </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Acquisition costs consist of legal, accounting, third-party valuations, and other due diligence costs related to our MVE Biological Solutions and CRYOPDP acquisitions.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under our stockholder approved stock-based compensation plan, we have granted incentive stock options, non-qualified stock options and restricted stock units that vest over four years.  Incentive and non-qualified stock options expire from <span style="-sec-ix-hidden:Hidden_ZfG7O0jahE-k_hKsMSMQbg;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">seven</span></span> to ten years from date of grant. The Company accounts for stock-based payments in accordance with stock-based payment accounting guidance which requires all stock-based payments to be recognized based upon their fair values. The fair value of stock options is estimated at the grant date using the Black-Scholes Option Pricing Model (“Black-Scholes”) and the portion that is ultimately expected to vest is recognized as compensation cost over the requisite service period.  The determination of fair value using Black-Scholes is affected by the Company’s stock price as well as assumptions regarding a number of complex and subjective variables, including expected stock price volatility, risk-free interest rate, expected dividends and expected term. The Company accounts for forfeitures of unvested awards as they occur. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The grant date fair value per share for restricted stock units is based upon the closing market price of our common stock on the award grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s stock-based compensation plans are discussed further in Note 14.</p> P4Y P10Y <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basic and Diluted Net Loss Per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We calculate basic and diluted net loss per share using the weighted average number of common shares outstanding during the periods presented. In periods of a net loss position, basic and diluted weighted average common shares are the same. For the diluted earnings per share calculation, we adjust the weighted average number of common shares outstanding to include dilutive stock options, warrants and shares associated with the conversion of the Senior Notes and convertible preferred stock outstanding during the periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following shows the amounts used in computing net loss per share (in thousands except per share data):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,527)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,942)</p></td></tr><tr><td style="vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Paid-in-kind dividend on Series C convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,196)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to common shareholders</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,723)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,942)</p></td></tr><tr><td style="vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average common shares outstanding - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,804,483</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 37,548,549</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net loss per share</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.13)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.11)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,149,186</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,867,924</p></td></tr><tr><td style="vertical-align:bottom;width:72.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 502,632</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 304,157</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:72.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series C convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,283,411</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Convertible senior notes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,810,002</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:72.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,546,756</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,370,556</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following shows the amounts used in computing net loss per share (in thousands except per share data):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,527)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,942)</p></td></tr><tr><td style="vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Paid-in-kind dividend on Series C convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,196)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to common shareholders</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,723)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,942)</p></td></tr><tr><td style="vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average common shares outstanding - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,804,483</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 37,548,549</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net loss per share</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.13)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.11)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p> -3527000 -3942000 2196000 -5723000 -3942000 43804483 37548549 -0.13 -0.11 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,149,186</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,867,924</p></td></tr><tr><td style="vertical-align:bottom;width:72.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 502,632</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 304,157</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:72.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series C convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,283,411</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Convertible senior notes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,810,002</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:72.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,546,756</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,370,556</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p> 6149186 3867924 502632 304157 5283411 4810002 16546756 4370556 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Foreign Currency Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Management has determined that the functional currency of its subsidiaries is the local currency.  Assets and liabilities of the Netherlands and United Kingdom subsidiaries are translated into U.S. dollars at the period-end exchange rates.  Income and expenses are translated at an average exchange rate for the period and the resulting translation gain (loss) adjustments are accumulated as a separate component of stockholders’ equity.  The translation gain (loss) adjustment totaled $(3.8) million and $0 for the three months ended March 31, 2021 and 2020, respectively. Foreign currency gains and losses from transactions denominated in other than respective local currencies are included in earnings.</p> -3800000 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Off-Balance Sheet Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not currently have any off-balance sheet arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Reclassification</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior year amounts in sales and marketing expense have been reclassified to selling, general and administrative expense to conform to the current period presentation, which reflects how the Company tracks operating costs. These reclassifications had no effect on the previously reported net loss.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Adopted Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2020, the FASB issued ASU 2020-06,<i style="font-style:italic;"> Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity</i>. Under ASU 2020-06, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives under Topic 815, <i style="font-style:italic;">Derivatives and Hedging</i>, or that do not result in substantial premiums accounted for as paid-in capital. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost, as long as no other features require bifurcation and recognition as derivatives. Similarly, equity-classified convertible preferred stock instruments will be accounted for as single units of account in equity unless the conversion feature needs to be bifurcated under Topic 815. The new guidance also made amendments to the earnings per share guidance in Topic 260, <i style="font-style:italic;">Earnings Per Share</i>, for convertible instruments, the most significant impact of which is requiring the use of the if- converted method for diluted earnings per share calculation. Further, ASU 2020-06 made revisions to Topic 815-40, which provides guidance on how an entity must determine whether a contract qualifies for a scope exception from derivative accounting. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted. Adoption of the standard requires using either a modified retrospective or a full retrospective approach. Effective January 1, 2021, we early adopted ASU 2020-06 using the modified retrospective approach. Adoption of the new standard did not have a material impact on the Company’s consolidated financial statements or disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2020, the FASB issued ASU 2020-01, “Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815): Clarifying the Interactions between Topic 321, Topic 323, and Topic 815.” The new guidance clarifies the interaction of accounting for the transition into and out of the equity method and the accounting for measuring certain purchased options and forward contracts to acquire investments. ASU 2020-01 is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The adoption of this guidance did not have an impact on the Company’s consolidated financial statements or disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Accounting Guidance Issued but Not Adopted at March 31, 2021 </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This ASU replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information for credit loss estimates on certain types of financial instruments, including trade receivables. In addition, new disclosures are required. The ASU, as subsequently amended, is effective for fiscal years beginning after December 15, 2022 for smaller reporting companies, as defined by the SEC. As a smaller reporting company, we are currently evaluating the impact of adopting this guidance.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Note 4. Acquisitions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">2020 Acquisitions – CRYOPDP and MVE</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">CRYOPDP Acquisition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 1, 2020, the Company completed its acquisition of CRYOPDP for a cash consideration of €48.3 million (approximately $57.0 million, the “CRYOPDP Acquisition”). This acquisition was funded with existing cash on hand. CRYOPDP, based in France, is a leading global provider of innovative temperature-controlled logistics solutions to the clinical research, pharmaceutical and cell and gene therapy markets. CRYOPDP conducts its business activities in the Americas, EMEA and APAC. As a result of the CRYOPDP Acquisition, the Company has extended its solutions to include broader temperature-controlled logistics and specialty courier services and has significantly expanded its global network through CRYOPDP’s 22 facilities in 12 countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The final purchase price for the CRYOPDP Acquisition was $56.7 million, after receiving $0.3 million net working capital settlement from the sellers during the three months ended March 31, 2021. As of October 1, 2020, the Company recorded net assets acquired of $57.0 million, including goodwill of $25.5 million. Through March 31, 2021, the Company recorded measurement period adjustments of $2.9 million, mainly comprised of $1.3 million fair value on the note payable and $1.5 million deferred tax adjustments, resulting in adjusted goodwill of $22.6 million and adjusted net assets acquired of $56.7 million. The purchase price allocation for the assets acquired and liabilities assumed remains open due to the finalization of the purchase price allocation during the measurement process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">MVE Acquisition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 1, 2020, the Company completed its acquisition of Chart Industries, Inc.’s MVE cryobiological storage business (the “MVE Acquisition”) for a cash consideration of $317.5 million, subject to customary closing working capital and other adjustments. The Company financed a portion of the closing cash payment of the MVE Acquisition with the net proceeds of the Blackstone Private Placement, as further discussed in Note 13. MVE is a global leader in manufactured vacuum insulated products and cryogenic freezer systems for the life sciences industry. MVE has manufacturing and distribution operations in the Americas, EMEA and APAC. As a result of the MVE Acquisition, the Company has extended its integrated logistics solutions to provide a broad range of cryogenic dewars and freezers to the life sciences industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of October 1, 2020, the Company recorded net assets acquired of $317.5 million, including goodwill of $106.2 million. Through March 31, 2021, the Company did not record any material measurement period adjustments. The purchase price allocation for the assets acquired and liabilities assumed remains open due to the finalization of the purchase price allocation during the measurement process.</p> 48300000 57000000.0 56700000 300000 57000000.0 25500000 2900000 1300000 1500000 22600000 56700000 317500000 317500000 106200000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 5. Cash, Cash Equivalents and Short-Term Investments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Cash, cash equivalents and short-term investments consisted of the following as of March 31, 2021 and December 31, 2020 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,913</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,053</p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Money market mutual fund</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 61,581</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,820</p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 85,494</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 36,873</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Short-term investments:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">U.S. Treasury notes and bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 234,578</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,309</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Mutual funds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,143</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,135</p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 267,721</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56,444</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash, cash equivalents and short-term investments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 353,215</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 93,317</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Available-for-sale investments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The amortized cost, gross unrealized gains, gross unrealized losses and fair value of available-for-sale investments by type of security at March 31, 2021 were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. Treasury notes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 235,185</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 128</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (735)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 234,578</p></td></tr><tr><td style="vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total available-for-sale investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 235,185</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 128</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (735)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 234,578</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="background-color:#ffff00;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes the fair value of available-for-sale investments based on stated contractual maturities as of March 31, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Due within one year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41,030</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41,058</p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Due between one and two years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 194,155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 193,520</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 235,185</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 234,578</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The amortized cost, gross unrealized gains, gross unrealized losses and fair value of available-for-sale investments by type of security at December 31, 2020 were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. Treasury notes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,179</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 173</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (43)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,309</p></td></tr><tr><td style="vertical-align:bottom;width:54.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total available-for-sale investments </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,179</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 173</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (43)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,309</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes the fair value of available-for-sale investments based on stated contractual maturities as of December 31, 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Due within one year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,084</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,111</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Due between one and two years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,095</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,198</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,179</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,309</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="background-color:#ffff00;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The primary objective of our investment portfolio is to enhance overall returns in an efficient manner while maintaining safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with primarily investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We review our available-for-sale investments for other-than-temporary declines in fair value below our cost basis each quarter and whenever events or changes in circumstances indicate that the cost basis of an asset may not be recoverable. The evaluation is based on a number of factors, including the length of time and the extent to which the fair value has been below our cost basis, as well as adverse conditions related specifically to the security such as any changes to the credit rating of the security and the intent to sell or whether we will more likely than not be required to sell the security before recovery of its amortized cost basis. Our assessment of whether a security is other-than-temporarily impaired could change in the future based on new developments or changes in assumptions related to that particular security.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the three months ended March 31, 2021, we had realized gains of $40,000 on available-for-sale investments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity Investments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We held investments in equity securities with readily determinable fair values of $33.1 million at March 31, 2021. These investments consist of mutual funds that invest primarily in tax-free municipal bonds and treasury inflation protected securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Unrealized gains (losses) during 2021 and 2020 related to equity securities held at March 31, 2021 and 2020 are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">    </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net losses recognized during the three months on equity securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (263)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (649)</p></td></tr><tr><td style="vertical-align:bottom;width:74.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Less: net gains (losses) recognized during the year on equity securities sold during the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">   </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (793)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unrealized gains (losses) recognized during the three months on equity securities still held at March 31, 2021 and 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (263)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 144</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Cash, cash equivalents and short-term investments consisted of the following as of March 31, 2021 and December 31, 2020 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,913</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,053</p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Money market mutual fund</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 61,581</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,820</p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 85,494</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 36,873</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Short-term investments:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">U.S. Treasury notes and bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 234,578</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,309</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Mutual funds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,143</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,135</p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 267,721</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56,444</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash, cash equivalents and short-term investments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 353,215</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 93,317</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p> 23913000 25053000 61581000 11820000 85494000 36873000 234578 23309 33143 33135 267721000 56444000 353215000 93317000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The amortized cost, gross unrealized gains, gross unrealized losses and fair value of available-for-sale investments by type of security at March 31, 2021 were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. Treasury notes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 235,185</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 128</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (735)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 234,578</p></td></tr><tr><td style="vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total available-for-sale investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 235,185</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 128</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (735)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 234,578</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="background-color:#ffff00;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The amortized cost, gross unrealized gains, gross unrealized losses and fair value of available-for-sale investments by type of security at December 31, 2020 were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. Treasury notes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,179</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 173</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (43)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,309</p></td></tr><tr><td style="vertical-align:bottom;width:54.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total available-for-sale investments </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,179</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 173</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (43)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,309</p></td></tr></table> 235185000 128000 735000 234578000 235185000 128000 735000 234578000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes the fair value of available-for-sale investments based on stated contractual maturities as of March 31, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Due within one year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41,030</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41,058</p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Due between one and two years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 194,155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 193,520</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 235,185</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 234,578</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes the fair value of available-for-sale investments based on stated contractual maturities as of December 31, 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Due within one year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,084</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,111</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Due between one and two years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,095</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,198</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,179</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,309</p></td></tr></table> 41030000 41058000 194155000 193520000 235185000 234578000 23179 173 43 23309 23179 173 43 23309 14084 14111 9095 9198 23179 23309 40000 33100000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Unrealized gains (losses) during 2021 and 2020 related to equity securities held at March 31, 2021 and 2020 are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">    </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net losses recognized during the three months on equity securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (263)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (649)</p></td></tr><tr><td style="vertical-align:bottom;width:74.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Less: net gains (losses) recognized during the year on equity securities sold during the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">   </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (793)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unrealized gains (losses) recognized during the three months on equity securities still held at March 31, 2021 and 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (263)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 144</p></td></tr></table> -263000 -649000 -793000 -263000 144000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 6. Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We measure fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Level 1:</i> Quoted prices (unadjusted) in active markets for identical assets or liabilities that are accessible at the measurement date. The fair value hierarchy gives the highest priority to Level 1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Level 2:</i> Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. These inputs include quoted prices for similar assets or liabilities; quoted market prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Level 3:</i> Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as consider counterparty credit risk in the assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We did not elect the fair value option, as allowed, to account for financial assets and liabilities that were not previously carried at fair value. Therefore, material financial assets and liabilities that are not carried at fair value, such as trade accounts receivable and payable, are reported at their historical carrying values.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The carrying values of our assets that are required to be measured at fair value on a recurring basis as of March 31, 2021 and 2020 approximate fair value because of our ability to immediately convert these instruments into cash with minimal expected change in value which are classified in the table below in one of the three categories of the fair value hierarchy described above (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:43.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value Measurements</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, 2021</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:54.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Money market mutual fund</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 61,581</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 61,581</p></td></tr><tr><td style="vertical-align:bottom;width:54.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Marketable equity securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Mutual funds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,143</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,143</p></td></tr><tr><td style="vertical-align:bottom;width:54.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Available-for-sale debt securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">U.S. Treasury notes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 234,578</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 234,578</p></td></tr><tr><td style="vertical-align:bottom;width:54.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 329,302</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 329,302</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:43.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value Measurements</b> </p></td></tr><tr><td style="vertical-align:bottom;width:54.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:54.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Money market mutual fund</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,820</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,820</p></td></tr><tr><td style="vertical-align:bottom;width:54.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Marketable equity securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Mutual funds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,135</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> —</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,135</p></td></tr><tr><td style="vertical-align:bottom;width:54.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Available-for-sale debt securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">U.S. Treasury notes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,309</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> —</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,309</p></td></tr><tr><td style="vertical-align:bottom;width:54.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 68,264</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 68,264</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our equity securities and available-for-sale debt securities, including U.S. treasury notes and U.S. treasury bills are valued using inputs observable in active markets for identical securities and are therefore classified as Level 1 within the fair value hierarchy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We did not have any financial liabilities measured at fair value on a recurring basis as of March 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We carry the Senior Notes (see Note 9) at face value less the unamortized discount and issuance costs on our consolidated balance sheets and present fair value for disclosure purposes only. As of March 31, 2021, the estimated fair value of the Notes was $108.8 million and was determined using the net present value of the payments, discounted at an interest rate that is consistent with market and risk-adjusted interest rates, which is a Level 2 input.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The carrying values of our assets that are required to be measured at fair value on a recurring basis as of March 31, 2021 and 2020 approximate fair value because of our ability to immediately convert these instruments into cash with minimal expected change in value which are classified in the table below in one of the three categories of the fair value hierarchy described above (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:43.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value Measurements</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, 2021</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:54.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Money market mutual fund</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 61,581</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 61,581</p></td></tr><tr><td style="vertical-align:bottom;width:54.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Marketable equity securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Mutual funds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,143</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,143</p></td></tr><tr><td style="vertical-align:bottom;width:54.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Available-for-sale debt securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">U.S. Treasury notes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 234,578</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 234,578</p></td></tr><tr><td style="vertical-align:bottom;width:54.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 329,302</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 329,302</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:43.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value Measurements</b> </p></td></tr><tr><td style="vertical-align:bottom;width:54.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:54.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Money market mutual fund</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,820</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,820</p></td></tr><tr><td style="vertical-align:bottom;width:54.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Marketable equity securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Mutual funds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,135</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> —</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,135</p></td></tr><tr><td style="vertical-align:bottom;width:54.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Available-for-sale debt securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">U.S. Treasury notes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,309</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> —</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,309</p></td></tr><tr><td style="vertical-align:bottom;width:54.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 68,264</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 68,264</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p> 61581000 0 0 61581000 33143000 0 0 33143000 234578000 0 0 234578000 329302000 0 0 329302000 11820000 0 0 11820000 33135000 0 0 33135000 23309000 0 0 23309000 68264000 0 0 68264000 108800000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Note 7. Inventory</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Inventories consist of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Raw materials</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,318</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,544</p></td></tr><tr><td style="vertical-align:bottom;width:73.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Work-in-process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 307</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 227</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finished goods</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,919</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,764</p></td></tr><tr><td style="vertical-align:bottom;width:73.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,535</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The inventory balance at December 31, 2020 includes an $0.8 million step up in inventory related to the acquisition of MVE.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Inventories consist of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Raw materials</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,318</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,544</p></td></tr><tr><td style="vertical-align:bottom;width:73.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Work-in-process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 307</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 227</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finished goods</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,919</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,764</p></td></tr><tr><td style="vertical-align:bottom;width:73.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,535</p></td></tr></table> 8318000 7544000 307000 227000 2919000 2764000 11544000 10535000 800000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 8. Goodwill and Intangible Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Goodwill</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table represents the changes in the carrying value of goodwill for the three months ended March 31, 2021 and 2020 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at beginning of year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 145,282</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Foreign currency adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,405)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Goodwill related to MVE acquisition</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Goodwill related to CRYOPDP acquisition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,590)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 141,305</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intangible Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table presents our intangible assets as of March 31, 2021 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net </b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross </b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period (years)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-compete agreement</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 390</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 143</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 247</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Technology</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,438</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,576</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,862</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Customer relationships</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 128,640</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,218</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 123,422</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cryogene trade name/trademark</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 480</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 421</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CRYOPDP agent network</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,597</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,415</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,182</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_vV1w6y8THU-DFMfRcAXHqg;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> 4</span></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">MVE order backlog</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_hWaV2KjmZEOfG_jOQobC2Q;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;">—</span></span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">MVE land use rights</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,378</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,342</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patents and trademarks</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,360</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 569</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 43,791</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_yTX3dzqom06GZkZPa2ZvMQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;">—</span></span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 221,883</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,616</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 209,267</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table presents our intangible assets as of December 31, 2020 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net</b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortization</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Period (years)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-compete agreement</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 390</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 123</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 267</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Technology</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 34,245</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,630</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32,615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer relationships</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 128,640</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,708</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 125,932</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cryogene trade name/trademark</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 480</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 429</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">CRYOPDP agent network</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,597</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 537</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,060</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">MVE order backlog</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_uDkd7sLkk0mr2jC9jyf_yA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;">—</span></span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">MVE land use rights</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,378</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,362</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 37</p></td></tr><tr><td style="vertical-align:bottom;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Patents and trademarks</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44,312</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44,243</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_lGiSfQWsb0ORM7G_8X2UZQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;">—</span></span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 221,642</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,734</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 213,908</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Amortization expense for intangible assets for the three months ended March 31, 2021 and 2020, was $3.6 million and $0.1 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Expected future amortization of intangible assets as of March 31, 2021 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years Ending March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Remainder of 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,722</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,296</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,296</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,678</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,064</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100,051</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 165,107</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background-color:#00ff00;font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table represents the changes in the carrying value of goodwill for the three months ended March 31, 2021 and 2020 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at beginning of year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 145,282</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Foreign currency adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,405)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Goodwill related to MVE acquisition</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Goodwill related to CRYOPDP acquisition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,590)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 141,305</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,000</p></td></tr></table> 145282000 11000000 -1405000 18000 2590000 141305000 11000000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table presents our intangible assets as of March 31, 2021 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net </b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross </b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period (years)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-compete agreement</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 390</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 143</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 247</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Technology</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,438</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,576</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,862</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Customer relationships</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 128,640</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,218</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 123,422</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cryogene trade name/trademark</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 480</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 421</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CRYOPDP agent network</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,597</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,415</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,182</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_vV1w6y8THU-DFMfRcAXHqg;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> 4</span></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">MVE order backlog</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_hWaV2KjmZEOfG_jOQobC2Q;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;">—</span></span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">MVE land use rights</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,378</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,342</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patents and trademarks</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,360</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 569</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 43,791</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_yTX3dzqom06GZkZPa2ZvMQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;">—</span></span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 221,883</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,616</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 209,267</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table presents our intangible assets as of December 31, 2020 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net</b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortization</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Period (years)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-compete agreement</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 390</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 123</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 267</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Technology</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 34,245</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,630</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32,615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer relationships</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 128,640</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,708</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 125,932</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cryogene trade name/trademark</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 480</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 429</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">CRYOPDP agent network</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,597</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 537</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,060</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">MVE order backlog</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_uDkd7sLkk0mr2jC9jyf_yA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;">—</span></span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">MVE land use rights</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,378</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,362</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 37</p></td></tr><tr><td style="vertical-align:bottom;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Patents and trademarks</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44,312</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44,243</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_lGiSfQWsb0ORM7G_8X2UZQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;">—</span></span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:54.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 221,642</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,734</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 213,908</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p> 390000 143000 247000 P3Y 34438000 2576000 31862000 P11Y 128640000 5218000 123422000 P14Y 480000 59000 421000 P13Y 8597000 1415000 7182000 2600000 2600000 2378000 36000 2342000 P37Y 44360000 569000 43791000 221883000 12616000 209267000 390000 123000 267000 P3Y 34245000 1630000 32615000 P11Y 128640000 2708000 125932000 P14Y 480000 51000 429000 P13Y 8597000 537000 8060000 P4Y 2600000 2600000 2378000 16000 2362000 P37Y 44312000 69000 44243000 221642000 7734000 213908000 3600000 100000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Expected future amortization of intangible assets as of March 31, 2021 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years Ending March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Remainder of 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,722</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,296</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,296</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,678</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,064</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100,051</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 165,107</p></td></tr></table> 10722000 14296000 14296000 13678000 12064000 100051000 165107000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 9. Convertible Senior Notes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May 2020, the Company issued $115.0 million aggregate principal amount of 3.00% convertible senior notes due in 2025 (the "Senior Notes"), which includes the initial purchasers’ exercise in full of their option to purchase an additional $15.0 million principal amount of the Senior Notes, in a private placement exempt from registration under the Securities Act of 1933. The Senior Notes are governed by an indenture (the “Indenture”) dated May 26, 2020 between the Company, as issuer, and U.S. Bank National Association, as trustee (the “Trustee”). The Company received $111.3 million from the offering, net of underwriting discounts and commissions of $3.7 million, and incurred approximately $0.3 million in third-party offering related costs. The Senior Notes bear cash interest at a rate of 3.00%, payable semi-annually on June 1 and December 1 of each year, beginning on December 1, 2020 and will mature on June 1, 2025, unless earlier repurchased, redeemed, or converted in accordance with the terms of the Senior Notes. At March 31, 2021 accrued interest of $1.2 million is included in accounts payable and accrued liabilities in the accompanying consolidated financial statements.  The Notes comprise the Company’s senior, unsecured obligations and are (i) equal in right of payment with the Company’s existing and future senior, unsecured indebtedness; (ii) senior in right of payment to the Company’s existing and future indebtedness that is expressly subordinated to the Senior Notes; (iii) effectively subordinated to the Company’s existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness; and (iv) structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to the extent the Company is not a holder thereof) preferred equity, if any, of the Company’s subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At any time before the close of business on the scheduled trading day immediately before the maturity date, holders of the Senior Notes may convert their Senior Notes at their option into shares of the Company’s common stock. The Senior Notes are initially convertible into approximately 4,810,002 shares of the Company’s common stock based on the initial conversion rate of 41.8261 shares of the Company’s common stock per $1,000 principal amount of the Senior Notes, which represents an initial conversion price of approximately $23.91 per share of the Company’s common stock. The conversion rate and conversion price are subject to customary adjustments upon the occurrence of certain events. Also, if certain corporate events that constitute a “Make-Whole Fundamental Change” (as defined in the Indenture) occur, then the conversion rate will, in certain circumstances, be increased for a specified period of time and is determined by reference to a make-whole table set forth in the Indenture governing the Senior Notes. However, in no event will the conversion rate be increased to an amount that exceeds 48.10 shares of the Company’s common stock per $1,000 principal amount of Senior Notes. In addition, the holders of the Senior Notes may require the Company to repurchase the Senior Notes at par value plus accrued and unpaid interest following the occurrence of a “Fundamental Change” (as described in the Indenture).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On or after June 5, 2023, we may redeem the Senior Notes at our option, in whole and not in part, at a cash redemption price equal to the principal amount of the Senior Notes to be redeemed, plus accrued and unpaid interest, if any, if:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">The last reported sale price per share of the Company’s common stock exceeds 130% of the conversion price on (i) each of at least 20 </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company send the related redemption notice; and (ii) the trading day immediately before the date the Company sends such notice; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">A registration statement covering the resale of the shares of the Company’s common stock issuable upon conversion of the Senior Notes is effective and available for use and is expected to remain effective and available during the redemption period as of the date the redemption notice is sent.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Senior Notes contain customary terms and events of default. If an event of default arising out of certain events of bankruptcy, insolvency, or reorganization involving the Company or a significant subsidiary (as set forth in the Indenture) occurs with respect to the Company, the principal amount of the Senior Notes and accrued and unpaid interest, if any, will automatically become immediately due and payable. If any other event of default (as defined in the Indenture) occurs and is continuing, either the Trustee or the holders of at least 25% in aggregate principal amount of the outstanding Senior Notes may declare the principal amount of the Senior Notes to be due and payable immediately by notice to the Company. There were no events of default at March 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Senior Notes are accounted for in accordance with ASC 470-20, <i style="font-style:italic;">Debt with Conversion and Other Options</i> (“ASC 470-20”) and ASC 815-40, <i style="font-style:italic;">Contracts in Entity’s Own Equity</i> (“ASC 815-40”)<i style="font-style:italic;">.</i> Under ASC 815-40, to qualify for equity classification (or nonbifurcation, if embedded) the instrument (or embedded feature) must be both (1) indexed to the issuer’s stock and (2) meet the requirements of the equity classification guidance. Based upon the Company’s analysis, it was determined the Senior Notes do contain embedded features indexed to its own stock, but do not meet the requirements for bifurcation, and therefore do not need to be separately accounted for as an equity component. Since the embedded conversion feature meets the equity scope exception from derivative accounting, and also since the embedded conversion option does not need to be separately accounted for as an equity component under ASC 470-20<i style="font-style:italic;">,</i> the proceeds received from the issuance of the convertible debt was recorded as a liability on the consolidated balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company incurred approximately $4.1 million of debt issuance costs relating to the issuance of the Senior Notes, which were recorded as a reduction to the Senior Notes on the consolidated balance sheet. The debt issuance costs are being amortized and recognized as additional interest expense over the expected life of the Senior Notes using the effective interest rate method. We determined the expected life of the debt is equal to the five-year term of the Senior Notes. The effective interest rate on the Senior Notes is 3.74%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Senior Notes payable consisted of the following at March 31, 2021 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:83.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, 2021</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:83.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Principal amount of Senior Notes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 115,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unamortized debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,464)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:83.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net carrying value of Senior Notes payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 111,536</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Interest expense incurred in connection with the Notes consisted of the following for the three months ended March 31, 2021 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, 2021</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:79.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Coupon interest</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 862</p></td></tr><tr><td style="vertical-align:bottom;width:79.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 192</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:79.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total interest expense on Senior Notes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,054</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company’s Senior Notes payable of $115.0 are due and payable in 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In connection with the issuance of the Senior Notes, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) to use its best efforts to file a registration statement for the resale of the Senior Notes and the shares of the Company's common stock issuable upon conversion of the Senior Notes, to cause the registration statement to become effective by January 31, 2021, and to keep the registration statement continuously effective for a specified period of time. If the Company fails to satisfy certain of its obligations under the Registration Rights Agreement (a “Registration Default”), it will be required to pay additional interest on the Senior Notes. Such additional interest will accrue at a rate per annum equal to 0.25% of the principal amount thereof for the first 90 days beginning on, and including the date on which such Registration Default occurs and, thereafter, at a rate per annum equal to 0.50% of the principal amount thereof. However, in no event will such additional interest, together with any special interest that accrues pursuant to the Indenture accrue on any day on a Note at a combined rate per annum that exceeds 0.50%. Additionally, if a Registration Default exists on the maturity date for the Senior Notes, then, in addition to any additional interest otherwise payable, the Company will be required to make a cash payment to each noteholder in an amount equal to 3% of the principal amount of Senior Notes outstanding and held by such holder as of the close of business on the business day immediately before the maturity date. As of March 31, 2021, the Company has not accrued any fees or expenses associated with the Registration Rights Agreement as no Registration Default exists and, therefore, it is not probable that a payment would be required. In December 2020, the Company filed an automatic shelf registration statement to register the resale of the Senior Notes and the shares of the Company’s common stock issuable upon conversion of the Senior Notes.</p> 115000000.0 0.0300 15000000.0 111300000 3700000 300000 0.0300 1200000 4810002 41.8261 1000 23.91 48.10 1000 130 20 30 0.25 4100000 P5Y 0.0374 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Senior Notes payable consisted of the following at March 31, 2021 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:83.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, 2021</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:83.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Principal amount of Senior Notes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 115,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unamortized debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,464)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:83.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net carrying value of Senior Notes payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 111,536</p></td></tr></table> 115000000 3464000 111536000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, 2021</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:79.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Coupon interest</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 862</p></td></tr><tr><td style="vertical-align:bottom;width:79.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 192</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:79.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total interest expense on Senior Notes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,054</p></td></tr></table> 862000 192000 1054000 115000000.0 0.0025 0.0050 0.0050 0.03 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 10. Note Payable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In connection with the acquisition of CRYOPDP, the Company assumed an interest free unsecured note payable of €4.0 million ($4.9 million) repayable in two installments of €0.5 million ($0.6 million) to be repaid in 2025 and €3.5 million ($4.3 million) to be repaid in 2028.  A fair market value discount of €1.1 million ($1.3 million) was recorded and is amortized to interest expense using the effective interest method over the term of the note.  During the three months ended March 31, 2021, the Company amortized €0.06 million ($0.07 million) of the debt discount to interest expense for this note. </p> 4000000.0 4900000 2 500000 600000 3500000 4300000 1100000 1300000 60000.00 70000.00 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note 11. Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company has operating and finance leases for corporate offices and certain equipment. These leases have remaining lease terms of one year to approximately nine years, some of which include options to extend the leases for multiple renewal periods of five years each. Under the terms of the facilities leases, the Company is required to pay its proportionate share of property taxes, insurance and normal maintenance costs. As of March 31, 2021 and December 31, 2020, assets recorded under finance leases were $0.3 million and $0.3 million, respectively, and accumulated depreciation associated with finance leases was $0.1 million and $0.08 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The components of lease cost were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost </p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 922</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 290</p></td></tr><tr><td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease cost:</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization of right-of-use assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td></tr><tr><td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest on finance lease liabilities</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 940</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 298</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Other information related to leases was as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:79.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Supplemental Cash Flows Information</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:79.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Operating cash flows from operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 851</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:79.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Operating cash flows from finance leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Financing cash flows from finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:79.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use assets obtained in exchange for lease liabilities (in thousands):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:79.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Operating leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,781</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:79.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-Average Remaining Lease Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:79.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Operating leases </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6.3 years</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2.7 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:79.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-Average Discount Rate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:79.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Operating leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.4</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 27.35pt;">Future minimum lease payments under non-cancellable leases that have commenced as of March 31, 2021 were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 27.35pt;"><span style="font-size:8pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:70.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years Ending March 31</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> Operating Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance Leases</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:70.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2021 (excluding the three months ended March 31, 2021)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,688</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45</p></td></tr><tr><td style="vertical-align:bottom;width:70.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,730</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 58</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,256</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 61</p></td></tr><tr><td style="vertical-align:bottom;width:70.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,049</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,866</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;width:70.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,738</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total future minimum lease payments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,327</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 164</p></td></tr><tr><td style="vertical-align:bottom;width:70.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,823)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (12)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,504</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 152</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported as of March 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Leases</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Current lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,002</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 60</p></td></tr><tr><td style="vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Noncurrent lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,502</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 92</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,504</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 152</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> P1Y P9Y P5Y 300000 300000 100000 80000.00 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The components of lease cost were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost </p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 922</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 290</p></td></tr><tr><td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease cost:</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization of right-of-use assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td></tr><tr><td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest on finance lease liabilities</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 940</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 298</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p> 922 290 15 6 3 2 18 8 940 298 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Other information related to leases was as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:79.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Supplemental Cash Flows Information</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:79.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Operating cash flows from operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 851</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:79.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Operating cash flows from finance leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Financing cash flows from finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:79.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use assets obtained in exchange for lease liabilities (in thousands):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:79.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Operating leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,781</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:79.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-Average Remaining Lease Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:79.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Operating leases </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6.3 years</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2.7 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:79.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-Average Discount Rate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:79.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Operating leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.4</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table> 851 22 20 2781 P6Y3M18D P2Y8M12D 0.054 0.053 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 27.35pt;">Future minimum lease payments under non-cancellable leases that have commenced as of March 31, 2021 were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 27.35pt;"><span style="font-size:8pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:70.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years Ending March 31</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> Operating Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance Leases</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:70.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2021 (excluding the three months ended March 31, 2021)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,688</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45</p></td></tr><tr><td style="vertical-align:bottom;width:70.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,730</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 58</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,256</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 61</p></td></tr><tr><td style="vertical-align:bottom;width:70.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,049</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,866</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;width:70.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,738</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total future minimum lease payments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,327</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 164</p></td></tr><tr><td style="vertical-align:bottom;width:70.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,823)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (12)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,504</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 152</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported as of March 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Leases</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Current lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,002</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 60</p></td></tr><tr><td style="vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Noncurrent lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,502</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 92</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,504</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 152</p></td></tr></table> 1688 45 2730 58 2256 61 2049 1866 0 9738 20327 164 3823 12 16504 152 2002000 60000 14502000 92000 16504 152 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 12. Commitments and Contingencies </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Facility and Equipment Leases </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We lease various corporate, global logistics and supply chain centers, biostorage, manufacturing, and research and development facilities in Tennessee, California, New Jersey, the Netherlands, Texas, Georgia, Minnesota, China, Portugal and France under operating leases. These lease agreements contain certain scheduled annual rent increases which are accounted for on a straight-line basis.   In addition, we lease certain equipment which expires through July 2024 (See Note 11).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employment Agreements </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have entered into employment agreements with certain of our officers under which payment and benefits would become payable in the event of termination by us for any reason other than cause, or upon a change in control of our Company, or by the employee for good reason.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Litigation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company may become a party to product litigation in the normal course of business. The Company accrues for open claims based on its historical experience and available insurance coverage. <span style="color:#212529;">We record a loss contingency when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. We also disclose material contingencies when we believe a loss is not probable but reasonably possible. Accounting for contingencies requires us to use judgment related to both the likelihood of a loss and the estimate of the amount or range of loss. The outcomes of our legal proceedings are inherently unpredictable, subject to significant uncertainties, and could be material to our financial condition, results of operations, and cash flows for a particular period.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Indemnities and Guarantees</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has made certain indemnities and guarantees, under which it may be required to make payments to a guaranteed or indemnified party, in relation to certain actions or transactions. The guarantees and indemnities do not provide for any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not been obligated nor incurred any payments for these obligations and, therefore, no liabilities have been recorded for these indemnities and guarantees in the accompanying consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company indemnifies its directors, officers, employees and agents, as permitted under the laws of the States of California and Nevada. In connection with its facility and equipment leases, the Company has indemnified its lessors for certain claims arising from the use of the facilities and equipment. The duration of the guarantees and indemnities varies and is generally tied to the life of the agreements.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 13. Stockholders’ Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Authorized Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has 100,000,000 authorized shares of common stock with a par value of $0.001 per share, and 2,500,000 undesignated or “blank check” preferred stock, with a par value of $0.001, of which, 800,000 shares have been designated as Class A Preferred Stock, 585,000 shares have been designated as Class B Preferred Stock and 250,000 shares have been designated as 4.0% Series C Convertible Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Common Stock Issued for Services</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the three months ended March 31, 2021, 229 shares of common stock with a fair value of $11,500 were issued to one member of the board of directors as compensation for services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the three months ended March 31, 2020, 1,269 shares of common stock with a fair value of $20,700 were issued to two members of the board of directors as compensation for services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">January 2021 Public Offering</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 25, 2021, the Company completed an underwritten public offering of 4,356,059 shares of its common stock. The shares were issued and sold pursuant to an underwriting agreement dated January 20, 2021, by and among the Company, on the one hand, and Morgan Stanley &amp; Co. LLC, Jefferies LLC, SVB Leerink LLC and UBS Securities LLC, as representatives of certain underwriters at a public offering price per share of $66.00, before deducting underwriting discounts and commissions. The shares include 568,181 shares issued and sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares of common stock pursuant to the underwriting agreement. The Company received net proceeds of approximately $269.8 million from the offering after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Blackstone Private Placement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the MVE Acquisition, on October 1, 2020 (the “Closing Date”), the Company completed a private placement with an investment vehicle of funds affiliated with The Blackstone Group Inc. (collectively, “Blackstone”), consisting of (i) 250,000 shares of a newly designated 4.0% Series C Convertible Preferred Stock, par value $0.001 per share (“Series C Preferred Stock”), at a price of $1,000 per share, for $250.0 million, and (ii) 675,536 shares of common stock of the Company, par value $0.001 per share (“Common Stock”) for $25.0 million, for an aggregate purchase price of $275.0 million. The Company paid Blackstone $1.0 million as reimbursement for transactional expenses incurred in connection with the private placement at the Closing Date. Also, the Company incurred direct and incremental expenses of approximately $8.6 million, including financial advisory fees, closing costs, legal expenses and other offering-related expenses. The Company allocated the net proceeds of $265.4 million on a relative fair value basis to the Series C Preferred Stock and the Common Stock, resulting in allocated proceeds of $28.2 million and $237.2 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Series C Preferred Stock ranks senior to the shares of the Company’s Common Stock, with respect to dividend rights and rights upon the voluntary or involuntary liquidation, dissolution, or winding up of the affairs of the Company (a “Liquidation”). The Series C Preferred Stock has the following rights, preferences and privileges:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Dividend Rights.</span> Holders of the Series C Preferred Stock (the “Holders”) are entitled to dividends at the rate of 4.0% per annum, paid-in-kind, accruing daily and paid quarterly in arrears when and if declared by the Board of Directors. The Holders are also entitled to participate in dividends declared or paid on the Common Stock on an as-converted basis. The Company and Holders do not have the option to pay dividends in kind, in cash, or in other form. Paid in-kind dividends for the three months ended March 31, 2021 and the year ended December 31, 2020 were $2.2 million and $2.5 million, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidation Preference.</span> Upon a Liquidation, each share of Series C Preferred Stock is entitled to receive an amount per share equal to the greater of (i) $1,000 per share, plus all accrued and unpaid dividends and (ii) the amount that the Holders of the Series C Preferred Stock would have been entitled to receive at such time if the Series C Preferred Stock were converted into Common Stock (the ”Liquidation Preference”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Conversion Features.</span> The Series C Preferred Stock is convertible at the option of the Holders at any time into shares of Common Stock at a conversion price of $38.6152 per share and a conversion rate of 25.90 shares of Common Stock per share of Series C Preferred Stock. The maximum number of Common Stock that could be required to be issued if converted is 6,474,135 shares. The conversion price is subject to certain customary adjustments in the event of certain adjustments to the Company’s Common Stock, including stock dividends, splits, combinations, tender offers, and exchange offers.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">After the second anniversary of the Closing Date, subject to certain conditions, the Company may at its option require conversion of all of the outstanding shares of the Series C Preferred Stock to Common Stock if, for at least 20 trading days during the 30 consecutive trading days immediately preceding the date the Company notifies the Holders of the election to convert, the closing price of the Common Stock is at least 150% of the conversion price. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On the October 1, 2020 issuance date, the effective conversion price per share was less than the fair value of the underlying Common Stock and, as a result, the Company determined that there was a beneficial conversion feature on that date. Accordingly, the Company recognized the resulting beneficial conversion feature amount of $39.5 million as a deemed dividend, equal to the number of common shares into which the Series C Preferred Stock is convertible multiplied by the difference between the fair value of the Common Stock and the effective conversion price per share on that date. Because the Series C Preferred Stock does not have a stated conversion date and was immediately convertible at the issuance date, the dividend is reflected as a one-time, non-cash, deemed dividend to the Holders of the Series C Preferred Stock on the date of issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, the Company determined that the nature of the Series C Preferred Stock is more akin to an equity instrument and that the economic characteristics and risks of the embedded conversion options are clearly and closely related to the Series C Preferred Stock. As such, the conversion options were not required to be bifurcated from the host under ASC 815, <i style="font-style:italic;">Derivatives and Hedging</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since the paid-in-kind dividends are nondiscretionary, the Company measures the beneficial conversion feature in the paid-in-kind dividend on the issuance date of the preferred stock and records such amount when the paid-in-kind dividend are accrued. Accordingly, the associated paid-in-kind dividends for the year ended December 31, 2020 generated a beneficial conversion feature amount of $0.3 million. On February 5, 2021, the Company received a waiver and conversion notice from Blackstone Freeze Parent L.P. and Blackstone Tactical Opportunities Fund – FD L.P. and converted an aggregate of 50,000 shares of the Series C Preferred Stock (see “—Blackstone Conversion” below for additional information).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Redemption Rights</span><span style="font-style:italic;font-weight:bold;">.</span> The Company may redeem the Series C Preferred Stock for cash, as follows:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">At any time beginning five years after the Closing Date (but prior to six years after the Closing Date), all of the Series C Preferred Stock at a price equal to 105% of the purchase price paid plus any accrued and unpaid dividends.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">At any time beginning six years after the Closing Date, all of the Series C Preferred Stock at a price equal to 100% of the purchase price paid plus any accrued and unpaid dividends.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Within 6 months of the Closing Date, the Company also had the right to redeem up to 50,000 shares of the Series C Preferred Stock at a price equal to 125% of the purchase price paid plus any accrued and unpaid dividends, which the Company waived (see “—Blackstone Conversion” below for additional information).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon a “Fundamental Change” (involving a change of control or de-listing of the Company as further described in the Certificate of Designation), each Holder has the right to require the Company to redeem all or any part of the Holder’s Series C Preferred Stock for an amount equal to the Liquidation Preference plus any accrued and unpaid dividends.  If the Company does not have sufficient funds legally available to pay the repurchase price, then the Company is required to (a) pay the maximum amount of the repurchase price that can be paid out of funds legally available for payment, and (b) purchase any shares of the Series C Preferred Stock not purchased because of the foregoing limitations at the repurchase price as soon as practicable after the Company is able to make such purchase out of assets legally available for the purchase of such shares. If the Company fails to pay the repurchase price in full when due, then the Company will pay dividends on such shares not repurchased at a rate of 5.5% per annum until such shares are repurchased, payable quarterly in arrears.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company evaluated the Series C Preferred Stock for liability or equity classification under the applicable accounting guidance including ASC 480, <i style="font-style:italic;">Distinguishing Liabilities from Equity</i>, and determined that equity treatment was appropriate because the Series C Preferred Stock did not meet the definition of the liability instruments defined thereunder for convertible instruments. Specifically, the convertible preferred shares are not mandatorily redeemable and do not embody an obligation to buy back the shares outside of the Company’s control in a manner that could require the transfer of assets. Additionally, the Company determined that the Series C Preferred Stock would be recorded as permanent equity given that they are not redeemable for cash or other assets (i) on a fixed or determinable date, (ii) at the option of the holder, or (iii) upon the occurrence of an event that is not solely within control of the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company also evaluated the embedded put and call options within the Series C Preferred Stock in accordance with the accounting guidance for derivatives to determine if bifurcation is required.  The Company determined that the economic characteristics and risks of the embedded put and call options are not clearly and closely related to the Series C Preferred Stock. Therefore, the Company assessed the put and call options further and determined they did not meet the definition of a derivative under ASC 815<i style="font-style:italic;">.</i> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the same analysis, the Company determined that the economic characteristics and risks of the embedded participating dividend feature are considered clearly and closely related to the equity host. Accordingly, the participating dividend feature is not required to be bifurcated under ASC 815. Also, the Company determined that the value of the contingent dividend feature is minimal and insignificant relative to the other components of the Series C Preferred Stock due to the circumstances surrounding the scenarios under which the provision would be triggered.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Voting Rights</span><b style="font-weight:bold;">.</b> Holders of the Series C Preferred Stock are generally entitled to vote with the holders of the shares of Common Stock on an as-converted basis, subject to certain Nasdaq voting limitations, if applicable. Also, the consent of the Holders of a majority of the outstanding shares of the Series C Preferred Stock is required with respect to (i) amendments to the Company’s organizational documents that have an adverse effect on the Holders of the Series C Preferred Stock, and (ii) issuances by the Company of securities that are senior to, or equal in priority with, the Series C Preferred Stock. Holders of the Series C Preferred Stock have the right to nominate for election one member to the board of directors of the Company for so long as they hold 66.67% of the Series C Preferred Stock issued to them at the Closing Date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Registration Rights</span><b style="font-weight:bold;">. </b>Holders of the Series C Preferred Stock have certain customary registration rights with respect to the Series C Preferred Stock and the shares of common stock into which they are converted, pursuant to the terms of a registration rights agreement. The Company is required to file within 90 days of the Closing Date, and use its commercially reasonable efforts to cause to go effective as promptly as practicable, a registration statement covering the sale or distribution of Common Stock issued or issuable upon conversion of the Series C Preferred Stock.   In December 2020, the Company filed an automatic shelf registration statement to register the resale of the Common Stock issued or issuable upon conversion of the Series C Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Blackstone Conversion</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 5, 2021, the Company received a waiver and conversion notice from Blackstone Freeze Parent L.P. and Blackstone Tactical Opportunities Fund – FD L.P. to convert an aggregate of 50,000 shares of the Company’s Series C Preferred Stock. Pursuant to the terms of the waiver and conversion notice, the Company also agreed to waive its right under the certificate of designations of the Series C Preferred Stock to redeem up to 50,000 shares of the Series C Preferred Stock prior to the 180-day anniversary of October 1, 2020, the issue date of the Series C Preferred Stock. Each share of Series C Preferred Stock has a liquidation preference of $1,000 per share plus any accumulated and unpaid dividends and is convertible into shares of the Company’s common stock, par value $0.001 per share, at a conversion price of $38.6152 per share. The forgoing conversion, effective as of February 5, 2021, resulted in the issuance of an aggregate of 1,312,860 shares of Common Stock and $1.8 million in expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Common Stock Reserved for Future Issuance </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2021, approximately 18.2 million shares of common stock were issuable upon conversion or exercise of rights granted under prior financing arrangements, stock options, RSU’s and the conversion of senior notes and series C Preferred stock, as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,793,769</p></td></tr><tr><td style="vertical-align:bottom;width:84.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vesting of restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 304,157</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of Series C Preferred Stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,283,411</p></td></tr><tr><td style="vertical-align:bottom;width:84.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of convertible senior notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,810,002</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total shares of common stock reserved for future issuances</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,191,339</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> 100000000 0.001 2500000 0.001 800000 585000 250000 0.040 229 11500 1 1269 20700 2 4356059 66.00 568181 269800000 250000 0.040 0.001 1000 250000000.0 675536 0.001 25000000.0 275000000.0 1000000.0 8600000 265400000 28200000 237200000 0.040 2200000 2500000 1000 38.6152 25.90 6474135 20 30 1.50 39500000 300000 50000 1.05 1 50000 1.25 0.055 1 0.6667 50000 50000 1000 0.001 38.6152 1312860 1800000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2021, approximately 18.2 million shares of common stock were issuable upon conversion or exercise of rights granted under prior financing arrangements, stock options, RSU’s and the conversion of senior notes and series C Preferred stock, as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,793,769</p></td></tr><tr><td style="vertical-align:bottom;width:84.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vesting of restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 304,157</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of Series C Preferred Stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,283,411</p></td></tr><tr><td style="vertical-align:bottom;width:84.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of convertible senior notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,810,002</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total shares of common stock reserved for future issuances</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,191,339</p></td></tr></table> 18200000 7793769 304157 5283411 4810002 18191339 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note 14. Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have five stock incentive plans: the 2002 Stock Incentive Plan (the “2002 Plan”), the 2009 Stock Incentive Plan (the “2009 Plan”), the 2011 Stock Incentive Plan (the “2011 Plan”), the 2015 Omnibus Equity Incentive Plan (the “2015 Plan”), and the 2018 Omnibus Equity Incentive Plan (the “2018 Plan”), (collectively, the “Plans”). The 2002 Plan, the 2009 Plan, the 2011 Plan and the 2015 Plan (the “Prior Plans”) have been superseded by the 2018 Plan. In May 2018, the stockholders approved the 2018 Plan for issuances up to an aggregate of 3,730,179 shares. The Prior Plans will remain in effect until all awards granted under such Prior Plans have been exercised, forfeited, cancelled, or have otherwise expired or terminated in accordance with the terms of such awards, but no awards will be made pursuant to the Prior Plans after the effectiveness of the 2018 Plan. As of March 31, 2021, the Company had 190,181 shares available for future awards under the 2018 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">During the three months ended March 31, 2021, we granted stock options at exercise prices equal to the quoted market price of our common stock on the grant date. The fair value of each option grant was estimated on the date of grant using Black-Scholes with the following weighted average assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:82.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected life (years)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3.5 – 6.1</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:82.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.5% - 0.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:82.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">64.4% - 80.8</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:82.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The expected option life assumption is estimated based on the simplified method. Accordingly, the Company has utilized the average of the contractual term of the options and the weighted average vesting period for all options to calculate the expected option term. The risk-free interest rate assumption is based upon observed interest rates appropriate for the expected term of our employee stock options. The expected volatility is based on the average of the historical volatility and the implied volatility of our stock commensurate with the expected life of the stock-based award. We do not anticipate paying dividends on the common stock in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We recognize stock-based compensation cost on a straight-line basis over the vesting period. Stock-based compensation expense is recognized only for those awards that ultimately vest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Total stock-based compensation expense related to all of our share-based payment awards is comprised of the following:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three months ended March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of revenues</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 239</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 69</p></td></tr><tr><td style="vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,505</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,443</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Engineering and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 246</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 108</p></td></tr><tr><td style="vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,620</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">A summary of stock option activity is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price/Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term (Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value (1)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding — December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,554,305</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10.29</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:55.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted (weighted-average fair value of $32.66 per share)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 435,298</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55.74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (187,486)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.46</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:55.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,348)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16.48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding — March 31, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,793,769</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.86</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6.4</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 306,822</p></td></tr><tr><td style="vertical-align:bottom;width:55.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested (exercisable) — March 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,904,443</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 261,287</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">Expected to vest after March 31, 2021 (unexercisable)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,889,326</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28.82</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">7.9</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,001</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:6.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of our common stock on March 31, 2021, which was </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$52.01</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> per share.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Total intrinsic value of options exercised during the three months ended March 31, 2021 was $9.4 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2021, there was unrecognized compensation expense of $32.5 million related to unvested stock options, which we expect to recognize over a weighted average period of 3.4 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Restricted stock units</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A summary of our restricted stock unit activity is as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted Average </b></p></td></tr><tr><td style="vertical-align:bottom;width:63.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of Restricted </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> Fair Value per  </b></p></td></tr><tr><td style="vertical-align:bottom;width:63.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Share </b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding – December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:63.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 304,157</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 53.94</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Share issuance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:63.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding March 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 304,157</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 53.94</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">For the three months ended March 31, 2021 and 2020, we recorded stock-based compensation expense on our issued restricted stock units of $0.3 million and $0, respectively.  As of March 31, 2021 there was unrecognized compensation expense of $16.1 million related to unvested restricted stock units, which we expect to recognize over a weighted average period of 4.0 years.</p> 3730179 190181 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:82.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected life (years)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3.5 – 6.1</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:82.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.5% - 0.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:82.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">64.4% - 80.8</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:82.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table> P3Y6M P6Y1M6D 0.005 0.009 0.644 0.808 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We recognize stock-based compensation cost on a straight-line basis over the vesting period. Stock-based compensation expense is recognized only for those awards that ultimately vest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Total stock-based compensation expense related to all of our share-based payment awards is comprised of the following:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three months ended March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of revenues</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 239</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 69</p></td></tr><tr><td style="vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,505</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,443</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Engineering and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 246</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 108</p></td></tr><tr><td style="vertical-align:bottom;width:73.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,620</p></td></tr></table> 239000 69000 2505000 1443000 246000 108000 2990000 1620000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">A summary of stock option activity is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price/Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term (Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value (1)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding — December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,554,305</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10.29</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:55.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted (weighted-average fair value of $32.66 per share)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 435,298</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55.74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (187,486)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.46</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:55.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,348)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16.48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding — March 31, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,793,769</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.86</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6.4</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 306,822</p></td></tr><tr><td style="vertical-align:bottom;width:55.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested (exercisable) — March 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,904,443</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 261,287</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">Expected to vest after March 31, 2021 (unexercisable)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,889,326</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28.82</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">7.9</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,001</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:6.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of our common stock on March 31, 2021, which was </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$52.01</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> per share.</span></td></tr></table><div style="margin-top:12pt;"/> 7554305 10.29 32.66 435298 55.74 187486 8.46 8348 16.48 7793769 12.86 P6Y4M24D 306822 5904443 7.76 P5Y9M18D 261287 1889326 28.82 P7Y10M24D 40001 52.01 9400000 32500000 P3Y4M24D <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A summary of our restricted stock unit activity is as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted Average </b></p></td></tr><tr><td style="vertical-align:bottom;width:63.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of Restricted </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> Fair Value per  </b></p></td></tr><tr><td style="vertical-align:bottom;width:63.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Share </b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding – December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:63.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 304,157</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 53.94</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Share issuance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:63.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding March 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 304,157</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 53.94</p></td></tr></table> 0 0 304157 53.94 304157 53.94 300000 0 16100000 P4Y <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Note 15. Subsequent Event</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Effective April 1, 2021, the Company completed the acquisition of Critical Transport Solutions Australia Pty Ltd. (“CTSA”) a market leader in providing premium healthcare logistics management services, specializing in time and temperature critical solutions for the medical and pharmaceutical industries based in Australia, for approximately $5.0 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The agreement includes an earnout provision which is (a) subject to and dependent on the Company achieving a 2024 EBITDA, as defined; and (b) is subject to certain employment requirements through December 31, 2024.  CTSA will be a part of the Company’s CRYOPDP business unit and will continue to be run by the current management team.</p> 5000000.0 XML 12 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Document and Entity Information - shares
3 Months Ended
Mar. 31, 2021
Apr. 23, 2021
Document and Entity Information    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Entity File Number 001-34632  
Entity Incorporation, State or Country Code NV  
Entity Tax Identification Number 88-0313393  
Entity Address, Address Line One 112 Westwood Place, Suite 350  
Entity Address, City or Town Brentwood  
Entity Address, State or Province TN  
Entity Address, Postal Zip Code 37027  
City Area Code 949  
Local Phone Number 470-2300  
Title of 12(b) Security Common Stock, $0.001 par value  
Security Exchange Name NASDAQ  
Document Period End Date Mar. 31, 2021  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q1  
Entity Registrant Name CRYOPORT, INC.  
Entity Central Index Key 0001124524  
Entity Interactive Data Current Yes  
Entity Current Reporting Status Yes  
Current Fiscal Year End Date --12-31  
Entity Filer Category Large Accelerated Filer  
Trading Symbol CYRX  
Entity Common Stock, Shares Outstanding   45,681,456
Entity Emerging Growth Company false  
Entity Small Business false  
Entity Shell Company false  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Current Assets:    
Cash and cash equivalents $ 85,494 $ 36,873
Short-term investments 267,721 56,444
Accounts receivable, net 36,504 31,377
Inventories 11,544 10,535
Prepaid expenses and other current assets 18,485 11,928
Total current assets 419,748 147,157
Property and equipment, net 31,694 30,036
Operating lease right-of-use assets 15,996 14,044
Intangible assets, net 209,267 213,908
Goodwill 141,305 145,282
Deposits 946 1,184
Other long-term assets 752 794
Total assets 819,708 552,405
Current Liabilities:    
Accounts payable and other accrued expenses 27,083 24,844
Accrued compensation and related expenses 8,233 7,441
Deferred revenue 495 445
Operating lease liabilities 2,002 2,231
Finance lease liabilities 60 59
Total current liabilities 37,873 35,020
Convertible senior notes, net of discount of $3.5 million and $3.7 million, respectively 111,536 111,344
Note payable, net of discount of $1.2 million and $0, respectively 3,497 4,912
Operating lease liabilities, net of current portion 14,502 12,261
Finance lease liabilities, net of current portion 92 112
Deferred tax liability 4,626 5,882
Other long-term liabilities 307 176
Total liabilities 172,433 169,707
Commitments and contingencies
Stockholders' Equity:    
Preferred stock value
Common stock, $0.001 par value; 100,000,000 shares authorized; 45,693,692 and 39,837,058 issued and outstanding at March 31, 2021 and December 31, 2020, respectively 45 40
Additional paid-in capital 837,615 566,451
Accumulated deficit (195,540) (192,013)
Accumulated other comprehensive income 880 5,376
Total stockholders' equity 647,275 382,698
Total liabilities and stockholders' equity 819,708 552,405
Class A convertible preferred stock [Member]    
Stockholders' Equity:    
Preferred stock value 0 0
Class B convertible preferred stock [Member]    
Stockholders' Equity:    
Preferred stock value 0 0
Class C convertible preferred stock    
Stockholders' Equity:    
Preferred stock value $ 4,275 $ 2,844
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Convertible Subordinated Debt, Discount $ 3,500,000 $ 3,700,000
Note payable, discount $ 1,200,000 $ 0
Preferred stock, par value per share (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized 2,500,000 2,500,000
Common stock, par value per share (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 45,693,692 39,837,058
Common stock, shares outstanding 45,693,692 39,837,058
Class A convertible preferred stock [Member]    
Preferred stock, par value per share (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized 800,000 800,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Class B convertible preferred stock [Member]    
Preferred stock, par value per share (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized 585,000 585,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Class C convertible preferred stock    
Preferred stock, par value per share (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized 250,000 250,000
Preferred stock, shares issued 200,000 200,000
Preferred stock, shares outstanding 200,000 200,000
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Revenues $ 53,284 $ 9,774
Cost of revenues 28,734 4,516
Gross margin 24,550 5,258
Operating costs and expenses:    
Selling, general and administrative 21,388 7,111
Engineering and development 4,304 1,733
Total operating costs and expenses 25,692 8,844
Loss from operations (1,142) (3,586)
Other income (expense):    
Investment income 398 307
Interest expense (1,210) (2)
Other expense, net (535) (628)
Total other expense, net (1,347) (323)
Loss before provision for income taxes (2,489) (3,909)
Provision for income taxes (1,038) (33)
Net loss (3,527) (3,942)
Paid-in-kind dividend on Series C convertible preferred stock (2,196)  
Net loss attributable to common stockholders $ (5,723) $ (3,942)
Net loss per share attributable to common stockholders - basic and diluted $ (0.13) $ (0.11)
Weighted average common shares outstanding - basic and diluted 43,804,483 37,548,549
Service [Member]    
Revenues $ 26,765 $ 9,774
Cost of revenues 15,552 $ 4,516
Product [Member]    
Revenues 26,519  
Cost of revenues $ 13,182  
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Condensed Consolidated Statements of Comprehensive Loss    
Net loss $ (3,527) $ (3,942)
Other comprehensive income (loss), net of tax:    
Net unrealized gain (loss) on available-for-sale debt securities (768) 471
Reclassification of realized (gain) loss on available-for-sale debt securities to earnings 30 (1)
Foreign currency translation adjustments (3,758) (2)
Other comprehensive income (loss) (4,496) 468
Total comprehensive loss $ (8,023) $ (3,474)
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
Common Stock [Member]
Additional Paid-In Capital [Member]
Accumulated Deficit [Member]
Other Comprehensive Income (Loss) [Member]
Class A Preferred Stock
Class B Preferred Stock
Class C Preferred Stock
Total
Balance at Dec. 31, 2019 $ 37,000 $ 285,609,000 $ (159,320,000) $ (45,000) $ 0 $ 0 $ 0 $ 126,281,000
Balance (in shares) at Dec. 31, 2019 37,339,787       0 0 0  
Net loss $ 0 0 (3,942,000) 0 $ 0 $ 0 $ 0 (3,942,000)
Other comprehensive income (loss), net of taxes 0 0 0 468,000 0 0 0 468,000
Stock-based compensation expense 0 1,600,000 0 0 0 0 0 1,600,000
Issuance of common stock for board of director compensation $ 0 21,000 0 0 0 0 $ 0 21,000
Issuance of common stock for board of director compensation (in shares) 1,269           0  
Proceeds from exercise of stock options and warrants $ 1,000 2,877,000 0 0 0 0 $ 0 2,878,000
Proceeds from exercise of stock options and warrants (in shares) 589,199           0  
Balance at Mar. 31, 2020 $ 38,000 290,107,000 (163,262,000) 423,000 $ 0 $ 0 $ 0 127,306,000
Balance (in shares) at Mar. 31, 2020 37,930,255       0 0 0  
Balance at Dec. 31, 2020 $ 40,000 566,451,000 (192,013,000) 5,376,000 $ 0 $ 0 $ 2,844,000 382,698,000
Balance (in shares) at Dec. 31, 2020 39,837,058       0 0 250,000  
Net loss $ 0 0 (3,527,000) 0 $ 0 $ 0 $ 0 (3,527,000)
Other comprehensive income (loss), net of taxes 0 0 0 (4,496,000) 0 0 0 (4,496,000)
Stock-based compensation expense 0 2,979,000 0 0 0 0 0 2,979,000
Cost of Series C preferred stock conversion   (1,800,000)           (1,800,000)
Issuance of common stock in public offering, net of costs of $17.7 million $ 4,000 269,821,000           269,825,000
Issuance of common stock in public offering, net of costs of $17.7 million (in shares) 4,356,059              
Issuance of common stock for board of director compensation $ 0 11,000 0 0 0 0 $ 0 11,000
Issuance of common stock for board of director compensation (in shares) 229           0  
Conversion of Series C preferred shares to common stock $ 1,000 764,000         $ (765,000)  
Conversion of Series C preferred shares to common stock (in shares) 1,312,860           50,000  
Paid-in-kind preferred stock dividend, including beneficial conversion feature   (2,196,000)         $ 2,196,000  
Proceeds from exercise of stock options and warrants $ 0 1,585,000 0 0 $ 0 $ 0 $ 0 1,585,000
Proceeds from exercise of stock options and warrants (in shares) 187,486       0 0 0  
Balance at Mar. 31, 2021 $ 45,000 $ 837,615,000 $ (195,540,000) $ 880,000 $ 0 $ 0 $ 4,275,000 $ 647,275,000
Balance (in shares) at Mar. 31, 2021 45,693,692       0 0 200,000  
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)
$ in Millions
3 Months Ended
Mar. 31, 2021
USD ($)
Public offering  
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs $ 17.7
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Cash Flows From Operating Activities:    
Net loss $ (3,527) $ (3,942)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 4,837 824
Amortization of debt discount 264 0
Unrealized loss (gain) on investments in equity securities 263 (144)
Realized loss on investments in equity securities 0 793
Realized loss (gain) on available-for-sale debt securities 40 (11)
Stock-based compensation expense 2,990 1,620
Loss on disposal of property and equipment 71 80
Provision for bad debt 63 4
Changes in operating assets and liabilities, net of effects of acquisition:    
Accounts receivable (5,213) 955
Inventories (988) 9
Prepaid expenses and other current assets (6,545) 95
Deposits 229 (46)
Change in operating lease right-of-use assets and lease liabilities 60 7
Accounts payable and other accrued expenses 532 65
Accrued compensation and related expenses 804 768
Deferred revenue 49 (27)
Deferred tax liability 80 9
Net cash provided by (used in) operating activities (5,991) 1,059
Cash Flows From Investing Activities:    
Purchases of property and equipment (2,811) (596)
Software development costs (193) 0
Purchases of short-term investments (215,318) (16,195)
Sales/maturities of short-term investments 3,000 16,279
Patent and trademark costs (48) (30)
Net cash used in investing activities (215,370) (542)
Cash Flows From Financing Activities:    
Proceeds from exercise of stock options and warrants 1,586 2,878
Proceeds from public offering, net of offering costs 269,825 0
Repayment of finance lease liabilities (18) (14)
Net cash provided by financing activities 271,393 2,864
Effect of exchange rate changes on cash and cash equivalents (1,411) 7
Net change in cash and cash equivalents 48,621 3,388
Cash and cash equivalents - beginning of year 36,873 47,234
Cash and cash equivalents - end of year 85,494 50,622
Supplemental Disclosure of Non-Cash Investing and Financing Activities:    
Conversion of Series C Preferred Stock to common stock 765 0
Cost of Series C Preferred stock conversion included in additional paid-in-capital and accounts payable and accrued liabilities 1,800 0
CRYOPDP goodwill adjustment included in deferred tax liability 1,394 0
CRYOPDP goodwill adjustment included in fixed assets 71 0
Note valuation adjustment included in note payable and goodwill 1,266 0
Net unrealized gain on available-for-sale debt securities 768 471
Reclassification of realized gain on available-for-sale debt securities to earnings 30 0
Purchase of equipment through capital lease obligations 0 203
Fixed assets included in accounts payable and accrued liabilities $ 198 $ 608
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Cash Flows (Parenthetical)
$ in Millions
3 Months Ended
Mar. 31, 2021
USD ($)
Public offering  
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs $ 17.7
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.21.1
Management's Representation and Basis of Presentation
3 Months Ended
Mar. 31, 2021
Management's Representation and Basis of Presentation  
Management's Representation and Basis of Presentation

Note 1. Management’s Representation and Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared by Cryoport, Inc. (the “Company”, “Cryoport”, “our” or “we”) in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X promulgated by the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statement presentation. However, the Company believes that the disclosures are adequate to make the information presented not misleading. In the opinion of management, all adjustments (consisting primarily of normal recurring accruals) considered necessary for a fair presentation have been included.

Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. The unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

The Company has evaluated subsequent events through the date of this filing and determined that no subsequent events have occurred that would require recognition in the unaudited condensed consolidated financial statements or disclosure in the notes thereto other than as disclosed in the accompanying notes.

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.21.1
Nature of the Business
3 Months Ended
Mar. 31, 2021
Nature of the Business  
Nature of the Business

Note 2. Nature of the Business

Cryoport is a life sciences services company that is an integral part of the temperature-controlled supply chain supporting the biopharma/pharma, animal health, and reproductive medicine markets. We are redefining logistics for the life sciences industry by providing a unique platform of critical solutions including highly differentiated temperature-controlled supply chain solutions, which include advanced packaging, informatics, specialty logistics services, biostorage services and cryogenic life sciences equipment. Through our products, services and expertise, we enable our clients to ship, store and deliver cellular-based materials and drug products as well as other life sciences commodities in a precise, defined temperature-controlled state.

Cryoport’s advanced platform, comprised of comprehensive and technology-centric systems and solutions are designed to support the global high-volume distribution of commercial biologic and cell-based products and therapies regulated by the United States Food and Drug Administration (FDA) and other international regulatory bodies for distribution in the Americas, EMEA (Europe, the Middle East, and Africa) and APAC (Asia-Pacific) regions. Cryoport’s solutions are also designed to support pre-clinical, clinical trials, Biologics License Applications (BLA), Investigational New Drug Applications (IND), New Drug Applications (NDA) and Commercialized Products with the FDA, as well as global clinical trials and commercialized products initiated in other countries, where strict regulatory compliance and quality assurance is mandated. Our industry standard setting Chain of ComplianceTM solutions, which include vital analytics, such as ‘chain-of-condition’ and ‘chain-of-custody’ information in a single data stream, empower our clients’ continuous vigilance over their respective commodities. In addition, our Chain of ComplianceTM standard ensures full traceability of all equipment used and the processes employed, further supporting each client’s goal of minimizing risk and maximizing success of their respective biologics or other products and therapies as they are introduced into the global markets.

On August 21, 2020, the Company entered into a Securities Purchase Agreement to acquire CRYOPDP, a leading global provider of innovative temperature-controlled logistics solutions to the clinical research, pharmaceutical and cell and gene therapy markets, headquartered in Paris, France. Under the terms of the Securities Purchase Agreement, the Company acquired 100% of the equity interests in Advanced Therapy Logistics and Solutions, a company organized under the laws of France, which is the holding company that owns CRYOPDP (the “CRYOPDP Acquisition”). The purchase price under the Securities Purchase Agreement was €49 million (approximately $58.0 million).

On August 24, 2020, the Company entered into a Purchase Agreement with Chart Industries, Inc. (“Chart”) pursuant to which the Company acquired Chart’s MVE Biological Solutions’ cryobiological storage business (the “MVE Acquisition”) for a cash purchase price at closing of $320 million, subject to customary closing working capital and other adjustments. The MVE Acquisition was structured as the acquisition of certain equity interests and assets and the transfer of certain liabilities in connection therewith.

On October 1, 2020, the Company completed both the MVE Acquisition and the CRYOPDP Acquisition.

The Company is a Nevada corporation and its common stock is traded on the NASDAQ Capital Market exchange under the ticker symbol “CYRX.”

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2021
Summary of Significant Accounting Policies  
Summary of Significant Accounting Policies

Note 3. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Cryoport, Inc. and its wholly-owned subsidiaries, Cryoport Systems, LLC, Cryogene, Inc., MVE Biological Solutions US LLC, and Cryoport Netherlands B.V. and subsidiaries (collectively, the “Company”). All intercompany accounts and transactions have been eliminated.

Cash and Cash Equivalents

Our cash and cash equivalents represent demand deposits, and money market funds which are readily convertible into cash, have maturities of 90 days or less when purchased and are considered highly liquid and easily tradeable.

Short-Term Investments

Our investments in equity securities consist of mutual funds with readily determinable fair values which are carried at fair value with changes in fair value recognized in earnings.

Investments in debt securities are classified as available-for-sale and are carried at fair value, with unrealized gains and losses, net of tax, reported as accumulated other comprehensive income (loss) and included as a separate component of stockholders’ equity.

Gains and losses are recognized when realized. When we have determined that an other than temporary decline in fair value has occurred, the amount related to a credit loss is recognized in earnings. Gains and losses are determined using the specific identification method.

Short-term investments are classified as current assets even though maturities may extend beyond one year because they represent investments of cash available for operations.

Use of Estimates

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from estimated amounts. The Company’s significant estimates include the allowance for doubtful accounts, fair value of short-term investments, valuations and purchase price allocations related to business combinations, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, intangible asset useful lives and amortization methods, allowance for inventory obsolescence, equity-based instruments, tax reserves and recoverability of the Company’s net deferred tax assets and related valuation allowance.

Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.

Future events, including the extent and the duration of the COVID-19 related economic impacts, and their effects cannot be predicted with certainty, and, accordingly the Company’s accounting estimates require the exercise of judgment.

Fair Value of Financial Instruments

The Company’s financial instruments consist of cash and cash equivalents, short-term investments, accounts receivable, accounts payable and accrued expenses, finance lease liabilities, note payable, and the Company’s 3.00% convertible senior notes due in 2025 (the “Senior Notes”). The carrying value for all such instruments, except finance lease liabilities, note payable and the Senior Notes, approximates fair value at March 31, 2021 and December 31, 2020 due to their short-term nature. The carrying value of finance lease liabilities approximates fair value because the interest rate approximates market rates available to us for similar obligations with the same maturities. For additional information related to fair value measurements, including the note payable and the Senior Notes, see Notes 9 and 10.

Concentrations of Credit Risk

Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. From time to time, we maintain cash, cash equivalent and short-term investment balances in excess of amounts insured by the Federal Deposit Insurance Corporation (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”).  Primarily all of our cash, cash equivalents and short-term investments at March 31, 2021 were in excess of amounts insured by the FDIC and SIPC.  The Company performs ongoing evaluations of these institutions to limit its concentration risk exposure.  We manage such risks in our portfolio by investing in highly liquid, highly-rated instruments, and limit investing in long-term maturity instruments.

Our investment policy requires that purchased instruments in marketable securities may only be in highly-rated instruments, which are primarily U.S. Treasury bills or treasury-backed securities, and also limits our investment in securities of any single issuer.

Customers

The Company grants credit to customers within the U.S. and international customers and does not require collateral. Revenues from international customers are generally secured by advance payments except for established foreign customers. The Company generally requires advance or credit card payments for initial revenues from new customers. The Company’s ability to collect receivables can be affected by economic fluctuations in the geographic areas and industries served by the Company. Reserves for uncollectible amounts are provided based on past experience and a specific analysis of the accounts, which management believes to be sufficient. Accounts receivable at March 31, 2021 and December 31, 2020 are net of reserves for doubtful accounts of $1.2 million and $1.1 million, respectively. Although the Company expects to collect amounts due, actual collections may differ from the estimated amounts. The Company maintains reserves for bad debt and such losses, in the aggregate, historically have not exceeded its estimates.

The Company’s customers are in the biopharma, pharmaceutical, animal health, reproductive medicine and other life science industries. Consequently, there is a concentration of accounts receivable within these industries, which is subject to normal credit risk. At March 31, 2021, there was one customer that accounted for 10.5% of net accounts receivable. At December 31, 2020, there were no customers that accounted for more than 10% of net accounts receivable. There were no other single customers that owed us more than 10% of net accounts receivable at March 31, 2021 and December 31, 2020.

The Company has revenue from foreign customers primarily in United Kingdom, Switzerland, France, Netherlands, Singapore, China and India. During the three months ended March 31, 2021 and 2020, the Company had revenues from foreign customers of approximately $25.5 million and $2.1 million, respectively, which constituted approximately 48.0% and 21.4%, respectively, of total revenues. There was one customer that accounted for 12.5% of revenues during the three months ended March 31, 2021. There were three customers that accounted for 17.9%, 16.7% and 10.8% of revenues during the three months ended March 31, 2020, respectively. No other single customer generated over 10% of revenues during the three months ended March 31, 2021 and 2020.

Inventories

Inventories are stated at the lower of cost and net realizable value. Cost is determined using the first-in, first-out (“FIFO”) method. Inventories are reviewed periodically for slow-moving or obsolete status. The Company writes down the carrying value of its inventories to reflect situations in which the cost of inventories is not expected to be recovered. Once established, write-downs of inventories are considered permanent adjustments to the cost basis of the obsolete or excess inventories. Raw materials and finished goods include material costs less reserves for obsolete or excess inventories. The Company evaluates the current level of inventories considering historical trends and other factors, such as selling prices and costs of completion, disposal and transportation, and based on the evaluation, records adjustments to reflect inventories at net realizable value. These adjustments are estimates, which could vary significantly from actual results if future economic conditions, customer demand, competition or other relevant factors differ from expectations. These estimates require us to make assessments about future demand for the Company’s products in order to categorize the status of such inventories items as slow-moving, obsolete or in excess-of-need. These estimates are subject to the ongoing accuracy of the Company’s forecasts of market conditions, industry trends, competition and other factors.

Property and Equipment

Property and equipment are stated at cost, less accumulated depreciation.  We compute depreciation using the straight-line method over the estimated useful lives of the assets which is generally three to twelve years for computer hardware and software, seven to ten years for freezers, four to ten years for trucks and autos, three to fifteen years for furniture and equipment and over the shorter of the lease term or useful live of the assets for leasehold improvements. Buildings are depreciated over a useful life ranging from 20 to 45 years. Maintenance and repairs are expensed as incurred.

Betterments, renewals and extraordinary repairs that extend the lives of the assets are capitalized; other repairs and maintenance charges are expensed as incurred. The cost and related accumulated depreciation and amortization applicable to assets retired are removed from the accounts, and the gain or loss on disposition is recognized in the consolidated statements of operations.

Leases

The Company determines if an arrangement is a lease at inception. Operating lease right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset during the lease term, and operating lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating leases are included in ROU assets, current operating lease liabilities, and long-term operating lease liabilities on our consolidated balance sheets. Finance leases are included in property and equipment, current finance lease liabilities, and long-term finance lease liabilities on our consolidated balance sheets.

Lease ROU assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments over the lease term at commencement date calculated using our incremental borrowing rate applicable to the lease asset, unless the implicit rate is readily determinable. ROU assets also include any lease payments made at or before lease commencement and exclude any lease incentives received. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets. The Company’s leases do not contain any residual value guarantees. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.

The Company accounts for lease and non-lease components as a single lease component for all its leases.

Business Combinations

Total consideration transferred for acquisitions is allocated to the assets acquired and liabilities assumed based on their fair values at the dates of acquisition. This purchase price allocation process requires management to make significant estimates and assumptions primarily with respect to intangible assets. The fair value of identifiable intangible assets is based on detailed valuations that use information and assumptions determined by management. Any excess of purchase price over the fair value of the net tangible and intangible assets acquired is allocated to goodwill. While the Company uses its best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date as well as any contingent consideration, where applicable, the Company’s estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company records adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill.

Goodwill

The Company evaluates goodwill on an annual basis in the fourth quarter or more frequently if management believes indicators of impairment exist. Such indicators could include, but are not limited to: (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. The Company compares the fair value of the reporting unit’s with its carrying amount and then recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting units fair value up to the total amount of goodwill allocated to the reporting unit. The Company assessed  triggering events indicating potential goodwill impairment, including the effects of the COVID-19 pandemic, and after assessment, concluded that there was no impairment during the three months ended March 31, 2021.

Intangible Assets

Intangible assets are comprised of patents, trademarks, software development costs and the intangible assets acquired in the MVE, CRYOPDP and Cryogene acquisitions which include a non-compete agreement, technology, customer relationships, trade name/trademark, agent network, order backlog, developed technology and land use rights. The Company capitalizes costs of obtaining patents and trademarks, which are amortized, using the straight-line method over their estimated useful life of five years once the patent or trademark has been issued. The non-compete agreement, technology, customer relationships, trade name/trademark, agent network, order backlog, developed technology and land use rights, acquired in the MVE, CRYOPDP and Cryogene acquisitions are amortized using the straight-line method over the estimated useful lives (see Note 8). The Company uses the following valuation methodologies to value the significant intangible assets acquired: income approach for customer relationships, replacement cost for agent network and software, and relief from royalty for trade name/trademarks and developed technology.

The Company evaluates the recoverability of identifiable intangible assets whenever events or changes in circumstances indicate that an intangible asset's carrying amount may not be recoverable. Such circumstances could include, but are not limited to: (1) a significant decrease in the market value of an asset, (2) a significant adverse change in the extent or manner in which an asset is used, or (3) an accumulation of costs significantly in excess of the amount originally expected for the acquisition of an asset. The Company measures the carrying amount of the asset against the estimated undiscounted future cash flows associated with it. Should the sum of the expected future net cash flows be less than the carrying value of the asset being evaluated, an impairment loss would be recognized. The impairment loss would be calculated as the amount by which the carrying value of the asset exceeds its fair value. The estimate of fair value is based on various valuation techniques, including the discounted value of estimated future cash flows. The evaluation of asset impairment requires the Company to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results may differ from assumed and estimated amounts. There was no impairment of intangible assets during the three months ended March 31, 2021.

Other Long-lived Assets

If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the fair value to the carrying value. We believe the future cash flows to be received from the long-lived assets will exceed the assets’ carrying value, and accordingly, we have not recognized any impairment losses through March 31, 2021.

Deferred Financing Costs

Deferred financing costs represent costs incurred in connection with the issuance of debt instruments and equity financings. Deferred financing costs related to the issuance of debt are amortized over the term of the financing instrument using the effective interest method and are presented in the consolidated balance sheets as an offset against the related debt. Offering costs from equity financings are netted against the gross proceeds received from the equity financings.

Income Taxes

The Company accounts for income taxes under the provision of ASC 740, “Income Taxes”, or ASC 740. As of March 31, 2021 and December 31, 2020, there were no material unrecognized tax benefits included in the accompanying consolidated balance sheets that would, if recognized, affect the effective tax rate.

Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. Based on the weight of available evidence, the Company’s management has determined that it is not more likely than not that the U.S. based net deferred tax assets will be realized. Therefore, the Company has recorded a full valuation allowance against its U.S. based net deferred tax assets. With respect to the foreign based deferred tax assets, the Company's management has reviewed these deferred tax assets on a jurisdictional basis. Based on the weight of each jurisdiction's evidence available, the Company's management has made separate determinations for each foreign jurisdiction regarding whether it is more likely than not that a net deferred tax asset within a particular jurisdiction will be realized. The Company has recorded full valuation allowances in jurisdictions where deferred tax assets are not deemed more likely than not to be realized.

Additionally, the Company maintains a deferred tax liability related to indefinite-lived assets that have been netted against deferred tax assets that also allow for indefinite carryforward periods subject to limitations.  The remaining taxable temporary difference cannot serve as a source for future taxable income to realize federal net operating losses, due to the fact that post-2017 federal net operating losses are only eligible to offset 80% of income in a given year or in the case of state net operating losses, the state net operating losses will expire prior to the reversal of the taxable temporary difference.

The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company has immaterial accruals for interest or penalties on its consolidated balance sheets at March 31, 2021 and December 31, 2020 and has recorded only immaterial interest and/or penalties in the consolidated statements of operations for the three months ended March 31, 2021 and 2020. The Company is subject to taxation in the U.S., various state jurisdictions and in various foreign countries. As of March 31, 2021, the Company is no longer subject to U.S. federal examinations for years before 2017 and for California franchise and income tax examinations for years before 2016. However, to the extent allowed by law, the taxing authorities may have the right to examine prior periods where net operating losses were generated and carried forward and make adjustments up to the amount of the net operating loss carry forward amount. The Company is not currently under examination by U.S. federal or state jurisdictions. Our foreign subsidiaries are generally subject to examination three years following the year in which the tax obligation originated.  The years subject to audit may be extended if the entity substantially understates corporate income tax. The Company's subsidiary in India is currently under examination by the Indian tax authorities for 2012-2013, 2013-2014 and 2015-2016 tax periods. Other than India, the Company does not have any foreign subsidiaries currently under audit by their local taxing authorities.

In December of 2019, the FASB issued Accounting Standards Update (“ASU”) 2019-12 Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. The Board issued this Update as part of its Simplification Initiative to improve areas of U.S. GAAP and reduce cost and complexity while maintaining usefulness. The main provision that impacts the company is the removal of the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, discontinued operations and other comprehensive income). ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 31, 2020. Different components of the guidance require retrospective, modified retrospective or prospective adoption. The Company elected to early adopt ASU 2019-12 on January 1, 2020, and the adoption of the standard did not have a material impact to our consolidated financial statements.

On March 27, 2020, the United States enacted the Coronavirus Aid, Relief and Economic Security Act (CARES Act). The Cares Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund a nationwide effort to curtail the effect of COVID-19. The CARES Act provides sweeping tax changes in response to the COVID-19 pandemic, some of the more significant provisions are removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years, and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act. At March 31, 2021, the Company has not recorded any income tax provision/(benefit) resulting from the CARES Act mainly due the Company’s history of net operating losses generated and the maintenance of a full valuation allowance against its net deferred tax assets.  

On June 29, 2020, the State of California passed Assembly Bill 85 which suspends the California net operating loss deduction for the 2020-2022 tax years and the R&D credit usage for the same period (for credit usages in excess of $5 million). These suspensions were considered in preparation of the March 31, 2021 and December 31, 2020 financial statements.

On December 27, 2020, the United States enacted the Consolidated Appropriations Act of 2021 (“CAA”).  The CAA includes provisions extending certain CARES Act provisions and adds coronavirus relief, tax and health extenders. The Company will continue to evaluate the impact of the CAA and its impact on our financial statements in 2021 and beyond.

On March 11, 2021, the United States enacted the American Rescue Plan (“ARP”). The ARP includes provisions extending certain CARES Act provisions, repeals a worldwide interest allocation election, modifies the $1 million executive compensation limitation for years after 2026 and extends the employee retention credit. The Company will continue to evaluate the impact of the ARP and its impact on our financial statements in 2021 and beyond.

Revenue Recognition

Revenues are recognized when control is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods and services. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied.

Performance Obligations

At contract inception, an assessment of the goods and services promised in the contracts with customers is performed and a performance obligation is identified for each distinct promise to transfer to the customer a good or service (or bundle of goods or services). To identify the performance obligations, the Company considers all of the goods or services promised in the contract regardless of whether they are explicitly stated or are implied by customary business practices. Revenue is recognized when our performance obligation has been met. The Company considers control to have transferred upon delivery because the Company has a present right to payment at that time, the Company has transferred use of the asset, and the customer is able to direct the use of, and obtain substantially all of the remaining benefits from, the asset.

For arrangements under which the Company provides biological specimen storage services and logistics support and management to the customer, the Company satisfies its performance obligations as those services are performed whereby the customer simultaneously receives and consumes the benefits of such services under the agreement.

Revenue generated from short-term logistics and engineering consulting services provided to customers is recognized when the Company satisfies the contractually defined performance obligations. When a contract includes multiple performance obligations, the contract price is allocated among the performance obligations based upon the stand-alone selling prices. Approved contract modifications are accounted for as either a separate contract or as part of the existing contract depending on the nature of the modification.

Our performance obligations on our orders and under the terms of agreements with customers are generally satisfied within one year from a given reporting date and, therefore, we omit disclosure of the transaction price allocated to remaining performance obligations on open orders.

Shipping and handling activities related to contracts with customers are accounted for as costs to fulfill our promise to transfer the associated products pursuant to the accounting policy election allowed under Topic 606 and are not considered a separate performance obligation to our customers. Accordingly, the Company records amounts billed for shipping and handling as a component of revenue. Shipping and handling fees and costs are included in cost of revenues in the accompanying condensed consolidated statements of operations.

Revenues are recognized net of any taxes collected from customers, which are subsequently remitted to governmental agencies.

Significant Payment Terms

Pursuant to the Company’s contracts with its customers, amounts billed for services or products delivered by the Company are generally due and payable in full within 15  to 60 days from the date of the invoice (except for any amounts disputed by the customer in good faith). Accordingly, the Company determined that its contracts with customers do not include extended payment terms or a significant financing component.

Variable Consideration

When a contract includes variable consideration, the Company evaluates the estimate of the variable consideration to determine whether the estimate needs to be constrained. Variable consideration is estimated at the most likely amount that is expected to be earned.

Estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the anticipated performance and all information (historical, current and forecasted) that is reasonably available. Variable consideration estimates are updated at each reporting date. Revenues are recorded net of variable consideration, such as discounts and allowances.

Warranties

The Company provides product warranties with varying terms and durations for some of its products. The Company estimates product warranty costs and accrues for these costs as products are sold with a charge to cost of sales. Factors considered in estimating warranty costs include historical and projected warranty claims, historical and projected cost-per-claim, and knowledge of specific product issues that are outside of typical experience. Warranty accruals are evaluated and adjusted as necessary based on actual claims experience and changes in future claim and cost estimates.

Product warranty accrued liabilities totaled $0.2 million and $0.2 million at March 31, 2021 and December 31, 2020, respectively, and are included in accounts payable and other accrued expenses. Warranty expense was not material for the three months ended March 31, 2021 and 2020.

Incremental Direct Costs

Incremental direct costs are expensed when incurred when the amortization period of the asset that would have been recognized is one year or less; otherwise, incremental contract costs are recognized as an asset and amortized over time as promised goods and services are transferred to a customer. Incremental direct costs were not material for the three months ended March 31, 2021 and 2020.

The Company expenses incremental direct costs of obtaining a contract (sales commissions) when incurred because the amortization period is generally 12 months or less. The Company does not incur costs to fulfill a customer contract that meet the requirements for capitalization.

Contract Assets

Typically, we invoice the customer and recognize revenue once we have satisfied our performance obligation. Accordingly, our contract assets comprise accounts receivable, which are recognized when payment is unconditional and only the passage of time is required before payment is due. Generally, we do not have material amounts of other contract assets since revenue is recognized as control of goods is transferred or as services are performed.

Contract Liabilities (Deferred Revenue)

Contract liabilities are recorded when cash payments are received in advance of the Company’s performance. Deferred revenue was $0.5 million and $0.3 million at March 31, 2021 and 2020, respectively.  During the three months ended March 31, 2021, the Company recognized revenues of $0.2 million from the related contact liabilities outstanding as the services were performed.

Nature of Goods and Services

The Company provides Cryoport Express® Shippers to its customers and charges a fee in exchange for the use of the Cryoport Express® Shipper under long-term master service agreements with customers. The Company’s arrangements convey to the customers the right to use the Cryoport Express® Shippers over a period of time. The Company retains title to the Cryoport Express® Shippers and provides its customers the use of the Cryoport Express® Shipper for a specified shipping cycle. At the culmination of the customer’s shipping cycle, the Cryoport Express® Shipper is returned to the Company.

The Company recognizes revenue for the use of the Cryoport Express® Shippers at the time of the delivery of the Cryoport Express® Shipper to the end user of the enclosed materials, and at the time that collectability is probable.

The Company also provides vacuum insulated aluminum dewars and cryogenic freezers systems to its customers. Revenue is recognized when the Company satisfies performance obligations by transferring the equipment to a customer, and at the time that collectability is probable.

The Company also provides global temperature-controlled logistics services, support and management. Revenue is recognized for these services as services are rendered and at the time that collectability is probable.

The Company also provides comprehensive and integrated temperature-controlled biostorage solutions to customers in the life sciences industry and charges a fee under long-term master service agreements with customers. These services include (1) biological specimen cryopreservation storage and maintenance, (2) archiving, monitoring, tracking, receipt and delivery of samples, (3) transport of frozen biological specimens to and from customer locations, and (4) management of incoming and outgoing biological specimens. The Company recognizes revenue for its biostorage solutions as services are rendered over time and at the time that collectability is probable.

The Company also provides short-term logistics and engineering consulting services to some customers, with fees tied to the completion of contractually defined services. We recognize revenue from these services over time as the customer simultaneously receives and consumes the benefit of these services as they are performed.

A significant portion of our revenues are covered under long-term agreements. We have determined that individual Statements of Work or Scope of Work (“SOW”), whose terms and conditions taken with a Master Services Agreement (“MSA”), create the Topic 606 contracts which are generally short-term in nature (e.g., 15-day shipping cycle) for the Cryoport Express® solutions and up to 12 months for biostorage solutions. Our agreements (including SOWs) generally do not have multiple performance obligations and, therefore, do not require an allocation of a single price amongst multiple goods or services.  Prices under these agreements are generally fixed.

Revenue Disaggregation

The Company views its operations, makes decisions regarding how to allocate resources and manages its business as one reportable segment and one reporting unit. As a result, the financial information disclosed herein represents all of the material financial information related to the Company. When disaggregating revenue, the Company considered all of the economic factors that may affect its revenues. We consider sales disaggregated by end-market to depict how the nature, amount, timing and uncertainty of revenues and cash flows are impacted by changes in economic factors. The following table disaggregates our revenues by major markets for the three months ended March 31, 2021 and 2020 (in thousands):

Three Months Ended March 31, 

    

2021

    

2020

Biopharma/Pharma

$

42,393

$

8,786

Animal Health

 

8,997

 

225

Reproductive Medicine

1,894

763

Total revenues

$

53,284

$

9,774

Given that the Company’s revenues are generated in different geographic regions, factors such as regulatory and geopolitical factors within those regions could impact the nature, timing and uncertainty of the Company’s revenues and cash flows. Our geographical revenues, by origin, for the three months ended March 31, 2021 and 2020, were as follows (in thousands):

Three Months Ended March 31, 

    

2021

    

2020

Americas

$

27,734

$

7,685

Europe, the Middle East and Africa (EMEA)

 

14,208

 

1,932

Asia Pacific (APAC)

 

11,342

 

157

Total revenues

$

53,284

$

9,774

Cost of Services Revenues

Our cost of services revenues is primarily comprised of freight charges, payroll and associated expenses related to our global logistics and supply chain centers, depreciation expenses of our Cryoport Express® Shippers and supplies and consumables used for our solutions.

Cost of Product Revenues

Our cost of product revenues is primarily comprised of materials, direct and indirect labor, inbound freight charges, purchasing and receiving, inspection, and distribution and warehousing of inventory. In addition, shop supplies, facility maintenance costs and depreciation expense for assets used in the manufacturing process are included in cost of product revenues.

Engineering and Development Expenses

Expenditures relating to engineering and development are expensed in the period incurred to engineering and development expense in the statement of operations.

Acquisition Costs

Acquisition costs consist of legal, accounting, third-party valuations, and other due diligence costs related to our MVE Biological Solutions and CRYOPDP acquisitions.

Stock-Based Compensation

Under our stockholder approved stock-based compensation plan, we have granted incentive stock options, non-qualified stock options and restricted stock units that vest over four years.  Incentive and non-qualified stock options expire from seven to ten years from date of grant. The Company accounts for stock-based payments in accordance with stock-based payment accounting guidance which requires all stock-based payments to be recognized based upon their fair values. The fair value of stock options is estimated at the grant date using the Black-Scholes Option Pricing Model (“Black-Scholes”) and the portion that is ultimately expected to vest is recognized as compensation cost over the requisite service period.  The determination of fair value using Black-Scholes is affected by the Company’s stock price as well as assumptions regarding a number of complex and subjective variables, including expected stock price volatility, risk-free interest rate, expected dividends and expected term. The Company accounts for forfeitures of unvested awards as they occur.

The grant date fair value per share for restricted stock units is based upon the closing market price of our common stock on the award grant date.

The Company’s stock-based compensation plans are discussed further in Note 14.

Basic and Diluted Net Loss Per Share

We calculate basic and diluted net loss per share using the weighted average number of common shares outstanding during the periods presented. In periods of a net loss position, basic and diluted weighted average common shares are the same. For the diluted earnings per share calculation, we adjust the weighted average number of common shares outstanding to include dilutive stock options, warrants and shares associated with the conversion of the Senior Notes and convertible preferred stock outstanding during the periods.

The following shows the amounts used in computing net loss per share (in thousands except per share data):

Three Months Ended March 31, 

    

2021

    

2020

Net loss

$

(3,527)

$

(3,942)

Paid-in-kind dividend on Series C convertible preferred stock

 

(2,196)

 

Net loss attributable to common shareholders

$

(5,723)

$

(3,942)

Weighted average common shares outstanding - basic and diluted

43,804,483

37,548,549

Basic and diluted net loss per share

$

(0.13)

$

(0.11)

The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:

Three Months Ended March 31, 

    

2021

    

2020

Stock options

6,149,186

 

3,867,924

Warrants

 

502,632

Restricted stock units

304,157

Series C convertible preferred stock

5,283,411

Convertible senior notes

4,810,002

 

16,546,756

 

4,370,556

Foreign Currency Transactions

Management has determined that the functional currency of its subsidiaries is the local currency.  Assets and liabilities of the Netherlands and United Kingdom subsidiaries are translated into U.S. dollars at the period-end exchange rates.  Income and expenses are translated at an average exchange rate for the period and the resulting translation gain (loss) adjustments are accumulated as a separate component of stockholders’ equity.  The translation gain (loss) adjustment totaled $(3.8) million and $0 for the three months ended March 31, 2021 and 2020, respectively. Foreign currency gains and losses from transactions denominated in other than respective local currencies are included in earnings.

Off-Balance Sheet Arrangements

We do not currently have any off-balance sheet arrangements.

Reclassification

Prior year amounts in sales and marketing expense have been reclassified to selling, general and administrative expense to conform to the current period presentation, which reflects how the Company tracks operating costs. These reclassifications had no effect on the previously reported net loss.

Recently Adopted Accounting Pronouncements

In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. Under ASU 2020-06, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost, as long as no other features require bifurcation and recognition as derivatives. Similarly, equity-classified convertible preferred stock instruments will be accounted for as single units of account in equity unless the conversion feature needs to be bifurcated under Topic 815. The new guidance also made amendments to the earnings per share guidance in Topic 260, Earnings Per Share, for convertible instruments, the most significant impact of which is requiring the use of the if- converted method for diluted earnings per share calculation. Further, ASU 2020-06 made revisions to Topic 815-40, which provides guidance on how an entity must determine whether a contract qualifies for a scope exception from derivative accounting. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted. Adoption of the standard requires using either a modified retrospective or a full retrospective approach. Effective January 1, 2021, we early adopted ASU 2020-06 using the modified retrospective approach. Adoption of the new standard did not have a material impact on the Company’s consolidated financial statements or disclosures.

In January 2020, the FASB issued ASU 2020-01, “Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815): Clarifying the Interactions between Topic 321, Topic 323, and Topic 815.” The new guidance clarifies the interaction of accounting for the transition into and out of the equity method and the accounting for measuring certain purchased options and forward contracts to acquire investments. ASU 2020-01 is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The adoption of this guidance did not have an impact on the Company’s consolidated financial statements or disclosures.

Accounting Guidance Issued but Not Adopted at March 31, 2021

In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This ASU replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information for credit loss estimates on certain types of financial instruments, including trade receivables. In addition, new disclosures are required. The ASU, as subsequently amended, is effective for fiscal years beginning after December 15, 2022 for smaller reporting companies, as defined by the SEC. As a smaller reporting company, we are currently evaluating the impact of adopting this guidance.

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.21.1
Acquisitions
3 Months Ended
Mar. 31, 2021
Acquisitions  
Acquisitions

Note 4. Acquisitions

2020 Acquisitions – CRYOPDP and MVE

CRYOPDP Acquisition

On October 1, 2020, the Company completed its acquisition of CRYOPDP for a cash consideration of €48.3 million (approximately $57.0 million, the “CRYOPDP Acquisition”). This acquisition was funded with existing cash on hand. CRYOPDP, based in France, is a leading global provider of innovative temperature-controlled logistics solutions to the clinical research, pharmaceutical and cell and gene therapy markets. CRYOPDP conducts its business activities in the Americas, EMEA and APAC. As a result of the CRYOPDP Acquisition, the Company has extended its solutions to include broader temperature-controlled logistics and specialty courier services and has significantly expanded its global network through CRYOPDP’s 22 facilities in 12 countries.

The final purchase price for the CRYOPDP Acquisition was $56.7 million, after receiving $0.3 million net working capital settlement from the sellers during the three months ended March 31, 2021. As of October 1, 2020, the Company recorded net assets acquired of $57.0 million, including goodwill of $25.5 million. Through March 31, 2021, the Company recorded measurement period adjustments of $2.9 million, mainly comprised of $1.3 million fair value on the note payable and $1.5 million deferred tax adjustments, resulting in adjusted goodwill of $22.6 million and adjusted net assets acquired of $56.7 million. The purchase price allocation for the assets acquired and liabilities assumed remains open due to the finalization of the purchase price allocation during the measurement process.

MVE Acquisition

On October 1, 2020, the Company completed its acquisition of Chart Industries, Inc.’s MVE cryobiological storage business (the “MVE Acquisition”) for a cash consideration of $317.5 million, subject to customary closing working capital and other adjustments. The Company financed a portion of the closing cash payment of the MVE Acquisition with the net proceeds of the Blackstone Private Placement, as further discussed in Note 13. MVE is a global leader in manufactured vacuum insulated products and cryogenic freezer systems for the life sciences industry. MVE has manufacturing and distribution operations in the Americas, EMEA and APAC. As a result of the MVE Acquisition, the Company has extended its integrated logistics solutions to provide a broad range of cryogenic dewars and freezers to the life sciences industry.

As of October 1, 2020, the Company recorded net assets acquired of $317.5 million, including goodwill of $106.2 million. Through March 31, 2021, the Company did not record any material measurement period adjustments. The purchase price allocation for the assets acquired and liabilities assumed remains open due to the finalization of the purchase price allocation during the measurement process.

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.21.1
Cash, Cash Equivalents and Short-Term Investments
3 Months Ended
Mar. 31, 2021
Cash, Cash Equivalents and Short-Term Investments  
Cash, Cash Equivalents and Short-Term Investments

Note 5. Cash, Cash Equivalents and Short-Term Investments

Cash, cash equivalents and short-term investments consisted of the following as of March 31, 2021 and December 31, 2020 (in thousands):

March 31, 

December 31, 

    

2021

    

2020

Cash

$

23,913

$

25,053

Cash equivalents:

 

Money market mutual fund

 

61,581

11,820

Total cash and cash equivalents

 

85,494

36,873

Short-term investments:

 

U.S. Treasury notes and bills

 

234,578

23,309

Mutual funds

 

33,143

33,135

Total short-term investments

 

267,721

56,444

Cash, cash equivalents and short-term investments

$

353,215

$

93,317

Available-for-sale investments

The amortized cost, gross unrealized gains, gross unrealized losses and fair value of available-for-sale investments by type of security at March 31, 2021 were as follows (in thousands):

    

Amortized

    

Unrealized

    

Unrealized

    

Cost

Gains

Losses

Fair Value

U.S. Treasury notes

$

235,185

$

128

$

(735)

$

234,578

Total available-for-sale investments

$

235,185

$

128

$

(735)

$

234,578

The following table summarizes the fair value of available-for-sale investments based on stated contractual maturities as of March 31, 2021:

    

Amortized Cost

    

Fair Value

Due within one year

$

41,030

$

41,058

Due between one and two years

 

194,155

 

193,520

Total

$

235,185

$

234,578

The amortized cost, gross unrealized gains, gross unrealized losses and fair value of available-for-sale investments by type of security at December 31, 2020 were as follows (in thousands):

    

    

Unrealized 

    

Unrealized 

    

Amortized Cost

Gains

Losses

Fair Value

U.S. Treasury notes

$

23,179

 

$

173

 

$

(43)

$

23,309

Total available-for-sale investments

$

23,179

 

$

173

$

(43)

$

23,309

The following table summarizes the fair value of available-for-sale investments based on stated contractual maturities as of December 31, 2020:

    

Amortized Cost

    

Fair Value

Due within one year

$

14,084

 

$

14,111

Due between one and two years

 

9,095

 

 

9,198

Total

$

23,179

 

$

23,309

The primary objective of our investment portfolio is to enhance overall returns in an efficient manner while maintaining safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with primarily investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer.

We review our available-for-sale investments for other-than-temporary declines in fair value below our cost basis each quarter and whenever events or changes in circumstances indicate that the cost basis of an asset may not be recoverable. The evaluation is based on a number of factors, including the length of time and the extent to which the fair value has been below our cost basis, as well as adverse conditions related specifically to the security such as any changes to the credit rating of the security and the intent to sell or whether we will more likely than not be required to sell the security before recovery of its amortized cost basis. Our assessment of whether a security is other-than-temporarily impaired could change in the future based on new developments or changes in assumptions related to that particular security.

During the three months ended March 31, 2021, we had realized gains of $40,000 on available-for-sale investments.

Equity Investments

We held investments in equity securities with readily determinable fair values of $33.1 million at March 31, 2021. These investments consist of mutual funds that invest primarily in tax-free municipal bonds and treasury inflation protected securities.

Unrealized gains (losses) during 2021 and 2020 related to equity securities held at March 31, 2021 and 2020 are as follows (in thousands):

    

2021

2020

Net losses recognized during the three months on equity securities

    

$

(263)

$

(649)

Less: net gains (losses) recognized during the year on equity securities sold during the year

 

   

(793)

Unrealized gains (losses) recognized during the three months on equity securities still held at March 31, 2021 and 2020

$

(263)

$

144

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements
3 Months Ended
Mar. 31, 2021
Fair Value Measurements  
Fair Value Measurements

Note 6. Fair Value Measurements

We measure fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include the following:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that are accessible at the measurement date. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. These inputs include quoted prices for similar assets or liabilities; quoted market prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as consider counterparty credit risk in the assessment of fair value.

We did not elect the fair value option, as allowed, to account for financial assets and liabilities that were not previously carried at fair value. Therefore, material financial assets and liabilities that are not carried at fair value, such as trade accounts receivable and payable, are reported at their historical carrying values.

The carrying values of our assets that are required to be measured at fair value on a recurring basis as of March 31, 2021 and 2020 approximate fair value because of our ability to immediately convert these instruments into cash with minimal expected change in value which are classified in the table below in one of the three categories of the fair value hierarchy described above (in thousands):

    

Fair Value Measurements

    

Level 1

    

Level 2

    

Level 3

    

Total

March 31, 2021

 

  

 

  

 

  

 

  

Cash equivalents:

 

  

 

  

 

  

 

  

Money market mutual fund

$

61,581

$

$

$

61,581

Marketable equity securities:

 

  

 

  

 

  

 

  

Mutual funds

 

33,143

 

 

 

33,143

Available-for-sale debt securities:

 

 

  

 

  

 

U.S. Treasury notes

 

234,578

 

 

 

234,578

$

329,302

$

$

$

329,302

Fair Value Measurements 

 

Level 1

 

Level 2

 

Level 3

 

Total

December 31, 2020

    

  

    

  

    

  

    

  

Cash equivalents:

 

  

 

  

 

  

 

  

Money market mutual fund

$

11,820

$

$

$

11,820

Marketable equity securities:

 

  

 

  

 

  

 

  

Mutual funds

 

33,135

 

 

 

33,135

Available-for-sale debt securities:

 

  

 

  

 

  

 

  

U.S. Treasury notes

 

23,309

 

 

 

23,309

$

68,264

$

$

$

68,264

Our equity securities and available-for-sale debt securities, including U.S. treasury notes and U.S. treasury bills are valued using inputs observable in active markets for identical securities and are therefore classified as Level 1 within the fair value hierarchy.

We did not have any financial liabilities measured at fair value on a recurring basis as of March 31, 2021.

We carry the Senior Notes (see Note 9) at face value less the unamortized discount and issuance costs on our consolidated balance sheets and present fair value for disclosure purposes only. As of March 31, 2021, the estimated fair value of the Notes was $108.8 million and was determined using the net present value of the payments, discounted at an interest rate that is consistent with market and risk-adjusted interest rates, which is a Level 2 input.

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.21.1
Inventory
3 Months Ended
Mar. 31, 2021
Inventory  
Inventory

Note 7. Inventory

Inventories consist of the following (in thousands):

    

March 31,

    

December 31,

2021

2020

Raw materials

$

8,318

$

7,544

Work-in-process

 

307

 

227

Finished goods

 

2,919

 

2,764

$

11,544

$

10,535

The inventory balance at December 31, 2020 includes an $0.8 million step up in inventory related to the acquisition of MVE.

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.21.1
Goodwill and Intangible Assets
3 Months Ended
Mar. 31, 2021
Goodwill and Intangible Assets  
Goodwill and Intangible Assets

Note 8. Goodwill and Intangible Assets

Goodwill

The following table represents the changes in the carrying value of goodwill for the three months ended March 31, 2021 and 2020 (in thousands):

    

March 31,

2021

    

2020

Balance at beginning of year

 

145,282

 

11,000

Foreign currency adjustment

 

(1,405)

 

Goodwill related to MVE acquisition

 

18

 

Goodwill related to CRYOPDP acquisition

 

(2,590)

 

Total

 

$

141,305

 

$

11,000

Intangible Assets

The following table presents our intangible assets as of March 31, 2021 (in thousands):

Weighted

Net

Average

Gross

Accumulated

Carrying

Amortization

    

Amount

    

Amortization

    

Amount

    

Period (years)

Non-compete agreement

$

390

$

143

$

247

 

3

Technology

34,438

2,576

31,862

11

Customer relationships

128,640

5,218

123,422

14

Cryogene trade name/trademark

480

59

421

13

CRYOPDP agent network

8,597

1,415

7,182

4

MVE order backlog

2,600

2,600

MVE land use rights

2,378

36

2,342

37

Patents and trademarks

44,360

569

43,791

Total

$

221,883

$

12,616

$

209,267

The following table presents our intangible assets as of December 31, 2020 (in thousands):

Weighted

Net

Average

Gross

Accumulated

Carrying

Amortization

    

Amount

    

Amortization

    

Amount

    

Period (years)

Non-compete agreement

$

390

$

123

$

267

 

3

Technology

34,245

1,630

32,615

11

Customer relationships

128,640

2,708

125,932

14

Cryogene trade name/trademark

480

51

429

13

CRYOPDP agent network

8,597

537

8,060

4

MVE order backlog

2,600

2,600

MVE land use rights

2,378

16

2,362

37

Patents and trademarks

44,312

69

44,243

 

Total

$

221,642

$

7,734

$

213,908

Amortization expense for intangible assets for the three months ended March 31, 2021 and 2020, was $3.6 million and $0.1 million, respectively.

Expected future amortization of intangible assets as of March 31, 2021 is as follows:

Years Ending March 31, 

    

Amount

Remainder of 2021

$

10,722

2022

 

14,296

2023

 

14,296

2024

 

13,678

2025

 

12,064

Thereafter

 

100,051

$

165,107

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.21.1
Convertible Senior Notes
3 Months Ended
Mar. 31, 2021
Convertible Senior Notes  
Convertible Senior Notes

Note 9. Convertible Senior Notes

In May 2020, the Company issued $115.0 million aggregate principal amount of 3.00% convertible senior notes due in 2025 (the "Senior Notes"), which includes the initial purchasers’ exercise in full of their option to purchase an additional $15.0 million principal amount of the Senior Notes, in a private placement exempt from registration under the Securities Act of 1933. The Senior Notes are governed by an indenture (the “Indenture”) dated May 26, 2020 between the Company, as issuer, and U.S. Bank National Association, as trustee (the “Trustee”). The Company received $111.3 million from the offering, net of underwriting discounts and commissions of $3.7 million, and incurred approximately $0.3 million in third-party offering related costs. The Senior Notes bear cash interest at a rate of 3.00%, payable semi-annually on June 1 and December 1 of each year, beginning on December 1, 2020 and will mature on June 1, 2025, unless earlier repurchased, redeemed, or converted in accordance with the terms of the Senior Notes. At March 31, 2021 accrued interest of $1.2 million is included in accounts payable and accrued liabilities in the accompanying consolidated financial statements.  The Notes comprise the Company’s senior, unsecured obligations and are (i) equal in right of payment with the Company’s existing and future senior, unsecured indebtedness; (ii) senior in right of payment to the Company’s existing and future indebtedness that is expressly subordinated to the Senior Notes; (iii) effectively subordinated to the Company’s existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness; and (iv) structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to the extent the Company is not a holder thereof) preferred equity, if any, of the Company’s subsidiaries.

At any time before the close of business on the scheduled trading day immediately before the maturity date, holders of the Senior Notes may convert their Senior Notes at their option into shares of the Company’s common stock. The Senior Notes are initially convertible into approximately 4,810,002 shares of the Company’s common stock based on the initial conversion rate of 41.8261 shares of the Company’s common stock per $1,000 principal amount of the Senior Notes, which represents an initial conversion price of approximately $23.91 per share of the Company’s common stock. The conversion rate and conversion price are subject to customary adjustments upon the occurrence of certain events. Also, if certain corporate events that constitute a “Make-Whole Fundamental Change” (as defined in the Indenture) occur, then the conversion rate will, in certain circumstances, be increased for a specified period of time and is determined by reference to a make-whole table set forth in the Indenture governing the Senior Notes. However, in no event will the conversion rate be increased to an amount that exceeds 48.10 shares of the Company’s common stock per $1,000 principal amount of Senior Notes. In addition, the holders of the Senior Notes may require the Company to repurchase the Senior Notes at par value plus accrued and unpaid interest following the occurrence of a “Fundamental Change” (as described in the Indenture).

On or after June 5, 2023, we may redeem the Senior Notes at our option, in whole and not in part, at a cash redemption price equal to the principal amount of the Senior Notes to be redeemed, plus accrued and unpaid interest, if any, if:

(1)The last reported sale price per share of the Company’s common stock exceeds 130% of the conversion price on (i) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company send the related redemption notice; and (ii) the trading day immediately before the date the Company sends such notice; and
(2)A registration statement covering the resale of the shares of the Company’s common stock issuable upon conversion of the Senior Notes is effective and available for use and is expected to remain effective and available during the redemption period as of the date the redemption notice is sent.

The Senior Notes contain customary terms and events of default. If an event of default arising out of certain events of bankruptcy, insolvency, or reorganization involving the Company or a significant subsidiary (as set forth in the Indenture) occurs with respect to the Company, the principal amount of the Senior Notes and accrued and unpaid interest, if any, will automatically become immediately due and payable. If any other event of default (as defined in the Indenture) occurs and is continuing, either the Trustee or the holders of at least 25% in aggregate principal amount of the outstanding Senior Notes may declare the principal amount of the Senior Notes to be due and payable immediately by notice to the Company. There were no events of default at March 31, 2021.

The Senior Notes are accounted for in accordance with ASC 470-20, Debt with Conversion and Other Options (“ASC 470-20”) and ASC 815-40, Contracts in Entity’s Own Equity (“ASC 815-40”). Under ASC 815-40, to qualify for equity classification (or nonbifurcation, if embedded) the instrument (or embedded feature) must be both (1) indexed to the issuer’s stock and (2) meet the requirements of the equity classification guidance. Based upon the Company’s analysis, it was determined the Senior Notes do contain embedded features indexed to its own stock, but do not meet the requirements for bifurcation, and therefore do not need to be separately accounted for as an equity component. Since the embedded conversion feature meets the equity scope exception from derivative accounting, and also since the embedded conversion option does not need to be separately accounted for as an equity component under ASC 470-20, the proceeds received from the issuance of the convertible debt was recorded as a liability on the consolidated balance sheet.

The Company incurred approximately $4.1 million of debt issuance costs relating to the issuance of the Senior Notes, which were recorded as a reduction to the Senior Notes on the consolidated balance sheet. The debt issuance costs are being amortized and recognized as additional interest expense over the expected life of the Senior Notes using the effective interest rate method. We determined the expected life of the debt is equal to the five-year term of the Senior Notes. The effective interest rate on the Senior Notes is 3.74%.

Senior Notes payable consisted of the following at March 31, 2021 (in thousands):

    

March 31, 2021

Principal amount of Senior Notes

$

115,000

Unamortized debt issuance costs

 

(3,464)

Net carrying value of Senior Notes payable

$

111,536

Interest expense incurred in connection with the Notes consisted of the following for the three months ended March 31, 2021 (in thousands):

    

Three Months Ended

March 31, 2021

Coupon interest

$

862

Amortization of debt issuance costs

192

Total interest expense on Senior Notes

$

1,054

The Company’s Senior Notes payable of $115.0 are due and payable in 2025.

In connection with the issuance of the Senior Notes, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) to use its best efforts to file a registration statement for the resale of the Senior Notes and the shares of the Company's common stock issuable upon conversion of the Senior Notes, to cause the registration statement to become effective by January 31, 2021, and to keep the registration statement continuously effective for a specified period of time. If the Company fails to satisfy certain of its obligations under the Registration Rights Agreement (a “Registration Default”), it will be required to pay additional interest on the Senior Notes. Such additional interest will accrue at a rate per annum equal to 0.25% of the principal amount thereof for the first 90 days beginning on, and including the date on which such Registration Default occurs and, thereafter, at a rate per annum equal to 0.50% of the principal amount thereof. However, in no event will such additional interest, together with any special interest that accrues pursuant to the Indenture accrue on any day on a Note at a combined rate per annum that exceeds 0.50%. Additionally, if a Registration Default exists on the maturity date for the Senior Notes, then, in addition to any additional interest otherwise payable, the Company will be required to make a cash payment to each noteholder in an amount equal to 3% of the principal amount of Senior Notes outstanding and held by such holder as of the close of business on the business day immediately before the maturity date. As of March 31, 2021, the Company has not accrued any fees or expenses associated with the Registration Rights Agreement as no Registration Default exists and, therefore, it is not probable that a payment would be required. In December 2020, the Company filed an automatic shelf registration statement to register the resale of the Senior Notes and the shares of the Company’s common stock issuable upon conversion of the Senior Notes.

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.21.1
Note Payable
3 Months Ended
Mar. 31, 2021
Note Payable  
Note Payable

Note 10. Note Payable

In connection with the acquisition of CRYOPDP, the Company assumed an interest free unsecured note payable of €4.0 million ($4.9 million) repayable in two installments of €0.5 million ($0.6 million) to be repaid in 2025 and €3.5 million ($4.3 million) to be repaid in 2028.  A fair market value discount of €1.1 million ($1.3 million) was recorded and is amortized to interest expense using the effective interest method over the term of the note.  During the three months ended March 31, 2021, the Company amortized €0.06 million ($0.07 million) of the debt discount to interest expense for this note.

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.21.1
Leases
3 Months Ended
Mar. 31, 2021
Leases  
Leases

Note 11. Leases

The Company has operating and finance leases for corporate offices and certain equipment. These leases have remaining lease terms of one year to approximately nine years, some of which include options to extend the leases for multiple renewal periods of five years each. Under the terms of the facilities leases, the Company is required to pay its proportionate share of property taxes, insurance and normal maintenance costs. As of March 31, 2021 and December 31, 2020, assets recorded under finance leases were $0.3 million and $0.3 million, respectively, and accumulated depreciation associated with finance leases was $0.1 million and $0.08 million, respectively.

The components of lease cost were as follows (in thousands):

March 31, 

    

2021

    

2020

Operating lease cost

$

922

$

290

Finance lease cost:

 

  

Amortization of right-of-use assets

15

6

Interest on finance lease liabilities

3

2

18

 

8

Total lease cost

$

940

$

298

Other information related to leases was as follows (in thousands):

Three Months Ended

 

Supplemental Cash Flows Information

    

March 31, 2020

 

Cash paid for amounts included in the measurement of lease liabilities:

 

Operating cash flows from operating leases

 

$

851

Operating cash flows from finance leases

 

$

22

Financing cash flows from finance leases

$

20

Right-of-use assets obtained in exchange for lease liabilities (in thousands):

Operating leases

 

$

2,781

Finance leases

$

Weighted-Average Remaining Lease Term

Operating leases

 

6.3 years

Finance leases

 

2.7 years

Weighted-Average Discount Rate

Operating leases

5.4

%

Finance leases

5.3

%

Future minimum lease payments under non-cancellable leases that have commenced as of March 31, 2021 were as follows (in thousands):

Years Ending March 31

Operating Leases

Finance Leases

2021 (excluding the three months ended March 31, 2021)

$

1,688

$

45

2022

 

2,730

 

58

2023

 

2,256

 

61

2024

 

2,049

 

2025

 

1,866

 

Thereafter

9,738

Total future minimum lease payments

 

20,327

 

164

Less imputed interest

 

(3,823)

 

(12)

Total

$

16,504

$

152

Operating

Finance 

Reported as of March 31, 2021

    

 Leases

    

Leases

Current lease liabilities

$

2,002

$

60

Noncurrent lease liabilities

 

14,502

 

92

Total

$

16,504

$

152

XML 32 R21.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2021
Commitments and Contingencies  
Commitments and Contingencies

Note 12. Commitments and Contingencies

Facility and Equipment Leases

We lease various corporate, global logistics and supply chain centers, biostorage, manufacturing, and research and development facilities in Tennessee, California, New Jersey, the Netherlands, Texas, Georgia, Minnesota, China, Portugal and France under operating leases. These lease agreements contain certain scheduled annual rent increases which are accounted for on a straight-line basis.   In addition, we lease certain equipment which expires through July 2024 (See Note 11).

Employment Agreements

We have entered into employment agreements with certain of our officers under which payment and benefits would become payable in the event of termination by us for any reason other than cause, or upon a change in control of our Company, or by the employee for good reason.

Litigation

The Company may become a party to product litigation in the normal course of business. The Company accrues for open claims based on its historical experience and available insurance coverage. We record a loss contingency when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. We also disclose material contingencies when we believe a loss is not probable but reasonably possible. Accounting for contingencies requires us to use judgment related to both the likelihood of a loss and the estimate of the amount or range of loss. The outcomes of our legal proceedings are inherently unpredictable, subject to significant uncertainties, and could be material to our financial condition, results of operations, and cash flows for a particular period.

Indemnities and Guarantees

The Company has made certain indemnities and guarantees, under which it may be required to make payments to a guaranteed or indemnified party, in relation to certain actions or transactions. The guarantees and indemnities do not provide for any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not been obligated nor incurred any payments for these obligations and, therefore, no liabilities have been recorded for these indemnities and guarantees in the accompanying consolidated balance sheets.

The Company indemnifies its directors, officers, employees and agents, as permitted under the laws of the States of California and Nevada. In connection with its facility and equipment leases, the Company has indemnified its lessors for certain claims arising from the use of the facilities and equipment. The duration of the guarantees and indemnities varies and is generally tied to the life of the agreements.

XML 33 R22.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' Equity
3 Months Ended
Mar. 31, 2021
Stockholders' Equity  
Stockholders' Equity

Note 13. Stockholders’ Equity

Authorized Stock

The Company has 100,000,000 authorized shares of common stock with a par value of $0.001 per share, and 2,500,000 undesignated or “blank check” preferred stock, with a par value of $0.001, of which, 800,000 shares have been designated as Class A Preferred Stock, 585,000 shares have been designated as Class B Preferred Stock and 250,000 shares have been designated as 4.0% Series C Convertible Preferred Stock.

Common Stock Issued for Services

During the three months ended March 31, 2021, 229 shares of common stock with a fair value of $11,500 were issued to one member of the board of directors as compensation for services.

During the three months ended March 31, 2020, 1,269 shares of common stock with a fair value of $20,700 were issued to two members of the board of directors as compensation for services.

January 2021 Public Offering

On January 25, 2021, the Company completed an underwritten public offering of 4,356,059 shares of its common stock. The shares were issued and sold pursuant to an underwriting agreement dated January 20, 2021, by and among the Company, on the one hand, and Morgan Stanley & Co. LLC, Jefferies LLC, SVB Leerink LLC and UBS Securities LLC, as representatives of certain underwriters at a public offering price per share of $66.00, before deducting underwriting discounts and commissions. The shares include 568,181 shares issued and sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares of common stock pursuant to the underwriting agreement. The Company received net proceeds of approximately $269.8 million from the offering after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.

Blackstone Private Placement

In connection with the MVE Acquisition, on October 1, 2020 (the “Closing Date”), the Company completed a private placement with an investment vehicle of funds affiliated with The Blackstone Group Inc. (collectively, “Blackstone”), consisting of (i) 250,000 shares of a newly designated 4.0% Series C Convertible Preferred Stock, par value $0.001 per share (“Series C Preferred Stock”), at a price of $1,000 per share, for $250.0 million, and (ii) 675,536 shares of common stock of the Company, par value $0.001 per share (“Common Stock”) for $25.0 million, for an aggregate purchase price of $275.0 million. The Company paid Blackstone $1.0 million as reimbursement for transactional expenses incurred in connection with the private placement at the Closing Date. Also, the Company incurred direct and incremental expenses of approximately $8.6 million, including financial advisory fees, closing costs, legal expenses and other offering-related expenses. The Company allocated the net proceeds of $265.4 million on a relative fair value basis to the Series C Preferred Stock and the Common Stock, resulting in allocated proceeds of $28.2 million and $237.2 million, respectively.

The Series C Preferred Stock ranks senior to the shares of the Company’s Common Stock, with respect to dividend rights and rights upon the voluntary or involuntary liquidation, dissolution, or winding up of the affairs of the Company (a “Liquidation”). The Series C Preferred Stock has the following rights, preferences and privileges:

Dividend Rights. Holders of the Series C Preferred Stock (the “Holders”) are entitled to dividends at the rate of 4.0% per annum, paid-in-kind, accruing daily and paid quarterly in arrears when and if declared by the Board of Directors. The Holders are also entitled to participate in dividends declared or paid on the Common Stock on an as-converted basis. The Company and Holders do not have the option to pay dividends in kind, in cash, or in other form. Paid in-kind dividends for the three months ended March 31, 2021 and the year ended December 31, 2020 were $2.2 million and $2.5 million, respectively.

Liquidation Preference. Upon a Liquidation, each share of Series C Preferred Stock is entitled to receive an amount per share equal to the greater of (i) $1,000 per share, plus all accrued and unpaid dividends and (ii) the amount that the Holders of the Series C Preferred Stock would have been entitled to receive at such time if the Series C Preferred Stock were converted into Common Stock (the ”Liquidation Preference”).

Conversion Features. The Series C Preferred Stock is convertible at the option of the Holders at any time into shares of Common Stock at a conversion price of $38.6152 per share and a conversion rate of 25.90 shares of Common Stock per share of Series C Preferred Stock. The maximum number of Common Stock that could be required to be issued if converted is 6,474,135 shares. The conversion price is subject to certain customary adjustments in the event of certain adjustments to the Company’s Common Stock, including stock dividends, splits, combinations, tender offers, and exchange offers.  

After the second anniversary of the Closing Date, subject to certain conditions, the Company may at its option require conversion of all of the outstanding shares of the Series C Preferred Stock to Common Stock if, for at least 20 trading days during the 30 consecutive trading days immediately preceding the date the Company notifies the Holders of the election to convert, the closing price of the Common Stock is at least 150% of the conversion price.

On the October 1, 2020 issuance date, the effective conversion price per share was less than the fair value of the underlying Common Stock and, as a result, the Company determined that there was a beneficial conversion feature on that date. Accordingly, the Company recognized the resulting beneficial conversion feature amount of $39.5 million as a deemed dividend, equal to the number of common shares into which the Series C Preferred Stock is convertible multiplied by the difference between the fair value of the Common Stock and the effective conversion price per share on that date. Because the Series C Preferred Stock does not have a stated conversion date and was immediately convertible at the issuance date, the dividend is reflected as a one-time, non-cash, deemed dividend to the Holders of the Series C Preferred Stock on the date of issuance.

Additionally, the Company determined that the nature of the Series C Preferred Stock is more akin to an equity instrument and that the economic characteristics and risks of the embedded conversion options are clearly and closely related to the Series C Preferred Stock. As such, the conversion options were not required to be bifurcated from the host under ASC 815, Derivatives and Hedging.

Since the paid-in-kind dividends are nondiscretionary, the Company measures the beneficial conversion feature in the paid-in-kind dividend on the issuance date of the preferred stock and records such amount when the paid-in-kind dividend are accrued. Accordingly, the associated paid-in-kind dividends for the year ended December 31, 2020 generated a beneficial conversion feature amount of $0.3 million. On February 5, 2021, the Company received a waiver and conversion notice from Blackstone Freeze Parent L.P. and Blackstone Tactical Opportunities Fund – FD L.P. and converted an aggregate of 50,000 shares of the Series C Preferred Stock (see “—Blackstone Conversion” below for additional information).

Redemption Rights. The Company may redeem the Series C Preferred Stock for cash, as follows:

(1)

At any time beginning five years after the Closing Date (but prior to six years after the Closing Date), all of the Series C Preferred Stock at a price equal to 105% of the purchase price paid plus any accrued and unpaid dividends.

(ii)

At any time beginning six years after the Closing Date, all of the Series C Preferred Stock at a price equal to 100% of the purchase price paid plus any accrued and unpaid dividends.

Within 6 months of the Closing Date, the Company also had the right to redeem up to 50,000 shares of the Series C Preferred Stock at a price equal to 125% of the purchase price paid plus any accrued and unpaid dividends, which the Company waived (see “—Blackstone Conversion” below for additional information).

Upon a “Fundamental Change” (involving a change of control or de-listing of the Company as further described in the Certificate of Designation), each Holder has the right to require the Company to redeem all or any part of the Holder’s Series C Preferred Stock for an amount equal to the Liquidation Preference plus any accrued and unpaid dividends.  If the Company does not have sufficient funds legally available to pay the repurchase price, then the Company is required to (a) pay the maximum amount of the repurchase price that can be paid out of funds legally available for payment, and (b) purchase any shares of the Series C Preferred Stock not purchased because of the foregoing limitations at the repurchase price as soon as practicable after the Company is able to make such purchase out of assets legally available for the purchase of such shares. If the Company fails to pay the repurchase price in full when due, then the Company will pay dividends on such shares not repurchased at a rate of 5.5% per annum until such shares are repurchased, payable quarterly in arrears.

The Company evaluated the Series C Preferred Stock for liability or equity classification under the applicable accounting guidance including ASC 480, Distinguishing Liabilities from Equity, and determined that equity treatment was appropriate because the Series C Preferred Stock did not meet the definition of the liability instruments defined thereunder for convertible instruments. Specifically, the convertible preferred shares are not mandatorily redeemable and do not embody an obligation to buy back the shares outside of the Company’s control in a manner that could require the transfer of assets. Additionally, the Company determined that the Series C Preferred Stock would be recorded as permanent equity given that they are not redeemable for cash or other assets (i) on a fixed or determinable date, (ii) at the option of the holder, or (iii) upon the occurrence of an event that is not solely within control of the Company.

The Company also evaluated the embedded put and call options within the Series C Preferred Stock in accordance with the accounting guidance for derivatives to determine if bifurcation is required.  The Company determined that the economic characteristics and risks of the embedded put and call options are not clearly and closely related to the Series C Preferred Stock. Therefore, the Company assessed the put and call options further and determined they did not meet the definition of a derivative under ASC 815.

Under the same analysis, the Company determined that the economic characteristics and risks of the embedded participating dividend feature are considered clearly and closely related to the equity host. Accordingly, the participating dividend feature is not required to be bifurcated under ASC 815. Also, the Company determined that the value of the contingent dividend feature is minimal and insignificant relative to the other components of the Series C Preferred Stock due to the circumstances surrounding the scenarios under which the provision would be triggered.

Voting Rights. Holders of the Series C Preferred Stock are generally entitled to vote with the holders of the shares of Common Stock on an as-converted basis, subject to certain Nasdaq voting limitations, if applicable. Also, the consent of the Holders of a majority of the outstanding shares of the Series C Preferred Stock is required with respect to (i) amendments to the Company’s organizational documents that have an adverse effect on the Holders of the Series C Preferred Stock, and (ii) issuances by the Company of securities that are senior to, or equal in priority with, the Series C Preferred Stock. Holders of the Series C Preferred Stock have the right to nominate for election one member to the board of directors of the Company for so long as they hold 66.67% of the Series C Preferred Stock issued to them at the Closing Date.

Registration Rights. Holders of the Series C Preferred Stock have certain customary registration rights with respect to the Series C Preferred Stock and the shares of common stock into which they are converted, pursuant to the terms of a registration rights agreement. The Company is required to file within 90 days of the Closing Date, and use its commercially reasonable efforts to cause to go effective as promptly as practicable, a registration statement covering the sale or distribution of Common Stock issued or issuable upon conversion of the Series C Preferred Stock.   In December 2020, the Company filed an automatic shelf registration statement to register the resale of the Common Stock issued or issuable upon conversion of the Series C Preferred Stock.

Blackstone Conversion

On February 5, 2021, the Company received a waiver and conversion notice from Blackstone Freeze Parent L.P. and Blackstone Tactical Opportunities Fund – FD L.P. to convert an aggregate of 50,000 shares of the Company’s Series C Preferred Stock. Pursuant to the terms of the waiver and conversion notice, the Company also agreed to waive its right under the certificate of designations of the Series C Preferred Stock to redeem up to 50,000 shares of the Series C Preferred Stock prior to the 180-day anniversary of October 1, 2020, the issue date of the Series C Preferred Stock. Each share of Series C Preferred Stock has a liquidation preference of $1,000 per share plus any accumulated and unpaid dividends and is convertible into shares of the Company’s common stock, par value $0.001 per share, at a conversion price of $38.6152 per share. The forgoing conversion, effective as of February 5, 2021, resulted in the issuance of an aggregate of 1,312,860 shares of Common Stock and $1.8 million in expenses.

Common Stock Reserved for Future Issuance

As of March 31, 2021, approximately 18.2 million shares of common stock were issuable upon conversion or exercise of rights granted under prior financing arrangements, stock options, RSU’s and the conversion of senior notes and series C Preferred stock, as follows:

Exercise of stock options

    

7,793,769

Vesting of restricted stock units

 

304,157

Conversion of Series C Preferred Stock

 

5,283,411

Conversion of convertible senior notes

 

4,810,002

Total shares of common stock reserved for future issuances

 

18,191,339

XML 34 R23.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-Based Compensation
3 Months Ended
Mar. 31, 2021
Stock-Based Compensation  
Stock-Based Compensation

Note 14. Stock-Based Compensation

Stock Options

We have five stock incentive plans: the 2002 Stock Incentive Plan (the “2002 Plan”), the 2009 Stock Incentive Plan (the “2009 Plan”), the 2011 Stock Incentive Plan (the “2011 Plan”), the 2015 Omnibus Equity Incentive Plan (the “2015 Plan”), and the 2018 Omnibus Equity Incentive Plan (the “2018 Plan”), (collectively, the “Plans”). The 2002 Plan, the 2009 Plan, the 2011 Plan and the 2015 Plan (the “Prior Plans”) have been superseded by the 2018 Plan. In May 2018, the stockholders approved the 2018 Plan for issuances up to an aggregate of 3,730,179 shares. The Prior Plans will remain in effect until all awards granted under such Prior Plans have been exercised, forfeited, cancelled, or have otherwise expired or terminated in accordance with the terms of such awards, but no awards will be made pursuant to the Prior Plans after the effectiveness of the 2018 Plan. As of March 31, 2021, the Company had 190,181 shares available for future awards under the 2018 Plan.

During the three months ended March 31, 2021, we granted stock options at exercise prices equal to the quoted market price of our common stock on the grant date. The fair value of each option grant was estimated on the date of grant using Black-Scholes with the following weighted average assumptions:

Expected life (years)

3.5 – 6.1

 

Risk-free interest rate

0.5% - 0.9

%

Volatility

64.4% - 80.8

%

Dividend yield

0

%

The expected option life assumption is estimated based on the simplified method. Accordingly, the Company has utilized the average of the contractual term of the options and the weighted average vesting period for all options to calculate the expected option term. The risk-free interest rate assumption is based upon observed interest rates appropriate for the expected term of our employee stock options. The expected volatility is based on the average of the historical volatility and the implied volatility of our stock commensurate with the expected life of the stock-based award. We do not anticipate paying dividends on the common stock in the foreseeable future.

We recognize stock-based compensation cost on a straight-line basis over the vesting period. Stock-based compensation expense is recognized only for those awards that ultimately vest.

Total stock-based compensation expense related to all of our share-based payment awards is comprised of the following:

Three months ended March 31,

    

2021

    

2020

Cost of revenues

$

239

$

69

Selling, general and administrative

 

2,505

 

1,443

Engineering and development

 

246

 

108

$

2,990

$

1,620

A summary of stock option activity is as follows:

    

    

    

Weighted-

    

Weighted-

Average

Average

Remaining

Aggregate

Number of

Exercise

Contractual

Intrinsic

Shares

Price/Share

Term (Years)

Value (1)

Outstanding — December 31, 2020

 

7,554,305

$

10.29

 

  

 

  

Granted (weighted-average fair value of $32.66 per share)

 

435,298

55.74

 

  

 

  

Exercised

 

(187,486)

 

8.46

 

  

 

  

Forfeited

 

(8,348)

 

16.48

 

  

 

  

Outstanding — March 31, 2021

 

7,793,769

$

12.86

 

6.4

$

306,822

Vested (exercisable) — March 31, 2021

 

5,904,443

$

7.76

 

5.8

$

261,287

Expected to vest after March 31, 2021 (unexercisable)

 

1,889,326

$

28.82

 

7.9

$

40,001

(1)Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of our common stock on March 31, 2021, which was $52.01 per share.

Total intrinsic value of options exercised during the three months ended March 31, 2021 was $9.4 million.

As of March 31, 2021, there was unrecognized compensation expense of $32.5 million related to unvested stock options, which we expect to recognize over a weighted average period of 3.4 years.

Restricted stock units

A summary of our restricted stock unit activity is as follows:

Weighted Average

Number of Restricted

 Fair Value per 

Stock Units

Share 

Outstanding – December 31, 2020

    

    

$

Granted

 

304,157

 

53.94

Share issuance

 

 

Outstanding March 31, 2021

 

304,157

$

53.94

For the three months ended March 31, 2021 and 2020, we recorded stock-based compensation expense on our issued restricted stock units of $0.3 million and $0, respectively.  As of March 31, 2021 there was unrecognized compensation expense of $16.1 million related to unvested restricted stock units, which we expect to recognize over a weighted average period of 4.0 years.

XML 35 R24.htm IDEA: XBRL DOCUMENT v3.21.1
Subsequent Event
3 Months Ended
Mar. 31, 2021
Subsequent Events  
Subsequent Events

Note 15. Subsequent Event

Effective April 1, 2021, the Company completed the acquisition of Critical Transport Solutions Australia Pty Ltd. (“CTSA”) a market leader in providing premium healthcare logistics management services, specializing in time and temperature critical solutions for the medical and pharmaceutical industries based in Australia, for approximately $5.0 million.

The agreement includes an earnout provision which is (a) subject to and dependent on the Company achieving a 2024 EBITDA, as defined; and (b) is subject to certain employment requirements through December 31, 2024.  CTSA will be a part of the Company’s CRYOPDP business unit and will continue to be run by the current management team.

XML 36 R25.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2021
Basis of Presentation

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Principles of Consolidation

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Cryoport, Inc. and its wholly-owned subsidiaries, Cryoport Systems, LLC, Cryogene, Inc., MVE Biological Solutions US LLC, and Cryoport Netherlands B.V. and subsidiaries (collectively, the “Company”). All intercompany accounts and transactions have been eliminated.

Cash and Cash Equivalents

Cash and Cash Equivalents

Our cash and cash equivalents represent demand deposits, and money market funds which are readily convertible into cash, have maturities of 90 days or less when purchased and are considered highly liquid and easily tradeable.

Short-Term Investments

Short-Term Investments

Our investments in equity securities consist of mutual funds with readily determinable fair values which are carried at fair value with changes in fair value recognized in earnings.

Investments in debt securities are classified as available-for-sale and are carried at fair value, with unrealized gains and losses, net of tax, reported as accumulated other comprehensive income (loss) and included as a separate component of stockholders’ equity.

Gains and losses are recognized when realized. When we have determined that an other than temporary decline in fair value has occurred, the amount related to a credit loss is recognized in earnings. Gains and losses are determined using the specific identification method.

Short-term investments are classified as current assets even though maturities may extend beyond one year because they represent investments of cash available for operations.

Use of Estimates

Use of Estimates

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from estimated amounts. The Company’s significant estimates include the allowance for doubtful accounts, fair value of short-term investments, valuations and purchase price allocations related to business combinations, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, intangible asset useful lives and amortization methods, allowance for inventory obsolescence, equity-based instruments, tax reserves and recoverability of the Company’s net deferred tax assets and related valuation allowance.

Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.

Future events, including the extent and the duration of the COVID-19 related economic impacts, and their effects cannot be predicted with certainty, and, accordingly the Company’s accounting estimates require the exercise of judgment.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The Company’s financial instruments consist of cash and cash equivalents, short-term investments, accounts receivable, accounts payable and accrued expenses, finance lease liabilities, note payable, and the Company’s 3.00% convertible senior notes due in 2025 (the “Senior Notes”). The carrying value for all such instruments, except finance lease liabilities, note payable and the Senior Notes, approximates fair value at March 31, 2021 and December 31, 2020 due to their short-term nature. The carrying value of finance lease liabilities approximates fair value because the interest rate approximates market rates available to us for similar obligations with the same maturities. For additional information related to fair value measurements, including the note payable and the Senior Notes, see Notes 9 and 10.

Concentrations of Credit Risk

Concentrations of Credit Risk

Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. From time to time, we maintain cash, cash equivalent and short-term investment balances in excess of amounts insured by the Federal Deposit Insurance Corporation (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”).  Primarily all of our cash, cash equivalents and short-term investments at March 31, 2021 were in excess of amounts insured by the FDIC and SIPC.  The Company performs ongoing evaluations of these institutions to limit its concentration risk exposure.  We manage such risks in our portfolio by investing in highly liquid, highly-rated instruments, and limit investing in long-term maturity instruments.

Our investment policy requires that purchased instruments in marketable securities may only be in highly-rated instruments, which are primarily U.S. Treasury bills or treasury-backed securities, and also limits our investment in securities of any single issuer.

Customers

Customers

The Company grants credit to customers within the U.S. and international customers and does not require collateral. Revenues from international customers are generally secured by advance payments except for established foreign customers. The Company generally requires advance or credit card payments for initial revenues from new customers. The Company’s ability to collect receivables can be affected by economic fluctuations in the geographic areas and industries served by the Company. Reserves for uncollectible amounts are provided based on past experience and a specific analysis of the accounts, which management believes to be sufficient. Accounts receivable at March 31, 2021 and December 31, 2020 are net of reserves for doubtful accounts of $1.2 million and $1.1 million, respectively. Although the Company expects to collect amounts due, actual collections may differ from the estimated amounts. The Company maintains reserves for bad debt and such losses, in the aggregate, historically have not exceeded its estimates.

The Company’s customers are in the biopharma, pharmaceutical, animal health, reproductive medicine and other life science industries. Consequently, there is a concentration of accounts receivable within these industries, which is subject to normal credit risk. At March 31, 2021, there was one customer that accounted for 10.5% of net accounts receivable. At December 31, 2020, there were no customers that accounted for more than 10% of net accounts receivable. There were no other single customers that owed us more than 10% of net accounts receivable at March 31, 2021 and December 31, 2020.

The Company has revenue from foreign customers primarily in United Kingdom, Switzerland, France, Netherlands, Singapore, China and India. During the three months ended March 31, 2021 and 2020, the Company had revenues from foreign customers of approximately $25.5 million and $2.1 million, respectively, which constituted approximately 48.0% and 21.4%, respectively, of total revenues. There was one customer that accounted for 12.5% of revenues during the three months ended March 31, 2021. There were three customers that accounted for 17.9%, 16.7% and 10.8% of revenues during the three months ended March 31, 2020, respectively. No other single customer generated over 10% of revenues during the three months ended March 31, 2021 and 2020.

Inventories

Inventories

Inventories are stated at the lower of cost and net realizable value. Cost is determined using the first-in, first-out (“FIFO”) method. Inventories are reviewed periodically for slow-moving or obsolete status. The Company writes down the carrying value of its inventories to reflect situations in which the cost of inventories is not expected to be recovered. Once established, write-downs of inventories are considered permanent adjustments to the cost basis of the obsolete or excess inventories. Raw materials and finished goods include material costs less reserves for obsolete or excess inventories. The Company evaluates the current level of inventories considering historical trends and other factors, such as selling prices and costs of completion, disposal and transportation, and based on the evaluation, records adjustments to reflect inventories at net realizable value. These adjustments are estimates, which could vary significantly from actual results if future economic conditions, customer demand, competition or other relevant factors differ from expectations. These estimates require us to make assessments about future demand for the Company’s products in order to categorize the status of such inventories items as slow-moving, obsolete or in excess-of-need. These estimates are subject to the ongoing accuracy of the Company’s forecasts of market conditions, industry trends, competition and other factors.

Property and Equipment

Property and Equipment

Property and equipment are stated at cost, less accumulated depreciation.  We compute depreciation using the straight-line method over the estimated useful lives of the assets which is generally three to twelve years for computer hardware and software, seven to ten years for freezers, four to ten years for trucks and autos, three to fifteen years for furniture and equipment and over the shorter of the lease term or useful live of the assets for leasehold improvements. Buildings are depreciated over a useful life ranging from 20 to 45 years. Maintenance and repairs are expensed as incurred.

Betterments, renewals and extraordinary repairs that extend the lives of the assets are capitalized; other repairs and maintenance charges are expensed as incurred. The cost and related accumulated depreciation and amortization applicable to assets retired are removed from the accounts, and the gain or loss on disposition is recognized in the consolidated statements of operations.

Leases

Leases

The Company determines if an arrangement is a lease at inception. Operating lease right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset during the lease term, and operating lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating leases are included in ROU assets, current operating lease liabilities, and long-term operating lease liabilities on our consolidated balance sheets. Finance leases are included in property and equipment, current finance lease liabilities, and long-term finance lease liabilities on our consolidated balance sheets.

Lease ROU assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments over the lease term at commencement date calculated using our incremental borrowing rate applicable to the lease asset, unless the implicit rate is readily determinable. ROU assets also include any lease payments made at or before lease commencement and exclude any lease incentives received. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets. The Company’s leases do not contain any residual value guarantees. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.

The Company accounts for lease and non-lease components as a single lease component for all its leases.

Business Combinations

Business Combinations

Total consideration transferred for acquisitions is allocated to the assets acquired and liabilities assumed based on their fair values at the dates of acquisition. This purchase price allocation process requires management to make significant estimates and assumptions primarily with respect to intangible assets. The fair value of identifiable intangible assets is based on detailed valuations that use information and assumptions determined by management. Any excess of purchase price over the fair value of the net tangible and intangible assets acquired is allocated to goodwill. While the Company uses its best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date as well as any contingent consideration, where applicable, the Company’s estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company records adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill.

Goodwill

Goodwill

The Company evaluates goodwill on an annual basis in the fourth quarter or more frequently if management believes indicators of impairment exist. Such indicators could include, but are not limited to: (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. The Company compares the fair value of the reporting unit’s with its carrying amount and then recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting units fair value up to the total amount of goodwill allocated to the reporting unit. The Company assessed  triggering events indicating potential goodwill impairment, including the effects of the COVID-19 pandemic, and after assessment, concluded that there was no impairment during the three months ended March 31, 2021.

Intangible Assets

Intangible Assets

Intangible assets are comprised of patents, trademarks, software development costs and the intangible assets acquired in the MVE, CRYOPDP and Cryogene acquisitions which include a non-compete agreement, technology, customer relationships, trade name/trademark, agent network, order backlog, developed technology and land use rights. The Company capitalizes costs of obtaining patents and trademarks, which are amortized, using the straight-line method over their estimated useful life of five years once the patent or trademark has been issued. The non-compete agreement, technology, customer relationships, trade name/trademark, agent network, order backlog, developed technology and land use rights, acquired in the MVE, CRYOPDP and Cryogene acquisitions are amortized using the straight-line method over the estimated useful lives (see Note 8). The Company uses the following valuation methodologies to value the significant intangible assets acquired: income approach for customer relationships, replacement cost for agent network and software, and relief from royalty for trade name/trademarks and developed technology.

The Company evaluates the recoverability of identifiable intangible assets whenever events or changes in circumstances indicate that an intangible asset's carrying amount may not be recoverable. Such circumstances could include, but are not limited to: (1) a significant decrease in the market value of an asset, (2) a significant adverse change in the extent or manner in which an asset is used, or (3) an accumulation of costs significantly in excess of the amount originally expected for the acquisition of an asset. The Company measures the carrying amount of the asset against the estimated undiscounted future cash flows associated with it. Should the sum of the expected future net cash flows be less than the carrying value of the asset being evaluated, an impairment loss would be recognized. The impairment loss would be calculated as the amount by which the carrying value of the asset exceeds its fair value. The estimate of fair value is based on various valuation techniques, including the discounted value of estimated future cash flows. The evaluation of asset impairment requires the Company to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results may differ from assumed and estimated amounts. There was no impairment of intangible assets during the three months ended March 31, 2021.

Other Long-lived Assets

Other Long-lived Assets

If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the fair value to the carrying value. We believe the future cash flows to be received from the long-lived assets will exceed the assets’ carrying value, and accordingly, we have not recognized any impairment losses through March 31, 2021.

Deferred Financing Costs

Deferred Financing Costs

Deferred financing costs represent costs incurred in connection with the issuance of debt instruments and equity financings. Deferred financing costs related to the issuance of debt are amortized over the term of the financing instrument using the effective interest method and are presented in the consolidated balance sheets as an offset against the related debt. Offering costs from equity financings are netted against the gross proceeds received from the equity financings.

Income Taxes

Income Taxes

The Company accounts for income taxes under the provision of ASC 740, “Income Taxes”, or ASC 740. As of March 31, 2021 and December 31, 2020, there were no material unrecognized tax benefits included in the accompanying consolidated balance sheets that would, if recognized, affect the effective tax rate.

Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. Based on the weight of available evidence, the Company’s management has determined that it is not more likely than not that the U.S. based net deferred tax assets will be realized. Therefore, the Company has recorded a full valuation allowance against its U.S. based net deferred tax assets. With respect to the foreign based deferred tax assets, the Company's management has reviewed these deferred tax assets on a jurisdictional basis. Based on the weight of each jurisdiction's evidence available, the Company's management has made separate determinations for each foreign jurisdiction regarding whether it is more likely than not that a net deferred tax asset within a particular jurisdiction will be realized. The Company has recorded full valuation allowances in jurisdictions where deferred tax assets are not deemed more likely than not to be realized.

Additionally, the Company maintains a deferred tax liability related to indefinite-lived assets that have been netted against deferred tax assets that also allow for indefinite carryforward periods subject to limitations.  The remaining taxable temporary difference cannot serve as a source for future taxable income to realize federal net operating losses, due to the fact that post-2017 federal net operating losses are only eligible to offset 80% of income in a given year or in the case of state net operating losses, the state net operating losses will expire prior to the reversal of the taxable temporary difference.

The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company has immaterial accruals for interest or penalties on its consolidated balance sheets at March 31, 2021 and December 31, 2020 and has recorded only immaterial interest and/or penalties in the consolidated statements of operations for the three months ended March 31, 2021 and 2020. The Company is subject to taxation in the U.S., various state jurisdictions and in various foreign countries. As of March 31, 2021, the Company is no longer subject to U.S. federal examinations for years before 2017 and for California franchise and income tax examinations for years before 2016. However, to the extent allowed by law, the taxing authorities may have the right to examine prior periods where net operating losses were generated and carried forward and make adjustments up to the amount of the net operating loss carry forward amount. The Company is not currently under examination by U.S. federal or state jurisdictions. Our foreign subsidiaries are generally subject to examination three years following the year in which the tax obligation originated.  The years subject to audit may be extended if the entity substantially understates corporate income tax. The Company's subsidiary in India is currently under examination by the Indian tax authorities for 2012-2013, 2013-2014 and 2015-2016 tax periods. Other than India, the Company does not have any foreign subsidiaries currently under audit by their local taxing authorities.

In December of 2019, the FASB issued Accounting Standards Update (“ASU”) 2019-12 Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. The Board issued this Update as part of its Simplification Initiative to improve areas of U.S. GAAP and reduce cost and complexity while maintaining usefulness. The main provision that impacts the company is the removal of the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, discontinued operations and other comprehensive income). ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 31, 2020. Different components of the guidance require retrospective, modified retrospective or prospective adoption. The Company elected to early adopt ASU 2019-12 on January 1, 2020, and the adoption of the standard did not have a material impact to our consolidated financial statements.

On March 27, 2020, the United States enacted the Coronavirus Aid, Relief and Economic Security Act (CARES Act). The Cares Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund a nationwide effort to curtail the effect of COVID-19. The CARES Act provides sweeping tax changes in response to the COVID-19 pandemic, some of the more significant provisions are removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years, and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act. At March 31, 2021, the Company has not recorded any income tax provision/(benefit) resulting from the CARES Act mainly due the Company’s history of net operating losses generated and the maintenance of a full valuation allowance against its net deferred tax assets.  

On June 29, 2020, the State of California passed Assembly Bill 85 which suspends the California net operating loss deduction for the 2020-2022 tax years and the R&D credit usage for the same period (for credit usages in excess of $5 million). These suspensions were considered in preparation of the March 31, 2021 and December 31, 2020 financial statements.

On December 27, 2020, the United States enacted the Consolidated Appropriations Act of 2021 (“CAA”).  The CAA includes provisions extending certain CARES Act provisions and adds coronavirus relief, tax and health extenders. The Company will continue to evaluate the impact of the CAA and its impact on our financial statements in 2021 and beyond.

On March 11, 2021, the United States enacted the American Rescue Plan (“ARP”). The ARP includes provisions extending certain CARES Act provisions, repeals a worldwide interest allocation election, modifies the $1 million executive compensation limitation for years after 2026 and extends the employee retention credit. The Company will continue to evaluate the impact of the ARP and its impact on our financial statements in 2021 and beyond.

Revenue Recognition

Revenue Recognition

Revenues are recognized when control is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods and services. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied.

Performance Obligations

At contract inception, an assessment of the goods and services promised in the contracts with customers is performed and a performance obligation is identified for each distinct promise to transfer to the customer a good or service (or bundle of goods or services). To identify the performance obligations, the Company considers all of the goods or services promised in the contract regardless of whether they are explicitly stated or are implied by customary business practices. Revenue is recognized when our performance obligation has been met. The Company considers control to have transferred upon delivery because the Company has a present right to payment at that time, the Company has transferred use of the asset, and the customer is able to direct the use of, and obtain substantially all of the remaining benefits from, the asset.

For arrangements under which the Company provides biological specimen storage services and logistics support and management to the customer, the Company satisfies its performance obligations as those services are performed whereby the customer simultaneously receives and consumes the benefits of such services under the agreement.

Revenue generated from short-term logistics and engineering consulting services provided to customers is recognized when the Company satisfies the contractually defined performance obligations. When a contract includes multiple performance obligations, the contract price is allocated among the performance obligations based upon the stand-alone selling prices. Approved contract modifications are accounted for as either a separate contract or as part of the existing contract depending on the nature of the modification.

Our performance obligations on our orders and under the terms of agreements with customers are generally satisfied within one year from a given reporting date and, therefore, we omit disclosure of the transaction price allocated to remaining performance obligations on open orders.

Shipping and handling activities related to contracts with customers are accounted for as costs to fulfill our promise to transfer the associated products pursuant to the accounting policy election allowed under Topic 606 and are not considered a separate performance obligation to our customers. Accordingly, the Company records amounts billed for shipping and handling as a component of revenue. Shipping and handling fees and costs are included in cost of revenues in the accompanying condensed consolidated statements of operations.

Revenues are recognized net of any taxes collected from customers, which are subsequently remitted to governmental agencies.

Significant Payment Terms

Pursuant to the Company’s contracts with its customers, amounts billed for services or products delivered by the Company are generally due and payable in full within 15  to 60 days from the date of the invoice (except for any amounts disputed by the customer in good faith). Accordingly, the Company determined that its contracts with customers do not include extended payment terms or a significant financing component.

Variable Consideration

When a contract includes variable consideration, the Company evaluates the estimate of the variable consideration to determine whether the estimate needs to be constrained. Variable consideration is estimated at the most likely amount that is expected to be earned.

Estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the anticipated performance and all information (historical, current and forecasted) that is reasonably available. Variable consideration estimates are updated at each reporting date. Revenues are recorded net of variable consideration, such as discounts and allowances.

Warranties

The Company provides product warranties with varying terms and durations for some of its products. The Company estimates product warranty costs and accrues for these costs as products are sold with a charge to cost of sales. Factors considered in estimating warranty costs include historical and projected warranty claims, historical and projected cost-per-claim, and knowledge of specific product issues that are outside of typical experience. Warranty accruals are evaluated and adjusted as necessary based on actual claims experience and changes in future claim and cost estimates.

Product warranty accrued liabilities totaled $0.2 million and $0.2 million at March 31, 2021 and December 31, 2020, respectively, and are included in accounts payable and other accrued expenses. Warranty expense was not material for the three months ended March 31, 2021 and 2020.

Incremental Direct Costs

Incremental direct costs are expensed when incurred when the amortization period of the asset that would have been recognized is one year or less; otherwise, incremental contract costs are recognized as an asset and amortized over time as promised goods and services are transferred to a customer. Incremental direct costs were not material for the three months ended March 31, 2021 and 2020.

The Company expenses incremental direct costs of obtaining a contract (sales commissions) when incurred because the amortization period is generally 12 months or less. The Company does not incur costs to fulfill a customer contract that meet the requirements for capitalization.

Contract Assets

Typically, we invoice the customer and recognize revenue once we have satisfied our performance obligation. Accordingly, our contract assets comprise accounts receivable, which are recognized when payment is unconditional and only the passage of time is required before payment is due. Generally, we do not have material amounts of other contract assets since revenue is recognized as control of goods is transferred or as services are performed.

Contract Liabilities (Deferred Revenue)

Contract liabilities are recorded when cash payments are received in advance of the Company’s performance. Deferred revenue was $0.5 million and $0.3 million at March 31, 2021 and 2020, respectively.  During the three months ended March 31, 2021, the Company recognized revenues of $0.2 million from the related contact liabilities outstanding as the services were performed.

Nature of Goods and Services

The Company provides Cryoport Express® Shippers to its customers and charges a fee in exchange for the use of the Cryoport Express® Shipper under long-term master service agreements with customers. The Company’s arrangements convey to the customers the right to use the Cryoport Express® Shippers over a period of time. The Company retains title to the Cryoport Express® Shippers and provides its customers the use of the Cryoport Express® Shipper for a specified shipping cycle. At the culmination of the customer’s shipping cycle, the Cryoport Express® Shipper is returned to the Company.

The Company recognizes revenue for the use of the Cryoport Express® Shippers at the time of the delivery of the Cryoport Express® Shipper to the end user of the enclosed materials, and at the time that collectability is probable.

The Company also provides vacuum insulated aluminum dewars and cryogenic freezers systems to its customers. Revenue is recognized when the Company satisfies performance obligations by transferring the equipment to a customer, and at the time that collectability is probable.

The Company also provides global temperature-controlled logistics services, support and management. Revenue is recognized for these services as services are rendered and at the time that collectability is probable.

The Company also provides comprehensive and integrated temperature-controlled biostorage solutions to customers in the life sciences industry and charges a fee under long-term master service agreements with customers. These services include (1) biological specimen cryopreservation storage and maintenance, (2) archiving, monitoring, tracking, receipt and delivery of samples, (3) transport of frozen biological specimens to and from customer locations, and (4) management of incoming and outgoing biological specimens. The Company recognizes revenue for its biostorage solutions as services are rendered over time and at the time that collectability is probable.

The Company also provides short-term logistics and engineering consulting services to some customers, with fees tied to the completion of contractually defined services. We recognize revenue from these services over time as the customer simultaneously receives and consumes the benefit of these services as they are performed.

A significant portion of our revenues are covered under long-term agreements. We have determined that individual Statements of Work or Scope of Work (“SOW”), whose terms and conditions taken with a Master Services Agreement (“MSA”), create the Topic 606 contracts which are generally short-term in nature (e.g., 15-day shipping cycle) for the Cryoport Express® solutions and up to 12 months for biostorage solutions. Our agreements (including SOWs) generally do not have multiple performance obligations and, therefore, do not require an allocation of a single price amongst multiple goods or services.  Prices under these agreements are generally fixed.

Revenue Disaggregation

The Company views its operations, makes decisions regarding how to allocate resources and manages its business as one reportable segment and one reporting unit. As a result, the financial information disclosed herein represents all of the material financial information related to the Company. When disaggregating revenue, the Company considered all of the economic factors that may affect its revenues. We consider sales disaggregated by end-market to depict how the nature, amount, timing and uncertainty of revenues and cash flows are impacted by changes in economic factors. The following table disaggregates our revenues by major markets for the three months ended March 31, 2021 and 2020 (in thousands):

Three Months Ended March 31, 

    

2021

    

2020

Biopharma/Pharma

$

42,393

$

8,786

Animal Health

 

8,997

 

225

Reproductive Medicine

1,894

763

Total revenues

$

53,284

$

9,774

Given that the Company’s revenues are generated in different geographic regions, factors such as regulatory and geopolitical factors within those regions could impact the nature, timing and uncertainty of the Company’s revenues and cash flows. Our geographical revenues, by origin, for the three months ended March 31, 2021 and 2020, were as follows (in thousands):

Three Months Ended March 31, 

    

2021

    

2020

Americas

$

27,734

$

7,685

Europe, the Middle East and Africa (EMEA)

 

14,208

 

1,932

Asia Pacific (APAC)

 

11,342

 

157

Total revenues

$

53,284

$

9,774

Cost of Services Revenues

Our cost of services revenues is primarily comprised of freight charges, payroll and associated expenses related to our global logistics and supply chain centers, depreciation expenses of our Cryoport Express® Shippers and supplies and consumables used for our solutions.

Cost of Product Revenues

Our cost of product revenues is primarily comprised of materials, direct and indirect labor, inbound freight charges, purchasing and receiving, inspection, and distribution and warehousing of inventory. In addition, shop supplies, facility maintenance costs and depreciation expense for assets used in the manufacturing process are included in cost of product revenues.

Engineering and Development Expenses

Engineering and Development Expenses

Expenditures relating to engineering and development are expensed in the period incurred to engineering and development expense in the statement of operations.

Acquisition Costs

Acquisition Costs

Acquisition costs consist of legal, accounting, third-party valuations, and other due diligence costs related to our MVE Biological Solutions and CRYOPDP acquisitions.

Stock-Based Compensation

Stock-Based Compensation

Under our stockholder approved stock-based compensation plan, we have granted incentive stock options, non-qualified stock options and restricted stock units that vest over four years.  Incentive and non-qualified stock options expire from seven to ten years from date of grant. The Company accounts for stock-based payments in accordance with stock-based payment accounting guidance which requires all stock-based payments to be recognized based upon their fair values. The fair value of stock options is estimated at the grant date using the Black-Scholes Option Pricing Model (“Black-Scholes”) and the portion that is ultimately expected to vest is recognized as compensation cost over the requisite service period.  The determination of fair value using Black-Scholes is affected by the Company’s stock price as well as assumptions regarding a number of complex and subjective variables, including expected stock price volatility, risk-free interest rate, expected dividends and expected term. The Company accounts for forfeitures of unvested awards as they occur.

The grant date fair value per share for restricted stock units is based upon the closing market price of our common stock on the award grant date.

The Company’s stock-based compensation plans are discussed further in Note 14.

Basic and Diluted Net Loss Per Share

Basic and Diluted Net Loss Per Share

We calculate basic and diluted net loss per share using the weighted average number of common shares outstanding during the periods presented. In periods of a net loss position, basic and diluted weighted average common shares are the same. For the diluted earnings per share calculation, we adjust the weighted average number of common shares outstanding to include dilutive stock options, warrants and shares associated with the conversion of the Senior Notes and convertible preferred stock outstanding during the periods.

The following shows the amounts used in computing net loss per share (in thousands except per share data):

Three Months Ended March 31, 

    

2021

    

2020

Net loss

$

(3,527)

$

(3,942)

Paid-in-kind dividend on Series C convertible preferred stock

 

(2,196)

 

Net loss attributable to common shareholders

$

(5,723)

$

(3,942)

Weighted average common shares outstanding - basic and diluted

43,804,483

37,548,549

Basic and diluted net loss per share

$

(0.13)

$

(0.11)

The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:

Three Months Ended March 31, 

    

2021

    

2020

Stock options

6,149,186

 

3,867,924

Warrants

 

502,632

Restricted stock units

304,157

Series C convertible preferred stock

5,283,411

Convertible senior notes

4,810,002

 

16,546,756

 

4,370,556

Foreign Currency Transactions

Foreign Currency Transactions

Management has determined that the functional currency of its subsidiaries is the local currency.  Assets and liabilities of the Netherlands and United Kingdom subsidiaries are translated into U.S. dollars at the period-end exchange rates.  Income and expenses are translated at an average exchange rate for the period and the resulting translation gain (loss) adjustments are accumulated as a separate component of stockholders’ equity.  The translation gain (loss) adjustment totaled $(3.8) million and $0 for the three months ended March 31, 2021 and 2020, respectively. Foreign currency gains and losses from transactions denominated in other than respective local currencies are included in earnings.

Off-Balance Sheet Arrangements

Off-Balance Sheet Arrangements

We do not currently have any off-balance sheet arrangements.

Reclassification

Prior year amounts in sales and marketing expense have been reclassified to selling, general and administrative expense to conform to the current period presentation, which reflects how the Company tracks operating costs. These reclassifications had no effect on the previously reported net loss.

Recently Adopted Accounting Pronouncements

Recently Adopted Accounting Pronouncements

In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. Under ASU 2020-06, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost, as long as no other features require bifurcation and recognition as derivatives. Similarly, equity-classified convertible preferred stock instruments will be accounted for as single units of account in equity unless the conversion feature needs to be bifurcated under Topic 815. The new guidance also made amendments to the earnings per share guidance in Topic 260, Earnings Per Share, for convertible instruments, the most significant impact of which is requiring the use of the if- converted method for diluted earnings per share calculation. Further, ASU 2020-06 made revisions to Topic 815-40, which provides guidance on how an entity must determine whether a contract qualifies for a scope exception from derivative accounting. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted. Adoption of the standard requires using either a modified retrospective or a full retrospective approach. Effective January 1, 2021, we early adopted ASU 2020-06 using the modified retrospective approach. Adoption of the new standard did not have a material impact on the Company’s consolidated financial statements or disclosures.

In January 2020, the FASB issued ASU 2020-01, “Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815): Clarifying the Interactions between Topic 321, Topic 323, and Topic 815.” The new guidance clarifies the interaction of accounting for the transition into and out of the equity method and the accounting for measuring certain purchased options and forward contracts to acquire investments. ASU 2020-01 is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The adoption of this guidance did not have an impact on the Company’s consolidated financial statements or disclosures.

Accounting Guidance Issued but Not Adopted at March 31, 2021

In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This ASU replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information for credit loss estimates on certain types of financial instruments, including trade receivables. In addition, new disclosures are required. The ASU, as subsequently amended, is effective for fiscal years beginning after December 15, 2022 for smaller reporting companies, as defined by the SEC. As a smaller reporting company, we are currently evaluating the impact of adopting this guidance.

XML 37 R26.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies (Tables)
3 Months Ended
Mar. 31, 2021
Summary of Significant Accounting Policies  
Schedule of disaggregation of revenue by major source

Three Months Ended March 31, 

    

2021

    

2020

Biopharma/Pharma

$

42,393

$

8,786

Animal Health

 

8,997

 

225

Reproductive Medicine

1,894

763

Total revenues

$

53,284

$

9,774

Schedule of geographical revenues, by origin

Given that the Company’s revenues are generated in different geographic regions, factors such as regulatory and geopolitical factors within those regions could impact the nature, timing and uncertainty of the Company’s revenues and cash flows. Our geographical revenues, by origin, for the three months ended March 31, 2021 and 2020, were as follows (in thousands):

Three Months Ended March 31, 

    

2021

    

2020

Americas

$

27,734

$

7,685

Europe, the Middle East and Africa (EMEA)

 

14,208

 

1,932

Asia Pacific (APAC)

 

11,342

 

157

Total revenues

$

53,284

$

9,774

Schedule of net loss per share

The following shows the amounts used in computing net loss per share (in thousands except per share data):

Three Months Ended March 31, 

    

2021

    

2020

Net loss

$

(3,527)

$

(3,942)

Paid-in-kind dividend on Series C convertible preferred stock

 

(2,196)

 

Net loss attributable to common shareholders

$

(5,723)

$

(3,942)

Weighted average common shares outstanding - basic and diluted

43,804,483

37,548,549

Basic and diluted net loss per share

$

(0.13)

$

(0.11)

Schedule of number of shares excluded from the computation of diluted loss per share

The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:

Three Months Ended March 31, 

    

2021

    

2020

Stock options

6,149,186

 

3,867,924

Warrants

 

502,632

Restricted stock units

304,157

Series C convertible preferred stock

5,283,411

Convertible senior notes

4,810,002

 

16,546,756

 

4,370,556

XML 38 R27.htm IDEA: XBRL DOCUMENT v3.21.1
Cash, Cash Equivalents and Short-Term Investments (Tables)
3 Months Ended
Mar. 31, 2021
Cash, Cash Equivalents and Short-Term Investments  
Schedule of cash, cash equivalents and short-term investments

Cash, cash equivalents and short-term investments consisted of the following as of March 31, 2021 and December 31, 2020 (in thousands):

March 31, 

December 31, 

    

2021

    

2020

Cash

$

23,913

$

25,053

Cash equivalents:

 

Money market mutual fund

 

61,581

11,820

Total cash and cash equivalents

 

85,494

36,873

Short-term investments:

 

U.S. Treasury notes and bills

 

234,578

23,309

Mutual funds

 

33,143

33,135

Total short-term investments

 

267,721

56,444

Cash, cash equivalents and short-term investments

$

353,215

$

93,317

Schedule of available-for-sale debt securities

The amortized cost, gross unrealized gains, gross unrealized losses and fair value of available-for-sale investments by type of security at March 31, 2021 were as follows (in thousands):

    

Amortized

    

Unrealized

    

Unrealized

    

Cost

Gains

Losses

Fair Value

U.S. Treasury notes

$

235,185

$

128

$

(735)

$

234,578

Total available-for-sale investments

$

235,185

$

128

$

(735)

$

234,578

The amortized cost, gross unrealized gains, gross unrealized losses and fair value of available-for-sale investments by type of security at December 31, 2020 were as follows (in thousands):

    

    

Unrealized 

    

Unrealized 

    

Amortized Cost

Gains

Losses

Fair Value

U.S. Treasury notes

$

23,179

 

$

173

 

$

(43)

$

23,309

Total available-for-sale investments

$

23,179

 

$

173

$

(43)

$

23,309

Schedule of investments based on stated contractual maturities

The following table summarizes the fair value of available-for-sale investments based on stated contractual maturities as of March 31, 2021:

    

Amortized Cost

    

Fair Value

Due within one year

$

41,030

$

41,058

Due between one and two years

 

194,155

 

193,520

Total

$

235,185

$

234,578

The following table summarizes the fair value of available-for-sale investments based on stated contractual maturities as of December 31, 2020:

    

Amortized Cost

    

Fair Value

Due within one year

$

14,084

 

$

14,111

Due between one and two years

 

9,095

 

 

9,198

Total

$

23,179

 

$

23,309

Schedule of unrealized gains (losses) on investments

Unrealized gains (losses) during 2021 and 2020 related to equity securities held at March 31, 2021 and 2020 are as follows (in thousands):

    

2021

2020

Net losses recognized during the three months on equity securities

    

$

(263)

$

(649)

Less: net gains (losses) recognized during the year on equity securities sold during the year

 

   

(793)

Unrealized gains (losses) recognized during the three months on equity securities still held at March 31, 2021 and 2020

$

(263)

$

144

XML 39 R28.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements (Tables)
3 Months Ended
Mar. 31, 2021
Fair Value Measurements  
Schedule of fair value hierarchy

The carrying values of our assets that are required to be measured at fair value on a recurring basis as of March 31, 2021 and 2020 approximate fair value because of our ability to immediately convert these instruments into cash with minimal expected change in value which are classified in the table below in one of the three categories of the fair value hierarchy described above (in thousands):

    

Fair Value Measurements

    

Level 1

    

Level 2

    

Level 3

    

Total

March 31, 2021

 

  

 

  

 

  

 

  

Cash equivalents:

 

  

 

  

 

  

 

  

Money market mutual fund

$

61,581

$

$

$

61,581

Marketable equity securities:

 

  

 

  

 

  

 

  

Mutual funds

 

33,143

 

 

 

33,143

Available-for-sale debt securities:

 

 

  

 

  

 

U.S. Treasury notes

 

234,578

 

 

 

234,578

$

329,302

$

$

$

329,302

Fair Value Measurements 

 

Level 1

 

Level 2

 

Level 3

 

Total

December 31, 2020

    

  

    

  

    

  

    

  

Cash equivalents:

 

  

 

  

 

  

 

  

Money market mutual fund

$

11,820

$

$

$

11,820

Marketable equity securities:

 

  

 

  

 

  

 

  

Mutual funds

 

33,135

 

 

 

33,135

Available-for-sale debt securities:

 

  

 

  

 

  

 

  

U.S. Treasury notes

 

23,309

 

 

 

23,309

$

68,264

$

$

$

68,264

XML 40 R29.htm IDEA: XBRL DOCUMENT v3.21.1
Inventory (Tables)
3 Months Ended
Mar. 31, 2021
Inventory  
Schedule of Inventory

Inventories consist of the following (in thousands):

    

March 31,

    

December 31,

2021

2020

Raw materials

$

8,318

$

7,544

Work-in-process

 

307

 

227

Finished goods

 

2,919

 

2,764

$

11,544

$

10,535

XML 41 R30.htm IDEA: XBRL DOCUMENT v3.21.1
Goodwill and Intangible Assets (Tables)
3 Months Ended
Mar. 31, 2021
Goodwill and Intangible Assets  
Schedule of goodwill

The following table represents the changes in the carrying value of goodwill for the three months ended March 31, 2021 and 2020 (in thousands):

    

March 31,

2021

    

2020

Balance at beginning of year

 

145,282

 

11,000

Foreign currency adjustment

 

(1,405)

 

Goodwill related to MVE acquisition

 

18

 

Goodwill related to CRYOPDP acquisition

 

(2,590)

 

Total

 

$

141,305

 

$

11,000

Schedule of intangible assets

The following table presents our intangible assets as of March 31, 2021 (in thousands):

Weighted

Net

Average

Gross

Accumulated

Carrying

Amortization

    

Amount

    

Amortization

    

Amount

    

Period (years)

Non-compete agreement

$

390

$

143

$

247

 

3

Technology

34,438

2,576

31,862

11

Customer relationships

128,640

5,218

123,422

14

Cryogene trade name/trademark

480

59

421

13

CRYOPDP agent network

8,597

1,415

7,182

4

MVE order backlog

2,600

2,600

MVE land use rights

2,378

36

2,342

37

Patents and trademarks

44,360

569

43,791

Total

$

221,883

$

12,616

$

209,267

The following table presents our intangible assets as of December 31, 2020 (in thousands):

Weighted

Net

Average

Gross

Accumulated

Carrying

Amortization

    

Amount

    

Amortization

    

Amount

    

Period (years)

Non-compete agreement

$

390

$

123

$

267

 

3

Technology

34,245

1,630

32,615

11

Customer relationships

128,640

2,708

125,932

14

Cryogene trade name/trademark

480

51

429

13

CRYOPDP agent network

8,597

537

8,060

4

MVE order backlog

2,600

2,600

MVE land use rights

2,378

16

2,362

37

Patents and trademarks

44,312

69

44,243

 

Total

$

221,642

$

7,734

$

213,908

Schedule of expected future amortization of intangible assets

Expected future amortization of intangible assets as of March 31, 2021 is as follows:

Years Ending March 31, 

    

Amount

Remainder of 2021

$

10,722

2022

 

14,296

2023

 

14,296

2024

 

13,678

2025

 

12,064

Thereafter

 

100,051

$

165,107

XML 42 R31.htm IDEA: XBRL DOCUMENT v3.21.1
Convertible Senior Notes (Tables)
3 Months Ended
Mar. 31, 2021
Convertible Senior Notes  
Schedule of components of notes payable

Senior Notes payable consisted of the following at March 31, 2021 (in thousands):

    

March 31, 2021

Principal amount of Senior Notes

$

115,000

Unamortized debt issuance costs

 

(3,464)

Net carrying value of Senior Notes payable

$

111,536

Schedule of interest expenses incurred in connection with the Notes

    

Three Months Ended

March 31, 2021

Coupon interest

$

862

Amortization of debt issuance costs

192

Total interest expense on Senior Notes

$

1,054

XML 43 R32.htm IDEA: XBRL DOCUMENT v3.21.1
Leases (Tables)
3 Months Ended
Mar. 31, 2021
Leases  
Schedule of components of lease cost

The components of lease cost were as follows (in thousands):

March 31, 

    

2021

    

2020

Operating lease cost

$

922

$

290

Finance lease cost:

 

  

Amortization of right-of-use assets

15

6

Interest on finance lease liabilities

3

2

18

 

8

Total lease cost

$

940

$

298

Schedule of other information related to leases

Other information related to leases was as follows (in thousands):

Three Months Ended

 

Supplemental Cash Flows Information

    

March 31, 2020

 

Cash paid for amounts included in the measurement of lease liabilities:

 

Operating cash flows from operating leases

 

$

851

Operating cash flows from finance leases

 

$

22

Financing cash flows from finance leases

$

20

Right-of-use assets obtained in exchange for lease liabilities (in thousands):

Operating leases

 

$

2,781

Finance leases

$

Weighted-Average Remaining Lease Term

Operating leases

 

6.3 years

Finance leases

 

2.7 years

Weighted-Average Discount Rate

Operating leases

5.4

%

Finance leases

5.3

%

Schedule of future minimum lease payments under non-cancellable leases

Future minimum lease payments under non-cancellable leases that have commenced as of March 31, 2021 were as follows (in thousands):

Years Ending March 31

Operating Leases

Finance Leases

2021 (excluding the three months ended March 31, 2021)

$

1,688

$

45

2022

 

2,730

 

58

2023

 

2,256

 

61

2024

 

2,049

 

2025

 

1,866

 

Thereafter

9,738

Total future minimum lease payments

 

20,327

 

164

Less imputed interest

 

(3,823)

 

(12)

Total

$

16,504

$

152

Operating

Finance 

Reported as of March 31, 2021

    

 Leases

    

Leases

Current lease liabilities

$

2,002

$

60

Noncurrent lease liabilities

 

14,502

 

92

Total

$

16,504

$

152

XML 44 R33.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' Equity (Tables)
3 Months Ended
Mar. 31, 2021
Stockholders' Equity  
Schedule of common stock were issuable upon exercise of stock options and the conversion of convertible senior notes and Series C Preferred stock

As of March 31, 2021, approximately 18.2 million shares of common stock were issuable upon conversion or exercise of rights granted under prior financing arrangements, stock options, RSU’s and the conversion of senior notes and series C Preferred stock, as follows:

Exercise of stock options

    

7,793,769

Vesting of restricted stock units

 

304,157

Conversion of Series C Preferred Stock

 

5,283,411

Conversion of convertible senior notes

 

4,810,002

Total shares of common stock reserved for future issuances

 

18,191,339

XML 45 R34.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-Based Compensation (Tables)
3 Months Ended
Mar. 31, 2021
Stock-Based Compensation  
Schedule of fair value assumptions of stock options

Expected life (years)

3.5 – 6.1

 

Risk-free interest rate

0.5% - 0.9

%

Volatility

64.4% - 80.8

%

Dividend yield

0

%

Schedule of share-based payment awards

We recognize stock-based compensation cost on a straight-line basis over the vesting period. Stock-based compensation expense is recognized only for those awards that ultimately vest.

Total stock-based compensation expense related to all of our share-based payment awards is comprised of the following:

Three months ended March 31,

    

2021

    

2020

Cost of revenues

$

239

$

69

Selling, general and administrative

 

2,505

 

1,443

Engineering and development

 

246

 

108

$

2,990

$

1,620

Schedule of stock option activity

A summary of stock option activity is as follows:

    

    

    

Weighted-

    

Weighted-

Average

Average

Remaining

Aggregate

Number of

Exercise

Contractual

Intrinsic

Shares

Price/Share

Term (Years)

Value (1)

Outstanding — December 31, 2020

 

7,554,305

$

10.29

 

  

 

  

Granted (weighted-average fair value of $32.66 per share)

 

435,298

55.74

 

  

 

  

Exercised

 

(187,486)

 

8.46

 

  

 

  

Forfeited

 

(8,348)

 

16.48

 

  

 

  

Outstanding — March 31, 2021

 

7,793,769

$

12.86

 

6.4

$

306,822

Vested (exercisable) — March 31, 2021

 

5,904,443

$

7.76

 

5.8

$

261,287

Expected to vest after March 31, 2021 (unexercisable)

 

1,889,326

$

28.82

 

7.9

$

40,001

(1)Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of our common stock on March 31, 2021, which was $52.01 per share.
Schedule of restricted stock unit activity

A summary of our restricted stock unit activity is as follows:

Weighted Average

Number of Restricted

 Fair Value per 

Stock Units

Share 

Outstanding – December 31, 2020

    

    

$

Granted

 

304,157

 

53.94

Share issuance

 

 

Outstanding March 31, 2021

 

304,157

$

53.94

XML 46 R35.htm IDEA: XBRL DOCUMENT v3.21.1
Nature of the Business (Details)
€ in Millions, $ in Millions
Oct. 01, 2020
USD ($)
Aug. 24, 2020
USD ($)
Aug. 21, 2020
EUR (€)
Aug. 21, 2020
USD ($)
MVE        
Restructuring Cost and Reserve [Line Items]        
Cash consideration $ 317.5 $ 320.0    
CRYOPDP        
Restructuring Cost and Reserve [Line Items]        
Cash consideration $ 56.7   € 49 $ 58.0
Percentage of equity interest agreed to be acquired     100.00% 100.00%
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies - Disaggregates Our Revenues by Major Source (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
May 31, 2020
Revenue Recognition [Line Items]      
Revenues $ 53,284 $ 9,774  
Interest rate (as a percent) 3.00%   3.00%
Global Logistics Solutions [Member]      
Revenue Recognition [Line Items]      
Revenues $ 53,284 9,774  
Biopharma/Pharma [Member] | Global Logistics Solutions [Member]      
Revenue Recognition [Line Items]      
Revenues 42,393 8,786  
Animal Health [Member] | Global Logistics Solutions [Member]      
Revenue Recognition [Line Items]      
Revenues 8,997 225  
Reproductive Medicine [Member] | Global Logistics Solutions [Member]      
Revenue Recognition [Line Items]      
Revenues $ 1,894 $ 763  
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies - Disaggregation Our Geographical Revenues by Origin (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Disaggregation of Revenue [Line Items]    
Revenues $ 53,284 $ 9,774
Americas [Member]    
Disaggregation of Revenue [Line Items]    
Revenues 27,734 7,685
Europe, the Middle East and Africa (EMEA) [Member]    
Disaggregation of Revenue [Line Items]    
Revenues 14,208 1,932
Asia Pacific (APAC) [Member]    
Disaggregation of Revenue [Line Items]    
Revenues $ 11,342 $ 157
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies - Earnings Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Summary of Significant Accounting Policies    
Net loss $ (3,527) $ (3,942)
Paid-in-kind preferred stock dividend, including beneficial conversion feature (2,196)  
Net loss attributable to common stockholders $ (5,723) $ (3,942)
Weighted average common shares outstanding - basic and diluted 43,804,483 37,548,549
Basic and diluted net loss per share $ (0.13) $ (0.11)
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies - Antidilutive Shares (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 16,546,756 4,370,556  
Product warranty accrued liabilities $ 0.2   $ 0.2
Class C convertible preferred stock      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 5,283,411    
Stock Options [Member]      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6,149,186 3,867,924  
Warrants [Member]      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount   502,632  
Restricted stock units      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 304,157    
Convertible Senior Notes [Member]      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 4,810,002    
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies - Additional Information (Details)
3 Months Ended 12 Months Ended
Mar. 11, 2021
USD ($)
Jun. 29, 2020
USD ($)
Mar. 31, 2021
USD ($)
customer
Mar. 31, 2020
USD ($)
customer
Dec. 31, 2020
USD ($)
customer
Sep. 30, 2020
USD ($)
Dec. 31, 2019
USD ($)
Significant Accounting Policies Additional Information [Line Items]              
Maturity Period Of Highly Liquid Investments     90 days        
Allowance for doubtful accounts receivable     $ 1,200,000       $ 1,100,000
Revenues     $ 53,284,000 $ 9,774,000      
Finite-Lived Intangible Asset, Useful Life     5 years        
Impairment of intangible assets     $ 0        
Material unrecognized Tax Benefits           $ 0 $ 0
Operating Loss Carryforwards, Percent     80.00%        
Period over which foreign subsidiaries subject to examination by indian tax authorities     3 years        
Amount of maximum allowed research and development credit usage   $ 5,000,000          
Charity Care, Reimbursements Received $ 1,000,000            
Omit disclosure of the transaction price allocated to remaining performance obligations     true        
Contract liabilities     $ 500,000   $ 300,000    
Contract with Customer, Liability, Revenue Recognized     $ 200,000        
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period     4 years        
Foreign Currency Transaction Gain (Loss), before Tax     $ (3,800,000) $ 0      
Minimum [Member]              
Significant Accounting Policies Additional Information [Line Items]              
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period     7 years        
Maximum [Member]              
Significant Accounting Policies Additional Information [Line Items]              
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period     10 years        
Furniture and Equipment [Member] | Minimum [Member]              
Significant Accounting Policies Additional Information [Line Items]              
Property, Plant and Equipment, Useful Life     3 years        
Furniture and Equipment [Member] | Maximum [Member]              
Significant Accounting Policies Additional Information [Line Items]              
Property, Plant and Equipment, Useful Life     15 years        
Building [Member] | Minimum [Member]              
Significant Accounting Policies Additional Information [Line Items]              
Property, Plant and Equipment, Useful Life     20 years        
Building [Member] | Maximum [Member]              
Significant Accounting Policies Additional Information [Line Items]              
Property, Plant and Equipment, Useful Life     45 years        
Computer Equipment [Member] | Minimum [Member]              
Significant Accounting Policies Additional Information [Line Items]              
Property, Plant and Equipment, Useful Life     3 years        
Computer Equipment [Member] | Maximum [Member]              
Significant Accounting Policies Additional Information [Line Items]              
Property, Plant and Equipment, Useful Life     12 years        
Freezer (Member) | Minimum [Member]              
Significant Accounting Policies Additional Information [Line Items]              
Property, Plant and Equipment, Useful Life     7 years        
Freezer (Member) | Maximum [Member]              
Significant Accounting Policies Additional Information [Line Items]              
Property, Plant and Equipment, Useful Life     10 years        
Truck and Auto (Member) | Minimum [Member]              
Significant Accounting Policies Additional Information [Line Items]              
Property, Plant and Equipment, Useful Life     4 years        
Truck and Auto (Member) | Maximum [Member]              
Significant Accounting Policies Additional Information [Line Items]              
Property, Plant and Equipment, Useful Life     10 years        
Foreign Customers [Member]              
Significant Accounting Policies Additional Information [Line Items]              
Concentration risk, percentage       21.40%      
Revenues     $ 25,500,000 $ 2,100,000      
Accounts Receivable [Member]              
Significant Accounting Policies Additional Information [Line Items]              
Number Of Customers | customer     1   0    
Concentration risk, percentage     10.00%   10.00%    
Accounts Receivable [Member] | Customer One [Member]              
Significant Accounting Policies Additional Information [Line Items]              
Concentration risk, percentage     10.50%        
Sales Revenue, Net [Member]              
Significant Accounting Policies Additional Information [Line Items]              
Number Of Customers | customer     1 3      
Concentration risk, percentage     10.00% 10.00%      
Sales Revenue, Net [Member] | Customer One [Member]              
Significant Accounting Policies Additional Information [Line Items]              
Concentration risk, percentage     12.50% 17.90%      
Sales Revenue, Net [Member] | Customer Two [Member]              
Significant Accounting Policies Additional Information [Line Items]              
Concentration risk, percentage       16.70%      
Sales Revenue, Net [Member] | Foreign Customers [Member]              
Significant Accounting Policies Additional Information [Line Items]              
Concentration risk, percentage     48.00%        
Sales Revenue, Net [Member] | Customer Three [Member]              
Significant Accounting Policies Additional Information [Line Items]              
Concentration risk, percentage       10.80%      
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.21.1
Acquisition of CryoGene Partners - Preliminary Purchase Price Allocation (Details
$ in Thousands, € in Millions
3 Months Ended
Oct. 01, 2020
USD ($)
Oct. 01, 2020
EUR (€)
Aug. 24, 2020
USD ($)
Aug. 21, 2020
USD ($)
Aug. 21, 2020
EUR (€)
Mar. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Purchase price allocation:                  
Goodwill           $ 141,305 $ 145,282 $ 11,000 $ 11,000
CRYOPDP                  
Business Acquisition [Line Items]                  
Total purchase consideration paid $ 57,000 € 48.3              
Purchase price allocation:                  
Note payable           1,500      
Goodwill 25,500         22,600      
Working capital           300      
Adjustments           2,900      
Comprised           1,300      
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net           56,700      
Payments to Acquire Businesses, Gross 56,700     $ 58,000 € 49.0        
MVE                  
Business Acquisition [Line Items]                  
Total purchase consideration paid 317,500                
Purchase price allocation:                  
Goodwill           $ 106,200      
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net 57,000                
Payments to Acquire Businesses, Gross $ 317,500   $ 320,000            
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.21.1
Cash, Cash Equivalents and Short-Term Investments (Details) - USD ($)
Mar. 31, 2021
Dec. 31, 2020
Cash and Cash Equivalents    
Cash $ 23,913,000 $ 25,053,000
Cash equivalents:    
Money market mutual fund 61,581,000 11,820,000
Total cash and cash equivalents 85,494,000 36,873,000
Short-term investments:    
Total short-term investments 267,721,000 56,444,000
Cash, cash equivalents and short-term investments 353,215,000 93,317,000
U.S. Treasury notes and bills [Member]    
Short-term investments:    
Short-term Investments 234,578 23,309
Mutual Funds [Member]    
Short-term investments:    
Short-term Investments $ 33,143 $ 33,135
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.21.1
Cash, Cash Equivalents and Short-Term Investments - Available-for-sale debt securities (Details) - USD ($)
Mar. 31, 2021
Dec. 31, 2020
Amortized Cost $ 235,185,000 $ 23,179
Unrealized Gains 128,000 173
Unrealized Losses (735,000) (43)
Fair Value 234,578,000 23,309
U.S. Treasury notes    
Amortized Cost 235,185,000 23,179
Unrealized Gains 128,000 173
Unrealized Losses (735,000) (43)
Fair Value $ 234,578,000 $ 23,309
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.21.1
Cash, Cash Equivalents and Short-Term Investments - Contractual Maturities (Details) - USD ($)
Mar. 31, 2021
Dec. 31, 2020
Cash, Cash Equivalents and Short-Term Investments    
Due within one year, Amortized Cost $ 41,030,000 $ 14,084
Due between one and two years, Amortized Cost 194,155,000 9,095
Total, Amortized Cost 235,185,000 23,179
Due within one year, Fair Value 41,058,000 14,111
Due between one and two years, Fair Value 193,520,000 9,198
Total, Fair Value $ 234,578,000 $ 23,309
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.21.1
Cash, Cash Equivalents and Short-Term Investments - Equity Investments (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Cash, Cash Equivalents and Short-Term Investments    
Net losses recognized during the three months on equity securities $ (263) $ (649)
Less: net gains (losses) recognized during the year on equity securities sold during the year   (793)
Unrealized gains (losses) recognized during the three months on equity securities still held at March 31, 2021 and 2020 $ (263) $ 144
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.21.1
Cash, Cash Equivalents and Short-Term Investments - Additional Information (Details)
3 Months Ended
Mar. 31, 2021
USD ($)
Cash, Cash Equivalents and Short-Term Investments  
Losses on available-for-sale investments $ 40,000
Equity Securities, FV-NI $ 33,100,000
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements (Details) - Fair Value, Measurements, Recurring [Member] - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Assets, Fair Value Disclosure $ 329,302 $ 68,264
Mutual funds    
Assets, Fair Value Disclosure 33,143 33,135
U.S. Treasury notes    
Assets, Fair Value Disclosure 234,578 23,309
Money market mutual fund    
Assets, Fair Value Disclosure 61,581 11,820
Fair Value, Inputs, Level 1 [Member]    
Assets, Fair Value Disclosure 329,302 68,264
Fair Value, Inputs, Level 1 [Member] | Mutual funds    
Assets, Fair Value Disclosure 33,143 33,135
Fair Value, Inputs, Level 1 [Member] | U.S. Treasury notes    
Assets, Fair Value Disclosure 234,578 23,309
Fair Value, Inputs, Level 1 [Member] | Money market mutual fund    
Assets, Fair Value Disclosure 61,581 11,820
Fair Value, Inputs, Level 2 [Member]    
Assets, Fair Value Disclosure 0 0
Fair Value, Inputs, Level 2 [Member] | Mutual funds    
Assets, Fair Value Disclosure 0 0
Fair Value, Inputs, Level 2 [Member] | U.S. Treasury notes    
Assets, Fair Value Disclosure 0 0
Fair Value, Inputs, Level 2 [Member] | Money market mutual fund    
Assets, Fair Value Disclosure 0 0
Fair Value, Inputs, Level 3 [Member]    
Assets, Fair Value Disclosure 0 0
Fair Value, Inputs, Level 3 [Member] | Mutual funds    
Assets, Fair Value Disclosure 0 0
Fair Value, Inputs, Level 3 [Member] | U.S. Treasury notes    
Assets, Fair Value Disclosure 0 0
Fair Value, Inputs, Level 3 [Member] | Money market mutual fund    
Assets, Fair Value Disclosure $ 0 $ 0
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements - Additional Information (Details)
$ in Millions
Mar. 31, 2021
USD ($)
Fair Value Measurements  
Convertible Senior notes $ 108.8
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.21.1
Inventory (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Inventory    
Raw materials $ 8,318 $ 7,544
Work-in-process 307 227
Finished goods 2,919 2,764
Inventory, Net, Total $ 11,544 10,535
Step up inventory related to acquisition   $ 800
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.21.1
Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Mar. 31, 2020
Dec. 31, 2019
Gross Amount $ 221,883 $ 221,642    
Accumulated Amortization 12,616 7,734    
Future amortization of intangible assets 209,267 213,908    
Goodwill 141,305 145,282 $ 11,000 $ 11,000
Cryoport patents and trademarks        
Gross Amount 44,360 44,312    
Accumulated Amortization 569 69    
Future amortization of intangible assets $ 43,791 $ 44,243    
Weighted Average Amortization Period (years) 0 years 0 years    
Non-compete agreement        
Gross Amount $ 390 $ 390    
Accumulated Amortization 143 123    
Future amortization of intangible assets $ 247 $ 267    
Weighted Average Amortization Period (years) 3 years 3 years    
Technology        
Gross Amount $ 34,438 $ 34,245    
Accumulated Amortization 2,576 1,630    
Future amortization of intangible assets $ 31,862 $ 32,615    
Weighted Average Amortization Period (years) 11 years 11 years    
Customer relationships        
Gross Amount $ 128,640 $ 128,640    
Accumulated Amortization 5,218 2,708    
Future amortization of intangible assets $ 123,422 $ 125,932    
Weighted Average Amortization Period (years) 14 years 14 years    
Trade name/trademarks        
Gross Amount $ 480 $ 480    
Accumulated Amortization 59 51    
Future amortization of intangible assets $ 421 $ 429    
Weighted Average Amortization Period (years) 13 years 13 years    
Order backlog        
Gross Amount $ 2,600 $ 2,600    
Accumulated Amortization $ 2,600 $ 2,600    
Weighted Average Amortization Period (years) 0 years 0 years    
Land use rights        
Gross Amount $ 2,378 $ 2,378    
Accumulated Amortization 36 16    
Future amortization of intangible assets $ 2,342 $ 2,362    
Weighted Average Amortization Period (years) 37 years 37 years    
Agent network        
Gross Amount $ 8,597 $ 8,597    
Accumulated Amortization 1,415 537    
Future amortization of intangible assets $ 7,182 $ 8,060    
Weighted Average Amortization Period (years) 0 years 4 years    
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.21.1
Goodwill and Intangible Assets - Expected Future Amortization (Details)
$ in Thousands
Mar. 31, 2021
USD ($)
Expected future amortization of intangible assets  
Remainder of 2021 $ 10,722
2022 14,296
2023 14,296
2024 13,678
2025 12,064
Thereafter 100,051
Future amortization of intangible assets $ 165,107
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.21.1
Goodwill and Other Intangible Assets - Schedule of goodwill (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2021
USD ($)
Goodwill [Roll Forward]  
Beginning Balance $ 145,282
Foreign currency adjustment (1,405)
Ending Balance 141,305
MVE  
Goodwill [Roll Forward]  
Additions (18)
Ending Balance 106,200
CRYOPDP  
Goodwill [Roll Forward]  
Additions (2,590)
Ending Balance $ 22,600
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.21.1
Goodwill and Intangible Assets - Additional Information (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Goodwill    
Amortization expense for intangible assets $ 3.6 $ 0.1
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.21.1
Convertible Senior Notes - Components of Convertible notes payable (Details)
$ in Thousands
Mar. 31, 2021
USD ($)
Convertible Senior Notes  
Principal amount of Senior Notes $ 115,000
Unamortized debt issuance costs (3,464)
Net carrying value of Notes payable $ 111,536
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.21.1
Convertible Senior Notes - Interest expenses incurred on Convertible notes payable (Details)
$ in Thousands
3 Months Ended
Sep. 30, 2020
USD ($)
Convertible Senior Notes  
Coupon interest $ 862
Amortization of debt issuance costs 192
Total interest expense on Notes $ 1,054
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.21.1
Convertible Senior Notes - Summary of total gross principal payments due under the Convertible notes payable (Details)
$ in Thousands
Mar. 31, 2021
USD ($)
Convertible Senior Notes  
Notes payable, 2025 $ 115,000
Total Payments $ 115,000
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.21.1
Convertible Senior Notes - Additional information (Details)
1 Months Ended 3 Months Ended
May 31, 2020
USD ($)
Mar. 31, 2021
USD ($)
item
$ / shares
shares
Debt Instrument [Line Items]    
Aggregate principal amount $ 115,000,000.0 $ 1,000
Interest rate (as a percent) 3.00% 3.00%
Underwriting discounts and commissions $ 3,700,000  
Common stock issued upon conversion of notes | shares   4,810,002
Conversion rate   130
Interest expense   $ 1,200,000
Initial conversion price (in dollars per share) | $ / shares   $ 23.91
Threshold maximum conversion rate   $ 48.10
Threshold trading days for redemption of notes | item   20
Threshold consecutive trading days for redemption of notes | item   30
Debt issuance costs   $ 4,100,000
Long-term Debt, Term   5 years
Debt Instrument, Interest Rate, Stated Percentage   3.74%
Notes payable, 2025   $ 115,000,000.0
Additional interest rate (as a percent)   25.00%
Threshold maximum combined interest rate (as a percent)   0.50%
Cash payment to each noteholder (as a percent)   3.00%
Senior Notes    
Debt Instrument [Line Items]    
Common stock issued upon conversion of notes | shares   4,810,002
Initial conversion price (in dollars per share) | $ / shares   $ 41.8261
Convertible Note [Member]    
Debt Instrument [Line Items]    
Debt Instrument, Interest Rate, Stated Percentage 3.00%  
Private Placement    
Debt Instrument [Line Items]    
Aggregate principal amount $ 15,000,000.0  
Proceeds from the offering 111,300,000  
Third-party offering related costs $ 300,000  
First 90 days beginning on, and including the date on which such Registration Default occurs    
Debt Instrument [Line Items]    
Additional interest rate (as a percent)   0.25%
After 90 days of the occurrence of Registration Default    
Debt Instrument [Line Items]    
Additional interest rate (as a percent)   0.50%
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.21.1
Note Payable (Details)
€ in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2021
USD ($)
item
Mar. 31, 2021
EUR (€)
item
Mar. 31, 2021
EUR (€)
Dec. 31, 2020
USD ($)
Debt Instrument [Line Items]        
Note payable | $ $ 3,497     $ 4,912
CRYOPDP        
Debt Instrument [Line Items]        
Number of installment | item 2 2    
Note payable $ 4,900   € 4,000  
Fair market value of debt discount 1,300   1,100  
Amortization of debt discount 70 € 60    
CRYOPDP | repaid in 2025        
Debt Instrument [Line Items]        
Note payable 600   500  
CRYOPDP | repaid in 2028        
Debt Instrument [Line Items]        
Note payable $ 4,300   € 3,500  
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.21.1
Leases - Components Of Lease Cost (Detail) - USD ($)
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Leases    
Operating lease cost $ 922 $ 290
Finance lease cost:    
Amortization of right-of-use assets 15 6
Interest on finance lease liabilities 3 2
Total finance lease cost 18 8
Total lease cost $ 940 $ 298
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.21.1
Leases - Supplemental Cash Flows Information (Detail)
3 Months Ended
Mar. 31, 2021
USD ($)
Cash paid for amounts included in the measurement of lease liabilities:  
Operating cash flows from operating leases $ 851
Operating cash flows from finance leases 22
Financing cash flows from finance leases 20
Right-of-use assets obtained in exchange for lease obligations:  
Operating leases $ 2,781
Weighted-Average Remaining Lease Term  
Operating leases 6 years 3 months 18 days
Finance leases 2 years 8 months 12 days
Weighted-Average Discount Rate  
Operating leases 5.40%
Finance leases 5.30%
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.21.1
Leases - Payments Under Non-Cancellable Leases (Details) - USD ($)
Mar. 31, 2021
Dec. 31, 2020
Operating Leases    
2021 (excluding the three months ended March 31, 2021) $ 1,688  
2022 2,730  
2023 2,256  
2024 2,049  
2025 1,866  
Thereafter 9,738  
Total future minimum lease payments 20,327  
Less imputed interest (3,823)  
Current lease liabilities 2,002,000 $ 2,231,000
Noncurrent lease liabilities 14,502,000 12,261,000
Total 16,504  
Finance Leases    
2021 (excluding the three months ended March 31, 2021) 45  
2022 58  
2023 61  
2025 0  
Total future minimum lease payments 164  
Less imputed interest (12)  
Current lease liabilities 60,000 59,000
Noncurrent lease liabilities 92,000 $ 112,000
Total $ 152  
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.21.1
Leases - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Lessee Option to Extend 5 years  
Finance Lease, Right-of-Use Asset $ 300 $ 300
Finance Lease Right-of-Use Asset Accumulated Depreciation $ 100 $ 80
Minimum [Member]    
Lease Weighted Average Remaining Lease Term 1 year  
Maximum [Member]    
Lease Weighted Average Remaining Lease Term 9 years  
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' Equity - Common Stock Reserved for Future Issuance (Details)
3 Months Ended
Mar. 31, 2021
shares
Mar. 31, 2021
shares
Class of Stock [Line Items]    
Common Stock Reserved for Future Issuance 18,191,339 18,191,339
Common stock issued upon conversion of notes   4,810,002
Stock Options [Member]    
Class of Stock [Line Items]    
Common Stock Reserved for Future Issuance 7,793,769 7,793,769
Warrants [Member]    
Class of Stock [Line Items]    
Common stock issued upon conversion of notes 18,200,000  
Class C convertible preferred stock    
Class of Stock [Line Items]    
Common Stock Reserved for Future Issuance 5,283,411 5,283,411
Restricted stock units    
Class of Stock [Line Items]    
Common Stock Reserved for Future Issuance 304,157 304,157
XML 75 R64.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' Equity - Additional Information (Details)
3 Months Ended 12 Months Ended
Mar. 31, 2021
$ / shares
shares
Feb. 05, 2021
USD ($)
$ / shares
shares
Oct. 01, 2020
USD ($)
item
$ / shares
shares
Jun. 24, 2019
USD ($)
$ / shares
shares
Mar. 31, 2021
USD ($)
director
$ / shares
shares
Mar. 31, 2020
USD ($)
director
shares
Dec. 31, 2020
USD ($)
$ / shares
shares
Class of Stock [Line Items]              
Common stock, shares authorized | shares 100,000,000       100,000,000   100,000,000
Stock Issued During Period, Value, Issued for Services         $ 11,500 $ 20,700  
Preferred stock, par value per share (in dollars per share) | $ / shares $ 0.001       $ 0.001   $ 0.001
Preferred stock, shares authorized | shares 2,500,000       2,500,000   2,500,000
Common stock, par value per share (in dollars per share) | $ / shares $ 0.001   $ 0.001   $ 0.001   $ 0.001
Dividends, paid-in-kind         $ 2,200,000   $ 2,500,000
Deemed dividend     $ 39,500,000        
Series C Preferred stock conversion expenses   $ 1,800,000          
Proceeds from public offering, net of offering costs         $ 269,825,000 $ 0  
Common stock, shares issued | shares 45,693,692       45,693,692   39,837,058
Common stock issued upon conversion of notes | shares         4,810,002    
Warrants [Member]              
Class of Stock [Line Items]              
Common stock issued upon conversion of notes | shares 18,200,000            
Director [Member]              
Class of Stock [Line Items]              
Stock Issued During Period, Shares, Issued for Services | shares         229 1,269  
Number of Members | director         1 2  
Class A convertible preferred stock [Member]              
Class of Stock [Line Items]              
Preferred stock, par value per share (in dollars per share) | $ / shares $ 0.001       $ 0.001   $ 0.001
Preferred stock, shares authorized | shares 800,000       800,000   800,000
Class B convertible preferred stock [Member]              
Class of Stock [Line Items]              
Preferred stock, par value per share (in dollars per share) | $ / shares $ 0.001       $ 0.001   $ 0.001
Preferred stock, shares authorized | shares 585,000       585,000   585,000
Class C convertible preferred stock              
Class of Stock [Line Items]              
Stock issued during period, new issues (in shares) | shares   50,000          
Preferred stock, dividend rate (as a percent)         4.00%    
Preferred stock, par value per share (in dollars per share) | $ / shares $ 0.001       $ 0.001   $ 0.001
Preferred stock, shares authorized | shares 250,000       250,000   250,000
Dividends, paid-in-kind             $ 300,000
Liquidation preference (in dollars per share) | $ / shares   $ 1,000 $ 1,000        
Conversion price (in dollars per share) | $ / shares     $ 38.6152        
Conversion rate     25.90        
Shares to be issued upon conversion | shares     6,474,135        
Threshold trading days for conversion of preferred stock     20        
Threshold consecutive trading days for conversion of preferred stock     30        
Stock price trigger as a percentage of conversion price for conversion of preferred stock     150.00%        
Dividend rate on shares not repurchased     5.50%        
Number of member to the board of directors who can be elected by the preferred stock holders | item     1        
Percentage of stock to be held to exercise the right to nominate member of board of directors     66.67%        
Class C convertible preferred stock | Prior to the 180-day anniversary of October 1, 2020              
Class of Stock [Line Items]              
Number of shares to be redeemed | shares   50,000 50,000        
Redemption price (as a percent)     125.00%        
Class C convertible preferred stock | At any time beginning five years after Closing Date (but prior to six years after the Closing Date)              
Class of Stock [Line Items]              
Redemption price (as a percent)     105.00%        
Class C convertible preferred stock | At any time beginning six years after Closing Date              
Class of Stock [Line Items]              
Redemption price (as a percent)     100.00%        
Common Stock [Member]              
Class of Stock [Line Items]              
Common stock, par value per share (in dollars per share) | $ / shares   $ 0.001          
Conversion price (in dollars per share) | $ / shares   $ 38.6152          
Shares to be issued upon conversion | shares   1,312,860          
Private Placement              
Class of Stock [Line Items]              
Proceeds from issuance of common stock, net of issuance costs     $ 25,000,000.0        
Aggregate purchase price     275,000,000.0        
Reimbursement of transactional expenses     1,000,000.0        
Net proceeds from private placement     265,400,000        
Direct and incremental expenses     $ 8,600,000        
Private Placement | Class C convertible preferred stock              
Class of Stock [Line Items]              
Stock issued during period, new issues (in shares) | shares     250,000        
Preferred stock, dividend rate (as a percent)     4.00%        
Preferred stock, par value per share (in dollars per share) | $ / shares     $ 0.001        
Shares issued, price per share (in dollars per share) | $ / shares     $ 1,000        
Proceeds from issuance of stock     $ 250,000,000.0        
Net proceeds from private placement     $ 28,200,000        
Private Placement | Common Stock [Member]              
Class of Stock [Line Items]              
Stock issued during period, new issues (in shares) | shares     675,536        
Net proceeds from private placement     $ 237,200,000        
Underwritten public offering              
Class of Stock [Line Items]              
Stock Issued During Period, Shares, Issued for Services | shares       568,181      
Stock issued during period, new issues (in shares) | shares       4,356,059      
Shares issued, price per share (in dollars per share) | $ / shares       $ 66.00      
Proceeds from issuance of common stock, net of issuance costs       $ 269,800,000      
XML 76 R65.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-Based Compensation - Assumptions Used to Estimate Fair Value of Stock Options (Details)
3 Months Ended
Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Risk-free interest rate, minimum 0.50%
Risk-free interest rate, maximum 0.90%
Volatility, minimum 64.40%
Volatility, maximum 80.80%
Dividend yield 0.00%
Minimum [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Expected life (years) 3 years 6 months
Maximum [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Expected life (years) 6 years 1 month 6 days
XML 77 R66.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-Based Compensation - Stock-based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Stock-based compensation expense $ 2,990 $ 1,620
Cost of revenues    
Stock-based compensation expense 239 69
Selling, general and administrative    
Stock-based compensation expense 2,505 1,443
Engineering and development    
Stock-based compensation expense $ 246 $ 108
XML 78 R67.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-Based Compensation - Stock Option Activity (Details) - Stock Options [Member]
3 Months Ended
Mar. 31, 2021
USD ($)
$ / shares
shares
Number of Shares  
Outstanding - December 31, 2020 | shares 7,554,305
Granted (weighted-average fair value of $32.66 per share) | shares 435,298
Exercised | shares (187,486)
Forfeited | shares (8,348)
Outstanding - March 31, 2021 | shares 7,793,769
Vested (exercisable) - March 31, 2021 | shares 5,904,443
Expected to vest after March 31, 2021 (unexercisable) | shares 1,889,326
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value $ 32.66
Weighted-Average Exercise Price/Share  
Outstanding - December 31, 2020 10.29
Granted (weighted-average fair value of $32.66 per share) 55.74
Exercised 8.46
Forfeited 16.48
Outstanding - March 31, 2021 12.86
Vested (exercisable) - March 31, 2021 7.76
Expected to vest after March 31, 2021 (unexercisable) $ 28.82
Weighted-Average Remaining Contractual Term (Years)  
Outstanding - March 31, 2021 6 years 4 months 24 days
Vested (exercisable) - March 31, 2021 5 years 9 months 18 days
Expected to vest after March 31, 2021 (unexercisable) 7 years 10 months 24 days
Aggregated Intrinsic Value  
Outstanding - March 31, 2021 | $ $ 306,822
Vested (exercisable) - March 31, 2021 | $ 261,287
Expected to vest after March 31, 2021 (unexercisable) | $ $ 40,001
XML 79 R68.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-Based Compensation - Restricted stock unit (Details) - Restricted stock units
3 Months Ended
Mar. 31, 2021
$ / shares
shares
Number of Restricted Stock Units  
Outstanding - December 31, 2020 | shares 0
Granted | shares 304,157
Outstanding March 31, 2021 | shares 304,157
Weighted Average Fair Value Per Share  
Outstanding - December 31, 2020 | $ / shares $ 0
Granted | $ / shares 53.94
Outstanding March 31, 2021 | $ / shares $ 53.94
XML 80 R69.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-Based Compensation - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
May 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value $ 9,400    
Share-based Compensation 2,990 $ 1,620  
Stock Options [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Unrecognized compensation cost related to unvested stock options $ 32,500    
Weighted average recognition period 3 years 4 months 24 days    
Intrinsic value per share $ 52.01    
Restricted stock units      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Weighted average recognition period 4 years    
Share-based Compensation $ 300 $ 0  
Unrecognized compensation expense $ 16,100    
Plan 2018 [Member] | Stock Options [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total shares available for future grant 190,181   3,730,179
XML 81 R70.htm IDEA: XBRL DOCUMENT v3.21.1
Subsequent Events (Details)
$ in Millions
Apr. 01, 2021
USD ($)
Subsequent Event | CTSA  
Subsequent Event [Line Items]  
Consideration for business acquisition $ 5.0
EXCEL 82 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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�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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 84 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 85 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 239 469 1 false 79 0 false 8 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 00300 - Statement - Condensed Consolidated Statements of Comprehensive Loss Sheet http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss Condensed Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 00400 - Statement - Condensed Consolidated Statements of Stockholders' Equity Sheet http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity Statements 6 false false R7.htm 00405 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) Sheet http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) Statements 7 false false R8.htm 00500 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 8 false false R9.htm 00505 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical) Sheet http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical Condensed Consolidated Statements of Cash Flows (Parenthetical) Statements 9 false false R10.htm 10101 - Disclosure - Management's Representation and Basis of Presentation Sheet http://www.Cryoport.com/role/DisclosureManagementSRepresentationAndBasisOfPresentation Management's Representation and Basis of Presentation Notes 10 false false R11.htm 10201 - Disclosure - Nature of the Business Sheet http://www.Cryoport.com/role/DisclosureNatureOfBusiness Nature of the Business Notes 11 false false R12.htm 10301 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 12 false false R13.htm 10401 - Disclosure - Acquisitions Sheet http://www.Cryoport.com/role/DisclosureAcquisitions Acquisitions Notes 13 false false R14.htm 10501 - Disclosure - Cash, Cash Equivalents and Short-Term Investments Sheet http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestments Cash, Cash Equivalents and Short-Term Investments Notes 14 false false R15.htm 10601 - Disclosure - Fair Value Measurements Sheet http://www.Cryoport.com/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 15 false false R16.htm 10701 - Disclosure - Inventory Sheet http://www.Cryoport.com/role/DisclosureInventory Inventory Notes 16 false false R17.htm 10801 - Disclosure - Goodwill and Intangible Assets Sheet http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssets Goodwill and Intangible Assets Notes 17 false false R18.htm 10901 - Disclosure - Convertible Senior Notes Notes http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotes Convertible Senior Notes Notes 18 false false R19.htm 11001 - Disclosure - Note Payable Sheet http://www.Cryoport.com/role/DisclosureNotePayable Note Payable Notes 19 false false R20.htm 11101 - Disclosure - Leases Sheet http://www.Cryoport.com/role/DisclosureLeases Leases Notes 20 false false R21.htm 11201 - Disclosure - Commitments and Contingencies Sheet http://www.Cryoport.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 21 false false R22.htm 11301 - Disclosure - Stockholders' Equity Sheet http://www.Cryoport.com/role/DisclosureStockholdersEquity Stockholders' Equity Notes 22 false false R23.htm 11401 - Disclosure - Stock-Based Compensation Sheet http://www.Cryoport.com/role/DisclosureStockBasedCompensation Stock-Based Compensation Notes 23 false false R24.htm 11501 - Disclosure - Subsequent Event Sheet http://www.Cryoport.com/role/DisclosureSubsequentEvent Subsequent Event Notes 24 false false R25.htm 20302 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPolicies 25 false false R26.htm 30303 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPolicies 26 false false R27.htm 30503 - Disclosure - Cash, Cash Equivalents and Short-Term Investments (Tables) Sheet http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsTables Cash, Cash Equivalents and Short-Term Investments (Tables) Tables http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestments 27 false false R28.htm 30603 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.Cryoport.com/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.Cryoport.com/role/DisclosureFairValueMeasurements 28 false false R29.htm 30703 - Disclosure - Inventory (Tables) Sheet http://www.Cryoport.com/role/DisclosureInventoryTables Inventory (Tables) Tables http://www.Cryoport.com/role/DisclosureInventory 29 false false R30.htm 30803 - Disclosure - Goodwill and Intangible Assets (Tables) Sheet http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsTables Goodwill and Intangible Assets (Tables) Tables http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssets 30 false false R31.htm 30903 - Disclosure - Convertible Senior Notes (Tables) Notes http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesTables Convertible Senior Notes (Tables) Tables http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotes 31 false false R32.htm 31103 - Disclosure - Leases (Tables) Sheet http://www.Cryoport.com/role/DisclosureLeasesTables Leases (Tables) Tables http://www.Cryoport.com/role/DisclosureLeases 32 false false R33.htm 31303 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.Cryoport.com/role/DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.Cryoport.com/role/DisclosureStockholdersEquity 33 false false R34.htm 31403 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.Cryoport.com/role/DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.Cryoport.com/role/DisclosureStockBasedCompensation 34 false false R35.htm 40201 - Disclosure - Nature of the Business (Details) Sheet http://www.Cryoport.com/role/DisclosureNatureOfBusinessDetails Nature of the Business (Details) Details http://www.Cryoport.com/role/DisclosureNatureOfBusiness 35 false false R36.htm 40301 - Disclosure - Summary of Significant Accounting Policies - Disaggregates Our Revenues by Major Source (Details) Sheet http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregatesOurRevenuesByMajorSourceDetails Summary of Significant Accounting Policies - Disaggregates Our Revenues by Major Source (Details) Details 36 false false R37.htm 40302 - Disclosure - Summary of Significant Accounting Policies - Disaggregation Our Geographical Revenues by Origin (Details) Sheet http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOurGeographicalRevenuesByOriginDetails Summary of Significant Accounting Policies - Disaggregation Our Geographical Revenues by Origin (Details) Details 37 false false R38.htm 40303 - Disclosure - Summary of Significant Accounting Policies - Earnings Per Share (Details) Sheet http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsPerShareDetails Summary of Significant Accounting Policies - Earnings Per Share (Details) Details 38 false false R39.htm 40304 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Shares (Details) Sheet http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSharesDetails Summary of Significant Accounting Policies - Antidilutive Shares (Details) Details 39 false false R40.htm 40305 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) Sheet http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails Summary of Significant Accounting Policies - Additional Information (Details) Details 40 false false R41.htm 40401 - Disclosure - Acquisition of CryoGene Partners - Preliminary Purchase Price Allocation (Details Sheet http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails Acquisition of CryoGene Partners - Preliminary Purchase Price Allocation (Details Uncategorized 41 false false R42.htm 40501 - Disclosure - Cash, Cash Equivalents and Short-Term Investments (Details) Sheet http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails Cash, Cash Equivalents and Short-Term Investments (Details) Details http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsTables 42 false false R43.htm 40502 - Disclosure - Cash, Cash Equivalents and Short-Term Investments - Available-for-sale debt securities (Details) Sheet http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsAvailableForSaleDebtSecuritiesDetails Cash, Cash Equivalents and Short-Term Investments - Available-for-sale debt securities (Details) Details 43 false false R44.htm 40503 - Disclosure - Cash, Cash Equivalents and Short-Term Investments - Contractual Maturities (Details) Sheet http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsContractualMaturitiesDetails Cash, Cash Equivalents and Short-Term Investments - Contractual Maturities (Details) Details 44 false false R45.htm 40504 - Disclosure - Cash, Cash Equivalents and Short-Term Investments - Equity Investments (Details) Sheet http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsEquityInvestmentsDetails Cash, Cash Equivalents and Short-Term Investments - Equity Investments (Details) Details 45 false false R46.htm 40505 - Disclosure - Cash, Cash Equivalents and Short-Term Investments - Additional Information (Details) Sheet http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsAdditionalInformationDetails Cash, Cash Equivalents and Short-Term Investments - Additional Information (Details) Details 46 false false R47.htm 40601 - Disclosure - Fair Value Measurements (Details) Sheet http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails Fair Value Measurements (Details) Details http://www.Cryoport.com/role/DisclosureFairValueMeasurementsTables 47 false false R48.htm 40602 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://www.Cryoport.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 48 false false R49.htm 40701 - Disclosure - Inventory (Details) Sheet http://www.Cryoport.com/role/DisclosureInventoryDetails Inventory (Details) Details http://www.Cryoport.com/role/DisclosureInventoryTables 49 false false R50.htm 40801 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details) Sheet http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails Goodwill and Intangible Assets - Intangible Assets (Details) Details 50 false false R51.htm 40802 - Disclosure - Goodwill and Intangible Assets - Expected Future Amortization (Details) Sheet http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsExpectedFutureAmortizationDetails Goodwill and Intangible Assets - Expected Future Amortization (Details) Details 51 false false R52.htm 40803 - Disclosure - Goodwill and Other Intangible Assets - Schedule of goodwill (Details) Sheet http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfGoodwillDetails Goodwill and Other Intangible Assets - Schedule of goodwill (Details) Details 52 false false R53.htm 40804 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details) Sheet http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails Goodwill and Intangible Assets - Additional Information (Details) Details 53 false false R54.htm 40901 - Disclosure - Convertible Senior Notes - Components of Convertible notes payable (Details) Notes http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesComponentsOfConvertibleNotesPayableDetails Convertible Senior Notes - Components of Convertible notes payable (Details) Details 54 false false R55.htm 40902 - Disclosure - Convertible Senior Notes - Interest expenses incurred on Convertible notes payable (Details) Notes http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesInterestExpensesIncurredOnConvertibleNotesPayableDetails Convertible Senior Notes - Interest expenses incurred on Convertible notes payable (Details) Details 55 false false R56.htm 40903 - Disclosure - Convertible Senior Notes - Summary of total gross principal payments due under the Convertible notes payable (Details) Notes http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesSummaryOfTotalGrossPrincipalPaymentsDueUnderConvertibleNotesPayableDetails Convertible Senior Notes - Summary of total gross principal payments due under the Convertible notes payable (Details) Details 56 false false R57.htm 40904 - Disclosure - Convertible Senior Notes - Additional information (Details) Notes http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails Convertible Senior Notes - Additional information (Details) Details 57 false false R58.htm 41001 - Disclosure - Note Payable (Details) Sheet http://www.Cryoport.com/role/DisclosureNotePayableDetails Note Payable (Details) Details http://www.Cryoport.com/role/DisclosureNotePayable 58 false false R59.htm 41101 - Disclosure - Leases - Components Of Lease Cost (Detail) Sheet http://www.Cryoport.com/role/DisclosureLeasesComponentsOfLeaseCostDetail Leases - Components Of Lease Cost (Detail) Details 59 false false R60.htm 41102 - Disclosure - Leases - Supplemental Cash Flows Information (Detail) Sheet http://www.Cryoport.com/role/DisclosureLeasesSupplementalCashFlowsInformationDetail Leases - Supplemental Cash Flows Information (Detail) Details 60 false false R61.htm 41103 - Disclosure - Leases - Payments Under Non-Cancellable Leases (Details) Sheet http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails Leases - Payments Under Non-Cancellable Leases (Details) Details 61 false false R62.htm 41104 - Disclosure - Leases - Additional Information (Details) Sheet http://www.Cryoport.com/role/DisclosureLeasesAdditionalInformationDetails Leases - Additional Information (Details) Details 62 false false R63.htm 41301 - Disclosure - Stockholders' Equity - Common Stock Reserved for Future Issuance (Details) Sheet http://www.Cryoport.com/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails Stockholders' Equity - Common Stock Reserved for Future Issuance (Details) Details 63 false false R64.htm 41302 - Disclosure - Stockholders' Equity - Additional Information (Details) Sheet http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails Stockholders' Equity - Additional Information (Details) Details 64 false false R65.htm 41401 - Disclosure - Stock-Based Compensation - Assumptions Used to Estimate Fair Value of Stock Options (Details) Sheet http://www.Cryoport.com/role/DisclosureStockBasedCompensationAssumptionsUsedToEstimateFairValueOfStockOptionsDetails Stock-Based Compensation - Assumptions Used to Estimate Fair Value of Stock Options (Details) Details 65 false false R66.htm 41402 - Disclosure - Stock-Based Compensation - Stock-based Compensation Expense (Details) Sheet http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails Stock-Based Compensation - Stock-based Compensation Expense (Details) Details 66 false false R67.htm 41403 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details) Sheet http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails Stock-Based Compensation - Stock Option Activity (Details) Details 67 false false R68.htm 41404 - Disclosure - Stock-Based Compensation - Restricted stock unit (Details) Sheet http://www.Cryoport.com/role/DisclosureStockBasedCompensationRestrictedStockUnitDetails Stock-Based Compensation - Restricted stock unit (Details) Details 68 false false R69.htm 41405 - Disclosure - Stock-Based Compensation - Additional Information (Details) Sheet http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails Stock-Based Compensation - Additional Information (Details) Details 69 false false R70.htm 41501 - Disclosure - Subsequent Events (Details) Sheet http://www.Cryoport.com/role/DisclosureSubsequentEventsDetails Subsequent Events (Details) Details http://www.Cryoport.com/role/DisclosureSubsequentEvent 70 false false All Reports Book All Reports cyrx-20210331x10q.htm cyrx-20210331.xsd cyrx-20210331_cal.xml cyrx-20210331_def.xml cyrx-20210331_lab.xml cyrx-20210331_pre.xml cyrx-20210331xex31d1.htm cyrx-20210331xex31d2.htm cyrx-20210331xex32d1.htm cyrx-20210331x10q004.jpg http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/us-gaap/2020-01-31 true true JSON 88 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cyrx-20210331x10q.htm": { "axisCustom": 1, "axisStandard": 24, "contextCount": 239, "dts": { "calculationLink": { "local": [ "cyrx-20210331_cal.xml" ] }, "definitionLink": { "local": [ "cyrx-20210331_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "cyrx-20210331x10q.htm" ] }, "labelLink": { "local": [ "cyrx-20210331_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "cyrx-20210331_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "cyrx-20210331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 605, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 26, "http://xbrl.sec.gov/dei/2020-01-31": 5, "total": 31 }, "keyCustom": 65, "keyStandard": 404, "memberCustom": 31, "memberStandard": 43, "nsprefix": "cyrx", "nsuri": "http://www.Cryoport.com/20210331", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - Management's Representation and Basis of Presentation", "role": "http://www.Cryoport.com/role/DisclosureManagementSRepresentationAndBasisOfPresentation", "shortName": "Management's Representation and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - Nature of the Business", "role": "http://www.Cryoport.com/role/DisclosureNatureOfBusiness", "shortName": "Nature of the Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - Acquisitions", "role": "http://www.Cryoport.com/role/DisclosureAcquisitions", "shortName": "Acquisitions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - Cash, Cash Equivalents and Short-Term Investments", "role": "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestments", "shortName": "Cash, Cash Equivalents and Short-Term Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - Fair Value Measurements", "role": "http://www.Cryoport.com/role/DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - Inventory", "role": "http://www.Cryoport.com/role/DisclosureInventory", "shortName": "Inventory", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - Goodwill and Intangible Assets", "role": "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssets", "shortName": "Goodwill and Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - Convertible Senior Notes", "role": "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotes", "shortName": "Convertible Senior Notes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "cyrx:NotesPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11001 - Disclosure - Note Payable", "role": "http://www.Cryoport.com/role/DisclosureNotePayable", "shortName": "Note Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "cyrx:NotesPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_beA2WdCyOE292EvsJmvv5Q", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_beA2WdCyOE292EvsJmvv5Q", "decimals": "-3", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "cyrx:LesseeOperatingAndFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11101 - Disclosure - Leases", "role": "http://www.Cryoport.com/role/DisclosureLeases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "cyrx:LesseeOperatingAndFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11201 - Disclosure - Commitments and Contingencies", "role": "http://www.Cryoport.com/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11301 - Disclosure - Stockholders' Equity", "role": "http://www.Cryoport.com/role/DisclosureStockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11401 - Disclosure - Stock-Based Compensation", "role": "http://www.Cryoport.com/role/DisclosureStockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11501 - Disclosure - Subsequent Event", "role": "http://www.Cryoport.com/role/DisclosureSubsequentEvent", "shortName": "Subsequent Event", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20302 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30303 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - Cash, Cash Equivalents and Short-Term Investments (Tables)", "role": "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsTables", "shortName": "Cash, Cash Equivalents and Short-Term Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30603 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30703 - Disclosure - Inventory (Tables)", "role": "http://www.Cryoport.com/role/DisclosureInventoryTables", "shortName": "Inventory (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": "-5", "first": true, "lang": null, "name": "cyrx:ConvertibleSubordinatedDebtDiscount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": "-5", "first": true, "lang": null, "name": "cyrx:ConvertibleSubordinatedDebtDiscount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30803 - Disclosure - Goodwill and Intangible Assets (Tables)", "role": "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsTables", "shortName": "Goodwill and Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30903 - Disclosure - Convertible Senior Notes (Tables)", "role": "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesTables", "shortName": "Convertible Senior Notes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "cyrx:LesseeOperatingAndFinanceLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31103 - Disclosure - Leases (Tables)", "role": "http://www.Cryoport.com/role/DisclosureLeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "cyrx:LesseeOperatingAndFinanceLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "cyrx:ScheduleOfCommonStockReservedForFutureIssuancesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31303 - Disclosure - Stockholders' Equity (Tables)", "role": "http://www.Cryoport.com/role/DisclosureStockholdersEquityTables", "shortName": "Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "cyrx:ScheduleOfCommonStockReservedForFutureIssuancesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31403 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://www.Cryoport.com/role/DisclosureStockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_10_1_2020_To_10_1_2020_us-gaap_BusinessAcquisitionAxis_cyrx_MveCryobiologicalStorageBusinessMember_tcP01x2HGEiNhtz8kdejcQ", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40201 - Disclosure - Nature of the Business (Details)", "role": "http://www.Cryoport.com/role/DisclosureNatureOfBusinessDetails", "shortName": "Nature of the Business (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R36": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - Summary of Significant Accounting Policies - Disaggregates Our Revenues by Major Source (Details)", "role": "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregatesOurRevenuesByMajorSourceDetails", "shortName": "Summary of Significant Accounting Policies - Disaggregates Our Revenues by Major Source (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_us-gaap_StatementBusinessSegmentsAxis_cyrx_GlobalLogisticsSolutionsMember_7WlWE7Airk6RQbcntC0aUg", "decimals": "-3", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40302 - Disclosure - Summary of Significant Accounting Policies - Disaggregation Our Geographical Revenues by Origin (Details)", "role": "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOurGeographicalRevenuesByOriginDetails", "shortName": "Summary of Significant Accounting Policies - Disaggregation Our Geographical Revenues by Origin (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_srt_StatementGeographicalAxis_srt_AmericasMember_Op2aeLfPH0e4MWUbFsGfwQ", "decimals": "-3", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40303 - Disclosure - Summary of Significant Accounting Policies - Earnings Per Share (Details)", "role": "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsPerShareDetails", "shortName": "Summary of Significant Accounting Policies - Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_VzQyw2T8jUKssaHG433ryQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40304 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Shares (Details)", "role": "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSharesDetails", "shortName": "Summary of Significant Accounting Policies - Antidilutive Shares (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_VzQyw2T8jUKssaHG433ryQ", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - Condensed Consolidated Statements of Operations", "role": "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations", "shortName": "Condensed Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "cyrx:MaturityPeriodOfHighlyLiquidInvestments", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40305 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "role": "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "cyrx:MaturityPeriodOfHighlyLiquidInvestments", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_beA2WdCyOE292EvsJmvv5Q", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - Acquisition of CryoGene Partners - Preliminary Purchase Price Allocation (Details", "role": "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails", "shortName": "Acquisition of CryoGene Partners - Preliminary Purchase Price Allocation (Details", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_10_1_2020_To_10_1_2020_us-gaap_BusinessAcquisitionAxis_cyrx_CryopdpMember_LQk33lNzwUqPyUM_2DPH_w", "decimals": "-5", "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_beA2WdCyOE292EvsJmvv5Q", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - Cash, Cash Equivalents and Short-Term Investments (Details)", "role": "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails", "shortName": "Cash, Cash Equivalents and Short-Term Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_beA2WdCyOE292EvsJmvv5Q", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_beA2WdCyOE292EvsJmvv5Q", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40502 - Disclosure - Cash, Cash Equivalents and Short-Term Investments - Available-for-sale debt securities (Details)", "role": "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsAvailableForSaleDebtSecuritiesDetails", "shortName": "Cash, Cash Equivalents and Short-Term Investments - Available-for-sale debt securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_beA2WdCyOE292EvsJmvv5Q", "decimals": "-3", "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_beA2WdCyOE292EvsJmvv5Q", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40503 - Disclosure - Cash, Cash Equivalents and Short-Term Investments - Contractual Maturities (Details)", "role": "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsContractualMaturitiesDetails", "shortName": "Cash, Cash Equivalents and Short-Term Investments - Contractual Maturities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_beA2WdCyOE292EvsJmvv5Q", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesFvNiRealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40504 - Disclosure - Cash, Cash Equivalents and Short-Term Investments - Equity Investments (Details)", "role": "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsEquityInvestmentsDetails", "shortName": "Cash, Cash Equivalents and Short-Term Investments - Equity Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesFvNiRealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtAndEquitySecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairment", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40505 - Disclosure - Cash, Cash Equivalents and Short-Term Investments - Additional Information (Details)", "role": "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsAdditionalInformationDetails", "shortName": "Cash, Cash Equivalents and Short-Term Investments - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtAndEquitySecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairment", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Q6wAHJ_Sn0m9L8x_10czsg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - Fair Value Measurements (Details)", "role": "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails", "shortName": "Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Q6wAHJ_Sn0m9L8x_10czsg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_beA2WdCyOE292EvsJmvv5Q", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ConvertibleDebtFairValueDisclosures", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40602 - Disclosure - Fair Value Measurements - Additional Information (Details)", "role": "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "shortName": "Fair Value Measurements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_beA2WdCyOE292EvsJmvv5Q", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ConvertibleDebtFairValueDisclosures", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_beA2WdCyOE292EvsJmvv5Q", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - Inventory (Details)", "role": "http://www.Cryoport.com/role/DisclosureInventoryDetails", "shortName": "Inventory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_beA2WdCyOE292EvsJmvv5Q", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - Condensed Consolidated Statements of Comprehensive Loss", "role": "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss", "shortName": "Condensed Consolidated Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_beA2WdCyOE292EvsJmvv5Q", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)", "role": "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails", "shortName": "Goodwill and Intangible Assets - Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_beA2WdCyOE292EvsJmvv5Q", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_beA2WdCyOE292EvsJmvv5Q", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40802 - Disclosure - Goodwill and Intangible Assets - Expected Future Amortization (Details)", "role": "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsExpectedFutureAmortizationDetails", "shortName": "Goodwill and Intangible Assets - Expected Future Amortization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_beA2WdCyOE292EvsJmvv5Q", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_12_31_2020_84wxnSosS0GYxjwCZQ69xw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40803 - Disclosure - Goodwill and Other Intangible Assets - Schedule of goodwill (Details)", "role": "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfGoodwillDetails", "shortName": "Goodwill and Other Intangible Assets - Schedule of goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": "-3", "lang": null, "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40804 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)", "role": "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails", "shortName": "Goodwill and Intangible Assets - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_beA2WdCyOE292EvsJmvv5Q", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - Convertible Senior Notes - Components of Convertible notes payable (Details)", "role": "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesComponentsOfConvertibleNotesPayableDetails", "shortName": "Convertible Senior Notes - Components of Convertible notes payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_beA2WdCyOE292EvsJmvv5Q", "decimals": "-3", "lang": null, "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "cyrx:ScheduleOfInterestExpensesOnConvertibleNotesPayableTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_7_1_2020_To_9_30_2020_rCLqIwrTl0WM9MSJSSqYVQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40902 - Disclosure - Convertible Senior Notes - Interest expenses incurred on Convertible notes payable (Details)", "role": "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesInterestExpensesIncurredOnConvertibleNotesPayableDetails", "shortName": "Convertible Senior Notes - Interest expenses incurred on Convertible notes payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "cyrx:ScheduleOfInterestExpensesOnConvertibleNotesPayableTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_7_1_2020_To_9_30_2020_rCLqIwrTl0WM9MSJSSqYVQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_beA2WdCyOE292EvsJmvv5Q", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "reportCount": 1, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40903 - Disclosure - Convertible Senior Notes - Summary of total gross principal payments due under the Convertible notes payable (Details)", "role": "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesSummaryOfTotalGrossPrincipalPaymentsDueUnderConvertibleNotesPayableDetails", "shortName": "Convertible Senior Notes - Summary of total gross principal payments due under the Convertible notes payable (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R57": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_5_31_2020_ozT_jmomtkKtF7Z2UhdB3A", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40904 - Disclosure - Convertible Senior Notes - Additional information (Details)", "role": "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails", "shortName": "Convertible Senior Notes - Additional information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_5_31_2020_ozT_jmomtkKtF7Z2UhdB3A", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_beA2WdCyOE292EvsJmvv5Q", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermNotesPayable", "reportCount": 1, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41001 - Disclosure - Note Payable (Details)", "role": "http://www.Cryoport.com/role/DisclosureNotePayableDetails", "shortName": "Note Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "cyrx:NotesPayableTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_us-gaap_BusinessAcquisitionAxis_cyrx_CryopdpMember_GA12CSFgW0aijQIm3ds_6g", "decimals": "-5", "lang": null, "name": "us-gaap:LongTermNotesPayable", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "cyrx:LesseeOperatingAndFinanceLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41101 - Disclosure - Leases - Components Of Lease Cost (Detail)", "role": "http://www.Cryoport.com/role/DisclosureLeasesComponentsOfLeaseCostDetail", "shortName": "Leases - Components Of Lease Cost (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "cyrx:LesseeOperatingAndFinanceLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xllZtV6cZUSgXhnNu7kguw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - Condensed Consolidated Statements of Stockholders' Equity", "role": "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "shortName": "Condensed Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xllZtV6cZUSgXhnNu7kguw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "cyrx:ScheduleOfLeaseSupplementalCashFlowAndOtherDisclosuresTableTextBlock", "cyrx:LesseeOperatingAndFinanceLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41102 - Disclosure - Leases - Supplemental Cash Flows Information (Detail)", "role": "http://www.Cryoport.com/role/DisclosureLeasesSupplementalCashFlowsInformationDetail", "shortName": "Leases - Supplemental Cash Flows Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "cyrx:ScheduleOfLeaseSupplementalCashFlowAndOtherDisclosuresTableTextBlock", "cyrx:LesseeOperatingAndFinanceLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_beA2WdCyOE292EvsJmvv5Q", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41103 - Disclosure - Leases - Payments Under Non-Cancellable Leases (Details)", "role": "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails", "shortName": "Leases - Payments Under Non-Cancellable Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_beA2WdCyOE292EvsJmvv5Q", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "p", "cyrx:LesseeOperatingAndFinanceLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "cyrx:LesseeOptionToExtend", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41104 - Disclosure - Leases - Additional Information (Details)", "role": "http://www.Cryoport.com/role/DisclosureLeasesAdditionalInformationDetails", "shortName": "Leases - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "cyrx:LesseeOperatingAndFinanceLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": null, "first": true, "lang": "en-US", "name": "cyrx:LesseeOptionToExtend", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "cyrx:ScheduleOfCommonStockReservedForFutureIssuancesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_beA2WdCyOE292EvsJmvv5Q", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "Unit_Standard_shares_VzQyw2T8jUKssaHG433ryQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41301 - Disclosure - Stockholders' Equity - Common Stock Reserved for Future Issuance (Details)", "role": "http://www.Cryoport.com/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails", "shortName": "Stockholders' Equity - Common Stock Reserved for Future Issuance (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R64": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_beA2WdCyOE292EvsJmvv5Q", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Unit_Standard_shares_VzQyw2T8jUKssaHG433ryQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41302 - Disclosure - Stockholders' Equity - Additional Information (Details)", "role": "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "shortName": "Stockholders' Equity - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": "0", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueIssuedForServices", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_rEoP-V4TJUua06pBL5mThw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41401 - Disclosure - Stock-Based Compensation - Assumptions Used to Estimate Fair Value of Stock Options (Details)", "role": "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAssumptionsUsedToEstimateFairValueOfStockOptionsDetails", "shortName": "Stock-Based Compensation - Assumptions Used to Estimate Fair Value of Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_rEoP-V4TJUua06pBL5mThw", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41402 - Disclosure - Stock-Based Compensation - Stock-based Compensation Expense (Details)", "role": "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails", "shortName": "Stock-Based Compensation - Stock-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_p6-oaRQxDUKGHx6x8WaKgw", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GoDaQMwcfUWIDVbLM6D6gw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_VzQyw2T8jUKssaHG433ryQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41403 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)", "role": "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "shortName": "Stock-Based Compensation - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GoDaQMwcfUWIDVbLM6D6gw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_VzQyw2T8jUKssaHG433ryQ", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_ihQ3jcG2-E2OpDu1unk0bA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_VzQyw2T8jUKssaHG433ryQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41404 - Disclosure - Stock-Based Compensation - Restricted stock unit (Details)", "role": "http://www.Cryoport.com/role/DisclosureStockBasedCompensationRestrictedStockUnitDetails", "shortName": "Stock-Based Compensation - Restricted stock unit (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_ihQ3jcG2-E2OpDu1unk0bA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_VzQyw2T8jUKssaHG433ryQ", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_beA2WdCyOE292EvsJmvv5Q", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41405 - Disclosure - Stock-Based Compensation - Additional Information (Details)", "role": "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "shortName": "Stock-Based Compensation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_beA2WdCyOE292EvsJmvv5Q", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_us-gaap_SubsidiarySaleOfStockAxis_cyrx_PublicOfferingMember_HnOp6OSQg0280mViQzTn4w", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "reportCount": 1, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00405 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)", "role": "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R70": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_4_1_2021_To_4_1_2021_us-gaap_BusinessAcquisitionAxis_cyrx_CriticalTransportSolutionsAustraliaPtyLtdMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_eKzoYsZsn0iu8vDiiSBT8A", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41501 - Disclosure - Subsequent Events (Details)", "role": "http://www.Cryoport.com/role/DisclosureSubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_4_1_2021_To_4_1_2021_us-gaap_BusinessAcquisitionAxis_cyrx_CriticalTransportSolutionsAustraliaPtyLtdMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_eKzoYsZsn0iu8vDiiSBT8A", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00500 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_yYhY_rU6EEifrbAhMiZfbQ", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_us-gaap_SubsidiarySaleOfStockAxis_cyrx_PublicOfferingMember_HnOp6OSQg0280mViQzTn4w", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "reportCount": 1, "unitRef": "Unit_Standard_USD_5rJLh77B6UK_fnQrDyZzsQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00505 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)", "role": "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical", "shortName": "Condensed Consolidated Statements of Cash Flows (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null } }, "segmentCount": 79, "tag": { "cyrx_Adjustments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This elements refers to adjustments", "label": "adjustments", "terseLabel": "Adjustments" } } }, "localname": "Adjustments", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_AdjustmentsToAdditionalPaidInCapitalConversionCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from costs associated with conversion of stock.", "label": "Adjustments to Additional Paid in Capital, Conversion, Costs", "terseLabel": "Cost of Series C preferred stock conversion" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalConversionCosts", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "cyrx_AdjustmentsToAdditionalPaidInCapitalPaidInKindDividends": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the paid-in-kind dividends on Series C Convertible Preferred Stock.", "label": "Adjustments to Additional Paid in Capital, Paid In Kind Dividends", "terseLabel": "Paid-in-kind preferred stock dividend, including beneficial conversion feature" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalPaidInKindDividends", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "cyrx_AgentNetworkMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agent network", "label": "Agent Network [Member]", "terseLabel": "Agent network" } } }, "localname": "AgentNetworkMember", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "cyrx_AnimalHealthMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Animal Health Member", "label": "Animal Health [Member]", "terseLabel": "Animal Health [Member]" } } }, "localname": "AnimalHealthMember", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregatesOurRevenuesByMajorSourceDetails" ], "xbrltype": "domainItemType" }, "cyrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedcost": { "auth_ref": [], "calculation": { "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsContractualMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing through second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Available For Sale Securities Debt Maturities After One Through Two Years, AmortizedCost", "verboseLabel": "Due between one and two years, Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedcost", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue": { "auth_ref": [], "calculation": { "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsContractualMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing through second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Available For Sale Securities Debt Maturities After One Through Two Years, Fair Value", "verboseLabel": "Due between one and two years, Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_BiopharmaceuticalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Biopharmaceutical Member", "label": "Biopharmaceutical [Member]", "terseLabel": "Biopharma/Pharma [Member]" } } }, "localname": "BiopharmaceuticalMember", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregatesOurRevenuesByMajorSourceDetails" ], "xbrltype": "domainItemType" }, "cyrx_BusinessCombinationsAcquisitionCostsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of accounting policy for Business combination acquisition costs.", "label": "Business Combinations, Acquisition Costs Policy [Policy Text Block]", "terseLabel": "Acquisition Costs" } } }, "localname": "BusinessCombinationsAcquisitionCostsPolicyPolicyTextBlock", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cyrx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]", "verboseLabel": "Cash paid for amounts included in the measurement of lease liabilities:" } } }, "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesSupplementalCashFlowsInformationDetail" ], "xbrltype": "stringItemType" }, "cyrx_ClassBConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class B Convertible Preferred Stock [Member]", "terseLabel": "Class B convertible preferred stock [Member]" } } }, "localname": "ClassBConvertiblePreferredStockMember", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "cyrx_ClassCConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Class C Convertible Preferred Stock.", "label": "Class C Convertible Preferred Stock [Member]", "terseLabel": "Class C convertible preferred stock" } } }, "localname": "ClassCConvertiblePreferredStockMember", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails", "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSharesDetails", "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "cyrx_ConvertibleSeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Senior Notes Member", "label": "Convertible Senior Notes [Member]", "terseLabel": "Convertible Senior Notes [Member]" } } }, "localname": "ConvertibleSeniorNotesMember", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSharesDetails" ], "xbrltype": "domainItemType" }, "cyrx_ConvertibleSubordinatedDebtDiscount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Discount on convertible subordinated debt.", "label": "Convertible Subordinated Debt, Discount" } } }, "localname": "ConvertibleSubordinatedDebtDiscount", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "cyrx_CostOfSeriesCPreferredStockConversionIncludedInAdditionalPaidInCapitalAndAccountsPayableAndAccruedLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the cost of Series C Preferred stock conversion included in additional paid-in-capital and accounts payable and accrued liabilities in non-cash investing and financing activities.", "label": "Cost Of Series C Preferred Stock Conversion Included In Additional Paid-In-Capital And Accounts Payable And Accrued Liabilities", "terseLabel": "Cost of Series C Preferred stock conversion included in additional paid-in-capital and accounts payable and accrued liabilities" } } }, "localname": "CostOfSeriesCPreferredStockConversionIncludedInAdditionalPaidInCapitalAndAccountsPayableAndAccruedLiabilities", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cyrx_CriticalTransportSolutionsAustraliaPtyLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Critical Transport Solutions Australia Pty Ltd.", "label": "Critical Transport Solutions Australia Pty Ltd [Member]", "terseLabel": "CTSA" } } }, "localname": "CriticalTransportSolutionsAustraliaPtyLtdMember", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "cyrx_CryopdpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for CRYOPDP.", "label": "Cryopdp [Member]", "terseLabel": "CRYOPDP" } } }, "localname": "CryopdpMember", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails", "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfGoodwillDetails", "http://www.Cryoport.com/role/DisclosureNatureOfBusinessDetails", "http://www.Cryoport.com/role/DisclosureNotePayableDetails" ], "xbrltype": "domainItemType" }, "cyrx_CustomerOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer One [Member].", "label": "Customer One [Member]", "terseLabel": "Customer One [Member]" } } }, "localname": "CustomerOneMember", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cyrx_CustomerThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to third customer.", "label": "Customer Three [Member]", "terseLabel": "Customer Three [Member]" } } }, "localname": "CustomerThreeMember", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cyrx_CustomerTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customer Two [Member]", "terseLabel": "Customer Two [Member]" } } }, "localname": "CustomerTwoMember", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cyrx_DebtInstrumentConvertibleThresholdMaximumConversionRatio": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Threshold maximum ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.", "label": "Debt Instrument, Convertible, Threshold Maximum Conversion Ratio", "terseLabel": "Threshold maximum conversion rate" } } }, "localname": "DebtInstrumentConvertibleThresholdMaximumConversionRatio", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_DebtInstrumentRedemptionThresholdConsecutiveTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of redeemable debt instrument must exceed threshold percentage for specified number of trading days to trigger redemption.", "label": "Debt Instrument, Redemption, Threshold Consecutive Trading Days", "terseLabel": "Threshold consecutive trading days for redemption of notes" } } }, "localname": "DebtInstrumentRedemptionThresholdConsecutiveTradingDays", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "cyrx_DebtInstrumentRedemptionThresholdTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified trading days that common stock price to conversion price of redeemable debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger redemption.", "label": "Debt Instrument, Redemption, Threshold Trading Days", "terseLabel": "Threshold trading days for redemption of notes" } } }, "localname": "DebtInstrumentRedemptionThresholdTradingDays", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "cyrx_DebtInstrumentRegistrationDefaultAdditionalInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of principal amount payable as additional interest, if the Company fails to satisfy certain of its obligations under the Registration Rights Agreement (a \"Registration Default\").", "label": "Debt Instrument, Registration Default, Additional Interest Rate", "terseLabel": "Additional interest rate (as a percent)" } } }, "localname": "DebtInstrumentRegistrationDefaultAdditionalInterestRate", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "cyrx_DebtInstrumentRegistrationDefaultCashPaymentToEachNoteholderPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of principal amount of the note payable as cash payment to each noteholder, if a Registration Default exists on the maturity date for the Notes, in addition to any additional interest.", "label": "Debt Instrument, Registration Default, Cash Payment To Each Noteholder, Percentage", "terseLabel": "Cash payment to each noteholder (as a percent)" } } }, "localname": "DebtInstrumentRegistrationDefaultCashPaymentToEachNoteholderPercentage", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "cyrx_DebtInstrumentRegistrationDefaultThresholdMaximumCombinedInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold maximum percentage of combined interest rate per annum, that in no event will be exceeded by the additional interest, together with any special interest that accrues pursuant to the Indenture accrue on any day on a Note.", "label": "Debt Instrument, Registration Default, Threshold Maximum Combined Interest Rate", "terseLabel": "Threshold maximum combined interest rate (as a percent)" } } }, "localname": "DebtInstrumentRegistrationDefaultThresholdMaximumCombinedInterestRate", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "cyrx_DeemedDividend": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deemed dividend recognized by the company.", "label": "Deemed Dividend", "terseLabel": "Deemed dividend" } } }, "localname": "DeemedDividend", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_EngineeringAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Engineering And Development [Member]", "terseLabel": "Engineering and development" } } }, "localname": "EngineeringAndDevelopmentMember", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "cyrx_EquipmentAndFurnitureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Equipment and furniture.", "label": "Equipment And Furniture [Member]", "terseLabel": "Furniture and Equipment [Member]" } } }, "localname": "EquipmentAndFurnitureMember", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cyrx_EquitySecuritiesRealizedGainLossSold": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI) sold during the period", "label": "Equity Securities Realized Gain loss Sold", "terseLabel": "Less: net gains (losses) recognized during the year on equity securities sold during the year" } } }, "localname": "EquitySecuritiesRealizedGainLossSold", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsEquityInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_FinanceLeaseCost": { "auth_ref": [], "calculation": { "http://www.Cryoport.com/role/DisclosureLeasesComponentsOfLeaseCostDetail": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of finance lease cost recognized by lessee for lease contract.", "label": "Finance Lease Cost", "totalLabel": "Total finance lease cost" } } }, "localname": "FinanceLeaseCost", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesComponentsOfLeaseCostDetail" ], "xbrltype": "monetaryItemType" }, "cyrx_FinanceLeaseRightofuseAssetAccumulatedDepreciation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease Right-of-Use Asset Accumulated Depreciation" } } }, "localname": "FinanceLeaseRightofuseAssetAccumulatedDepreciation", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": { "auth_ref": [], "calculation": { "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsExpectedFutureAmortizationDetails": { "order": 6.0, "parentTag": "cyrx_FutureAmortizationOfFiniteLivedIntangibleAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsExpectedFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_ForeignCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign Customers [Member].", "label": "Foreign Customers [Member]", "terseLabel": "Foreign Customers [Member]" } } }, "localname": "ForeignCustomersMember", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cyrx_FreezerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member represents freezer.", "label": "Freezer [Member]", "terseLabel": "Freezer (Member)" } } }, "localname": "FreezerMember", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cyrx_FutureAmortizationOfFiniteLivedIntangibleAssets": { "auth_ref": [], "calculation": { "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsExpectedFutureAmortizationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of future amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Future Amortization of Finite Lived Intangible Assets", "totalLabel": "Future amortization of intangible assets" } } }, "localname": "FutureAmortizationOfFiniteLivedIntangibleAssets", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsExpectedFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_GlobalLogisticsSolutionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Global Logistics Solutions segment.", "label": "Global Logistics Solutions [Member]", "terseLabel": "Global Logistics Solutions [Member]" } } }, "localname": "GlobalLogisticsSolutionsMember", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregatesOurRevenuesByMajorSourceDetails" ], "xbrltype": "domainItemType" }, "cyrx_GoodwillAdjustmentIncludedInDeferredTaxLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of goodwill adjustment included in deferred tax liability in non-cash investing and financing activities.", "label": "Goodwill Adjustment Included In Deferred Tax Liability", "terseLabel": "CRYOPDP goodwill adjustment included in deferred tax liability" } } }, "localname": "GoodwillAdjustmentIncludedInDeferredTaxLiability", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cyrx_GoodwillAdjustmentIncludedInFixedAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of goodwill adjustment included in fixed assets in non-cash investing and financing activities.", "label": "Goodwill Adjustment Included In Fixed Assets", "terseLabel": "CRYOPDP goodwill adjustment included in fixed assets" } } }, "localname": "GoodwillAdjustmentIncludedInFixedAssets", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cyrx_InstallmentOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Installment one", "label": "Installment One [Member]", "terseLabel": "repaid in 2025" } } }, "localname": "InstallmentOneMember", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureNotePayableDetails" ], "xbrltype": "domainItemType" }, "cyrx_InstallmentTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Installment two", "label": "Installment Two [Member]", "terseLabel": "repaid in 2028" } } }, "localname": "InstallmentTwoMember", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureNotePayableDetails" ], "xbrltype": "domainItemType" }, "cyrx_InterestAmountOnAccountsPayableAndAccruedLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount on interest include in accounts payable and accrued liabilities.", "label": "Interest amount on Accounts Payable and Accrued Liabilities", "terseLabel": "Interest expense" } } }, "localname": "InterestAmountOnAccountsPayableAndAccruedLiabilities", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_InventoryRelatedToAcquisition": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory related to acquisition.", "label": "Inventory Related To Acquisition", "terseLabel": "Step up inventory related to acquisition" } } }, "localname": "InventoryRelatedToAcquisition", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureInventoryDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_LeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating and finance lease.", "label": "Lease Weighted Average Remaining Lease Term 1", "verboseLabel": "Lease Weighted Average Remaining Lease Term" } } }, "localname": "LeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "cyrx_LesseeOperatingAndFinanceLeasesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for lessee, operating and finance leases.", "label": "Lessee Operating And Finance Leases [Text Block]", "verboseLabel": "Leases" } } }, "localname": "LesseeOperatingAndFinanceLeasesTextBlock", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeases" ], "xbrltype": "textBlockItemType" }, "cyrx_LesseeOptionToExtend": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of terms and conditions of option to extend operating and finance sublease.", "label": "Lessee Option to Extend", "terseLabel": "Lessee Option to Extend" } } }, "localname": "LesseeOptionToExtend", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "cyrx_MaturityPeriodOfHighlyLiquidInvestments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maturity period of highly liquid investments.", "label": "Maturity Period Of Highly Liquid Investments" } } }, "localname": "MaturityPeriodOfHighlyLiquidInvestments", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "cyrx_MutualFundsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Mutual Funds [Member]", "terseLabel": "Mutual Funds [Member]" } } }, "localname": "MutualFundsMember", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "cyrx_MveCryobiologicalStorageBusinessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for MVE cryobiological storage business.", "label": "Mve Cryobiological Storage Business [Member]", "terseLabel": "MVE" } } }, "localname": "MveCryobiologicalStorageBusinessMember", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails", "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfGoodwillDetails", "http://www.Cryoport.com/role/DisclosureNatureOfBusinessDetails" ], "xbrltype": "domainItemType" }, "cyrx_NatureOfBusinessAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "n/a", "label": "Nature of the Business" } } }, "localname": "NatureOfBusinessAbstract", "nsuri": "http://www.Cryoport.com/20210331", "xbrltype": "stringItemType" }, "cyrx_NetProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Net Proceeds From Issuance Of Private Placement", "terseLabel": "Net proceeds from private placement" } } }, "localname": "NetProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_NonCashNetUnrealizedGainOnAvailableForSaleSecurities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net unrealized gain on available-for-sale debt securities", "label": "Non Cash Net Unrealized gain on Available for Sale Securities", "terseLabel": "Net unrealized gain on available-for-sale debt securities" } } }, "localname": "NonCashNetUnrealizedGainOnAvailableForSaleSecurities", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cyrx_NoteValuationAdjustmentIncludedInNotePayableAndGoodwill": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of note valuation adjustment included in note payable and goodwill in non-cash investing and financing activities.", "label": "Note Valuation Adjustment Included In Note Payable And Goodwill", "terseLabel": "Note valuation adjustment included in note payable and goodwill" } } }, "localname": "NoteValuationAdjustmentIncludedInNotePayableAndGoodwill", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cyrx_NotesComprised": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This elements refers to Notes comprised .", "label": "Notes comprised", "terseLabel": "Comprised" } } }, "localname": "NotesComprised", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_NotesPayableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Entire disclosure of note payable.", "label": "Notes Payable [Text Block]", "terseLabel": "Note Payable" } } }, "localname": "NotesPayableTextBlock", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureNotePayable" ], "xbrltype": "textBlockItemType" }, "cyrx_NumberOfBoardMemberWhoCanBeElectedByPreferredStockHolders": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of board members who can be elected by preferred stock holders.", "label": "Number Of Board Member Who Can Be Elected By Preferred Stock Holders", "terseLabel": "Number of member to the board of directors who can be elected by the preferred stock holders" } } }, "localname": "NumberOfBoardMemberWhoCanBeElectedByPreferredStockHolders", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "cyrx_NumberOfCustomers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Its Represents number Of Customers involved in the process.", "label": "Number Of Customers", "terseLabel": "Number Of Customers" } } }, "localname": "NumberOfCustomers", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "cyrx_NumberOfInstallments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of installments under which notes to be repayable.", "label": "Number of Installments", "terseLabel": "Number of installment" } } }, "localname": "NumberOfInstallments", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureNotePayableDetails" ], "xbrltype": "integerItemType" }, "cyrx_NumberOfMembers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of members of the board of directors.", "label": "Number of Members" } } }, "localname": "NumberOfMembers", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "cyrx_OperatingLossCarryforwardsPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the operating loss carryforwards percentage.", "label": "Operating Loss Carryforwards Percent", "terseLabel": "Operating Loss Carryforwards, Percent" } } }, "localname": "OperatingLossCarryforwardsPercent", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "cyrx_PaidInKindDividendOnSeriesCConvertiblePreferredStockValue": { "auth_ref": [], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid-in-kind dividend on Series C convertible preferred stock.", "label": "Paid-in-Kind Dividend on Series C Convertible Preferred Stock, Value", "negatedLabel": "Paid-in-kind preferred stock dividend, including beneficial conversion feature", "negatedTerseLabel": "Paid-in-kind dividend on Series C convertible preferred stock" } } }, "localname": "PaidInKindDividendOnSeriesCConvertiblePreferredStockValue", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsPerShareDetails", "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "cyrx_PatentsAndTrademarksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law and rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.", "label": "Patents And Trademarks [Member]", "terseLabel": "Cryoport patents and trademarks" } } }, "localname": "PatentsAndTrademarksMember", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "cyrx_PercentageOfEquityInterestAgreedToBeAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of equity interest agreed to be acquired by the company.", "label": "Percentage Of Equity Interest Agreed To Be Acquired", "terseLabel": "Percentage of equity interest agreed to be acquired" } } }, "localname": "PercentageOfEquityInterestAgreedToBeAcquired", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureNatureOfBusinessDetails" ], "xbrltype": "percentItemType" }, "cyrx_Plan2018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Plan2018 [Member]", "terseLabel": "Plan 2018 [Member]" } } }, "localname": "Plan2018Member", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cyrx_PreferredClassCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable preferred class C stock or outstanding preferred class C stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Preferred Class C [Member]", "terseLabel": "Class C Preferred Stock" } } }, "localname": "PreferredClassCMember", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "cyrx_PreferredStockConvertibleConversionCost": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the cost of Series C Preferred stock conversion cost.", "label": "Preferred Stock Convertible Conversion Cost", "terseLabel": "Series C Preferred stock conversion expenses" } } }, "localname": "PreferredStockConvertibleConversionCost", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_PreferredStockConvertibleConversionPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share conversion price of convertible preferred stock.", "label": "Preferred Stock, Convertible, Conversion Price Per Share", "terseLabel": "Conversion price (in dollars per share)" } } }, "localname": "PreferredStockConvertibleConversionPricePerShare", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "cyrx_PreferredStockConvertibleConversionRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion rate of convertible preferred stock.", "label": "Preferred Stock, Convertible, Conversion Rate", "terseLabel": "Conversion rate" } } }, "localname": "PreferredStockConvertibleConversionRate", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "cyrx_PreferredStockConvertibleStockPriceTriggerPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of the entity's common stock as a percentage of conversion price, which would be required to be attained for the conversion of convertible preferred stock to become effective.", "label": "Preferred Stock, Convertible, Stock Price Trigger, Percentage", "terseLabel": "Stock price trigger as a percentage of conversion price for conversion of preferred stock" } } }, "localname": "PreferredStockConvertibleStockPriceTriggerPercentage", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "cyrx_PreferredStockConvertibleThresholdConsecutiveTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible preferred stock must exceed threshold percentage for specified number of trading days to trigger conversion feature.", "label": "Preferred Stock, Convertible, Threshold Consecutive Trading Days", "verboseLabel": "Threshold consecutive trading days for conversion of preferred stock" } } }, "localname": "PreferredStockConvertibleThresholdConsecutiveTradingDays", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "cyrx_PreferredStockConvertibleThresholdTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible preferred stock must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.", "label": "Preferred Stock, Convertible, Threshold Trading Days", "terseLabel": "Threshold trading days for conversion of preferred stock" } } }, "localname": "PreferredStockConvertibleThresholdTradingDays", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "cyrx_PreferredStockIfNotRepurchasedDividendRatePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage rate used to calculate dividend payments on preferred stock, if not repurchased.", "label": "Preferred Stock If Not Repurchased, Dividend Rate, Percentage", "terseLabel": "Dividend rate on shares not repurchased" } } }, "localname": "PreferredStockIfNotRepurchasedDividendRatePercentage", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "cyrx_PreferredStockOwnershipPercentageToExerciseRightToNominateBoard": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold percentage of ownership of shares to be held by preferred stock holders, to exercise their right to nominate the members of the board.", "label": "Preferred Stock, Ownership Percentage, To Exercise Right To Nominate Board", "terseLabel": "Percentage of stock to be held to exercise the right to nominate member of board of directors" } } }, "localname": "PreferredStockOwnershipPercentageToExerciseRightToNominateBoard", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "cyrx_PreferredStockRedemptionPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of information pertaining to redemption period for preferred stock.", "label": "Preferred Stock, Redemption Period [Axis]" } } }, "localname": "PreferredStockRedemptionPeriodAxis", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "cyrx_PreferredStockRedemptionPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to redemption period for preferred stock.", "label": "Preferred Stock Redemption Period [Domain]", "terseLabel": "Preferred Stock, Redemption Period [Domain]" } } }, "localname": "PreferredStockRedemptionPeriodDomain", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cyrx_PreferredStockRedemptionPeriodOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for redemption period for preferred stock, one.", "label": "Preferred Stock Redemption Period One [Member]", "terseLabel": "Prior to the 180-day anniversary of October 1, 2020" } } }, "localname": "PreferredStockRedemptionPeriodOneMember", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cyrx_PreferredStockRedemptionPeriodThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for redemption period for preferred stock, three.", "label": "Preferred Stock Redemption Period Three [Member]", "terseLabel": "At any time beginning six years after Closing Date" } } }, "localname": "PreferredStockRedemptionPeriodThreeMember", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cyrx_PreferredStockRedemptionPeriodTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for redemption period for preferred stock, two.", "label": "Preferred Stock Redemption Period Two [Member]", "terseLabel": "At any time beginning five years after Closing Date (but prior to six years after the Closing Date)" } } }, "localname": "PreferredStockRedemptionPeriodTwoMember", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cyrx_PreferredStockRedemptionPricePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redemption price of preferred stock as a percentage of the purchase price paid by plus any accrued and unpaid dividends.", "label": "Preferred Stock, Redemption Price, Percentage", "terseLabel": "Redemption price (as a percent)" } } }, "localname": "PreferredStockRedemptionPricePercentage", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "cyrx_PreferredStockSharesToBeRedeemed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares of preferred stock, that may be redeemed by the company.", "label": "Preferred Stock, Shares To Be Redeemed", "terseLabel": "Number of shares to be redeemed" } } }, "localname": "PreferredStockSharesToBeRedeemed", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "cyrx_PublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Public Offering [Member]", "terseLabel": "Public offering" } } }, "localname": "PublicOfferingMember", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical", "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "cyrx_PurchaseOfEquipmentThroughCapitalLeaseObligation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Purchase of equipment through capital lease obligations in non cash investing and financing activities.", "label": "Purchase Of Equipment Through Capital Lease Obligation", "verboseLabel": "Purchase of equipment through capital lease obligations" } } }, "localname": "PurchaseOfEquipmentThroughCapitalLeaseObligation", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cyrx_RealizedLossOnInvestmentsInEquitySecurities": { "auth_ref": [], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Realized loss on investments in equity securities.", "label": "Realized loss on investments in equity securities", "terseLabel": "Realized loss on investments in equity securities" } } }, "localname": "RealizedLossOnInvestmentsInEquitySecurities", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cyrx_ReclassificationOfRealizedGainOnAvailableForSaleDebtSecuritiesToEarnings": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of reclassification of realized gain on available-for-sale debt securities to earnings.", "label": "Reclassification of Realized Gain on Available-For-Sale Debt Securities to Earnings", "terseLabel": "Reclassification of realized gain on available-for-sale debt securities to earnings" } } }, "localname": "ReclassificationOfRealizedGainOnAvailableForSaleDebtSecuritiesToEarnings", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cyrx_ReimbursementOfTransactionalExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transactional expenses reimbursed by the company.", "label": "Reimbursement Of Transactional Expenses", "terseLabel": "Reimbursement of transactional expenses" } } }, "localname": "ReimbursementOfTransactionalExpenses", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_RepaymentOfFinanceLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow of finance lease liabilities repayment", "label": "Repayment of finance lease liabilities", "negatedLabel": "Repayment of finance lease liabilities" } } }, "localname": "RepaymentOfFinanceLeaseLiabilities", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cyrx_ReproductiveMedicineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reproductive Medicine Member", "label": "Reproductive Medicine [Member]", "terseLabel": "Reproductive Medicine [Member]" } } }, "localname": "ReproductiveMedicineMember", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregatesOurRevenuesByMajorSourceDetails" ], "xbrltype": "domainItemType" }, "cyrx_RevenueRecognitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue Recognition", "label": "Revenue Recognition [Line Items]" } } }, "localname": "RevenueRecognitionLineItems", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregatesOurRevenuesByMajorSourceDetails" ], "xbrltype": "stringItemType" }, "cyrx_RevenueRecognitionTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue Recognition", "label": "Revenue Recognition [Table]" } } }, "localname": "RevenueRecognitionTable", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregatesOurRevenuesByMajorSourceDetails" ], "xbrltype": "stringItemType" }, "cyrx_RightOfUseAssetObtainedInExchangeForOperatingLeasesLiability": { "auth_ref": [], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right Of Use Asset Obtained In Exchange For Operating Leases Liability", "negatedLabel": "Change in operating lease right-of-use assets and lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeasesLiability", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cyrx_RightofuseAssetsObtainedInExchangeForLeaseObligationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "n/a", "label": "Right-Of-Use Assets Obtained In Exchange For Lease Obligations [Abstract]", "verboseLabel": "Right-of-use assets obtained in exchange for lease obligations:" } } }, "localname": "RightofuseAssetsObtainedInExchangeForLeaseObligationsAbstract", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesSupplementalCashFlowsInformationDetail" ], "xbrltype": "stringItemType" }, "cyrx_ScenarioOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for scenario, one.", "label": "Scenario One [Member]", "terseLabel": "First 90 days beginning on, and including the date on which such Registration Default occurs" } } }, "localname": "ScenarioOneMember", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cyrx_ScenarioTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for scenario, two.", "label": "Scenario Two [Member]", "terseLabel": "After 90 days of the occurrence of Registration Default" } } }, "localname": "ScenarioTwoMember", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cyrx_ScheduleOfCommonStockReservedForFutureIssuancesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of common stock reserved for future issuance.", "label": "Schedule Of Common Stock Reserved For Future Issuances [Table Text Block]", "terseLabel": "Schedule of common stock were issuable upon exercise of stock options and the conversion of convertible senior notes and Series C Preferred stock" } } }, "localname": "ScheduleOfCommonStockReservedForFutureIssuancesTableTextBlock", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "cyrx_ScheduleOfInterestExpensesOnConvertibleNotesPayableTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for interest expenses on convertible notes payable.", "label": "Schedule Of Interest Expenses On Convertible Notes Payable [Table Text Block]", "terseLabel": "Schedule of interest expenses incurred in connection with the Notes" } } }, "localname": "ScheduleOfInterestExpensesOnConvertibleNotesPayableTableTextBlock", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesTables" ], "xbrltype": "textBlockItemType" }, "cyrx_ScheduleOfLeaseSupplementalCashFlowAndOtherDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lease supplemental cash flow and other disclosures.", "label": "Schedule Of Lease Supplemental Cash Flow And Other Disclosures [Table Text Block]", "verboseLabel": "Schedule of other information related to leases" } } }, "localname": "ScheduleOfLeaseSupplementalCashFlowAndOtherDisclosuresTableTextBlock", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "cyrx_ScheduleOfSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Significant Accounting Policies [Table].", "label": "Schedule Of Significant Accounting Policies [Table]" } } }, "localname": "ScheduleOfSignificantAccountingPoliciesTable", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "cyrx_ScheduleOfStockholdersEquityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Stockholders Equity [Table].", "label": "Schedule Of Stockholders Equity [Table]" } } }, "localname": "ScheduleOfStockholdersEquityTable", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "stringItemType" }, "cyrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract].", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]", "verboseLabel": "Aggregated Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "cyrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract].", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]", "verboseLabel": "Weighted-Average Remaining Contractual Term (Years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "cyrx_SignificantAccountingPoliciesAdditionalInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies Additional Information [Line Items]" } } }, "localname": "SignificantAccountingPoliciesAdditionalInformationLineItems", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "cyrx_StatutoryCreditUsageLimitForResearchAndDevelopmentForTaxRelief": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of statutory limit of Research and development credit usage limit for the purpose of allowing tax relief.", "label": "Statutory Credit Usage Limit for Research and Development for Tax Relief", "terseLabel": "Amount of maximum allowed research and development credit usage" } } }, "localname": "StatutoryCreditUsageLimitForResearchAndDevelopmentForTaxRelief", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of share options and warrants exercised during the current period.", "label": "Stock Issued During Period Shares Stock Options And Warrants Exercised", "verboseLabel": "Proceeds from exercise of stock options and warrants (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "cyrx_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options and warrants.", "label": "Stock Issued During Period Value Stock Options And Warrants Exercised", "terseLabel": "Proceeds from exercise of stock options and warrants" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "cyrx_TaxExaminationPeriodForForeignSubsidiaries": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The period over which foreign subsidiaries are subject to examination by Indian tax authorities.", "label": "Tax Examination Period for Foreign Subsidiaries", "terseLabel": "Period over which foreign subsidiaries subject to examination by indian tax authorities" } } }, "localname": "TaxExaminationPeriodForForeignSubsidiaries", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "cyrx_ThirdPartyOfferingRelatedCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of third party offering related costs incurred by the company.", "label": "Third Party Offering Related Costs", "terseLabel": "Third-party offering related costs" } } }, "localname": "ThirdPartyOfferingRelatedCosts", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_TruckAndAutoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member represents both truck and auto.", "label": "Truck And Auto [Member]", "terseLabel": "Truck and Auto (Member)" } } }, "localname": "TruckAndAutoMember", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cyrx_WeightedAverageDiscountRateAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Discount Rate [Abstract]", "verboseLabel": "Weighted-Average Discount Rate" } } }, "localname": "WeightedAverageDiscountRateAbstract", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesSupplementalCashFlowsInformationDetail" ], "xbrltype": "stringItemType" }, "cyrx_WeightedAverageRemainingLeaseTermAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Lease Term [Abstract]", "verboseLabel": "Weighted-Average Remaining Lease Term" } } }, "localname": "WeightedAverageRemainingLeaseTermAbstract", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesSupplementalCashFlowsInformationDetail" ], "xbrltype": "stringItemType" }, "cyrx_WorkingCapital": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This refers to working capital", "label": "working capital", "terseLabel": "Working capital" } } }, "localname": "WorkingCapital", "nsuri": "http://www.Cryoport.com/20210331", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r542" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r544" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r540" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_AmericasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Americas [Member]", "terseLabel": "Americas [Member]" } } }, "localname": "AmericasMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOurGeographicalRevenuesByOriginDetails" ], "xbrltype": "domainItemType" }, "srt_AsiaPacificMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Asia Pacific [Member]", "terseLabel": "Asia Pacific (APAC) [Member]" } } }, "localname": "AsiaPacificMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOurGeographicalRevenuesByOriginDetails" ], "xbrltype": "domainItemType" }, "srt_DirectorMember": { "auth_ref": [ "r182" ], "lang": { "en-us": { "role": { "label": "Director [Member]", "terseLabel": "Director [Member]" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r181", "r278", "r283", "r498" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r300", "r303", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r495", "r499" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAssumptionsUsedToEstimateFairValueOfStockOptionsDetails", "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r300", "r303", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r495", "r499" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAssumptionsUsedToEstimateFairValueOfStockOptionsDetails", "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r181", "r278", "r283", "r498" ], "lang": { "en-us": { "role": { "label": "Name Of Major Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r177", "r278", "r281", "r458", "r494", "r496" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregatesOurRevenuesByMajorSourceDetails", "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r177", "r278", "r281", "r458", "r494", "r496" ], "lang": { "en-us": { "role": { "label": "Products And Services [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregatesOurRevenuesByMajorSourceDetails", "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r290", "r300", "r303", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r495", "r499" ], "lang": { "en-us": { "role": { "label": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAssumptionsUsedToEstimateFairValueOfStockOptionsDetails", "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r290", "r300", "r303", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r495", "r499" ], "lang": { "en-us": { "role": { "label": "Range [Member]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAssumptionsUsedToEstimateFairValueOfStockOptionsDetails", "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "label": "Scenario Unspecified [Domain]", "terseLabel": "Scenario, Unspecified [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureNotePayableDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r178", "r179", "r278", "r282", "r497", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536" ], "lang": { "en-us": { "role": { "label": "Segment Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOurGeographicalRevenuesByOriginDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r178", "r179", "r278", "r282", "r497", "r524", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOurGeographicalRevenuesByOriginDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r243", "r301", "r443" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureNotePayableDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r182", "r440" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title Of Individual With Relationship To Entity [Domain]", "terseLabel": "Relationship to Entity [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r33" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "verboseLabel": "Accounts payable and other accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r5", "r17", "r183", "r184" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, Net, Current", "verboseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r20", "r55", "r56", "r57", "r483", "r504", "r505" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "verboseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r54", "r57", "r60", "r112", "r113", "r114", "r387", "r500", "r501" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Income [Member]", "terseLabel": "Other Comprehensive Income (Loss) [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r18" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "verboseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r112", "r113", "r114", "r333", "r334", "r335" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional Paid-In Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r304", "r306", "r339", "r340" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r258", "r266" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "terseLabel": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical", "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r306", "r330", "r338" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r185", "r201", "r202", "r204" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Allowance for Doubtful Accounts Receivable", "verboseLabel": "Allowance for doubtful accounts receivable" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r79", "r94", "r420" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureNotePayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r73", "r94", "r422" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "verboseLabel": "Amortization of debt issuance costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesInterestExpensesIncurredOnConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r94", "r422" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "verboseLabel": "Amortization of debt discount" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r94", "r216", "r221" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "verboseLabel": "Amortization expense for intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r134" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r134" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r134" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSharesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r106", "r164", "r169", "r175", "r199", "r381", "r388", "r405", "r462", "r482" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "verboseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r7", "r52", "r106", "r199", "r381", "r388", "r405" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "verboseLabel": "Current Assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r394" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r189", "r206" ], "calculation": { "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsContractualMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-for-sale Securities, Amortized Cost Basis", "totalLabel": "Total, Amortized Cost", "verboseLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsAvailableForSaleDebtSecuritiesDetails", "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r191" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax", "verboseLabel": "Unrealized Gains" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsAvailableForSaleDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Unrealized Losses" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsAvailableForSaleDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "auth_ref": [ "r193" ], "calculation": { "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsContractualMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost", "verboseLabel": "Due within one year, Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r192", "r193", "r476" ], "calculation": { "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsContractualMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value", "verboseLabel": "Due within one year, Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r188", "r190", "r206", "r467" ], "calculation": { "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsContractualMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-for-sale Securities", "totalLabel": "Total, Fair Value", "verboseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsAvailableForSaleDebtSecuritiesDetails", "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r308", "r332" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationRestrictedStockUnitDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "verboseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]", "terseLabel": "Building [Member]" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r299", "r302" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails", "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfGoodwillDetails", "http://www.Cryoport.com/role/DisclosureNatureOfBusinessDetails", "http://www.Cryoport.com/role/DisclosureNotePayableDetails", "http://www.Cryoport.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r299", "r302", "r363", "r364" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails", "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfGoodwillDetails", "http://www.Cryoport.com/role/DisclosureNatureOfBusinessDetails", "http://www.Cryoport.com/role/DisclosureNotePayableDetails", "http://www.Cryoport.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r372", "r373", "r374" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Total purchase consideration paid", "verboseLabel": "Consideration for business acquisition" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails", "http://www.Cryoport.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Acquisitions" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitions" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationGoodwillAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Goodwill [Abstract]", "terseLabel": "Goodwill" } } }, "localname": "BusinessCombinationGoodwillAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": { "auth_ref": [ "r365" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt", "terseLabel": "Note payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r365" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]", "terseLabel": "Purchase price allocation:" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acquisitions" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r102", "r362" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Business Combinations" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r98", "r99", "r100" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Fixed assets included in accounts payable and accrued liabilities" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r29", "r507", "r508" ], "calculation": { "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents and Short-Term Investments" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r29", "r96" ], "calculation": { "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments", "weight": 1.0 }, "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "totalLabel": "Total cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails", "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r9", "r97", "r102" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "verboseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r29" ], "calculation": { "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Cash, Cash Equivalents, and Short-term Investments", "totalLabel": "Cash, cash equivalents and short-term investments" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock": { "auth_ref": [ "r196" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.", "label": "Cash, Cash Equivalents, and Short-term Investments [Text Block]", "verboseLabel": "Cash, Cash Equivalents and Short-Term Investments" } } }, "localname": "CashCashEquivalentsAndShortTermInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r91", "r96", "r101" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents - end of year", "periodStartLabel": "Cash and cash equivalents - beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r91", "r410" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Equivalents, at Carrying Value [Abstract]", "verboseLabel": "Cash equivalents:" } } }, "localname": "CashEquivalentsAtCarryingValueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CharityCareReimbursementsReceived": { "auth_ref": [ "r525" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of subsidies received by the entity for providing charity care, for example, from an uncompensated care fund.", "label": "Charity Care, Reimbursements Received" } } }, "localname": "CharityCareReimbursementsReceived", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r104", "r106", "r126", "r127", "r128", "r131", "r133", "r138", "r139", "r140", "r199", "r405" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class Of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSharesDetails", "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r41", "r242", "r469", "r487" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies.", "verboseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r239", "r240", "r241", "r244" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common Stock Reserved for Future Issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r112", "r113" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value per share (in dollars per share)", "verboseLabel": "Common stock, par value per share (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "verboseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "verboseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r16", "r258" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "verboseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r16" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.001 par value; 100,000,000 shares authorized; 45,693,692 and 39,837,058 issued and outstanding at March 31, 2021 and December 31, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r63", "r65", "r66", "r71", "r472", "r490" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer Equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r148", "r149", "r181", "r403", "r404" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r148", "r149", "r181", "r403", "r404", "r506" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r144", "r479" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "verboseLabel": "Concentrations of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r148", "r149", "r181", "r403", "r404" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "verboseLabel": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r102", "r383" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "verboseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r268", "r269", "r279" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "terseLabel": "Contract liabilities" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r268", "r269", "r279" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred Revenue, Current", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r280" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockAmountConverted1": { "auth_ref": [ "r98", "r99", "r100" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Amount Converted", "terseLabel": "Conversion of Series C Preferred Stock to common stock" } } }, "localname": "ConversionOfStockAmountConverted1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtFairValueDisclosures": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt, Fair Value Disclosures", "terseLabel": "Convertible Senior notes" } } }, "localname": "ConvertibleDebtFairValueDisclosures", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]", "terseLabel": "Convertible Note [Member]" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtNoncurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.", "label": "Convertible Debt, Noncurrent", "terseLabel": "Convertible senior notes, net of discount of $3.5 million and $3.7 million, respectively" } } }, "localname": "ConvertibleDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.", "label": "Convertible Debt [Table Text Block]", "terseLabel": "Schedule of components of notes payable" } } }, "localname": "ConvertibleDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertibleLongTermNotesPayable": { "auth_ref": [ "r39" ], "calculation": { "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesComponentsOfConvertibleNotesPayableDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible Notes Payable, Noncurrent", "totalLabel": "Net carrying value of Notes payable" } } }, "localname": "ConvertibleLongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesComponentsOfConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]", "terseLabel": "Class A convertible preferred stock [Member]" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "auth_ref": [ "r14", "r15", "r259", "r262" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "terseLabel": "Shares to be issued upon conversion" } } }, "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r75", "r106", "r199", "r405" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "verboseLabel": "Cost of revenues" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost Of Sales [Member]", "terseLabel": "Cost of revenues" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtAndEquitySecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in debt and equity securities. Excludes other-than-temporary impairment (OTTI).", "label": "Available-for-sale Securities, Gross Realized Gains", "terseLabel": "Losses on available-for-sale investments" } } }, "localname": "DebtAndEquitySecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r98", "r100" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion, Converted Instrument, Shares Issued", "terseLabel": "Common stock issued upon conversion of notes" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Senior Notes" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r254" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Convertible Senior Notes" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r13", "r250", "r463", "r480" ], "calculation": { "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesComponentsOfConvertibleNotesPayableDetails": { "order": 2.0, "parentTag": "us-gaap_ConvertibleLongTermNotesPayable", "weight": 1.0 }, "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesSummaryOfTotalGrossPrincipalPaymentsDueUnderConvertibleNotesPayableDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "totalLabel": "Total Payments", "verboseLabel": "Principal amount of Senior Notes" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesComponentsOfConvertibleNotesPayableDetails", "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesSummaryOfTotalGrossPrincipalPaymentsDueUnderConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Initial conversion price (in dollars per share)" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "auth_ref": [ "r38", "r259", "r262", "r264" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.", "label": "Debt Instrument, Convertible, Conversion Ratio", "terseLabel": "Conversion rate" } } }, "localname": "DebtInstrumentConvertibleConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "pureItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r421", "r423" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Aggregate principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r37", "r252", "r421" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "verboseLabel": "Interest rate (as a percent)" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregatesOurRevenuesByMajorSourceDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureNotePayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r39", "r108", "r259", "r263", "r264", "r265", "r420", "r421", "r423", "r478" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureNotePayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r420", "r423" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "terseLabel": "Fair market value of debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureNotePayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent": { "auth_ref": [ "r420", "r423" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of debt discount to be amortized after one year or the normal operating cycle, if longer.", "label": "Debt Instrument, Unamortized Discount, Noncurrent", "verboseLabel": "Note payable, discount" } } }, "localname": "DebtInstrumentUnamortizedDiscountNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": { "auth_ref": [ "r194" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-for-sale Securities, Gross Realized Gain (Loss)", "negatedLabel": "Realized loss (gain) on available-for-sale debt securities" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r196" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-for-sale Securities [Table Text Block]", "verboseLabel": "Schedule of available-for-sale debt securities" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredChargesPolicyTextBlock": { "auth_ref": [ "r32", "r102" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.", "label": "Deferred Charges, Policy [Policy Text Block]", "verboseLabel": "Deferred Financing Costs" } } }, "localname": "DeferredChargesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredFinanceCostsGross": { "auth_ref": [ "r422" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Gross", "terseLabel": "Debt issuance costs" } } }, "localname": "DeferredFinanceCostsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r32", "r422" ], "calculation": { "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesComponentsOfConvertibleNotesPayableDetails": { "order": 1.0, "parentTag": "us-gaap_ConvertibleLongTermNotesPayable", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "negatedLabel": "Unamortized debt issuance costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesComponentsOfConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r94", "r107", "r353", "r358", "r359", "r360" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "verboseLabel": "Deferred tax liability" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r346", "r347" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsAssets": { "auth_ref": [ "r32" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.", "label": "Deposits Assets", "verboseLabel": "Deposits" } } }, "localname": "DepositsAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r94", "r159" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "verboseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOurGeographicalRevenuesByOriginDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r278", "r281", "r282", "r283", "r284", "r285", "r286", "r287" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOurGeographicalRevenuesByOriginDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of disaggregation of revenue by major source" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "verboseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": { "auth_ref": [ "r94", "r227", "r230" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.", "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal", "negatedLabel": "Loss on disposal of property and equipment" } } }, "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPaidinkind": { "auth_ref": [ "r266", "r477" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid paid-in-kind dividends (PIK) declared for classes of stock, for example, but not limited to, common and preferred.", "label": "Dividends, Paid-in-kind", "terseLabel": "Dividends, paid-in-kind" } } }, "localname": "DividendsPaidinkind", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EMEAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Regions of Europe, Middle East and Africa.", "label": "E M E A [Member]", "terseLabel": "Europe, the Middle East and Africa (EMEA) [Member]" } } }, "localname": "EMEAMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOurGeographicalRevenuesByOriginDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "definitionGuidance": "Basic and diluted net loss per share", "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Net loss per share attributable to common stockholders - basic and diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsPerShareDetails", "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r102", "r134", "r135" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "verboseLabel": "Basic and Diluted Net Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r410" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r35" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "verboseLabel": "Accrued compensation and related expenses" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r331" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition", "verboseLabel": "Weighted average recognition period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r331" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options", "verboseLabel": "Unrecognized compensation cost related to unvested stock options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Stock Options [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.Cryoport.com/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails", "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSharesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r112", "r113", "r114", "r116", "r121", "r123", "r137", "r200", "r258", "r266", "r333", "r334", "r335", "r355", "r356", "r411", "r412", "r413", "r414", "r415", "r416", "r500", "r501", "r502" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r401" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": { "auth_ref": [ "r197", "r492" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Realized Gain (Loss)", "terseLabel": "Net losses recognized during the three months on equity securities" } } }, "localname": "EquitySecuritiesFvNiRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsEquityInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "auth_ref": [ "r197", "r492" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "totalLabel": "Unrealized gains (losses) recognized during the three months on equity securities still held at March 31, 2021 and 2020" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsEquityInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r394", "r395" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of fair value hierarchy" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r395", "r445", "r446", "r447" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r394", "r395", "r396", "r397", "r399" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "verboseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r291", "r292", "r297", "r298", "r395", "r445" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value Inputs Level1 [Member]", "terseLabel": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r291", "r292", "r297", "r298", "r395", "r446" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value Inputs Level2 [Member]", "terseLabel": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r395", "r447" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Inputs Level3 [Member]", "terseLabel": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r445", "r446", "r447" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r398", "r399" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value Measurements Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r102", "r400", "r402" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "verboseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r426", "r431", "r439" ], "calculation": { "http://www.Cryoport.com/role/DisclosureLeasesComponentsOfLeaseCostDetail": { "order": 2.0, "parentTag": "cyrx_FinanceLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "verboseLabel": "Interest on finance lease liabilities" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesComponentsOfLeaseCostDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "auth_ref": [ "r428", "r433" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest paid on finance lease liability.", "label": "Finance Lease, Interest Payment on Liability", "verboseLabel": "Operating cash flows from finance leases" } } }, "localname": "FinanceLeaseInterestPaymentOnLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesSupplementalCashFlowsInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finance Leases Future Minimum Payment [Abstract]", "verboseLabel": "Finance Leases" } } }, "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r425", "r438" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Total" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r425" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Finance lease liabilities", "verboseLabel": "Current lease liabilities" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails", "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r425" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Noncurrent lease liabilities", "verboseLabel": "Finance lease liabilities, net of current portion" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails", "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r438" ], "calculation": { "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payments, Due", "totalLabel": "Total future minimum lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r438" ], "calculation": { "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Capital Leases, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r438" ], "calculation": { "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails": { "order": 4.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, Payments, Due Year Four", "verboseLabel": "2025" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r438" ], "calculation": { "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, Payments, Due Year Two", "verboseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r438" ], "calculation": { "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.", "label": "Finance Lease, Liability, Payments, Remainder of Fiscal Year", "verboseLabel": "2021 (excluding the three months ended March 31, 2021)" } } }, "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r438" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less imputed interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r427", "r433" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "verboseLabel": "Financing cash flows from finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesSupplementalCashFlowsInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r424" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r426", "r431", "r439" ], "calculation": { "http://www.Cryoport.com/role/DisclosureLeasesComponentsOfLeaseCostDetail": { "order": 1.0, "parentTag": "cyrx_FinanceLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "verboseLabel": "Amortization of right-of-use assets" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesComponentsOfLeaseCostDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r436", "r439" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "verboseLabel": "Finance leases" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesSupplementalCashFlowsInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r435", "r439" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "verboseLabel": "Finance leases" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesSupplementalCashFlowsInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r220" ], "calculation": { "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r222" ], "calculation": { "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsExpectedFutureAmortizationDetails": { "order": 2.0, "parentTag": "cyrx_FutureAmortizationOfFiniteLivedIntangibleAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsExpectedFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsExpectedFutureAmortizationDetails": { "order": 1.0, "parentTag": "cyrx_FutureAmortizationOfFiniteLivedIntangibleAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year", "terseLabel": "Remainder of 2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsExpectedFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r222" ], "calculation": { "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsExpectedFutureAmortizationDetails": { "order": 5.0, "parentTag": "cyrx_FutureAmortizationOfFiniteLivedIntangibleAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsExpectedFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r222" ], "calculation": { "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsExpectedFutureAmortizationDetails": { "order": 4.0, "parentTag": "cyrx_FutureAmortizationOfFiniteLivedIntangibleAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsExpectedFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r222" ], "calculation": { "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsExpectedFutureAmortizationDetails": { "order": 3.0, "parentTag": "cyrx_FutureAmortizationOfFiniteLivedIntangibleAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsExpectedFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r217", "r218", "r220", "r223", "r459", "r460" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expected future amortization of intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsExpectedFutureAmortizationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r220", "r460" ], "calculation": { "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "verboseLabel": "Gross Amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r217", "r219" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite Lived Intangible Assets Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r220", "r459" ], "calculation": { "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Future amortization of intangible assets", "verboseLabel": "Intangible assets, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails", "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Weighted Average Amortization Period (years)" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r406", "r407", "r408", "r409" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r102", "r418" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Transactions" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r210", "r211", "r461" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails", "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails", "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfGoodwillDetails", "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r212" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "negatedLabel": "Additions" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r225" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r102", "r214" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "verboseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r213" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "terseLabel": "Foreign currency adjustment" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r74", "r106", "r164", "r168", "r171", "r174", "r176", "r199", "r405" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross margin" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r94", "r224" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "terseLabel": "Impairment of intangible assets" } } }, "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r102", "r226", "r233" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "verboseLabel": "Other Long-lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r109", "r164", "r168", "r171", "r174", "r176" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Operations" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r107", "r122", "r123", "r162", "r348", "r357", "r361", "r493" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r67", "r102", "r344", "r345", "r350", "r351", "r352", "r354", "r526" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "verboseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r93" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and other accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r93" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Deferred Revenue", "verboseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDepositOtherAssets": { "auth_ref": [ "r93" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.", "label": "Increase (Decrease) in Deposit Assets", "negatedLabel": "Deposits" } } }, "localname": "IncreaseDecreaseInDepositOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r93" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (Decrease) in Employee Related Liabilities", "verboseLabel": "Accrued compensation and related expenses" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r93" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent": { "auth_ref": [ "r93" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount due within one year (or one business cycle) of receivables that were originally due beyond one year (or one business cycle).", "label": "Increase (Decrease) in Long-term Receivables, Current", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInLongTermReceivablesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Changes in operating assets and liabilities, net of effects of acquisition:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r93" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "auth_ref": [ "r102", "r219", "r455", "r456", "r457", "r459" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.", "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]", "verboseLabel": "Intangible Assets" } } }, "localname": "IntangibleAssetsFiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r68", "r158", "r419", "r422", "r473" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r79", "r253" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "totalLabel": "Total interest expense on Notes" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesInterestExpensesIncurredOnConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "auth_ref": [ "r81" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.", "label": "Interest Expense, Debt, Excluding Amortization", "terseLabel": "Coupon interest" } } }, "localname": "InterestExpenseDebtExcludingAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesInterestExpensesIncurredOnConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "verboseLabel": "Inventory" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureInventory" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r46" ], "calculation": { "http://www.Cryoport.com/role/DisclosureInventoryDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "verboseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r4", "r49" ], "calculation": { "http://www.Cryoport.com/role/DisclosureInventoryDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Inventory, Net, Total", "verboseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureInventoryDetails", "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r8", "r50", "r102", "r136", "r207", "r208", "r209" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "verboseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r48" ], "calculation": { "http://www.Cryoport.com/role/DisclosureInventoryDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "verboseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r47" ], "calculation": { "http://www.Cryoport.com/role/DisclosureInventoryDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNet": { "auth_ref": [ "r77", "r79" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Net", "terseLabel": "Investment income" } } }, "localname": "InvestmentIncomeNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r198", "r491" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "verboseLabel": "Short-Term Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsAvailableForSaleDebtSecuritiesDetails", "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails", "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investment Type Categorization [Member]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsAvailableForSaleDebtSecuritiesDetails", "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails", "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "verboseLabel": "Schedule of investments based on stated contractual maturities" } } }, "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r437", "r439" ], "calculation": { "http://www.Cryoport.com/role/DisclosureLeasesComponentsOfLeaseCostDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesComponentsOfLeaseCostDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finance Lease, Cost [Abstract]", "verboseLabel": "Finance lease cost:" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesComponentsOfLeaseCostDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r437" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "verboseLabel": "Schedule of components of lease cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r430" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "verboseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Schedule Of Future Minimum Operating And Finance Lease Payments Under Non Cancellable Leases Table Text Block", "terseLabel": "Schedule of future minimum lease payments under non-cancellable leases" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r438" ], "calculation": { "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total future minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r438" ], "calculation": { "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r438" ], "calculation": { "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r438" ], "calculation": { "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "verboseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r438" ], "calculation": { "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "verboseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r438" ], "calculation": { "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "verboseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r438" ], "calculation": { "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "verboseLabel": "2021 (excluding the three months ended March 31, 2021)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r438" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r34", "r106", "r170", "r199", "r382", "r388", "r389", "r405" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r23", "r106", "r199", "r405", "r464", "r485" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r36", "r106", "r199", "r382", "r388", "r389", "r405" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "verboseLabel": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r110", "r247" ], "calculation": { "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesSummaryOfTotalGrossPrincipalPaymentsDueUnderConvertibleNotesPayableDetails": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Five", "terseLabel": "Notes payable, 2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesSummaryOfTotalGrossPrincipalPaymentsDueUnderConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTerm": { "auth_ref": [ "r397" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Long-term Debt, Term" } } }, "localname": "LongTermDebtTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LongTermNotesPayable": { "auth_ref": [ "r39" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Notes Payable, Noncurrent", "terseLabel": "Note payable", "verboseLabel": "Note payable, net of discount of $1.2 million and $0, respectively" } } }, "localname": "LongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureNotePayableDetails", "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermNotesPayableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note Payable" } } }, "localname": "LongTermNotesPayableAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r39" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r39", "r248" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Longterm Debt Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MajorCustomersPolicyPolicyTextBlock": { "auth_ref": [ "r147", "r148", "r149", "r181" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for major customers. Major customers are those that the loss of such customers would have a material adverse effect on the entity.", "label": "Major Customers, Policy [Policy Text Block]", "verboseLabel": "Customers" } } }, "localname": "MajorCustomersPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "auth_ref": [], "calculation": { "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails": { "order": 2.0, "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "Money Market Funds, at Carrying Value", "verboseLabel": "Money market mutual fund" } } }, "localname": "MoneyMarketFundsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market mutual fund" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MutualFundMember": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Regulated investment instrument that pools funds from multiple investors to invest principally in a portfolio of securities and money market instruments to match the investment objective.", "label": "Mutual Fund [Member]", "terseLabel": "Mutual funds" } } }, "localname": "MutualFundMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r141", "r153" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "Nature of the Business" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureNatureOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r91" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "Cash Flows From Financing Activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r91" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "Cash Flows From Investing Activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r91", "r92", "r95" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by (used in) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Cash Flows From Operating Activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r61", "r64", "r70", "r95", "r106", "r115", "r117", "r118", "r119", "r120", "r122", "r123", "r129", "r164", "r168", "r171", "r174", "r176", "r199", "r405", "r471", "r489" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsPerShareDetails", "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss", "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r117", "r118", "r119", "r120", "r124", "r125", "r130", "r133", "r164", "r168", "r171", "r174", "r176" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net loss attributable to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsPerShareDetails", "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "verboseLabel": "Recently Adopted Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Supplemental Disclosure of Non-Cash Investing and Financing Activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NoncompeteAgreementsMember": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.", "label": "Noncompete Agreements [Member]", "terseLabel": "Non-compete agreement" } } }, "localname": "NoncompeteAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r78" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "verboseLabel": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock": { "auth_ref": [ "r186", "r205" ], "lang": { "en-us": { "role": { "documentation": "Description of accounting policies and methodologies used to estimate the entity's liability for off-balance sheet credit exposures and related charges for those credit exposures.", "label": "Off-Balance-Sheet Credit Exposure, Policy [Policy Text Block]", "verboseLabel": "Off-Balance Sheet Arrangements" } } }, "localname": "OffBalanceSheetCreditExposurePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating costs and expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "verboseLabel": "Operating costs and expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r164", "r168", "r171", "r174", "r176" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r432", "r439" ], "calculation": { "http://www.Cryoport.com/role/DisclosureLeasesComponentsOfLeaseCostDetail": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "verboseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesComponentsOfLeaseCostDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r425" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Total" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r425" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities", "verboseLabel": "Current lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails", "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r425" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Noncurrent lease liabilities", "verboseLabel": "Operating lease liabilities, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails", "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r429", "r433" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "verboseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesSupplementalCashFlowsInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r424" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "verboseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r436", "r439" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "verboseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesSupplementalCashFlowsInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r435", "r439" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "verboseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesSupplementalCashFlowsInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]", "verboseLabel": "Operating Leases" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OrderOrProductionBacklogMember": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Orders, production or production backlog arising from contracts such as purchase or sales orders acquired in a business combination.", "label": "Order Or Production Backlog [Member]", "terseLabel": "Order backlog" } } }, "localname": "OrderOrProductionBacklogMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Management's Representation and Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r2", "r393" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Management's Representation and Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureManagementSRepresentationAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r32" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other long-term assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r53", "r55", "r379", "r386" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "negatedLabel": "Net unrealized gain (loss) on available-for-sale debt securities" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r379", "r380", "r386" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "verboseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r62", "r65", "r379", "r380", "r386" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Other comprehensive income (loss)", "verboseLabel": "Other comprehensive income (loss), net of taxes" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss", "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "verboseLabel": "Other comprehensive income (loss), net of tax:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": { "auth_ref": [ "r55", "r58", "r59", "r195" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax", "negatedLabel": "Reclassification of realized (gain) loss on available-for-sale debt securities to earnings" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r80" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "verboseLabel": "Other expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherShortTermInvestments": { "auth_ref": [ "r51", "r470", "r488" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term investments classified as other.", "label": "Other Short-term Investments", "verboseLabel": "Short-term Investments" } } }, "localname": "OtherShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over Allotment Option [Member]", "terseLabel": "Underwritten public offering" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r88" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "terseLabel": "Underwriting discounts and commissions" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r89" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "verboseLabel": "Direct and incremental expenses" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r83", "r375" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash consideration" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails", "http://www.Cryoport.com/role/DisclosureNatureOfBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r84" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedLabel": "Patent and trademark costs" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r84" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "auth_ref": [ "r85" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Payments to Acquire Short-term Investments", "negatedLabel": "Purchases of short-term investments" } } }, "localname": "PaymentsToAcquireShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToDevelopSoftware": { "auth_ref": [ "r84" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the development or modification of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.", "label": "Payments to Develop Software", "negatedLabel": "Software development costs" } } }, "localname": "PaymentsToDevelopSoftware", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r308", "r332" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable preferred class A stock or outstanding convertible preferred class A stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Preferred Class A [Member]", "terseLabel": "Class A Preferred Stock" } } }, "localname": "PreferredClassAMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredClassBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable preferred class B stock or outstanding preferred class B stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Preferred Class B [Member]", "terseLabel": "Class B Preferred Stock" } } }, "localname": "PreferredClassBMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockDividendRatePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage rate used to calculate dividend payments on preferred stock.", "label": "Preferred Stock, Dividend Rate, Percentage", "terseLabel": "Preferred stock, dividend rate (as a percent)" } } }, "localname": "PreferredStockDividendRatePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_PreferredStockLiquidationPreference": { "auth_ref": [ "r15", "r104", "r259", "r260" ], "lang": { "en-us": { "role": { "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.", "label": "Preferred Stock, Liquidation Preference Per Share", "terseLabel": "Liquidation preference (in dollars per share)" } } }, "localname": "PreferredStockLiquidationPreference", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value per share (in dollars per share)", "verboseLabel": "Preferred stock, par value per share (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "verboseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "verboseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "verboseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r15" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock value" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r6", "r27", "r28" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "verboseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]", "terseLabel": "Private Placement" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r87" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from Convertible Debt", "terseLabel": "Proceeds from the offering" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r86" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from Issuance Initial Public Offering", "terseLabel": "Proceeds from public offering, net of offering costs", "verboseLabel": "Proceeds from public offering, net of offering costs" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r86" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "verboseLabel": "Proceeds from issuance of common stock, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "auth_ref": [ "r86" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.", "label": "Proceeds from Issuance of Convertible Preferred Stock", "terseLabel": "Proceeds from issuance of stock", "verboseLabel": "Proceeds from issuance of Series C convertible preferred stock, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r86" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Proceeds from Issuance of Private Placement", "terseLabel": "Aggregate purchase price" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": { "auth_ref": [ "r82" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Proceeds from Sale, Maturity and Collection of Short-term Investments", "verboseLabel": "Sales/maturities of short-term investments" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r86" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from Warrant Exercises", "terseLabel": "Proceeds from exercise of stock options and warrants" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product [Member]" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_ProductWarrantyAccrual": { "auth_ref": [ "r245", "r246", "r468" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.", "label": "Standard and Extended Product Warranty Accrual", "verboseLabel": "Product warranty accrued liabilities" } } }, "localname": "ProductWarrantyAccrual", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSharesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r61", "r64", "r90", "r106", "r115", "r122", "r123", "r164", "r168", "r171", "r174", "r176", "r199", "r379", "r384", "r385", "r391", "r392", "r405", "r474" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r31", "r229" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r10", "r11", "r229", "r486" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "verboseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r30", "r102", "r229", "r527", "r528" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "verboseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r10", "r228" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property Plant And Equipment Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r72", "r203" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Provision for Doubtful Accounts", "terseLabel": "Provision for bad debt" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r342", "r538" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "verboseLabel": "Engineering and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r102", "r342" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "verboseLabel": "Engineering and Development Expenses" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units R S U [Member]", "terseLabel": "Restricted stock units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationRestrictedStockUnitDetails", "http://www.Cryoport.com/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails", "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSharesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureNatureOfBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r19", "r266", "r336", "r484", "r503", "r505" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "verboseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r112", "r113", "r114", "r116", "r121", "r123", "r200", "r333", "r334", "r335", "r355", "r356", "r500", "r502" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerMember": { "auth_ref": [ "r148", "r181" ], "lang": { "en-us": { "role": { "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue From Contract With Customer [Member]", "terseLabel": "Sales Revenue, Net [Member]" } } }, "localname": "RevenueFromContractWithCustomerMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r103", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r289" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue Recognition, Policy [Policy Text Block]", "verboseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r180" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "terseLabel": "Schedule of geographical revenues, by origin" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuePracticalExpedientInitialApplicationAndTransitionNondisclosureOfTransactionPriceAllocationToRemainingPerformanceObligation": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether practical expedient was elected not to disclose amount of transaction price allocated to remaining performance obligation and explanation of expected timing of revenue recognition for reporting period presented prior to date of initial application under retrospective method.", "label": "Revenue, Practical Expedient, Initial Application and Transition, Nondisclosure of Transaction Price Allocation to Remaining Performance Obligation [true false]", "terseLabel": "Omit disclosure of the transaction price allocated to remaining performance obligations" } } }, "localname": "RevenuePracticalExpedientInitialApplicationAndTransitionNondisclosureOfTransactionPriceAllocationToRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r69", "r106", "r155", "r156", "r167", "r172", "r173", "r177", "r178", "r181", "r199", "r405", "r474" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "verboseLabel": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregatesOurRevenuesByMajorSourceDetails", "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOurGeographicalRevenuesByOriginDetails", "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r434", "r439" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "verboseLabel": "Operating leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesSupplementalCashFlowsInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale Of Stock Name Of Transaction [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical", "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r134" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r134" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of number of shares excluded from the computation of diluted loss per share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r363", "r364" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.", "label": "Cash, Cash Equivalents and Investments [Table Text Block]", "verboseLabel": "Schedule of cash, cash equivalents and short-term investments" } } }, "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "verboseLabel": "Schedule of net loss per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r217", "r219" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of intangible assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r214", "r215" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r214", "r215" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r8", "r24", "r25", "r26" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureInventoryTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r235", "r236", "r237" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureNatureOfBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r318", "r321", "r323" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "Share-based Compensation, Activity [Table Text Block]", "verboseLabel": "Schedule of share-based payment awards" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r308", "r332" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAssumptionsUsedToEstimateFairValueOfStockOptionsDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of restricted stock unit activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r313", "r321", "r323" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]", "verboseLabel": "Schedule of stock option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r326" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "verboseLabel": "Schedule of fair value assumptions of stock options" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r42", "r104", "r138", "r139", "r255", "r256", "r257", "r259", "r260", "r261", "r263", "r264", "r265", "r266" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of expected future amortization of intangible assets" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r181", "r494" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segment [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregatesOurRevenuesByMajorSourceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r76" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling General And Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior Notes" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]", "terseLabel": "Service [Member]" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r93" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Compensation", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationRestrictedStockUnitDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationRestrictedStockUnitDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Outstanding March 31, 2021", "periodStartLabel": "Outstanding - December 31, 2020" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationRestrictedStockUnitDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Outstanding March 31, 2021", "periodStartLabel": "Outstanding - December 31, 2020" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationRestrictedStockUnitDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Weighted Average Fair Value Per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationRestrictedStockUnitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "verboseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAssumptionsUsedToEstimateFairValueOfStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Volatility, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAssumptionsUsedToEstimateFairValueOfStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Volatility, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAssumptionsUsedToEstimateFairValueOfStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk-free interest rate, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAssumptionsUsedToEstimateFairValueOfStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk-free interest rate, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAssumptionsUsedToEstimateFairValueOfStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAssumptionsUsedToEstimateFairValueOfStockOptionsDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Number of Restricted Stock Units" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationRestrictedStockUnitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "verboseLabel": "Total shares available for future grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value", "terseLabel": "Intrinsic value per share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Granted (weighted-average fair value of $32.66 per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r332" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Outstanding - March 31, 2021" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r315", "r332" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding - March 31, 2021", "periodStartLabel": "Outstanding - December 31, 2020" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "verboseLabel": "Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding - March 31, 2021", "periodStartLabel": "Outstanding - December 31, 2020" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "verboseLabel": "Weighted-Average Exercise Price/Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r325" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Vested (exercisable) - March 31, 2021" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Vested (exercisable) - March 31, 2021" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "terseLabel": "Vested (exercisable) - March 31, 2021" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r323" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "verboseLabel": "Expected to vest after March 31, 2021 (unexercisable)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "verboseLabel": "Expected to vest after March 31, 2021 (unexercisable)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "verboseLabel": "Expected to vest after March 31, 2021 (unexercisable)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r305", "r311" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationRestrictedStockUnitDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Granted (weighted-average fair value of $32.66 per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r102", "r308", "r312" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r327", "r337" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "verboseLabel": "Expected life (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAssumptionsUsedToEstimateFairValueOfStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r332" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding - March 31, 2021" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Vested (exercisable) - March 31, 2021" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "verboseLabel": "Expected to vest after March 31, 2021 (unexercisable)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Shares issued, price per share (in dollars per share)" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r12", "r465", "r466", "r481" ], "calculation": { "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments", "weight": 1.0 }, "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term Investments", "terseLabel": "Total short-term investments", "verboseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails", "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Short-term Investments [Abstract]", "verboseLabel": "Short-term investments:" } } }, "localname": "ShortTermInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "verboseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r0", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r181", "r214", "r232", "r234", "r238", "r494" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregatesOurRevenuesByMajorSourceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r14", "r15", "r16", "r104", "r106", "r126", "r127", "r128", "r131", "r133", "r138", "r139", "r140", "r199", "r258", "r405" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSharesDetails", "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r45", "r112", "r113", "r114", "r116", "r121", "r123", "r137", "r200", "r258", "r266", "r333", "r334", "r335", "r355", "r356", "r411", "r412", "r413", "r414", "r415", "r416", "r500", "r501", "r502" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "verboseLabel": "Consolidated Statements of Comprehensive Loss [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsAvailableForSaleDebtSecuritiesDetails", "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails", "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails", "http://www.Cryoport.com/role/DisclosureLeasesAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationRestrictedStockUnitDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails", "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical", "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Cash Flows" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Balance Sheets" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Comprehensive Loss" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r112", "r113", "r114", "r137", "r458" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsAvailableForSaleDebtSecuritiesDetails", "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails", "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails", "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails", "http://www.Cryoport.com/role/DisclosureLeasesAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationRestrictedStockUnitDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails", "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical", "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r44", "r258", "r259", "r266" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "verboseLabel": "Conversion of Series C preferred shares to common stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Stock Issued During Period, Shares, Issued for Services" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r15", "r16", "r258", "r266" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Stock issued during period, new issues (in shares)", "verboseLabel": "Issuance of common stock in public offering, net of costs of $17.7 million (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r15", "r16", "r258", "r266" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures", "terseLabel": "Issuance of common stock for board of director compensation (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r15", "r16", "r258", "r266", "r316" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r45", "r258", "r266" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "verboseLabel": "Conversion of Series C preferred shares to common stock" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Stock Issued During Period, Value, Issued for Services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r15", "r16", "r258", "r266" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "verboseLabel": "Issuance of common stock in public offering, net of costs of $17.7 million" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r15", "r16", "r266", "r307", "r322" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures", "terseLabel": "Issuance of common stock for board of director compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r16", "r21", "r22", "r106", "r187", "r199", "r405" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Stockholders' Equity", "verboseLabel": "Stockholders' Equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r106", "r112", "r113", "r114", "r116", "r121", "r199", "r200", "r266", "r333", "r334", "r335", "r355", "r356", "r377", "r378", "r390", "r405", "r411", "r412", "r416", "r501", "r502" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance", "periodStartLabel": "Balance" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r105", "r266", "r267" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r417", "r442" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r417", "r442" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r417", "r442" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r417", "r442" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r441", "r444" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSubsequentEvent" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical", "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.", "label": "Technology Based Intangible Assets [Member]", "terseLabel": "Technology" } } }, "localname": "TechnologyBasedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TrademarksAndTradeNamesMember": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trademarks And Trade Names [Member]", "terseLabel": "Trade name/trademarks" } } }, "localname": "TrademarksAndTradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasuryNotesSecuritiesMember": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one to ten years, are interest bearing, and are backed by the full faith and credit of the United States government.", "label": "U S Treasury Notes Securities [Member]", "terseLabel": "U.S. Treasury notes" } } }, "localname": "USTreasuryNotesSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsAvailableForSaleDebtSecuritiesDetails", "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r291", "r298", "r475" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "U S Treasury Securities [Member]", "terseLabel": "U.S. Treasury notes and bills [Member]" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r94" ], "calculation": { "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment.", "label": "Unrealized Gain (Loss) on Investments", "negatedLabel": "Unrealized loss (gain) on investments in equity securities" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of unrealized gains and losses on investments.", "label": "Unrealized Gain (Loss) on Investments [Table Text Block]", "verboseLabel": "Schedule of unrealized gains (losses) on investments" } } }, "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r343", "r349" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Material unrecognized Tax Benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r142", "r143", "r145", "r146", "r150", "r151", "r152" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "verboseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_UseRightsMember": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Legal right to use or benefit from the use of natural resources or access. Examples include, but are not limited to, drilling rights, water rights, air rights, timber cutting rights and route authorities.", "label": "Use Rights [Member]", "terseLabel": "Land use rights" } } }, "localname": "UseRightsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails", "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSharesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "definitionGuidance": "Weighted average common shares outstanding - basic and diluted", "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Weighted average common shares outstanding - basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsPerShareDetails", "http://www.Cryoport.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04.(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r111": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r153": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5144-111524" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563" }, "r196": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117546-209714" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919272-210447" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r209": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r225": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r241": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r244": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(5)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870" }, "r254": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r267": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(3)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r289": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r341": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5227-128473" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5333-128473" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5333-128473" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r376": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r393": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r418": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r444": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(b)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.5)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "605", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=68052803&loc=d3e8255-115641" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r539": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r540": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r541": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r542": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r543": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r544": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e689-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724391-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "8", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" } }, "version": "2.1" } ZIP 89 0001104659-21-062496-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-062496-xbrl.zip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